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Preface 
I made the decision to do this thesis while on a field epidemiology mission with 
Médecins sans Frontières in the Democratic Republic of the Congo. A PhD thesis based in 
Paris, with occasional travel to Cairo to work on a large cohort study, was an attractive and 
secure situation in comparison to my leaking hut and work/personal encounters with parasites 
in South Kivu.  
Over the first year and a half, I made many trips back and forth to Cairo, setting up a 
cohort study for 7500 persons with hepatitis C receiving direct acting antivirals. In January 
2016, on the cusp of enrolling the first patients, the entire project was halted for reasons 
outside of our control. This timing coincided with the emergence of Zika virus as a non-
benign threat in the Americas, and the subsequent involvement of my supervisor, and then 
myself, in the pregnant women and infant cohort studies in the Caribbean. We also obtained 
funding for a Zika-related microcephaly surveillance study, for which I became the 
coordinator, in sub-Saharan Africa and Asia. Originally this study was in six countries, 
including: Thailand, Vietnam, China, Sri Lanka, Cameroon, and Ivory Coast.  
So, rather than the stable and settled situation I had imagined… four years, three full-
passports, and two thesis topics later, I present you with a story of many scientific (and just as 
many diplomatic) lessons learned. For me, it has been fascinating, and I hope you will agree.  
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Abstract 
Initial epidemiological investigations following emerging disease events sometimes 
uncover spurious associations and lead to misinterpretations of eventual disease severity. This 
may occur due to poorly understood biological mechanisms and infection dynamics, or 
inappropriate study methods and case definitions. In this thesis, this phenomenon will be 
discussed for two recent examples, including the estimation of Zika-related birth defects and 
evaluations of the introduction of direct acting antivirals for hepatitis C in Egypt.   
In the French Territories of the Americas, we estimated the risk of Zika-related birth 
defects to be 7% (95%CI: 5.0%-9.5%) through follow-up a prospective cohort of 546 infected 
pregnant women. When a subset of this cohort was compared to a control group of non-
exposed pregnancies from the same region, our estimate of the risk of birth defects attributable 
to Zika virus decreased to 1.6% (95%CI: 0.4-4.1%). In addition, in a surveillance study in four 
cities in sub-Saharan Africa and Asia, we found high, and regionally variable, proportions of 
microcephaly when using a standardised definition - from 3% in China to 35% in Ivory Coast. 
Difficulties in reconciling our findings with other contemporary estimates on Zika-related 
birth defects are likely due to variation in study procedures, a lack of appropriate control 
groups, and use of problematic definitions for key conditions, such as microcephaly.  
In Egypt, highly effective direct acting antivirals for hepatitis C virus were introduced 
on a large scale in 2014. Our research, conducted through ‘real-life’ cohort studies, found a 
strong association between liver cancer recurrence and treatment with these new regimens, as 
well as a non-negligible risk of hepatitis B reactivation following therapy for persons co-
infected with both viruses. In comparing these findings with those of other groups outside of 
Egypt, we encountered difficulties in drawing conclusions due to variability in research 
methods as well as in the definitions used for the adverse events.   
Following an emerging disease event, research priorities and hypotheses can be 
focused using techniques such as expert opinion elicitation, as well as collaboration through 
diverse research networks. Transparency in reporting, as well as use of standardised protocols 
and case definitions will ameliorate delays in drawing a consensus from initial findings. 
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Resumé 
Les enquêtes épidémiologiques initiales effectuées à la suite d'événements 
épidémiques émergents révèlent parfois des associations fallacieuses et conduisent à des 
interprétations erronées de la gravité éventuelle de la maladie. Cela peut être dû à des 
mécanismes biologiques et à une dynamique d'infection mal compris, ou à des méthodes 
d'étude et à des définitions de cas inappropriées. Dans cette thèse, je discuterai ce phénomène 
avec deux exemples récents, à savoir l'estimation des anomalies congénitales liées au virus 
Zika et les évaluations de l'introduction d'antiviraux à action directe contre l'hépatite C en 
Égypte. 
Dans les Districts Français d’Amérique, nous avons estimé le risque d'anomalies 
congénitales liées au virus Zika à 7% (IC 95%: 5,0-9,5%) grâce au suivi d'une cohorte 
prospective de 546 femmes enceintes infectées. Lorsqu'un sous-groupe de cette cohorte a été 
comparé à un groupe témoin de grossesses non exposées de la même région, notre estimation 
du risque de malformations congénitales imputable au virus Zika a diminué à 1,6% (IC 95%: 
0,4-4,1%). En outre, une étude de surveillance menée dans quatre villes d’Afrique 
subsaharienne et d’Asie et basée sur une définition standardisée de la microcéphalie, a révélé 
des proportions élevées, et variables d’une région à l’autre, de cette condition - allant de 3% 
en Chine à 35% en Côte d’Ivoire. Nos difficultés pour réconcilier ces résultats avec d'autres 
estimations contemporaines des malformations congénitales liées au virus Zika est 
probablement due aux différences entre les schémas d'étude utilisés, à l’absence de groupes 
contrôles appropriés, et à l'utilisation de définitions de cas discutables pour des affections clés 
telles que la microcéphalie. 
En Égypte, des antiviraux à action directe très efficaces contre le virus de l'hépatite C 
ont été introduits à grande échelle en 2014. Nos recherches, menées dans le cadre d'études de 
cohortes «en vie réelle», ont mis en évidence un lien étroit entre la récurrence du cancer du 
foie et le traitement par ces nouvelles thérapies, ainsi qu'un risque non négligeable de 
réactivation de l'hépatite B après le traitement pour les personnes co-infectées par les deux 
virus. En comparant ces résultats avec ceux d’autres groupes situés en dehors de l’Égypte, 
nous avons eu des difficultés à tirer des conclusions en raison de la variabilité des méthodes de 
recherche ainsi que des définitions utilisées pour les effets indésirables. 
Après une maladie émergente, les priorités et hypothèses de recherche peuvent être 
ciblées à l'aide de techniques telles que la collecte d'opinions d'experts et la collaboration via 
divers réseaux de recherche. La transparence dans les publications, de même que l'utilisation 
de protocoles standardisés et de définitions de cas, permettra de réduire les délais d'obtention 
d'un consensus sur les premières conclusions. 
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Part 1. Epidemiological investigations of emerging 
infectious diseases 
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1.1 Epidemiological investigations of emerging disease events 
An emerging infectious disease is commonly defined as illness due to a newly 
discovered pathogen or one for whom the number of persons infected has increased over the 
past twenty years or so. This can therefore include newly identified pathogens, those that have 
recently started affecting different populations, and old infections that are re-emerging as 
threats due to changes in the environment or because of drug resistance (CDC, 1994; Morse 
and Schluederberg, 1990; Rosenthal et al., 2015). In this thesis manuscript I will be discussing 
epidemiological investigations surrounding emerging disease events. While the term ‘event’ 
has previously been used to describe the origin and identification of a novel emerging diseases 
(Jones et al., 2008), in this manuscript I will expand this definition to also include occurrences 
that change drastically the forecast, control, and understanding of an emerging disease. The 
recent spread of Zika virus (ZIKV) into the Americas and realization that infection can cause 
severe neurological manifestations in infants (i.e. birth defects) and in adults (i.e. Guillain-
Barre syndrome) conforms to the traditional definition of an emerging disease event. The 
introduction of highly effective direct acting antivirals for the treatment of chronic Hepatitis C 
virus (HCV) infection, a disease identified approximately 30 years ago and for which 
worldwide spread dates back from the 1960s, will adhere to my expanded terminology for an 
‘event’.  
Following an emerging disease event, it can understandably take time to tease out 
important disease parameters that are key to understand in order to properly implement control 
measures. Depending on the type of infectious agent, the delay by which we have been able to 
identify the culprit behind each emerging disease has varied. It took more than 10 years to 
isolate the cause of non-A non-B hepatitis (i.e. HCV) (Alter, 1999), two years to identify the 
agent (i.e. human immune deficiency virus (HIV)) responsible for acquired immune 
deficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983), and only two months to identify the 
novel coronavirus behind Severe Acute Respiratory Syndrome (SARS) (Drosten et al., 2003).  
The full range of clinical symptoms related to an infectious illness, and the side effects of the 
personal or environmental treatments we use to control them, may equally take time to 
unravel. An example of this is the greater than 50 year delay in recognition of the severe 
neurological manifestations linked to ZIKV infection, as well as the fact that, for more than 
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five years around the early 1990s, early antiviral regimens for HIV were administered with 
little or no benefit to persons who had not yet progressed to AIDS (Concorde Coordinating 
Committee, 1994).  
 Even prior to having a full medical and biological understanding of the infectious 
agent and disease parameters, epidemiological and clinical studies may play a role in guiding 
control and prevention efforts. Relatively simple and rapid assessments, such as surveillance 
analyses and case studies, can identify the clinical presentation of infection, characteristics of 
the populations affected by the disease, and the rate at which the disease is circulating. This 
allows for inference of the method of transmission, and then, appropriate control measures. 
However, in this initial period, where some or all of the biological mechanisms behind a 
disease are still elusive, it is also the case that epidemiological analyses can have incorrect or 
misinterpreted conclusions.  This may lead to any of inappropriate, insufficient, or harmfully 
over-reactive actions in disease management. To showcase this, below I will briefly describe 
some recent historical examples of initial emerging disease investigations with inaccurate 
findings, along with the impact these had on further research direction and the affected 
populations.  
 
“Poppers” as a strong confounder of HIV infection causing Kaposi’s sarcoma 
In 1981, reports of an increase in typically rare opportunistic infections, such as 
Kaposi’s sarcoma and pneumocystis pneumonia, in men who have sex with men (MSM) in the 
United States were actually the first published observations AIDS caused by HIV (Friedman- 
Gottlieb et al., 1981; Kien et al., 1981; Masur et al., 1981; Siegal et al., 1981; Thomasen et al., 
1981), At the time, the virus itself had not been identified, and the condition was temporarily 
defined based on a combination of the populations it seemed to be disproportionately 
affecting, as well as the unusual clinical manifestations being observed in these groups. The 
result of this was misleading initial names for AIDS, by both the media and scientists, 
including “lymphadenopathy” (CDC, 1982a), “Kaposi’s sarcoma and opportunistic infections” 
(CDC Task Force on Kaposi’s Sarcoma and Opportunistic Infections, 1982), “Gay-related 
immune deficiency (GRID)” (The New York Times, 1981), “the 4H disease” (indicating 
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heroin users, homosexuals, hemophiliacs, and Haitians) (Marc et al., 2010). Although the 
CDC adopted a more objective terminology in 1982, with the first mention of AIDS (CDC, 
1982b), these latter labels had lasting stigmatizing effects.  
Fairly rapidly, the involvement of a blood-borne pathogen in AIDS was hypothesized 
based on the populations most affected (Curran et al., 2011). While microbiological attempts 
to identify a potential underlying infectious agent were underway, epidemiological studies 
were also being performed to examine the risk factors of persons with this unique pattern of 
opportunistic infections in order to determine causal relationships. One case-control study 
published in The Lancet in 1982, found a strong and significant association between Kaposi’s 
sarcoma and amyl nitrite use in MSM (Marmor et al., 1982). Amyl nitrite is a recreational 
drug, also called “Poppers” that was started become popular in the 1970s (Israelstam et al., 
1978). The magnitude of the association found through this seemingly robust study, with a 
risk ratio of 12.3 (95%CI: 4.2-35.8), even after controlling for factors such as sexual activity 
and other recreational drug use, led to the temporary belief that this may indeed be the cause 
of AIDS. The hypothesis was that the amyl nitrite could be inducing immune suppression 
itself, leading to the development of Kaposi’s sarcoma; however, the authors of the study 
could not rule out that a likely alternative explanations was that the drug was a surrogate for 
exposure to an unknown oncogenic virus (Marmor et al., 1982).  
In 1983, a novel retrovirus, to eventually be called HIV, was discovered in a person 
with lymphadenopathy, and this became known as the true cause of AIDS (Barre-Sinoussi et 
al., 1983). However, there has now been more than 30 years of research on the subject of 
poppers and HIV, with findings that amyl nitrite itself could cause immune suppression in 
mice (Guo et al., 2000; Soderberg, 1999), that its use in humans could lead to sexual inhibition 
and increased likelihood of seroconversion (Buchbinder et al., 2005; Daskalopoulou et al., 
2014; Plankey et al., 2007), but more recently, that there is no association between heavy 
popper use and cancer risk in HIV-positive men (Dutta et al., 2017). This initial confused 
relationship between poppers and Kaposi’s sarcoma has been considered as a very strong 
empirical example of confounding (Morabia, 1995), and demonstrates clearly how, in initial 
emerging disease investigations, even apparently robust correlations may actually be covering 
a yet-to-be understood biological mechanism. 
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The expected vCJD disease burden in the United Kingdom 
Variant Creutzfeldt-Jakob’s Disease (vCJD) is a prion disease that is caused by the 
same agent that leads to bovine spongiform encephalopathy (BSE or ‘mad cow’ disease) and 
was first discovered in the United Kingdom in 1996 (Bruce et al., 1997; Hill et al., 1997; Will 
et al., 1996). The mean duration of vCJD is 14 months, and is characterized initially by 
psychological abnormalities (e.g. depression and anxiety) and joint and limb pain, followed by 
a diminution in cognitive function and an increase in involuntary movements, eventually 
leading to severe sporadic muscle contractions, abnormal eye movements, speech inability, 
and death in all cases (Zerr and Poser, 2002).  
The prion causing vCJD is thought to be transmitted to humans through the ingestion 
of certain meat products (e.g. brain, spinal cord, eye) from cows with BSE, and it has been 
estimated that more than 450000 infected cows were slaughtered for consumption prior to the 
1989 bovine specified risk materials ban in the UK (FAO, 2002; Ferguson et al., 1997). This 
led to considerable concern over the eventual number of persons who would contract the 
disease, all for whom the result would be fatality. Some factors that complicated the ability to 
estimate the possible disease burden were the unusual nature of the infectious agent and, 
related to this, uncertainty on the incubation period in humans. Through modeling studies 
using varying scenarios for the incubation period and the number of cases appearing over that 
next year, Cousens and colleagues (1997) and Ghani and colleagues (2000), ended up with a 
wide range of possible vCJD cases that may occur in the UK, from 74 to 80000, and 63 to 
136000, respectively.  
By early 2001, there had been a total of 97 reported vCJD cases in the UK (Valleron et 
al., 2001). One interesting, and unique feature of the vCJD cases that had been reported up 
until that point, was their young age (mean 28 years) at the time of symptom onset; this varied 
from sporadic CJD, an already established prion disease, where the mean age of cases is closer 
to 70 (The National CJD Research & Surveillance Unit, 2001). At this time, Valleron and 
colleagues (2001) mentioned two possible, and possibly overlapping, hypotheses for this 
young mean age in cases - the first was that young people were more susceptible to infection, 
and the second was that the incubation period differed for persons of different ages contracting 
! 18!
the disease (i.e. shorter in younger persons). This study group quickly ruled out the second 
hypothesis, as there was no obvious correlation between the age of cases and the date of 
diagnosis. Instead, they fit a model assuming that after 15 years of age, the force of infection 
decreased exponentially, and using this, estimated that the incubation period was 
approximately 17 years and that the eventual total number of cases in the UK would be around 
200 (upper limit approximately 400).   
As of the end of December 2017, a total of 178 cases of vCJD had been reported in the 
UK (The National CJD Research & Surveillance Unit, 2017), closely aligning with the results 
of the modeling study performed in 2001 by Valleron and colleagues. Considering that the 
policy implications for disease management in the UK, not to mention national panic, would 
differ significantly with an expected 200 versus >100000 cases/deaths due to vCJD, this 
highlights the impact of analysis assumptions in early emerging disease event research. In this 
case, the unusual infectious agent involved, and its related unknown disease parameters, 
exacerbated these complications.  
 
Super-spreaders and perceived aerosolized transmission of SARS  
The outbreak of SARS started in late 2002 in Guangdong province, P.R. China; 
however, for some months, the world was largely uninformed about this event, hearing only 
rumors of many cases of atypical pneumonia occurring in that region (WHO, 2003a). In 
February 2003, a doctor who had treated SARS patients in Guangzhou (Guangdong) visited 
Hong Kong for a wedding and stayed on the 9th floor of the Metropole Hotel, where he 
infected seven other persons staying on the same floor; this included three from Singapore, 
one from Vietnam, two from Canada, and one local resident. Subsequent spread of SARS back 
to the countries of origin of each of these international secondary cases rapidly brought global 
attention and involvement in the outbreak (Hung, 2003; WHO, 2003). In early March 2003, a 
physician who contracted the illness while treating a patient in Singapore was taken off of his 
flight during a layover in Frankfurt and hospitalized there, allowing for isolation of a novel 
coronavirus (i.e. SARS-CoV) by a German team (Drosten et al., 2003).   
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Hong Kong was one of the regions most affected by the SARS outbreak, with 
approximately 1800 infections and a 17% case fatality risk (CFR) (WHO, 2003b). Certain 
characteristic events that occurred in Hong Kong led to initial misunderstanding about the 
transmissibility of the virus, which also led to increased, and retrospectively, unwarranted, 
panic and preventive measures with lasting social and economic impact (Smith et al., 2006; 
Qiu et al., 2018). In a SARS-naïve population, one infected person will transmit to an average 
of about 3 others (Ro=2.7), which represents low-moderate transmissibility (Riley et al., 2003). 
However, early in the SARS outbreak, some super-spreader individuals transmitted the 
infection to between 20-180 persons each (Wong et al., 2015). In Hong Kong, there were 
multiple important super-spreading events leading to large disease clusters; for example, the 
initial patient at the Metropole Hotel is assumed to have eventually infected up to 20 others 
(CDC, 2003a; 2003b), and one of those individuals, admitted to the local Prince of Wales 
Hospital, is estimated to have infected more than 100 others (Lee et al., 2003; Tomlinson and 
Cockram, 2003). Another large case cluster occurred at the private residence called Amoy 
Gardens, where 331 patients were infected, comprising almost a fifth of all cases in Hong 
Kong (Yu et al., 2014). Here, an index SARS patient with comorbidities visited a relative in 
Block E of the complex, and had an episode of diarrhea there. Subsequently, many persons in 
Block E became infected, but the majority of cases in this cluster occurred in adjacent 
apartment blocks (Government of Hong Kong, 2003). Some initial investigations into this 
cluster suggested possible aerosolisation of SARS (Yu et al., 2014), others concluded that it 
occurred because of a poorly functioning sewage system and other environmental factors 
(Government of Hong Kong, 2003; Lee, 2003), and later, some suggest possible exceptional 
airborne transmission due to unique environmental factors (i.e. the high concentrations of viral 
droplets in the sewage system) (McKinney et al., 2006).   
In the case of SARS, both the occurrence of super-spreading events, a phenomenon 
little experienced until that time, as well as the unique case cluster at Amoy Gardens, confused 
initial estimates of the transmissibility of the novel virus. It could be seen that, positively, 
confusion surrounding these events initially led to heightened preventive measures as well as 
global attention on SARS which may have limited its eventual spread, and which has allowed 
for an increased understanding of super-spreading events as well as the role of environmental 
factors in transmission of such diseases (McKinney et al., 2006; Wong et al., 2015). On the 
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other hand, the resulting level of caution and panic, as well as public communication 
surrounding this, had a disproportionate effect on the economy and social wellbeing in Hong 
Kong and mainland China, when compared to the absolute morbidity and mortality linked to 
the outbreak (Smith, 2006; Qiu et al., 2018; Yip et al., 2010).   
!
Estimation!of!CFR!during!the!2009!influenza!A(H1N1)!pandemic!
The 2009 influenza A(H1N1) virus pandemic, also called “Swine Flu”, started in April 
of that year, in Mexico. In order to understand the potential severity of an influenza pandemic, 
it is necessary to consider both the estimate of the transmissibility of the new or re-emerging 
virus as well as the risk of fatality for those infected (i.e. the CFR) (Lipsitch et al., 2009; Van 
Kerkhove et al., 2010). The transmissibility of the 2009 influenza A(H1N1) virus was 
established relatively early on during the pandemic period; the median reproductive number 
was 1.5, which is similar to previous influenza pandemics (Boëlle et al., 2011). Conversely, 
deriving a reliable estimate of the severity of infection, in terms of the proportion of cases who 
were likely to die, proved much more difficult. Initial approximations of the CFR were greater 
than 5% in Mexico, approximately 4% in Colombia, and around 14% in Argentina (Castro-
Jimenez et al., 2009; Chowell et al., 2011; Nishiura et al., 2010; Wong, Kelly, et al., 2013); for 
comparison, the 1918 “Spanish” influenza A(H1N1) pandemic had a CFR of roughly 3%, and 
that of seasonal influenza is <0.1% (Taubenberger and Morens, 2006). These initial high 
estimates from Latin America led to the first ever Public Health Emergency of International 
Concern (PHEIC) issued by the WHO, and an increasing of the level of influenza pandemic 
alert to phase 6 (WHO, 2009a; WHO 2009b).  
We now know that an accurate estimate of the CFR for the 2009 influenza A(H1N1) 
pandemic is up to 10 per 100000 (0.01%), meaning that initial estimates that highly influenced 
international policy for disease control (e.g. vaccine production and purchase), were grossly 
overestimated (Wong, Kelly, et al., 2013). A retrospective review by Wong, Kelly, and 
colleagues (2013) demonstrates the variability in CFR estimates during the entire pandemic 
period, ranging from as low as 0% to as high as 14%. The case definition for the denominator 
in each study accounted for some, but not all, of the magnitude of difference across the 
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estimates. Ideally, CFR is calculated based on an understanding of the total number of persons 
infected (i.e. infection fatality risk), but this is a measure complicated to determine at the start 
of an outbreak, as it requires extensive serological testing (Wong, Wu, et al., 2013). A likely 
reason for initial overestimates of the CFR during the 2009 influenza A(H1N1) pandemic, was 
the fact that laboratory confirmed and hospitalized cases were often used as the denominator 
in early-reported studies in Latin America, likely with a severe selection bias on which cases 
had samples sent for confirmation (Wong, Kelly, et al., 2013). In this case, the wide 
uncertainty around the seriousness of the influenza pandemic hindered the ability to perform 
an accurate risk assessment and subsequently to implement an appropriate level of control, 
and this has led to recommendations for the improvement of defining CFR in the face of a 
pandemic (WHO, 2011). !!!
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 1.2 Aims of this thesis 
As described earlier, in the preface of this thesis, the aims of my research and what I 
imagined I would be presenting in this manuscript have changed dramatically over the past 
four years. The primary objective of my first thesis topic was to demonstrate the ‘real-life’ 
safety and efficacy of direct acting antivirals for HCV in Egypt. Secondary objectives of that 
project included a description of adherence to these treatment regimens, as well as an 
evaluation of methods to improve data collection in large centralized national treatment 
programs. In my second thesis topic, on ZIKV, my goal was to estimate the risk of ZIKV-
related birth defects in both epidemic and non-epidemic regions. This work was meant to 
include a description of the proportion of ZIKV-related birth defects, and factors related to 
these abnormalities, in the French Territories in the Americas, as well as an estimate of the 
proportion of ZIKV-related microcephaly in different settings across Africa and Asia.   
I will be able to present you with my findings on the many of the above listed specific 
objectives in this manuscript; however, its own overall goal will be broader. Here, may aim is 
to draw your attention to the difficulties in bringing together initial epidemiological findings 
related to emerging infectious disease parameters in order to draw meaningful conclusions that 
will responsibly inform policy actions for control.   
My specific objectives for each of the next chapters will be: 
• To describe how our own findings on the risk of ZIKV-related birth defects in 
epidemic and non-epidemic regions compare to other contemporary studies, drawing 
specific attention to differences in study methodologies as well as issues with the case 
definition used for research on a key birth defect - microcephaly.  
• To demonstrate the challenges in drawing a consensus on adverse events linked to new 
direct acting antivirals for HCV in Egypt due to non-standardization of study 
methodologies and case definitions used.  
• To discuss the utility of methods such as protocol standardization, collaborative 
research networks, and expert opinion elicitation to generate comparable results and to 
focus research priorities during emerging disease events.  
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In this section, I will focus on the emergence of Zika virus (ZIKV) as a public health 
threat – specifically with regards to the recent realization that infection with the virus during 
pregnancy can lead to adverse fetal outcomes and infant birth defects. This has been the 
subject of my thesis work for the past two years. In early 2016 we started collaborating with a 
research group working in the French Territories of America (FTA) on ZIKV-infected 
pregnant women and infant cohorts; personally this has meant my involvement in analyzing 
and interpreting data on ZIKV-related birth defects. Also in 2016, we secured funding to start 
a multi-country study doing surveillance for ZIKV-related microcephaly in sub-Saharan 
Africa and Asia. I have been coordinating this study, which is taking place in Vietnam, Sri 
Lanka, China, Cameroon, and Ivory Coast.  
 
I will start with some background information on ZIKV, describing its discovery and 
epidemiological history over the past 60 years. The severe manifestations of ZIKV infection 
will be presented, as have been made apparent through the more recent French Polynesian 
(2013-2014) and Americas (2015-2017) outbreaks. I will then describe the methods of the 
pregnant women cohort in the FTA, along with two articles that use data from this cohort to 
estimate the risk of birth defects in ZIKV-exposed pregnancies. After this, a short description 
of our multi-country ZIKV-related microcephaly surveillance study will be given, followed by 
an article that includes our preliminary findings on the proportion of infants with 
microcephaly in four of the included countries.  Finally I will discuss potential reasons for our 
findings and their differences or similarities with other reports, with a specific focus on use of 
a standardized case definition for microcephaly and the importance of control groups.  
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2.1 Background 
2.1.1 Discovery of ZIKV 
In 1947, in the Zika forest of Uganda, a flavivirus of the family flaviviridae was isolated 
from a sentinel rhesus monkey showing signs of fever. A year later, another strain of the virus 
was isolated from wild Aedes africanus mosquitoes (Dick et al., 1952). When inoculated into 
the brains of mice, the first strain caused mortality in all, and the second strain led to transient 
motor dysfunction and paralysis (Dick et al., 1952; Dick, 1952). This work was done in the 
well-equipped Uganda Virus Research Institute, situated in the Zika forest near Entebbe, 
which had been started by the Rockefeller Foundation in 1936 for the study of yellow fever, 
and later expanded its mandate to study various other viruses in the region (Zhou et al., 2016). 
A subsequent serosurvey in 45 persons residing in two Western regions of Uganda, Bwamba 
and West Nile, demonstrated that 6.1% of persons had evidence of past infection of ZIKV, 
however, near to Zika forest, none of the sera of 54 persons tested contained antibodies  (Dick, 
1952; Dick, 1953). It is commonly thought that the first reported description of human illness 
due to ZIKV was in West Africa, reported by Macnamara in 1954 for three persons in Nigeria; 
this virus was isolated and later inoculated into a human volunteer (Bearcroft, 1956). 
However, subsequent research has confirmed that the virus isolated by Macnamara was more 
closely related to Spondweni virus than ZIKV (Boorman and Draper, 1968; Moore et al., 
1975; Simpson, 1964; Wikan and Smith, 2017). Therefore, the first official recorded human 
case of ZIKV was a decade later in (and reported by) David Simpson (1964), a physician who 
contracted the virus while working in the Uganda Virus Research Institute in Entebbe. 
Simpson carefully recorded his symptoms, which included fever, headache, fatigue, backache, 
and leg pain over a period of two days, as well as a full-body maculopapular rash that 
appeared on the second day of illness but which had faded by the end of the fifth day of illness 
(Simpson, 1964).  
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2.1.2 ZIKV circulation 1947-2007 
Serological studies indicate that ZIKV circulated widely throughout Africa and Asia in 
the five decades following its discovery - this has been summarized in a number of reviews 
(Faye et al., 2014; Kindhauser et al., 2016; Musso and Gubler, 2016; Petersen et al., 2016; 
Posen et al., 2016;). As mentioned previously, the first serostudies were performed in East 
Africa, namely Tanzania and Uganda, in the late 1940s (Dick, 1952; Dick, 1953; Smithburn, 
1952). Posen and colleagues (2016) and Kindhauser and colleagues (2016) describe well the 
appearance (i.e. reporting) of ZIKV in other countries in these two continents following that 
time period, which, in order, occurred in: Nigeria, India, Malaysia, the Philippines, Central 
African Republic, Chad, Egypt, Republic of Congo, Thailand, and Vietnam (1950-1955); 
Mozambique (1957); Angola, Ethiopia, Kenya, Senegal, Cote d’Ivoire, Burkina Faso, 
Cameroon, Guinea Bisau, Mali, and Togo (1960-1965); Niger, Somalia, Benin, Gabon, 
Morocco, and Liberia (1965-1970); Republic of Seychelles, Sierra Leone, Hong Kong, and 
Indonesia (1970-1975); Sudan, Madagascar, and Pakistan (1975-1980); Burundi (1980); 
Djibouti (1991). The seroprevalence reported for some countries, notably Benin, Burkina 
Faso, Mali, Senegal, and Malaysia were around 40% or higher (Posen et al., 2016). 
Serological methods for detecting ZIKV and other viruses evolved significantly between the 
1950s and early 2000s, and therefore the seroprevalence estimate each region/country 
obtained through the studies should be interpreted along with the type of test used. In most 
early studies, hemagglutination inhibition assays (HI) were employed, which, compared to 
more specific methods, such as plaque reduction neutralization tests (PRNT), are known to 
overestimate seroprevalence (Omer et al., 1981; Waggoner and Pinsky, 2016).  
Interestingly, two studies took place in Spain in the late 1970s, which, via HI testing, 
revealed a 2.9% seroprevalence of ZIKV (Gonzalez and Filipe, 1977; Lozano and Filipe, 
1998). In addition, one laboratory worker in Portugal was reported to have contracted the virus 
in 1973 (Filipe et al., 1973).  
Despite detection of ZIKV in many countries, prior to 2007, only 14 cases of acute human 
illness with the virus had been documented (Fagbami, 1979; Filipe et al., 1973; Moore et al., 
1975; Olson et al., 1981; Simpson, 1964). In all these cases, the disease caused by ZIKV was 
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described as generally mild, causing symptoms such as fever, headache, as well as joint and 
eye pain; only in the very first clinical case of ZIKV, that of Simpson in 1964, was rash 
portrayed (Kindhauser et al., 2016; Simpson, 1964). No deaths, hospitalizations, or ZIKV-
related birth defects were reported.  
  
2.1.3 Outbreaks in the South Pacific (2007-2015)  
The first significant outbreak of ZIKV ever recorded was in Micronesia (the Yap 
Islands), lasting for three months from mid-April to mid-July of 2007 (Barboza et al., 2008; 
Duffy et al., 2009). On this small island with a population of <8000 persons, a subsequent 
serosurvey demonstrated that 73% (95%CI: 68-77) of persons had been infected. Of those 
showing evidence of ZIKV infection, approximately one-fifth had symptoms, including rash 
in 90%, fever, joint pain and conjunctivitis in 55-65% of patients, and muscle pain, headache, 
and eye pain in 40-50% of persons (Duffy et al., 2009). In mid-October 2013, ZIKV cases 
were observed in French Polynesia, an archipelago of islands more than 8000 km distance 
away from Yap (Cao-Lormeau et al., 2014; Mallet et al., 2016). This was the beginning of an 
outbreak that lasted approximately six months and led to almost 32000 symptomatic cases 
presenting to health care facilities; a post-epidemic serological survey indicates that 49% of 
the population had been infected (Aubry et al., 2017; Mallet et al., 2016). Similar symptoms 
were reported as those seen in the Yap Island outbreak (Duffy et al., 2009; Musso et al., 
2018). In French Polynesia, the first severe manifestations of ZIKV were noted; these were 
cases of Guillain-Barre Syndrome (GBS), an autoimmune condition that causes acute or 
subacute paralysis (Cao-Lormeau et al., 2016; Musso et al., 2014; Oehler et al, 2014). 
Following the outbreak in French Polynesia, ZIKV spread through other islands in the South 
Pacific, including New Caledonia, the Cook Islands, Easter Island, American Samoa, Vanuatu, 
and the Solomon Islands (Dupont-Rouzeyrol et al., 2015; Healy et al., 2016; INVS, 2014; 
Musso et al., 2015; Roth 2014; Tognarelli et al, 2016) 
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2.1.4 ZIKV Outbreak in the Americas (2015 - present) 
The virus arrived in South America in early 2015, signaled by notifications of a large 
outbreak of rash-causing illness in Bahia State, as well as transmission noted in Rio Grande de 
Norte State, Brazil (Campos et al, 2015; Cardoso et al, 2015; Zanluca et al, 2015). By 
December 2015, the outbreak had spread across most of Brazil (Secretaria de Vigilância em 
Saúde, 2016), with the Ministry of Health estimating that there had been between 440 000 and 
1 300 000 cases (Ministério da Saúde (Brazil), 2015a). Furthermore, the virus had also spread, 
at that time, to seven other countries in the Americas, including Colombia, El Salvador, 
Guatemala, Mexico, Panama, Paraquay and Venezuela (Gomez, 2015; Instituto Nacional de 
Salud, 2015; Ministry of Health of the Republic of Panama, 2015, Ministry of Public Health 
and Social Welfare Paraguay, 2015; WHO, 2015a; WHO, 2015b; WHO, 2015c). At that time, 
ZIKV cases had also been detected in the Cape Verde Islands in Africa (Ministério da Saúde 
(Capo Verde), 2015).  By the end of the following year, 2016, autochtonous transmission of 
ZIKV had been confirmed in 48 countries and territories of the Americas, including in the 
southern United States. To date, in all of the Americas, only Canada, Chile, and Uruguay have 
not reported any locally acquired cases (PAHO, 2017a).  
In March of 2016, the WHO declared the outbreak in the Americas to be a Public Health 
Emergency of International Concern (PHEIC), due to the surfacing associations between 
ZIKV infection and microcephaly in infants whose mothers were infected during pregnancy, 
as well as other severe neurological manifestations in adults, such as GBS (Heymann et al., 
2016; Oehler et al., 2016; PAHO, 2016; WHO, 2016a). A more detailed description of these 
findings, as well as an update on ZIKV-related birth defects, will be given later in this 
background section. At present, the outbreak situation in the Americas had declined, with 
limited circulation being recorded (PAHO, 2017b; Siedner et al., 2018). The PHEIC was 
declared over in November of 2016, with a recommendation for sustained research (WHO, 
2016b)  
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2.1.5 Diagnosis of ZIKV infection 
Molecular diagnosis and persistence of ZIKV RNA in body fluids 
ZIKV infection can be definitively diagnosed by molecular methods (e.g. real-time 
polymerase chain reaction (RT-PCR)); however, depending on the body fluid used and the 
time since initial infection, the likelihood of detecting ZIKV ribonucleic acid (RNA) differs. 
One study by Paz-Bailey and colleagues observed 150 participants with confirmed 
symptomatic ZIKV infection and detected RNA in 88% of serum samples with a median 
duration of positivity of 14 days, with no detection in 95% of participants after 54 days. For 
urine, ZIKV could be detected in 62% of participants; the median duration of positivity was 8 
days, with no detection in 95% of participants after 39 days (Paz-Bailey et al., 2017). These 
results are in contrast to some previous smaller studies that reported detecting ZIKV RNA in 
urine more frequently (i.e. in up to 100% of patients) and for longer median durations than in 
serum (Bingham et al., 2016; Gourinat et al., 2015). Saliva presents another possibility for 
molecular diagnosis of ZIKV infection, but the reported sensitivities of this sample when 
compared to serum vary. Of the larger studies that have evaluated this topic, two have reported 
detection of ZIKV RNA more frequently in saliva when compared to serum (19% vs 8% and 
81% vs 51%) (Bingham et al., 2016; Musso et al., 2015); however, Paz-Bailey and colleagues 
report detection in only 10% of saliva samples when compared to 88% of serum samples (Paz-
Bailey et al., 2017). ZIKV RNA has been seen to persist for longer periods in whole blood 
samples when compared to serum, and has therefore been proposed as an alternative and 
superior sample for diagnosis (Barzon et al., 2018; Baud et al., 2017).  
In ZIKV infected men, semen is frequently positive for ZIKV RNA, and the virus is 
detectable for longer durations than in other body fluids. In the study by Paz-Bailey et al., 
ZIKV RNA was detected in semen samples from 81% of 68 male participants, with a median 
disappearance time of 34 days (Paz-Bailey et al., 2017). In a prospective cohort study of 184 
men in Puerto Rico, ZIKV RNA could be detected in 60 (33%) of participants, with a median 
time until non-detection of 35 days (Mead et al., 2018). It is also possible to detect ZIKV 
RNA in vaginal secretions and conjunctival fluid, however, these samples are rarely positive 
(Paz-Bailey et al., 2017; Tan et al., 2017). Semen, vaginal secretions and conjunctival fluid are 
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not typically proposed as samples for diagnosis, but rather for monitoring and research 
purposes.  
ZIKV RNA has been seen to persist for long periods in pregnant women, up to three 
times longer than in non-pregnant women in the same age range (Lozier et al., 2018; Meaney-
Delman et al., 2016). The reason for this is not completely understood, although an altered 
immune state, or replication of the virus in additional reservoirs such as the placenta or the 
fetus itself, have been proposed as possible explanations (Aagaard et al., 2017; Bhatnagar et 
al., 2017; Lozier et al., 2018; Meaney-Delman et al., 2016).  
 
Serological diagnosis 
While detection of RNA is the only way to definitely confirm acute infection with 
ZIKV, this type of diagnosis has limited use due because of short duration of positivity, as 
well as the need for symptomatic infection to prompt testing. Serological diagnosis of ZIKV, 
on the other hand, provides a more flexible window of time to define exposure. Serum can be 
tested for immunoglobulin M (IgM) using an enzyme-linked immunosorbent assay (ELISA); 
IgM appears within a week but typically wanes after a few months and is therefore not 
recommended for diagnosis after 12 weeks of presumed infection (Landry and St. George, 
2017; Rabe et al., 2016). In a study of 29 travelers returning to Italy, ZIKV IgM was 
detectable as early as five days (median 12 days) following estimated time of infection 
(Barzon et al., 2018). Another study in 15 persons in Guadeloupe found that IgM was 
detectable for the majority of patients within one week of infection and for all patients by the 
eleventh day after infection; in this study, two different commercial immunoassays were used 
and sensitivities at various time-points differed for each. In the same study in Guadeloupe, 
IgM had decreased to the point of being undetectable by both immunoassays in the majority of 
patients within two months of infection (Pasquier et al, 2018).  
ZIKV immunoglobulin G (IgG) appears shortly after IgM, and is detectable for long 
periods using commercial immunoassays (Barzon et al., 2018; Pasquier et al., 2018). 
Experience with other flaviviruses indicates that these neutralizing antibodies could remain for 
! 31!
years and may confer lifelong immunity, however, this is not yet certain for ZIKV (Baud et 
al., 2017; Busch et al., 2008; Poland et al., 1981; Whitehead et al., 2007). A follow-up survey 
in French Polynesia, 18 months after the original outbreak in 2013-2014, demonstrated a 
decrease in seroprevalence that, although non-significant, may indicate that IgG may wane to 
undetectable levels over time (Aubry et al., 2017)  
While serological diagnosis provides a time-advantage when compared to molecular 
methods for detection of ZIKV, this method is complicated by flavivirus cross-reactivity 
(Lanciotti et al., 2008). Therefore, in the case of any positive or uncertain serological test 
result, whether or not ZIKV has been the most recent infection, cannot be confirmed unless 
plaque reduction neutralization test (PRNT) for ZIKV and other flaviviruses (e.g. Dengue 
virus (DENV)) are performed and compared against each other (Rabe et al., 2016). 
Unfortunately, in the case of a secondary flavivirus infection (e.g. recent infection with either 
ZIKV or DENV with past infection of the other), PRNT is not able to conclude the culprit of 
the recent infection. This results from the phenomenon of the ‘original antigenic sin’ where 
IgM results by ELISA testing may be negative for ZIKV, or have equally high results for both 
ZIKV and DENV by PRNT, because of a more rapid and exponential increase in DENV 
antibodies if infection has occurred with it in the past (Barzon et al., 2018; Halstead et al., 
1983; Morens et al., 2010; Rabe et al., 2016). Further complicating the use of PRNT for ZIKV 
confirmation is that it is typically only available in specialized and well-equipped laboratories, 
and therefore not accessible in all settings.  
 
2.1.6 Transmission  
• Vector-borne  
ZIKV is primarily a vector-borne illness, transmitted mainly by mosquitoes of the 
genus Aedes (Ae.), with the role of Culex mosquitoes still debated (Boyer et al., 2018; Guedes 
et al., 2017). Transmission can occur through a sylvatic cycle where infection is passed 
between non-human primates and forest-dwelling mosquitoes, eventually leading to infection 
of a dead-end human host. This cycle involves a range of zoophilic Aedes and other 
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mosquitoes, and has been observed in some countries in Africa, with proposed potential for 
occurring in the Americas (Althouse et al., 2015; Althouse et al., 2016; Boyer et al., 2018; 
Bueno et al., 2016). Alternatively, transmission can occur through an urban cycle, where 
mosquitoes move the virus from human to human. This urban cycle is the culprit of large 
human outbreaks of ZIKV, such as those seen recently in the Pacific Islands and the 
Americas; three species of mosquito, Ae. aegypti, Ae. albopictus, and Ae. hensilii are involved 
in this transmission. (Boyer et al., 2018).  The efficiency of different mosquitoes as vectors of 
ZIKV varies by region as well as viral genotype, as has been seen previously with DENV 
(Boyer et al., 2018; Lambrechts et al., 2009). However, of the mosquitoes implicated in urban 
transmission of ZIKV, Ae. aegypti has been shown to be the most competent vector in the 
recent epidemics, likely due to an acquired infectivity-increasing mutation (Liu et al., 2017).  
Ae. aegypti is present worldwide in tropical regions; this distribution corresponds to places 
where DENV is endemic, and serves to highlight areas where ZIKV may, or already is, 
occurring (Boyer et al., 2018, Messina et al., 2016). Ae. albopictus, an invasive species and 
another competent vector, is partially responsible for autochthonous transmission that 
occurred in the southern United States, as well as elsewhere, in the recent epidemics (Boyer et 
al., 2018). This mosquito is seen to be a potential threat for eventual endemicity of the virus in 
Europe; however, vector competence studies that have taken place in Italy and France so far 
have indicated minimal threat (Di Luca et al., 2016; Jupille et al., 2016).   
 
• Mother to child  
Vertical transmission of ZIKV, from mother to child during pregnancy, was not 
realized until the recent epidemics in the Americas. In early 2016, the virus was detected in 
the amniotic fluid of Brazilian pregnant women whose fetuses had evidence of microcephaly 
(Calvet et al., 2016; Melo et al., 2016). Around the same time, ZIKV was detected in brain and 
placental tissues for two infants with microcephaly who died within 20 hours of birth as well 
as two miscarried fetuses, all from symptomatic mothers, which indicated the ability of the 
virus to cross the placental barrier and infect the fetus (Martines et al., 2016). In addition, 
ZIKV was detected in the brain of a terminated fetus from a pregnant woman returning to 
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Slovenia from Rio Grande de Norte State in Brazil; she had experienced symptomatic 
infection at the end of the first trimester of pregnancy, and microcephaly and other brain 
malformations in the fetus initially detected by ultrasound were later confirmed via autopsy 
(Mlakar et al., 2016). Noronha and colleagues (2016) further evidenced vertical transmission 
of ZIKV through description of placental barrier destruction, similar to that occurring with 
other harmful mother-child transmitted viruses, using tissue samples from exposed 
pregnancies. The risk of vertical transmission of ZIKV, and identification of demographic and 
clinical factors that may increase it, are not yet known. One study following 301 ZIKV 
exposed pregnancies prospectively estimated the proportion of cases with vertical 
transmission to be approximately 11% (Pomar et al. 2017). More studies on this topic are 
needed, but it is eventually possible that risk of mother-child transmission of ZIKV in-utero 
will be similar to analogous teratogenic infections, such as cytomegalovirus, for which the 
likelihood of the virus breaching the placental barrier is approximately 30% (Benoist et al., 
2013; Panchaud et al., 2016; Revello and Gerna, 2002; Yinon et al., 2010).   
Perinatal transmission of ZIKV infection was seen in two live born infants in French 
Polynesia where mothers had symptomatic infection at or within one week of delivery. The 
serum of both neonates showed evidence of ZIKV RNA within 1 week of birth, however, only 
one infant presented with symptoms (rash), and neither of the breast-milk samples was 
positive by cell culture (Besnard et al., 2014). Three case reports have described identification 
of infectious ZIKV particles in breast milk when women are infected close to the time of 
delivery, this includes one case in New Caledonia in 2015, one case in Brazil in early 2017, 
and one case from Venezuela in late 2017 (Blohm et al., 2018; Blohm et al., 2017; Dupont-
Rouzeyrol et al., 2016; Sotelo et al., 2017). However, only for the most recent case in 
Venezuela has mother to child transmission through this means been proposed (Blohm et al., 
2017; Blohm et al., 2018).  
 
• Sexual  
ZIKV RNA has been detected in human semen, vaginal fluid, and saliva and possible 
sexual transmission of the virus has been reported through penile-vaginal intercourse as well 
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as, limitedly, through both anal and oral intercourse. Sexual transmission of, and the 
susceptibility of different reproductive organs for, ZIKV has been well evidenced through in 
vitro studies, in vivo animal models, and also through observational studies in humans. A 
thorough summary of these studies has been given by various reviews, including in a living 
systematic review (continuously updated online at: http://zika.ispm.unibe.ch/stf/) by Counotte 
and colleagues that was published in May 2018 (Counotte et al., 2018; Moreira et al., 2017; 
Sherley and Ong, 2018).  
Sexual transmission of ZIKV was first evidenced in 2008 after a field-researcher 
working in Senegal returned to the United States and transmitted the virus to his wife (Foy et 
al., 2011).  Then again in the 2013 outbreak in French Polynesia, one possible case of sexual 
transmission was described (Musso et al., 2015).  Although sexual transmission is difficult to 
confirm in areas with ongoing circulation, following the large outbreak in the Americas and 
increased circulation/detection in Asia and Africa, the United States CDC and European 
Center for Disease Prevention and Control (ECDC) have reported more than 50 and 20 cases 
of confirmed sexual transmission in returning travelers, respectively (CDC, 2018a; Spiteri et 
al., 2017).  Most of these reports signify male to female infection, however, there has also 
been one case of potential female-to-male, and one case of male-to-male, transmission noted 
(Counotte et al., 2018; Davidson et al., 2016; Deckard et al., 2016). In 2016, a report of ZIKV 
persistence (detection of viral RNA) in semen for greater than 6 months prompted interim 
guidelines from the WHO for use of protection for prevention of sexual transmission for at 
least this length of time (Nicastri et al., 2016; WHO, 2016c). However, the review from 
Counotte and colleagues indicates that when bringing together many observational studies in 
humans, ZIKV RNA and ZIKV infectious viral particles are present for a median of 40 days 
(95%CI: 30-49) and 10 days (95%CI: 1-20), respectively (Counotte et al., 2018). Within this 
review, a clear demonstration of the rapid reduction of infectious virus shedding (indicating 
risk of transmission) comes from a study of 184 men, which found that infectious virus was 
only present in three participants in whom semen was collected within 30 days of illness onset 
(Mead et al., 2018). These findings have led to proposed changes (i.e. to decrease the time 
period protection is needed) to the guidelines on prevention of sexual transmission (Vouga et 
al., 2018).  
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• Transfusion associated 
Blood transfusion was first proposed as a possible route of ZIKV transmission 
following the outbreak in French Polynesia in 2013, where 3% of asymptomatic blood donors 
were found to be RNA-positive during the acute phase of the epidemic (Musso et al., 2014). 
This possibility was confirmed with the reports of three cases in Brazil that were potentially 
linked to platelet transfusion in 2016 (Barjas-Castro et al., 2016; Motta et al., 2016). This risk 
has led to various agencies releasing guidelines for prevention of transfusion associated ZIKV 
transmission through screening (FDA, 2016a; FDA, 2016b; WHO, 2016d; AABB, 2016), as 
well as research towards new strategies to inactivate ZIKV in plasma and platelet components 
(Blumel et al., 2017; Santa Maria et al., 2017).  
 
• Other 
Finally, the occurrence of one non-sexual secondary case has been reported in the 
United States. In this case, a 73-year old man with comorbidities, who had recently returned 
from Mexico, fell fatally ill with ZIKV; quantitative tests for ZIKV RNA indicated that the 
patient was highly viremic. A healthy 38-year old man who visited the case in hospital came 
down with rash and other ZIKV symptoms five days later, with urine analysis showing 
positivity for ZIKV IgM. It has therefore been proposed that transmission may have occurred 
through either sweat or tears (Swaminathan et al., 2016).  
 
2.1.7 Clinical and neurological manifestations of ZIKV in humans 
• Symptomatic infection 
The incubation period of ZIKV in humans following mosquito-borne transmission is 
estimated to be a median 6 days; this was found by both a meta-analysis including data for 25 
persons, as well as a study of 79 returning travelers (Krow-Lucal et al, 2017; Lessler et al., 
2016;). There is not yet a reliable estimate of incubation period for cases of sexual 
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transmission (Counotte et al., 2018). Symptoms of ZIKV infection last for approximately one 
week and typically include maculopapular rash, fever, headache, itching, joint pain, muscle 
pain, conjunctivitis, pain behind the eyes, fatigue, and edema of hands or feet. Rash is 
typically the most commonly experienced symptom, followed sometimes by fever (self-
reported), arthralgia, or headache (Brasil et al., 2016; Cerbino-Neto et al., 2016; Duffy et al., 
2009; Hoen et al., 2018; Li et al., 2017; Mallet et al., 2016; Read et al., 2018;). Some example 
symptom distributions from studies in the general adult population, pregnant women, and 
children can be seen in Table 1.  A slightly itchy rash associated with ZIKV infection typically 
appears within a few days of symptom onset, can be specific to certain parts of the body or be 
generalized, and fades after approximately one week (He et al., 2017).  
 
Table 1: Sample symptom distributions for persons with ZIKV infection in the general 
adult population, pregnant women cohort studies, and children 
 General Adult Population Pregnant Women Children  
 Yap, 
Micronesia  
French 
Polynesia 
Brazil 
 
Brazil 
 
FTA Puerto 
Rico 
(≤17 yrs) 
Singa-
pore 
(≤16 yrs) 
 
# Persons 31 297 57 134 546 351 14 
Maculopapular 
rash 
90% 93% 98% 100%*
* 
95% 80% 100% 
Itching NR NR 56% 90% 48% 59% NR 
Fatigue NR 78% NR 52% NR 67% NR 
Fever 65%* 72%* 67%* 27% 23% 99%* 93%* 
Arthralgia 65% 65% 58% 62% 55% 37% 14% 
Conjunctivitis  55% 63% 39% 58% 36% 58% 29% 
Myalgia 48% 44% 49% 41% 23% 37% 21% 
Headache 45% 46% 67% 54% 30% 64% 21% 
Retro-orbital 
pain 
39% 16% 40% 41% 19% 38% NR 
Edema 19% 47% 23% 55% 19% NR NR 
Publication Duffy et al., 
2009 
Mallet et 
al., 2016 
Cerbino-
Neto et 
al., 2016 
Brasil 
et al., 
2016 
Hoen et 
al., 2018 
Read et 
al., 2018 
Li et al., 
2017 
*Fever is self-reported or self-reported/measured by a clinician mix **Rash was an inclusion criteria 
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A recent meta-analysis combined results from 23 studies to report that the proportion 
of asymptomatic cases of ZIKV infection was approximately 62%; however, the authors 
concluded that due to considerable heterogeneity in studies included, this estimate is not 
likely robust (Haby et al., 2018). In the same meta-analysis, three cross-sectional 
seroprevalence studies were included; these were performed in Yap Island, French Polynesia, 
and Puerto Rico and found asymptomatic proportions of 82% (95%CI: 81-83), 49% (95%CI: 
43-55), and 57% (48-66) (Aubry et al., 2017; Duffy et al., 2009; Haby et al., 2018; Lozier et 
al., 2017).  A study in 114 ZIKV positive persons in Puerto-Rico found that being female, 
younger than 40, and having asthma, were all factors significantly associated with having 
symptomatic infection (Lozier et al., 2018). 
 
• Severe manifestations  
In the first mouse models of ZIKV infection, performed by Dick in the late 1940s, 
marked neurotropism and mortality were seen when the brains of mice were inoculated 
repeatedly with strains of the virus recovered from infected rhesus monkeys and mosquitoes 
(Dick, 1952). However, the first severe manifestation of ZIKV infection in humans that was 
recorded was a case (female, early 40s) of GBS observed during the 2013-2014 outbreak in 
French Polynesia (Oehler et al., 2014). GBS is a severe autoimmune condition that affects 
peripherals nerves, causing paralysis and often requiring respiratory support in intensive care 
units; while most patients recover within a period of months, it can be fatal where adequate 
supportive care is not available (Hughes and Cornblath, 2005). In total, 42 cases of GBS were 
reported after the outbreak in French Polynesia; this was considered unexpectedly high, and 
was retrospectively linked directly to ZIKV exposure through a case-control study (Cao-
Lormeau et al., 2016; Watrin et al., 2016). Following the establishment of GBS as a severe 
clinical manifestation of ZIKV infection, descriptions of linked cases and increased incidence 
were reported in many places in the Americas during the outbreak period there (Araujo et al., 
2016; Dirilkov et al., 2017; Dos Santos et al., 2016; Parra et al., 2016; Roze et al., 2017). A 
multi-country report, including studies from South America as well as Yap Island and French 
Polynesia, estimated the risk of GBS to be 2 per 10000 cases (0.02%) (Mier et al., 2018). 
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There are four subtypes of GBS (Hughes and Cornblath, 2005), and two of these, including 
acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal 
neuropathy (AMAN), have been indicated in ZIKV infection, however, so far, the relative 
frequency of each varies depending on the case series being considered (Cao-Lormeau et al., 
2016; Parra et al., 2016).  
During this recent outbreak period, other severe manifestations, such as autonomic 
disorders, cardiac anomalies, encephalopathy, meningoencephalitis, have also been linked to 
ZIKV infection in very rare cases (Abdalla et al., 2018; Brito Ferreira et al., 2017; Carteaux et 
al, 2016; Malta et al., 2017; Rodriguez et al, 2018; Roth et al, 2017; Roze et al., 2016). Fatal 
cases of ZIKV have also been reported (Azevedo et al., 2016; Sarmiento-Ospina et al., 2016; 
Swaminathan et al., 2016).  
 
• ZIKV-related birth defects  
One of the most concerning manifestations of ZIKV infection is the occurrence of 
neurological defects in fetuses and infants whose mothers are infected with the virus during 
pregnancy. This was first noticed in Brazil in 2015, signalled by an unprecedented rise in 
incident cases of neonatal microcephaly (a small head for gestational age) that coincided 
regionally and temporally with the ZIKV epidemic (Ministério da Saúde (Brazil), 2015b; 
Kleber de Oliveira et al., 2016). As described in the previous part of this thesis that outlined 
mother to child transmission of ZIKV, discovery of ZIKV RNA in amniotic fluid as well as in 
brain and placental tissues of pregnancies/foetuses/infants where there was evidence of 
microcephaly, further evidenced this potential link (Calvet et al., 2016; Martines et al., 2016; 
Melo et al., 2016; Mlakar et al., 2016). In late 2015, the Brazilian Ministry of Health declared 
a possible connection between the birth defect and ZIKV infection (Ministério da Saúde 
(Brazil), 2015c). The World Health Organisation declared a Public Health Emergency of 
International Concern in early 2016, with the aim to encourage further clarification (through 
research) on this and other severe side effects of ZIKV (Heymann et al., 2016; WHO, 2016a).  
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Since that time, some robust case-control studies examining the association between 
ZIKV infection during pregnancy and microcephaly have been carried out, and a causal link 
between the two has been solidified (de Araujo et al, 2018; Krow-Lucal et al., 2018; 
Rasmussen et al., 2016; Santa-Rita et al, 2017). Case series and imaging studies performed 
during the ZIKV outbreak in the Americas identified a series of neurological and ocular 
abnormalities that could be linked to infection during pregnancy. Moore and colleagues (2017) 
brought these findings together to give a working definition of ‘Congenital Zika Syndrome’ 
(CZS), which includes: severe microcephaly with collapsed skull, specific structural brain 
abnormalities (i.e. calcifications, lissencephaly, ventriculomegaly, corpus callosum anomalies, 
underdeveloped cerebellum, decreased white matter, thin cerebral cortex), congenital 
contractures (i.e. club foot, arthrogryposis), eye abnormalities (i.e. structural ocular anomalies, 
cataracts, posterior eye anomalies), early-life presentation of neurological sequelae (i.e. 
increased or decreased muscle tension, irritability, swallowing problems, motor and cognitive 
disabilities, hearing and visual impairment, epilepsy) (CDC, 2018b). This describes the pattern 
of unique features that can be seen in fetuses/infants that are affected in-utero by ZIKV, to aid 
in differential diagnosis, but does not include all possible effects of ZIKV infection on the 
fetus. Other reported conditions in infants with ZIKV exposure in-utero include things such as 
cardiac anomalies, abnormal sleep findings, neurogenic bladder, respiratory problems, 
digestive disorders, and hydrocephalus (Angelidou et al., 2018; Carvalho et al., 2017; 
Cavalcanti et al., 2017; Costa Monteiro et al., 2018; Moura da Silva et al., 2016; Pinato et al., 
2018; van der Linden, Pessoa et al., 2016; van der Linden, Filho, et al., 2016). Features of 
CZS, such as structural brain abnormalities and consequences of central nervous system 
dysfunction can also appear in the absence of microcephaly (Cardoso et al., 2018; van der 
Linden, Pessoa et al., 2016). It was previously thought that neural tube defects were linked to 
ZIKV infection, but this is no longer considered so (Delaney et al., 2018; Rice et al., 2018).  
The proposed risk of birth defects following ZIKV infection, as investigated by 
prospective cohort studies, varies greatly, and unfortunately, there has been limited use of 
control groups in order to estimate the baseline risk of similar defects in the absence of ZIKV 
infection. Initially, a cohort study of 125 pregnant women with symptomatic (i.e. rash) ZIKV 
infection in Brazil estimated a 46% risk of overall adverse foetal outcomes, which was 
significantly higher than the 11.5% found in their group of 61 ZIKV non-infected women 
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(Brasil et al., 2016).  In the United States Zika Pregnancy and Infant Registry (USZPIR), a 5% 
overall prevalence of birth defects possibly linked to ZIKV infection was determined through 
follow-up of 2549 completed pregnancies (Shapiro-Mendoza et al, 2017). In our own study, in 
the FTA, we reported on foetal/infant outcomes up until the time of delivery for 546 ZIKV-
infected pregnant women and concluded a 7% risk of neurological and ocular birth defects 
(Hoen et al., 2018); this paper will be presented in full later in this thesis. In both the USZPIR 
and our own cohort study in the FTA, there are no prospective ZIKV negative control groups 
with which to compare.  One ultrasound-based study in French Guiana followed 301 ZIKV 
exposed and 399 non-exposed pregnancies to examine the risk of foetopathy. This study found 
central nervous system abnormalities to be 9% and 4% in the ZIKV exposed versus unexposed 
groups, respectively (Pomar et al., 2017). In Colombia, a retrospective cohort study of 86 
ZIKV-exposed pregnancies, without a control group, found a 2% risk of adverse neurological 
outcomes; all of these were microcephaly cases without any other neurological signs 
(Rodriguez-Morales et al., 2018).   
So far, only one study, a cohort follow-up of infants from the USZPIR, has evaluated 
the risk of presentation of neurological, visual, and auditory sequelae in the first year of life. 
Here, Rice and colleagues (2018) evaluated outcomes for 1450 infants whose mothers had 
possible ZIKV infection during pregnancy, and found that 8% of infants who had no apparent 
ZIKV-associated defect at birth presented with a possible or confirmed neurodevelopmental 
abnormality. Multiple longer term cohort studies following infants up until 5-7 years of age, 
ideally with control groups, will be needed to draw a consensus on the proportion of infants 
who have consequences of ZIKV infection in-utero.   
The risk of having an infant with birth defects appears to be highest in the first, 
followed by the second and third, trimesters of pregnancy (Brasil et al, 2016; Cauchemez et al, 
2016; Hoen et al, 2018; Pacheco et al, 2016; Pomar et al, 2017; Shapiro-Mendoza et al, 2018).  
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2.1.9 Prevention and Treatment of ZIKV  
 Currently, the main protective strategies against ZIKV infection are the prevention of 
mosquito bites and use of protection with sexual partners with recent or current infection. The 
vector control strategies recommended by the WHO include employment of traditional 
methods such as insecticide spraying (both targeted residual and space), larvicide use and 
reduction of mosquito breeding sites, and personal protection against bites (WHO 2016e). In 
addition, some newer control methods, such as introduction of Wolbachia spp bacteria into 
populations of Ae aegypti mosquitoes to reduce their ability to transmit ZIKV, and the release 
of mosquitoes with dominant lethal genes to reduce mosquito population density through 
limiting the number that survive until adulthood, have both undergone some field testing in 
Latin America (Carvalho et al., 2015). Deployment of these novel methods are recommended, 
following carefully planned pilot phases, by both the WHO and others (WHO, 2016e; Yakob 
and Walker, 2016a; 2016b). For prevention of sexual transmission, it was originally 
recommended that there should be use of physical (e.g. male or female condom) protection 
during intercourse for 6 months following confirmed or probable ZIKV infection in men, 
however, due to recent findings that indicate that infectious virus is found for a much shorter 
period of time, this recommendation will likely change to be less conservative (Counotte et al., 
2018; Mead et al., 2018; Nicastri et al., 2016; Vouga et al., 2018; WHO, 2016b)  
Besides management of mild symptomatic infection through taking painkillers and 
antihistamines (Valentine et al., 2016), there is currently no approved treatment for ZIKV 
infection. Many studies have been performed which evaluate the repurposing of already 
approved drugs for treatment of ZIKV; Masmejan and colleagues (2018) have summarized 
this in a recent review. They describe that while many treatments that have been approved by 
the United States Food and Drug Administration (FDA) have demonstrated activity against 
ZIKV, few have been adequately tested and proven to be safe in pregnant women, which is a 
necessary consideration for a treatment that may eventually be recommended for large-scale 
use. There is equally no current treatment for CZS, although, early diagnosis through pre-natal 
diagnostic techniques and imaging, or screening at birth, may help to confer a better prognosis 
through allowing appropriate and rapid referrals to appropriate therapists. (Karoly et al., 2005; 
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Rice et al., 2018 ; Sonksen et al., 1991, Ventura et al., 2017; Wheeler, 2018; Yoshinaga-Itano 
et al., 2017) 
As with treatments against ZIKV, an important, but complicating, factor for 
development of a vaccine is its eventual use and safety in pregnant women. Various types of 
ZIKV vaccines are currently being evaluated, including deoxyribonucleic acid (DNA), 
inactivated virus, recombinant protein subunit, messenger RNA (mRNA), virus-like particles, 
and live-attenuated. Most of these candidates have only undergone testing in mice or 
macaques, with very few results from early-phase clinical trials being available. Mamejan and 
colleagues (2018) have summarized progress in vaccine research in a systematic review, for 
the period up until June 2018.  Multiple DNA vaccines have and are being evaluated in phase 
one clinical trials and two of these have demonstrated adequate safety to move to phase II 
trials (Gaudinski et al., 2018; Makhluf and Shresta, 2018; Tebas et al., 2017). Multiple 
inactivated virus vaccines, and at least one ZIKV mRNA lipid nano-particle vaccine is 
undergoing phase one clinical trials (Makhluf and Shresta, 2018; Modjarrad et al., 2017). 
Finally, in mid-August, 2018, the National Institutes for Health in the United States of 
America announced the first live-attenuated vaccine undergoing a phase one trial in 28 
healthy, non-pregnant, persons; however, live-attenuated vaccines are typically 
contraindicated in pregnant women (Masmejan et al., 2018; NIH, 2018). Phase one clinical 
trial results for vaccines are typically only available after at least one year, and these will need 
to be followed by phase II-IV trials. The length of time needed for proper evaluation, coupled 
with the increasingly limited ability to test vaccines in real-life populations due to decreasing 
ZIKV transmission, means that it will be quite some time before a vaccine for ZIKV is 
available for large-scale use (Cohen, 2018; Masmejan et al., 2018; PAHO, 2017b).  
 
2.1.10 ZIKV in Africa and Asia  
Circulation of ZIKV has been reported in many Southeast Asian countries as well as 
India, over the past years (Gu et al., 2017; Khongwichit et al., 2018; Ngwe et al., 2018; 
Perkasa et al., 2016; Pettersson et al., 2018; Sapkal et al., 2018; Tappe et al., 2015), and 
notable outbreaks occurred in Singapore and Vietnam in 2016 (Chu et al., 2017; Singapore 
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Zika Study Group, 2017). Besides the Cape Verde Islands off the western coast, no large 
outbreaks have been reported in recent years in Africa, even though seroprevalence studies 
indicate that transmission has, and still is, occurring in many countries across the continent 
(Gake et al., 2017; Herrera et al., 2017; Kraemer et al., 2017; Lourenco et al., 2018; Mathe et 
al., 2018; Rosenstierne et al., 2018; Sherman et al., 2018). Due to a possibly high at-risk 
population in these regions, there is a need for increased surveillance of ZIKV and related 
manifestations (Bogoch et al., 2016; Lucey, 2016; Siraj et al., 2017).  
There are two distinct lineages of ZIKV, an African and an Asian one. Descendants of 
the Asian lineage have led to the strain of ZIKV that circulated in French Polynesia and Latin 
America during the recent outbreaks (Pettersson et al., 2016). Differences in the pathogenicity 
of the older Asian strains and their descendants that led the Pacific islands and American 
outbreaks, has been proposed as the reason for the lack of large outbreaks and ZIKV-related 
birth defects seen in Asia over the past six decades. Additional research shows that the recent 
descendants of the Asian strain that have been implicated in the South Pacific and Americas 
outbreaks have specific mutations which lead to increased infection rates in mosquitoes as 
well as augmented cytopathic effects and ability to cause foetal brain defects in mice 
(Alpuche-Lazcano et al., 2018; Xia et al., 2018; Yuan et al., 2017; Zhange et al., 2017). 
However, there have been recent reports of microcephaly and CZS linked to earlier Asian 
isolates found in Thailand and Cambodia (Chu et al., 2018; Wongsurawat et al., 2018). In 
contrast, both Shao and colleagues (2017), and Smith and colleagues (2018), have 
demonstrated that the African ZIKV strain is more lethal in mice than older Asian isolates. In 
addition, Sheridan and colleagues (2018) reported that the African strains caused increased 
placental destruction, with the conclusion that infection with this strain early in pregnancy 
would likely lead to miscarriage rather than foetal defects. Some cases of microcephaly 
possibly linked to infection with the African ZIKV strain have been reported in Guinea-Bissau 
(Rosenstierne et al., 2018). One case of congenital ZIKV syndrome was recently described 
through infection in Angola, although this was caused by a newer Asian lineage of ZIKV, 
which would contain recent pathogenic mutations (Sassetti et al., 2018).  
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2.2 Investigations within the ZIKA-DFA cohort studies 
2.2.1 Description of the ZIKA-DFA-FE cohort study 
ZIKA-DFA-FE is a French acronym that stands for ‘Zika - Districts Francais 
d’Amerique - Femmes Enceintes’, which translates to ‘Zika - French Territories in the 
Americas - Pregnant Women’. Below is a description of the methods of this cohort study, 
taken from the first supplement our paper published in the New England Journal of Medicine 
(Hoen et al., 2018). A link to the full version of the supplement can be found here at link 1 in 
Appendix 4 at the end of this manuscript. This cohort study is registered with 
ClinicalTrials.gov (NCT02916732) and received ethics approval by the Comité de Protection 
des Personnes Sud-Ouest et Outremer III (CEBH2016/03). Funding for this study comes from 
the by the French Ministry of Health (Soutien Exceptionnel à la Recherche et à l’Innovation), 
Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases project (ANR-
10-LABEX-62-IBEID), the European Union’s Horizon 2020 Research and Innovation 
Program through the ZikAlliance consortium, and by the Institut national de la santé et da la 
recherche médicale (INSERM). 
 
• Background 
After the start of its rapid spread throughout South America in late 2015, it appeared 
obvious that an outbreak of ZIKV infection would be unavoidable in the Caribbean region. A 
study group headed by the Centre d’Investigation Clinique (CIC) Antilles therefore decided to 
implement a prospective observational study on ZIKV infection in pregnant women in the 
FTA, which include the islands of Guadeloupe, Martinique, Saint-Martin, and Saint-
Barthelemy and the territory of French Guyana in South America. The overall population of 
these territories is about 1.1 million persons. The purpose of these cohorts would be to follow 
enrolled women until their pregnancy outcomes (ZIKA-DFA-FE), and then to enroll their 
infants (ZIKA-DFA-BB – to be described very briefly at the end of this section). The 
Gynecology and Obstetrics departments of the public hospitals of Pointe-à-Pitre, Basse-Terre, 
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and Saint-Martin in Guadeloupe, Cayenne and Saint-Laurent-du-Maroni in French Guyana, 
and Fort-de-France in Martinique participated in this study. 
• Research questions 
The main objectives of the ZIKA-DFA-FE study were to describe the clinical 
manifestations of ZIKV infection during pregnancy, estimate the proportion of microcephaly 
and other neurological defects among fetuses and infants whose mothers had been infected 
with ZIKV infection during pregnancy, identify other complications not yet known as possible 
complications of ZIKV infection, identify factors associated with birth defects /other 
complications, with a focus on the roles of gestational age at the time of ZIKV infection, 
symptomatic ZIKV infection, and environmental cofactors. 
 
• Cohort Recruitment and Sample Size Considerations 
ZIKA-DFA-FE  
There was no predetermined sample size for the pregnant women cohort, rather, the 
aim was reach and enroll the highest proportion of ZIKV infected pregnant women during the 
epidemic period in the FTA.  There were four recruitment methods used. Each recruitment 
method applied to all women living in the FTA whose pregnancy overlapped with the ZIKV 
epidemic period for any amount of time. Figure 1 shows the various recruitment methods used 
in ZIKA-DFA-FE and ZIKA-DFA-BB. The first recruitment method (RM1) was the 
identification of pregnant women who presented with clinical symptoms of acute ZIKV 
infection and/or tested positive for ZIKV through serology or RT-PCR, at any time during 
their pregnancy, either at a local hospital or during their routine antenatal visits. In a second 
recruitment method (RM2) study enrollment was proposed to all pregnant women in whom a 
fetal defect was detected during routine pregnancy ultrasound monitoring in the FTA during 
the epidemic period; this was independent of whether or not they had been symptomatic or 
tested positive for ZIKV during their pregnancy. If not already enrolled through RM1 or RM2, 
then any woman who had been pregnant during the epidemic period would still be proposed 
enrollment on the day of their pregnancy outcome, whether this outcome was delivery of a 
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live birth (RM3), or delivery of a still birth, experiencing a miscarriage or undertaking a 
medically indicated abortion (RM4).  In order to maximize enrolment, extensive efforts were 
made by the study team to sensitize all of the local obstetrician/gynecologists to the study 
objectives, and include all of the large hospitals in the study regions. In this way, doctors 
throughout the regions could propose enrolment to all women as early as possible in their 
pregnancy when they presented for routine antenatal care. 
As part of ZIKA-DFA-FE, a serum biobank was also established, which aimed to 
collect samples from all pregnant women in the FTA during the ZIKV epidemic period once 
per trimester of pregnancy. This would allow eventual confirmation of the trimester of 
seroconversion for each pregnant woman included in the study. Constitution of this biobank 
was made possible through referral by all locally sensitized gynecologists/obstetricians and 
hospital doctors. Indeed a validated tool for ZIKV serology was not available when ZIKA-
DFA-FE study began. Therefore, the tubes that were collected by the laboratories in each 
region were transferred to the Centres de Ressources Biologiques of Martinique and 
Guadeloupe, which served as biobanks in these territories. In French Guyana, an in-house 
serological test was made available from the beginning of the ZIKV outbreak by the local 
Institut Pasteur, which provided results in real time.  
 
 
Figure 1: Methods of recruitment into ZIKA-DFA-FE. Note: TOP = termination of pregnancy 
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• Follow-up of enrolled participants and data collection 
Through RM1 and RM2 of ZIKA-DFA-FE, women could be enrolled at any moment 
during their pregnancy. During their enrollment visit, women were interviewed for 30 minutes 
regarding their life-style practices (e.g. smoking, alcohol intake, mosquito bite exposure) and 
medical and obstetric history, followed by collection of samples for laboratory testing. 
Following this, a dedicated obstetrician performed one ultrasound per month on participants 
and asked the women at each visit about any complications experienced, biological tests and 
examinations done, and treatments received between visits. These visits lasted approximately 
15 minutes each. This meant that there was one enrollment visit and 0-6 ultrasound/follow-up 
visits per participating woman, depending on the moment in her pregnancy at which she was 
recruited. If the woman had been enrolled through RM2 (fetal defect had been detected by 
ultrasound), it was possible that the parents would opt for termination of pregnancy prior to 
term; in this case follow-up visits would also occur monthly until the day of termination of 
pregnancy, at which point, further information and samples would be collected if the mother 
agreed. If recruited into ZIKA-DFA-FE at the time of delivery through RM3, then all data 
were collected at the time of recruitment (i.e. one visit); this included retrospective data about 
events occurring/exposures during pregnancy as well as the pregnancy outcome and collection 
of biological samples. Similarly if women were being recruited into the study due to 
experiencing a miscarriage, stillbirth or termination of pregnancy (RM4) all data and sample 
collection was done at one moment on the day of recruitment. The specific information 
collected for each pregnant woman enrolled and at the timing of this, is indicated in the 
supplementary material (see link 1 in Appendix 4) 
 
• Data management and statistical analysis 
Paper forms were used to collect data of participants in hospitals, clinics, and 
maternities, which were then input into an electronic case report form (CRF) implemented 
under Ennov Clinical (Clinical Data Management System). Data was systematically checked, 
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with original records being retrieved to answer queries. The statistical analysis performed on 
the database varies by topic of analysis and is/will be described separately for each paper 
produced from these cohorts.  
 
• Infant cohort (ZIKA-DFA-BB) 
Women with live born infants were proposed enrolment in a follow-up cohort study 
entitled ZIKA-DFA-BB (BB = bébé = baby). This included infants with or without 
abnormalities present at birth, as well as a control group of infants born to ZIKV-uninfected 
mothers. Enrolled infants would be followed for two years in order to observe the clinical and 
developmental evolution of those with congenital CZS identified at birth and evaluate any 
late-appearing abnormalities in infants whose mothers were infected with ZIKV during 
pregnancy, but who were apparently normal at birth. This cohort study is ongoing and will not 
be discussed further in this thesis.  
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2.2.2 Original research (full article): Estimation of ZIKV-related birth defects in an 
epidemic region 
In the paper described below, we demonstrate the risk of fetal abnormalities following 
confirmed ZIKV infection during pregnancy in a large prospective cohort of 546 women from 
the FTA.  The population from this analysis was drawn from the first recruitment method (i.e. 
proposal of the study to ZIKV symptomatic pregnant women presenting at hospital or clinics) 
of the ZIKA-DFA-FE cohort study, which has been described in the previous section. At the 
time that we produced this analysis, two large prospective cohort studies had already been 
published on the same topic. These two studies were from Brazil and the United States, and 
the estimates that had been presented by each differed greatly. In Brazil, 125 ZIKV 
symptomatic pregnancies were followed, with an eventual risk of adverse outcomes of 46%. 
Alternatively, in the first report of the USZIPR, a Zika-related birth defect risk estimate of 6% 
was derived. Considering this stark variation, further studies on this subject were (and still are) 
warranted. 
One of our aims in formulating this manuscript was to be as comparable as possible 
with the case-definitions and abnormalities-categories used by the prospective studies that had 
been published before us. Ideally this would facilitate bringing the results of studies on these 
topics together to aid in creating consensus estimates; this would be useful for clinical practice 
and policy. This also included my taking an in-depth look at birth defects classifications as 
presented by the research group in Brazil in their supplementary materials of their article, and 
creating our own supplement (see link 1 in Appendix 4) with a similar format. The idea behind 
this was to enable detailed comparison of the individual conditions for each infant that were 
considered as birth defects in order to see whether or not this would explain the differences 
being seen.   
Eventually, our own estimate of an approximate 7% risk of Zika-related birth defects 
was closely aligned with that of the USZIPR. The reasons for the large differences between 
the estimates of the FTA and USZIPR studies, when compared to the original study performed 
in Brazil, remain largely elusive, but will be featured in some discussions later in this thesis 
manuscript. The PDF of this article can be found in Appendix 5.  
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Pregnancy outcomes after Zika infection in the French territories of America 
Bruno Hoen, Bruno Schaub, Anna L Funk, Vanessa Ardillon, Manon Boullard, André Cabié, 
Caroline Callier, Gabriel Carles, Sylvie Cassadou, Raymond Césaire, Maylis Douine, Cécile 
Herrmann-Storck, Philippe Kadhel, Cédric Laouenan, Yoann Madec, Alice Monthieux, 
Mathieu Nacher, Fatiha Najioullah, Dominique Rousset, Catherine Ryan, Kinda Schepers, 
Sofia Stegmann-Planchard, Benoit Tressières, Jean-Luc Voluménie, Samson Yassinguezo, 
Eustase Janky, Arnaud Fontanet 
 
• Abstract 
Background: The risk of ZIKV-related congenital neurological defects varies from 6% 
to 42% in the two largest studies of pregnant women published so far. The aim of this study 
was to estimate this risk in pregnant women with symptomatic ZIKV infection in the French 
territories of America. Methods: From March 2016 onwards, pregnant women diagnosed with 
symptomatic and PCR-positive ZIKV infection were enrolled in this prospective cohort study. 
The analysis included all data up to April 27, 2017, date of the last delivery in the cohort. 
Results: Among the 546 women included in the analysis, there were 28 (5.0 %) pregnancy 
losses and 527 live births. Neurological and ocular defects potentially associated with ZIKV 
infection were seen in 39 (7.0%, 95% confidence interval = [5.0% - 9.5%]) fetuses and 
infants: 10 terminations of pregnancy, 1 stillbirth, and 28 live births. Microcephaly was 
detected in 32 (5.8%) infants and fetuses, of which 9 (1.6%) were severe (-3 standard 
deviations (SD)). Neurological and ocular defects were more common when ZIKV infection 
occurred during the first trimester (24/189, 12.7%), compared to infection during second 
(9/252 = 3.6%) or third trimester (6/114 = 5.3%) (P = 0.001). Conclusions: Among pregnant 
women with PCR-confirmed symptomatic ZIKV infection, birth defects potentially associated 
with ZIKV infection were present in 7% of fetuses and infants. They were more frequent in 
fetuses and infants whose mothers had been infected early in pregnancy. Longer-term follow-
up of infants is required to assess any manifestations not detected at birth. 
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• Introduction 
It has been recognized recently that ZIKV infection during pregnancy can cause severe 
birth defects (Baud et al., 2017), including microcephaly (Melo et al., 2016), other brain 
defects (Brasil et al., 2016), and the Zika congenital syndrome (Moore et al., 2017). However, 
the magnitude of this risk is not clearly defined. It was estimated above 40% in a prospective 
observational study of women who developed symptomatic ZIKV infection during pregnancy 
in Brazil (Brasil et al., 2016). In the USZIPR, it was 6% overall and 11% when ZIKV 
exposure occurred during the first trimester (Honein et al., 2017). The latter risk has been 
updated recently to 15% (Reynolds et al., 2016). The ZIKV epidemic in the French Territories 
of America began in early 2016 and presented another opportunity to assess the risk of ZIKV-
related congenital neurological defects in a population of pregnant women living in a territory 
exposed to a ZIKV outbreak. The centralized antenatal and maternal facilities enabled 
enhanced surveillance of all pregnancies during the ZIKV epidemic. This study presents the 
pregnancy outcomes of a cohort of women living in the French Territories of America, who 
developed symptomatic, laboratory-confirmed ZIKV infection during pregnancy.  
 
• Patients and methods 
Overview of the ZIKA-DFA-FE study (see link 1 in Appendix 4) 
ZIKA-DFA-FE is a cohort study that uses four different recruitment methods in an 
attempt to capture all women whose pregnancies have overlapped with the ZIKV epidemic 
period in the French Territories of America. This study is registered with ClinicalTrials.gov 
(NCT02916732) and received ethics approval by the Comité de Protection des Personnes Sud-
Ouest et Outremer III (CEBH2016/03). All participants provided written informed consent.  
A key component of ZIKA-DFA-FE cohort is the prospective follow-up, until the end 
of pregnancy, of women who developed clinical symptoms of ZIKV infection during 
pregnancy. In accordance with the guidelines by the French High Council of Public Health 
and the National College of Gynecologists and Obstetricians that were released on January 25, 
2016 and February 5, 2016, respectively, whenever a pregnant woman presented to the 
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outpatient clinic or emergency room of a participating center with symptoms consistent with 
acute ZIKV infection, she was examined clinically and had blood and urine sampled for 
confirmation of recent ZIKV infection (Haut Conseil de la Santé Publique, 2017; Collège 
National Professionnel de Gynécologie et Obstétrique, 2016). 
 
Enrolment criteria  
Pregnant women with suspected ZIKV infection were referred to the prenatal diagnosis 
center in each territory, where they were tested for ZIKV infection and invited to consent to 
participate in ZIKA-DFA-FE. Women were included in this analysis if they met all of the 
following criteria: 1) ongoing pregnancy at any gestational age; 2) development of clinical 
symptoms consistent with acute ZIKV infection, with at least one of pruritic skin rash, fever, 
conjunctival hyperemia, arthralgia, and myalgia; and 3) laboratory confirmation of recent 
ZIKV infection, based on a positive ZIKV RT-PCR test on serum and/or urine. The date of 
ZIKV infection was considered to be the date of the first ZIKV-related symptom onset. 
 
Follow-up and cohort endpoints 
Once enrolled, women underwent monthly clinical and ultrasound examinations until 
reaching a pregnancy outcome. During the monthly follow-up visits, the clinician also 
inquired as to events that may have occurred (e.g. pregnancy complications, treatments 
received) since the previous visit. If a fetal defect was identified during ultrasound follow-up, 
foetal magnetic resonance imaging (MRI) was performed and a close laboratory and 
ultrasound follow-up was conducted, as reported elsewhere (Pomar et al., 2017; Schaub, 
Gueneret et al., 2017; Schaub, Vouga, et al., 207). The endpoint for each woman enrolled in 
the cohort was the pregnancy outcome: delivery of live born infants with or without birth 
defects, miscarriage, medical termination of pregnancy (TOP), or stillbirth. 
 
Data and sample collection in mothers 
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During the enrolment visit, sociodemographic data were collected for each woman. 
These included age, ethnic origin, residence, education, professional activity, and lifestyle 
factors. Clinical information including the number of previous pregnancies and live births, 
prior history of adverse pregnancy outcomes, significant medical history, body mass index, 
symptoms of ZIKV, gestational age, and any clinically significant medical event during 
pregnancy was collected during this baseline visit, as well as a blood and urine sample.  
Laboratory tests included detection of ZIKV by RT-PCR (Real Star® Zika Virus RT-
PCR Kit 1.0, Altona diagnostics) in blood and urine at baseline in all women and at the end of 
pregnancy in case of fetal death, TOP, or stillbirth. In addition, results of TORCH serologic 
tests routinely performed during pregnancy in the French territories of America were recorded, 
which included syphilis, toxoplasmosis, rubella, and HIV (Tolan, 2008; de Jong et al., 2013). 
Cytomegalovirus (CMV) serology was performed only on an elective basis, when fetal 
abnormalities were detected. 
 
Data collection in infants 
For live born infants, maternal and cord blood samples were collected on the day of 
delivery and sera were frozen. From these infants, the following information was also 
collected on the day of birth: gestational age, length, weight, and head circumference, 
Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) score at 5 minutes of life, 
and a standardized clinical examination.  
 
Pregnancy outcomes 
Pregnancy outcomes included live birth delivery (with or without abnormalities) or 
pregnancy loss through miscarriage, TOP, or stillbirth. For purpose of comparability, 
miscarriage was defined as intrauterine fetal death earlier than 20 weeks gestational age. 
Stillbirth was defined as intrauterine fetal death at or after 20 weeks gestational age or 
intrapartum death during delivery (Honein et al, 2017).  
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Likewise, we summarized our data into the two mutually exclusive categories of birth 
defects potentially associated with ZIKV infection: 1) brain abnormalities with or without 
microcephaly regardless of the presence of additional birth defects; and 2) neural tube defects 
and other early brain malformations, eye abnormalities, and other consequences of central 
nervous system dysfunction among those who had neither evident brain abnormalities nor 
microcephaly (Honein et al, 2017). Consequences of central nervous system dysfunction 
included conditions such as arthrogryposis, clubfoot, congenital hip dysplasia, and congenital 
deafness. In case of live birth, microcephaly was defined as moderate when head 
circumference was between – 3 SD and – 2 SD and severe when head circumference was < -
3SD, based on the International Fetal and Newborn Growth Consortium for the 21st century 
(INTERGROWTH-21st) standards (http://intergrowth21.ndog.ox.ac.uk/) for gestational age 
and sex. Moderate microcephaly was further defined as proportionate or disproportionate 
depending on whether the neonate was small for gestational age (von der Hagen M, 2014). 
Small for gestational age was defined as having a weight < -1.28 SD according to the 
INTERGROWTH-21st standards for gestational age and sex. In case of pregnancy loss or 
medical TOP, autopsy measurements when available and the last ultrasound data were used to 
assess microcephaly, which was defined as a head circumference of < -3SD when ultrasound 
data were considered. 
In addition, we specified the number of cases who had any of the severe neurological 
birth defects that are included in the currently proposed definition of CZS, i.e. one or more of 
severe microcephaly (< -3SD), brain abnormalities with a specific pattern of damage (e.g. 
calcifications, ventriculomegaly, cortical malformations), damage to the back of the eye, joints 
with limited range of motion (e.g. clubfoot), or hypertonia that restricts body movement (e.g. 
arthrogryposis) (Moore et al, 2017). 
Statistical analysis 
The proportion of fetuses/infants with birth defects potentially associated with ZIKV 
infection was estimated by trimester of ZIKV infection for pregnant women, and compared 
across the three groups using Fisher’s exact test. Data were analyzed by using Stata 13 
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(StataCorp LP Lakeway, Texas, United States of America). All authors vouch for the 
completeness and accuracy of the data and analyses presented. 
 
• Results 
From March 2, 2016 onwards, 1152 women were evaluated at prenatal diagnosis 
centers for suspicion of acute ZIKV infection. Of these, 108 were not enrolled in ZIKA-DFA-
FE (36 refusals, 48 lost during the recruitment process, 16 less than 18 years, and 8 living 
outside the French territories of America), 458 had a negative ZIKV RT-PCR, and 25 had no 
symptoms of the pre-specified list, leaving 561 women with symptomatic, PCR-confirmed, 
ZIKV infection for analysis in this study (Figure 2). Of these, six (1.1%) women were 
excluded after updated information on eligibility criteria and nine (1.6%) women were lost to 
follow-up. For the latter 9 women, fetal ultrasound follow-up was normal, with the last 
available ultrasound from the 3rd trimester for 5 women and from the 2nd trimester for 4 
women. Among the 546 women whose pregnancy outcome was known, there were 9 twin 
pregnancies. We were therefore able to describe pregnancy outcomes for 555 infants and 
fetuses (Figure 2).  
The 9 twin pregnancies resulted in 17 live births and one miscarried fetus. No 
abnormalities were detected in any of the live born neonates from twin pregnancies. In the 
twin pregnancy that resulted in one live birth and one miscarried fetus, the mother had been 
infected with ZIKV during the sixth week of pregnancy, and the loss of one fetus occurred at 
10 weeks of gestation, with the other fetus being carried until 41 weeks of gestation and born 
healthy without any abnormalities. Table 2 shows the main characteristics of the 546 women 
(mean age, 29.7 years) with known pregnancy outcomes. Table 3 shows the main 
characteristics of ZIKV infection in these women. Co-infections with TORCH 
microorganisms are summarized in Table 4.  
 
 
! 56!
                       
Figure 2: Disposition of the 561 pregnant women enrolled in ZIKA-DFA-FE with 
symptomatic laboratory-confirmed ZIKV infection during the Zika outbreak in the 3 
French territories of America in 2016 
 
Overall, the mean number of fetal ultrasound examinations performed between the 
date of ZIKV infection and pregnancy outcome was 3.5 and 2.2 when ZIKV infection 
occurred during the first and the second trimester, respectively. There were 28 (5.0%) 
pregnancy losses, including 11 miscarriages, 10 medical TOP, 6 stillbirths, and 1 voluntary 
abortion. Among the 527 live births, 75 neonates (14.2%) were delivered through emergency 
caesarian section. There were 31 (5.9%) infants hospitalized immediately after birth, 7 of 
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whom (1.3%) were admitted into the neonatal intensive care unit. There were 8 (1.5%) infants 
with an APGAR score <7 at 5 minutes after birth. These proportions were not different by 
trimester of infection.  
Neurological and ocular abnormalities potentially associated with ZIKV infection were 
observed in 39 (7.0%, 95% confidence interval = [5.0%-9.5%]) infants/fetuses (28 live births, 
10 medical TOP, and 1 stillbirth). Microcephaly was detected in 32 (5.8%) infants/fetuses, 
with 9 (1.6%) severe, 9 (1.6%) moderate-disproportionate, and 14 (2.5%) moderate-
proportionate. Additional defects were observed in only one of the 23 infants with moderate 
microcephaly; this was a case of medical TOP with moderate-disproportionate microcephaly. 
Severe microcephaly or other brain abnormalities described in CZS were seen in 17 (3.1%) 
fetuses/infants. Neurological and ocular abnormalities were more frequent when ZIKV 
infections had occurred during the first trimester (n=24, 12.7%), compared to second (n=9, 
3.6%) or third trimester (n=6, 5.3%) (P = 0.001). The same was true for severe microcephaly 
(3.7%, 0.8%, 0.0%, respectively, P= 0.02), and Zika congenital syndrome (6.9%, 1.2%, and 
0.9%, respectively, P =0.002). The risk of birth defects potentially associated with ZIKV 
infection and those included within Zika congenital syndrome in Guadeloupe and Martinique 
were both similar, with 7.2% and 7.5%, and 3.6% and 2.8%, in each territory respectively. 
There was no statistical association between any potentially identifiable toxic pre-natal 
exposures (i.e., larvicides, repellants, alcohol, tobacco, illicit drugs) and birth defects.  
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Table 2: Demographic, social, and pregnancy characteristics of the 546 women with 
symptomatic and PCR-confirmed ZIKV infection 
 n % 
Residence  
French Guyana 24 4.4 
Guadeloupe 245 44.9 
Martinique 277 50.7 
Age in years, mean (SD; Range) 29.7 (6.2; 18-46) 
Occupation    
Student 23 4.2 
Artisan, merchant, business owner 30 5.5 
Highly qualified professional 55 10.1 
Intermediate professions 56 10.3 
Employee 177 32.4 
Labourer/Factory worker/Farmer 5 0.9 
Unemployed 187 34.2 
Missing/Does not wish to respond 13 2.4 
Medical history   
Arterial hypertension 23 4.2 
Diabetes 8 1.5 
Sickle cell disease 4 0.7 
Number of previous pregnancies     
0 131 24.0 
1 153 28.0 
2 126 23.1 
≥3 136 24.9 
Previous pregnancy adverse outcomes     
Congenital abnormalities 6 1.1 
Still births 10 1.8 
TOP 10 1.8 
BMI prior to pregnancy, mean (SD) 26.1* (6.3) 
Lifestyle practices during this pregnancy   
Alcohol consumption 2 0.4 
Drug use 6 1.1 
Smoking  23 4.2 
Use of mosquito repellents 445 81.5 
Use of larvicides 337 61.7 
Data are displayed as n (%) unless otherwise stated. *BMI missing in 90 women (16.5%) 
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Table 3: Characteristics of infection in the 546 women with symptomatic and PCR-confirmed 
ZIKV infection 
 
n %  
Trimester of symptomatic ZIKV infection   
First 185 33.9 
Second 249 45.6 
Third 112 20.5 
Number of symptoms at time of Zika 
diagnosis     
1 66 12.1 
2 111 20.3 
3 121 22.2 
4 95 17.4 
5+ 153 28.0 
Zika symptoms     
Rash 519 95.1 
Arthralgia 300 54.9 
Itching 263 48.2 
Conjunctival hyperemia  199 36.4 
Headache 161 29.5 
Myalgia 128 23.4 
Fever 123 22.5 
Limb swelling 104 19.0 
Pain behind eyes 102 18.7 
Petechiae 38 7.0 
Bleeding 1 0.2 
 
 
No fetus abnormality or birth defect was observed in any of the cases of co-exposure to 
ZIKV and syphilis (n=4), HIV (n=2), toxoplasmosis (n=3), or cytomegalovirus (n=1). Thirty-
one women had an amniocentesis performed during the course of their pregnancy, with 27 
karyotypings and 20 ZIKV RT-PCR assays. All karyotypes were normal except for one 
pericentric inversion of chromosome 2 and 7 ZIKV positive cases detected through RT-PCR. 
Additionally, 6 (1.1%) non-neurological birth defects were detected through this cohort and 
are described in the third supplementary appendix (see link 1 in Appendix 4) where a detailed 
description of all birth defects can be found.  
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Table 4. Results of ZIKV and TORCH testing in the 546 women with symptomatic and PCR-
confirmed ZIKV infection 
 
Time of Zika infection 
1st 
Trimester 
2nd  
Trimester 
3rd 
Trimester 
ZIKV RT-PCR Positive 185 100.0 249 100.0 112 100.0 
ZIKV RT-PCR 
      Blood and urine positive 121 65.4 159 63.9 66 58.9 
Blood only positive* 40 21.6 63 25.3 23 20.5 
Urine only positive** 24 13.0 27 10.8 23 20.5 
Syphilis                             # Women tested 150 81.1 206 82.7 87 77.7 
Positive 4 2.7 0 0 0 0 
HIV                                   # Women tested 161 87.0 210 84.3 97 86.6 
Positive 1 0.6 1 0.4 0 0 
Toxoplasmosis (IgM)      # Women tested 165 89.2 235 94.4 105 93.8 
Positive 1 0.6 0 0 2 1.9 
Rubella (IgM)                  # Women tested 152 82.2 222 89.2 97 86.6 
Positive 0 0 0 0 0 0 
Cytomegalovirus (IgM)  # Women tested 20 10.8 30 12.0 14 12.5 
Positive 0 0 1 3.3 0 0 
Any TORCH positive 6 3.2 2 0.8 2 1.8 
*Urine results are negative, unknown, or not done **Blood results were negative, unknown, or not done  
Note: in highly febrile women, DENV RT-PCR was performed on blood samples. Of the 267 tests performed, 
only 1 was positive.  
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Table 5: Pregnancy outcomes, by trimester of ZIKV infection, in the 546 pregnant women 
and 555 fetuses and neonates (9 twin pregnancies) 
 Trimester of Zika infection 
 1st  2nd  3rd  
NUMBER FETUSES AND NEONATES 189 252 114 
PREGNANCY OUTCOMES    
Pregnancy losses 24 (12.7) 4 (1.6) 0 
Miscarriage 11 (5.8) 0  
Voluntary termination of pregnancy 1 (0.5) 0  
Medical termination of pregnancy (TOP) 9 (4.8) 1 (0.4)  
Stillbirth 3 (1.6) 3 (1.2)  
Live births 
Live births with no prenatal ultrasound examination 
after ZIKV infection 
165 (87.3) 
 
13 (7.9) 
248 (98.4) 
 
28 (11.3) 
114 (100) 
 
55 (48.3) 
ABNORMALITIES IN ANY FETUS/ INFANT     
Neurological or ocular birth defects++ 24 (12.7) 9 (3.6)* 6 (5.3) 
Severe microcephaly 7 (3.7) 2 (0.8) 0 
Moderate microcephaly (disproportionate)** 4 (2.1) 2 (0.8) 3 (2.6) 
Moderate microcephaly (proportionate)** 8 (4.2) 4 (1.6) 2 (1.8) 
Intracranial calcifications 8 (4.2) 0 0 
Ventriculomegaly 7 (3.7) 1 (0.4) 0 
Lissencephaly 2 (1.1) 0 0 
Other brain abnormalities 8 (4.2) 1 (0.4) 0 
Neural tube defects 1 (0.5) 0 0 
Eye abnormalities 0 0 0 
Consequences of CNS dysfunction 1 (0.5) 0 1 (0.9) 
Other birth defects 2 (1.1) 3 (1.2) 1 (0.9) 
Chromosomal 0 1 (0.4)+ 0 
Skeleton abnormalities 2 (1.1) 1 (0.4) 1 (0.9) 
Other 0  1 (0.4) 0 
ZIKA CONGENITAL SYNDROME 13 (6.9) 3 (1.2) 1 (0.9) 
*One of these infant’s mothers was co-infected with Parvovirus B19 **Moderate microcephaly (less than -2SD) 
if detected by autopsy + This infant had Down’s syndrome with severe microcephaly ++ Potentially associated 
with Zika infection. CNS = central nervous system dysfunction 
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• Discussion 
The main findings of this cohort study are two-fold. Firstly, it showed that in the FTA 
the overall risk of neurological/ocular defects potentially associated with ZIKV infection in 
the offspring of women who developed acute symptomatic PCR-confirmed ZIKV infection 
during pregnancy was 7.0%. Similarly, the overall risk of birth defects included in the current 
definition of CZS and severe microcephaly were 3.1% and 1.6%, respectively. Secondly, 
although birth defects could be observed as a consequence of ZIKV infection at any 
pregnancy trimester, consistent with previous findings (Honein et al, 2017; Shapiro-Mendoza 
et al, 2017), it confirmed that the risk of birth defects and CZS was higher when ZIKV 
infection occurred early in pregnancy, with proportions of 12.7%, 3.6% and 5.3%, and 6.9%, 
1.2%, and 0.9% when ZIKV infection occurred in the 1st, 2nd, and 3rd trimesters respectively. 
The proportion of fetuses/infants with neurological birth defects (7.0%) in this study is 
similar to the 6% observed in the US women cohort (Honein et al, 2017) and the 5% more 
recently reported in the US territories (Shapiro-Mendoza et al, 2017), but is much lower than 
the 42% proportion observed in the Brazilian cohort (Brasil et al, 2016). The difference does 
not come from the proportion of infants/fetuses with microcephaly, which is similar in the 
three studies (5.8%, 3.4%, and 4.1%, respectively). Rather it is in the identification of wider 
neurological birth defects. The proportion of small for gestational age infants was similar in 
the FTA and in the Brazilian cohort (13.7% and 9%, respectively), but differences between the 
FTA and Brazilian cohorts appear when examining the proportion of infants needing 
admission to neonatal intensive care immediately after birth (1.3% and 21%, respectively), 
and the proportion of infants with abnormal neurological findings at clinical examination at 
birth (0.5% and 26.5%). The termination of 10 (1.8%) pregnancies in the FTA (compared to 
0% in Brazil) may have led to a decreased rate of neurological abnormalities detected at birth 
in the FTA compared to Brazil, but this cannot explain the entire difference between the two 
cohorts. In addition, the intensive use of MRI in the Brazilian cohort may have led to isolated 
abnormal imaging findings that have not been observed in other studies where the use of MRI 
has been less frequent. The clinical implications of these findings in Brazil are not yet known 
and will only be determined through longer-term follow-up of infants. 
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The strengths of our study include the size and homogeneity of the cohort of pregnant 
women living in a territory exposed to an outbreak of ZIKV and prospectively followed from 
acute symptoms and PCR-confirmed ZIKV infection. The diagnosis of ZIKV infection was 
made by PCR-based ZIKV detection in patients' blood, and the date of infection could be 
ascertained by consistent dates of clinical symptoms and ZIKV PCR testing. The study was 
conducted in well-defined geographical areas with high standards of care available to all 
pregnant women living in these territories. Linkage to care of pregnant women who developed 
ZIKV infection was effective with a low rate of loss to follow-up of 1.6%. In addition, the 
results were consistent across the two territories that recruited the largest number of women, 
Martinique and Guadeloupe.  
We acknowledge that our study may have some limitations. Firstly, it focused only on 
pregnant women who developed acute symptomatic ZIKV infection. Although the rate of 
complications would be expected to be higher among women with symptomatic compared to 
asymptomatic infections, an observational study of US women did not find any difference in 
the rate of birth defects in the offspring of women who had symptomatic compared to 
asymptomatic ZIKV infection during pregnancy (Honein et al, 2017). A recent study also 
showed the absence of association between disease severity or viral load and adverse 
outcomes (Halai et al, 2017). Secondly, we were not able to fully assess the presence of birth 
defects potentially associated with ZIKV infection in the eleven miscarriages, as well as in 
two of the six stillbirths, the only case of voluntary abortion, and 96 (18.2%) of the 527 live 
births who did not have prenatal ultrasound examination after ZIKV infection. While missing 
ultrasounds may have led to under-diagnosis of ZIKV-related birth defects, it is noteworthy 
that in our cohort, only one live birth had an isolated brain abnormality (ventriculomegaly) 
following an infection during the second trimester of pregnancy, detected by MRI, in the 
absence of clinical abnormalities.  All other live births with ZIKV-related defects had at least 
one abnormality that would have been picked up by the clinical examination at birth, whether 
it was microcephaly, clubbed feet, or neural tube defect (spina bifida).  Also, the majority of 
missing ultrasounds implicated pregnancies in which infections took place during the third 
trimester, where the consequences of infection were shown to be very limited in the other 
children of the same cohort. Thirdly, our endpoint was based on pregnancy ultrasound and 
neonatal clinical examinations and did not include postnatal ultrasound or specialized hearing 
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and ophthalmological examinations. We believe that it had limited impact on the rate of birth 
defects that could have been identified if all neonates had been subject to brain imaging early 
after birth. Indeed, it has been shown that when ZIKV infection occurs during the first or early 
second trimester, all brain abnormalities can be detected by ultrasound before 28 weeks of 
gestation (Schaub et al, 2017). Another study showed that none of 103 infants with normal 
prenatal ultrasound and clinical examination at birth had anomalies attributable to ZIKV at 
brain MRI performed after birth (Mejdoubi et al, 2017). Still the absence of microcephaly at 
birth does not exclude the delayed development of microcephaly or other ZIKV-related brain 
and other abnormalities (van der Linden, Pessoa, et al, 2016). This information is now being 
collected as part of a cohort study of the infants, including regular clinical examinations with 
specialized hearing and ophthalmological testing. Only the longer-term follow-up of the 
children born to these women, initiated as a follow-up to this study, will be able to identify full 
spectrum of ZIKV-related complications. 
 
In conclusion, among pregnant women with PCR-confirmed symptomatic ZIKV 
infection, birth defects potentially associated with ZIKV infection were present in 7% of 
infants and fetuses. They were more common in fetuses and infants whose mothers had been 
infected early in pregnancy. Longer-term follow-up of infants is required to assess for late-
onset manifestations not detected at birth. 
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2.2.3 Original fesearch (full article): Comparison of ZIKV-related birth defects in ZIKV 
exposed and unexposed pregnancies 
 
In our work on ZIKV-related birth defects in the FTA we had derived an overall risk of 
7.2%, with a 12.7%, 3.6% and 5.3%, risk per trimester of pregnancy for women with 
symptomatic ZIKV infection, respectively. However, many of these abnormalities (59%) were 
cases of moderate microcephaly, defined, as in similar cohort studies, as having a head 
circumference of less than -2SD according to a pooled international growth standard for 
gestational age and sex (in our case, this was the INTERGROWTH-21st standards). In the 
birth records for 96% of the infants (i.e. 22/23) with an eventual classification of moderate 
microcephaly, there were no abnormalities noted (i.e. no diagnosis of microcephaly); this 
infant was defined as abnormal not by a pediatrician, but rather, by our analysis program. This 
left us with a feeling that, although technically ‘microcephaly’ according to the internationally 
accepted definition at the time as well as by the definition used in other cohort studies on the 
subject, it may be incorrect to label these infants as being abnormal due to ZIKV exposure. In 
that publication, we were able to distinguish between these infants, and those with more 
severe abnormalities, based on a further narrowed down classification using the proposed 
definition of CZS. However, in that report, without a ZIKV-negative control group to match 
our prospective cohort of symptomatic ZIKV-positive women, we were unable to link 
moderate microcephaly with being affected by the virus.  
 
In the paper that will be presented below, we compare the proportion of live born 
infants with birth defects that are deemed ‘potentially linked to ZIKV infection’ in a 
retrospective cohort of ZIKV non-exposed pregnancies from Guadeloupe during the epidemic 
period, to the subset of women with confirmed ZIKV infection who had live born infants from 
the same region out of our previously published symptomatic prospective cohort. Considering 
that no prospective ZIKV negative cohort could be identified, comparison with this 
retrospective cohort was a compromise, rather than the perfect solution to understanding the 
baseline of adverse pregnancy outcomes and birth defects in the population. Through a 
retrospective cohort we were limited to comparing abnormalities in live born infants, as we 
were unable to capture miscarriage, stillbirth, and pregnancy termination due to abnormalities 
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in the ZIKV non-exposed pregnancies. The restraints of this approach will be discussed in the 
article.  
 
Our findings, as you will see, lead to a significant adjustment of our original estimate 
of the proportion of infants with birth defects that can be confidently linked to ZIKV infection. 
This research highlights the importance of having a control group in cohort studies examining 
the risk of ZIKV-related birth defects.  
 
Note: At the time of submitting this thesis manuscript to the referees on October 17th 
2018, the manuscript below is submitted at BMJ. The PDF of this article can be found in 
Appendix 5. 
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Comparison of the risk of birth defects in live births of pregnant women infected and not 
infected by Zika virus in Guadeloupe, 2016-2017 
Anna L Funk, Bruno Hoen, Ingrid Vingadassalon, Catherine Ryan, Philippe Kadhel, Kinda 
Schepers, Stanie Gaete, Benoit Tressières, Arnaud Fontanet 
 
• Abstract   
Objectives: To compare the risk of ZIKV-related congenital abnormalities among 
exposed and non-exposed live born infants in the FTA. Design: Cross-sectional study of 
pregnant women and live born infants without exposure to ZIKV, compared to those from a 
previously reported prospective cohort with confirmed ZIKV exposure.  Setting: Guadeloupe 
(France) during the 2016 ZIKV epidemic period.  Participants: 484 ZIKV negative pregnant 
women and their 490 live born infants. Main outcome measures: ZIKV-related congenital 
abnormalities as measured by clinical examination at birth and foetal ultrasound imaging 
during pregnancy Results: Of the 490 live born infants without in-utero exposure to ZIKV, 42 
infants (8.6%) had indication of neurological abnormalities known as ‘potentially linked to 
ZIKV infection’; all but one of these were microcephaly without any other brain or clinical 
abnormalities. When compared to the 241 live born infants from pregnancies with ZIKV 
exposure, the proportion of such abnormalities was similar (6.6%, p=0.36). Conclusions: 
Isolated microcephaly and other mild neurological conditions were as prevalent among infants 
with and without ZIKV exposure in-utero. As a result, when considering 249 foetuses and 
infants of women with confirmed ZIKV infection in Guadeloupe, only one (0.4%) live born 
infant and three (1.2%) medically-aborted foetuses had birth defects that could be linked to 
ZIKV infection. Trial registration: This study is registered at ClinicalTrials.gov 
(NCT02916732).  
 
• What is already known ? Based on different studies, the risk of birth defects following ZIKV infection during 
pregnancy varies from as low as 5 to as high as 46%. 
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? The most precise estimate obtained through a prospective cohort study with PCR-
confirmed diagnosis of infection in the pregnant mother comes from French territories 
in the Americas, with a risk estimated at 7.0% (95%CI: 5-10%). ? However, in the absence of a control group of ZIKV non-infected pregnant women, it 
is difficult to attribute all observed birth defects to ZIKV infection.  
 
• What this study adds ? This study found no difference in the prevalence at birth of anthropometric and other 
mild abnormalities that may be potentially associated with ZIKV infection when 
comparing a group of ZIKV-infected and ZIKV non-infected women.   ? In both exposure groups, most abnormalities described at birth were isolated 
microcephaly, i.e. without any additional clinical or imaging abnormalities.  ? This study leads to a reduction of our estimate of the risk of ZIKV-related birth 
defects among women infected during pregnancy down to 1.6% (95% CI: 0.4% - 
4.1%), with no risk related to ZIKV infection in the 3rd trimester of pregnancy.  
 
• Introduction 
Since the first evidence surfaced that linked ZIKV to foetal microcephaly and other 
brain abnormalities (Calvet et al., 2016; Cordeiro et al., 2016), key research priorities have 
been to define the range of defects associated with ZIKV infection during pregnancy, as well 
as to establish the risk of a foetus or infant being affected by them following infection during 
pregnancy. A multitude of case-series and case-control studies of foetuses and infants exposed 
to ZIKV in-utero have now been summarized to establish a preliminary definition of CZS that 
includes a range of ocular abnormalities and neurological defects, such as microcephaly, 
structural brain abnormalities (e.g. calcifications, lissencephaly, ventriculomegaly), 
consequences of central nervous system dysfunction (e.g. congenital contractures, abnormal 
muscle tension, hearing impairment), swallowing disorders, irritability, seizures, 
neurodevelopmental issues, and others (de Araujo et al., 2018; de Oliveira Dias et al., 2018; 
Krow-Lucal et al., 2018; Moore et al., 2017; Oliveira-Filho et al., 2018; Santa-Rita et al., 
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2017; Wheeler, 2018). In addition, studies from Brazil, the United States of America, and the 
FTA, have attempted to answer the question of how likely it is for the foetus or infant to be 
affected by any of these negative outcomes after infection during pregnancy, deriving 
differing risks of 46% (95%CI: 37-56%), 5% (95%CI: 4-6%), and 7% (95%CI: 5-10%), 
respectively (Brasil et al., 2016; Hoen et al., 2018; Shapiro-Mendoza et al., 2017). In addition, 
a retrospective cohort study of 86 pregnancies in Colombia found a 2.4% (95%CI: 0.3-8%) 
risk of adverse foetal outcomes; all of these were microcephaly cases without indication of 
brain abnormalities or clinical signs (Rodriguez-Morales et al., 2018). 
For the purpose of determining those birth defects that can actually be attributed to 
ZIKV in an exposed population, the estimation of the baseline level of birth defects in an 
appropriate ZIKV non-infected control group is necessary. In Brazil, a prospectively followed 
control group of 61 symptomatic pregnant women negative for ZIKV by RT-PCR was 
compared to 125 symptomatic pregnant women showing evidence of ZIKV infection; they 
found that total adverse outcomes were significantly less in women without evidence of ZIKV  
(11.5% versus 46.0%, p<0.001), although for some specific outcome categories, such as foetal 
demise and proportion of infants with microcephaly, there were no differences between the 
two groups (Brasil et al., 2016). Two other prospective studies have used control groups: a 
prospective ultrasound study examined foetopathy in French Guiana and found central 
nervous system abnormalities in 9.0% and 4.3% of the ZIKV-exposed and non-exposed 
foetuses, respectively (Pomar et al., 2017), and a prospective study of 29 ZIKV exposed 
pregnancies compared to 518 ZIKV non-exposed in the United States found no difference in 
outcomes between the two (Adhikari et al., 2017). 
In the French Territories in the Americas, in the absence of co-circulation of viral 
infections with similar symptoms at the time of the ZIKV epidemic, it was not possible to 
enrol a non-ZIKV symptomatic control group as done in Brazil.  We therefore enrolled 
women and their live born infants at the time of delivery, known for not being infected with 
ZIKV during pregnancy.  Thus, we were able to compare the proportion of live births with 
anthropometric abnormalities, including microcephaly and small weight for gestational age, 
and other neurological abnormalities in the recently published prospective cohort of ZIKV 
symptomatic women with that of a control group of ZIKV non-infected pregnant women and 
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their live born infants (Hoen et al., 2018).  To optimize the comparability of the two groups 
and study environment, the analysis was restricted to the women from Guadeloupe where 
sufficient numbers were available. 
.
• Methods   
Study!design!and!participants!
The ZIKA-DFA-FE cohort study (a French acronym representing “Zika in the French 
Territories in the Americas in Pregnant Women”), which has been described elsewhere (Hoen 
et al., 2018), used four different recruitment methods in an attempt to capture all women 
whose pregnancies overlapped with the ZIKV epidemic period, 2016-2017, in the FTA 
(Guadeloupe, Martinique, French Guyana). These included: enrolment of women presenting to 
hospital with symptoms consistent with ZIKV infection, enrolment of pregnant women for 
which a foetal abnormality was detected during routine ultrasound, enrolment of pregnant 
women for which there was foetal demise, and finally, enrolment of pregnant women not yet 
included through other methods who presented at participating hospitals to deliver during and 
up until nine months following the ZIKV epidemic period. Those final women recruited at 
delivery in Guadeloupe, and their live born infants, were used for the study presented in this 
article.    
 
Procedures!
At the time of admission to hospital for labour, each eligible woman was informed of 
the study and invited to participate; oral consent was obtained before delivery and written 
informed consent was obtained before delivery whenever possible or within 24 hours after 
delivery otherwise. A questionnaire including socio-demographic data, such as age, ethnic 
origin, residence, education, professional activity, and lifestyle factors, was administered. 
Clinical information, including the number of previous pregnancies, history of adverse 
pregnancy outcomes, significant medical history, symptoms of ZIKV experienced during 
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pregnancy, and any clinically significant medical event during pregnancy, was also collected 
at this time. From the live born infants of participating women, clinical data such as 
gestational age, length, weight, and head circumference, APGAR score at 1, 5 and 10 minutes 
of life were collected on the day of birth, and a standardized clinical examination was carried 
out in the first four days of life. After enrolment, the medical files of participating women 
were retrospectively reviewed and data were collected on clinical and ultrasound examinations 
that had been performed during the pregnancy.  
Blood samples were collected from all participating women recruited at the time of 
delivery.  These were tested for serological presence of ZIKV, including IgG, using the 
Euroimmun ZIKV IgG immunoassay (Euroimmun, Medizinische Labordiagnostika AG, 
Lübeck, Germany). In addition, some women had had other biological samples collected 
during the pregnancy that were tested for the presence of ZIKV by serological tests and/or by 
RT-PCR; when available these results were also taken into account. Results of TORCH 
serologic tests that were routinely performed during pregnancy in the French territories in the 
Americas were recorded, which included syphilis, toxoplasmosis, rubella, and HIV (Tolan, 
2008; de Jong et al., 2013). CMV serology was performed only on an elective basis, for high-
risk pregnancies or when foetal abnormalities were detected.  
 
Statistical analysis 
Out of the women enrolled in the study, data was included in this analysis if they gave 
birth in Guadeloupe, had a confirmed negative IgG serology test for ZIKV from maternal 
blood taken at time of delivery as well as no other positive ZIKV tests during pregnancy, and 
if their infant was live born.  Evidence (i.e. seen and reported by a clinician) or recollection of 
symptoms evocative of ZIKV infection during the pregnancy was not an exclusion criterion.  
Microcephaly was defined as moderate when head circumference was between – 2 SD 
and – 3 SD and severe when head circumference was less than – 3 SD, based on the 
INTERGROWTH-21st standards (http://intergrowth21.ndog.ox.ac.uk/) for gestational age and 
sex. Moderate microcephaly was further defined as proportionate or disproportionate 
! 72!
depending on whether the neonate was small for gestational age (Brasil et al., 2016; Hoen et 
al., 2018; von der Hagen et al., 2014). Small for gestational age was defined as having a 
weight less than –1.28 SD according to the INTERGROWTH-21st standards for gestational 
age and sex (Brasil et al., 2016; Hoen et al., 2018). 
In addition to determination of anthropometric abnormalities, we reviewed clinical 
examination records and ultrasound files of participants for evidence of birth defects that are 
considered to be potentially associated with ZIKV infection according to the current definition 
of CZS, including: structural brain abnormalities (e.g. calcifications, ventriculomegaly, 
lissencephaly), neural tube defects and other early brain malformations, eye abnormalities, 
hearing impairment, and other consequences of central nervous system dysfunction (e.g 
arthrogryposis, clubfoot) (Moore et al., 2017; Hoen et al., 2018).  Other birth defects that are 
not currently considered to be associated with ZIKV infection during pregnancy (e.g. skeletal 
and other malformations) were also noted. 
Baseline characteristics of women with ZIKV infection during pregnancy were 
compared to those of women without ZIKV infection during pregnancy using the Student’s t-
test for continuous variables and chi-square or Fisher’s exact test for categorical variables. The 
proportion of infants with anthropometric abnormalities and other birth defects was compared 
to data of live born infants whose mothers had RT-PCR confirmed ZIKV infection during 
pregnancy within the same setting and timeframe in Guadeloupe (Hoen et al., 2018), using 
Fisher’s exact test. Data were analysed using Stata 13 (StataCorp LP Lakeway, TX, USA).  
The ZIKA-DFA-FE study is registered with ClinicalTrials.gov (NCT02916732) and 
received ethics approval by the Comité de Protection des Personnes Sud-Ouest et Outremer III 
(CEBH2016/03).  
!
Patient involvement 
The pregnant women and their infants were not involved in the development of the 
research question or design of the study. Each woman was notified of her ZIKV status 
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following testing by her attending physician. Women have been given information to able 
them to contact the study investigators to receive information on the results of the study. 
 
• Results  
Participants 
Of 1484 women enrolled at delivery in Guadeloupe, 1088 had available ZIKV test 
results. Of these, 588 showed evidence of ZIKV infection through either serological or RT-
PCR testing, 16 had negative RT-PCR results but indeterminate ZIKV serological tests, and 
484 were confirmed negative by serological tests at the time of delivery with no other positive 
test seen during pregnancy. Of these 484 ZIKV non-infected women, 6 had twin pregnancies; 
490 live born infants were therefore considered in this analysis. In the previously published 
prospective cohort by Hoen and colleagues (2018) of the 254 pregnant women in Guadeloupe 
who had symptomatic RT-PCR confirmed ZIKV infection during pregnancy and were 
enrolled into the prospective cohort, nine pregnancies were excluded either because of loss to 
follow-up (n=5) or for mistaken inclusion in the cohort (n=4). Of the remaining 245 
pregnancies, there were four sets of twins, and eight cases of foetal demise, including: two 
miscarriages and three stillbirths all without evidence of neurological birth defects, and three 
cases of medical abortion all with evidence of neurological abnormalities potentially linked to 
ZIKV infection. The lack of neurological birth defects was confirmed via autopsy for one of 
the two miscarriages, and all three of the stillborn infants. Therefore, we were able to compare 
490 ZIKV-unexposed live born infants with 241 ZIKV exposed live born infants (with ZIKV 
exposure confirmed by RT-PCR), all born to mothers living in Guadeloupe during the ZIKV 
outbreak. See Figure 3. 
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Figure 3: Flow chart of inclusion of ZIKV un-exposed and exposed pregnant women for 
inclusion of live births in this analysis !
The mean age of ZIKV non-infected women was 30.7 years (SD=6.4), and that of 
ZIKV infected women was 30.0 years (SD=6.3). There was a higher proportion of reported 
smoking in the ZIKV-infected cohort during pregnancy compared to the ZIKV non-infected: 
4.2% (95%CI: 2.0-7.6%) versus 0.6% (95%CI: 0.4-1.8%). There were also more unemployed 
women in the ZIKV non-infected group compared to the ZIKV-infected one: 48.1% (95%CI: 
43.3-52.4) versus 34.6% (95%CI: 28.6-41.0). See Table 6.  
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Anthropometric and other birth defects in live born infants 
Of the 490 live born infants of women without ZIKV infection during pregnancy, 66 
(13.5%, 95%CI: 10.6-16.8) were small for gestational age, and 41 (8.4%, 95%CI: 6.1-11.2) 
had microcephaly. One of these moderate microcephaly cases had a possible genetic aetiology 
(Adams Oliver syndrome). Of the remaining infants with microcephaly, 29 (5.9%, 95%CI: 
4.0-8.4%) had either moderate-proportionate or moderate-disproportionate microcephaly with 
no other structural brain or clinical abnormalities. Eleven (2.2%, 95%CI: 1.1-4.0) infants had 
severe microcephaly, seven of which were proportionate. One infant (0.2%, 95%CI: 0.01-1.1) 
had an abnormality that could be a consequence of central nervous system (CNS) dysfunction, 
which was clubfoot.  Five infants (1.0%, 95CI: 0.3-2.4) had skeletal or other abnormalities 
that are not currently classified as potentially linked to ZIKV infection, including: skeletal 
abnormalities of the fingers or toes (n=2) anal imperforation (n=1), and urinary tract 
abnormalities (n=2). Besides two small-for-gestational-age infants whose mothers were HIV-
positive, there were no other abnormalities (including microcephaly) identified in the 
remaining four infants of TORCH-positive mothers. See Table 7. 
There were no significant differences in the anthropometric or other birth defects in 
live born infants whose mothers had a symptomatic PCR-confirmed ZIKV infection during 
pregnancy compared to those whose mothers had no evidence of prior ZIKV infection at the 
time of delivery in Guadeloupe. In two categories, ‘neurological or ocular abnormalities 
without microcephaly’ and ‘neural tube defects’, there were no cases seen in live born infants 
of women without ZIKV infection during pregnancy, and one case each in infants born to 
women infected with ZIKV during pregnancy. See Table 8.  
 
 
!!!!!!!!
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Table 6: Baseline characteristics of ZIKV non-infected and infected (Hoen et al., 2018) 
women from Guadeloupe who delivered live born infants  
Characteristic ZIKV  
non-infected 
 (N=484) 
ZIKV 
infected 
(N=237) 
Age — yr (mean and range) 30.7 (18-46) 30.0 (18-46) 
Missing 0 0 
Occupation — no. (%)   
Student  13 (2.7) 6 (2.5) 
Artisan, merchant, or business owner  14 (2.9) 17 (7.2) 
Professional  75 (15.5) 39 (16.5) 
Employee  148 (30.4) 91 (38.4) 
Laborer, factory worker, or farmer  1 (0.2) 1 (0.4) 
Unemployed  233 (48.1)* 82 (34.6)* 
Missing data or declined to respond 0 1 (0.4) 
Medical history — no. (%)   
Arterial hypertension  12 (2.5) 7 (3.0) 
Diabetes  12 (2.5) 4 (1.7) 
Sickle cell disease 7 (1.5) 2 (0.8) 
Previous pregnancies — no. (%)   
0 110 (22.7) 65 (27.4) 
1 133 (27.5) 57 (24.1) 
2 109 (22.5) 52 (21.9) 
>=3 130 (26.9) 63 (26.6) 
Missing 2 (0.4) 0  
Previous adverse pregnancy outcomes — no. (%)   
Congenital abnormalities  2 (0.4) 3 (1.3) 
Stillbirth  6 (1.2) 2 (0.8) 
Termination of pregnancy for medical reasons 4 (0.8) 4 (1.7) 
Lifestyle practices during this pregnancy — no. (%)   
Alcohol consumption 0 0 
Drug use 1 (0.2) 2 (0.8) 
Current smoker 3 (0.6)* 10 (4.2)* *Comparison!between!Zika!non?infected!and!infected!women!with!p=0.001!!
.
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Table 7: TORCH results in ZIKV non-infected and ZIKV-infected (Hoen et al., 2018) 
women giving birth in Guadeloupe during the ZIKV epidemic period 2016-2017 
 ZIKV non-infected 
(N=484) 
ZIKV infected 
 (N=237) 
Positive results on any TORCH test 6 (1.2) 5 (2.1) 
Toxoplasmosis   
Tested 468 (96.9) 219 (92.4) 
Positive 3 (1.0) 0 
Syphilis   
Tested 249 (51.6) 184 (77.6) 
Positive 0 2 (0.8) 
HIV   
Tested 449 (93.0) 188 (79.3) 
Positive 3 (0.6) 2 (0.8) 
Rubella   
Tested 464 (96.1) 199 (84.0) 
Positive 0  0 
Cytomegalovirus   
Tested 17 (3.5) 36 (15.2) 
Positive 0  1 (0.4) 
.
.
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Table 8: Abnormalities in live births of ZIKV non-infected and infected (Hoen et al., 
2018) women in Guadeloupe during the epidemic period in 2016-2017 
 ZIKV non-infected 
(N=490) 
ZIKV infected 
 (N=241) 
 
Any neurological or ocular abnormalities  
 
42 (8.6) 
 
16 (6.6) 
Microcephaly (<-2SD) 41 (8.4) 12 (5.0) 
Severe microcephaly alone 11 (2.2) 1 (0.4) 
Moderate-disproportionate alone 10 (2.0) 6 (2.5) 
Moderate-proportionate alone 19 (3.9) 4 (1.7) 
Severe or moderate microcephaly with other 
neurological abnormalities 0 0 
Severe or moderate microcephaly with a genetic 
or chromosomal syndrome 1 (0.2) 1 (0.4) 
Missing 6 (1.2) 5 (2.1) 
Structural brain abnormalities  0 1 (0.4) 
Ocular abnormalities 0 0 
Neural tube defects 0 1 (0.4) 
Consequences of CNS dysfunction 1 (0.2) 2 (0.8)^ 
   
Other abnormalities 5 (1.0) 2 (0.8) 
Skeletal abnormalities 2 (0.4) 2 (0.8)^ 
Other 3 (0.6) 0 
 
Small for gestational age (weight <-1.28 SD) 
(with or without any of the above abnormalities) 
 
66 (13.5) 
 
33 (13.7) 
Missing 1 (0.2) 3 (1.2) 
^ One infant represented in each category as they had both club-foot and polydactyly.  Note: No significantly 
different values  
.
. .
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• Discussion 
We found no statistically significant difference in the risk of neurological birth defects 
in live born infants of ZIKV infected and non-infected women in Guadeloupe during the 
epidemic period in 2016-2017. These findings have important implications for the estimation 
of the number of congenital birth defects that can be attributed to ZIKV when the mother is 
infected during pregnancy. Originally, through a prospective cohort of 249 RT-PCR 
confirmed ZIKV infected pregnant women in Guadeloupe, we reported a total of 18 (7.2%) 
neurological or ocular birth defects that were potentially linked to ZIKV infection; 13 (72%) 
of these were isolated anthropometric abnormalities (i.e. microcephaly) or isolated mild CNS 
dysfunction defects (i.e. clubfoot) in live born infants (Hoen et al., 2018), which on the basis 
of the current study cannot be linked to ZIKV exposure. In live born infants, we are left then 
only with two severe neurological abnormalities (i.e. ventriculomegaly and spina bifida) that 
have no known alternative etiologies; this is, however, reduced to one abnormality when we 
remove the neural tube defect (i.e. spina bifida), which is no longer considered as linked to 
ZIKV infection (Rice et al., 2018; Delaney et al., 2018). As our ZIKV non-exposed study 
looked back retrospectively from the time of delivery, we are unable to compare the 
proportion of foetal demise with that of the full 249 ZIKV-exposed foetuses in the prospective 
cohort. However, the two (0.5%) miscarriages and three (1.2%) stillbirths of the ZIKV-
exposed cohort are within the generally expected historical range (Serfaty, 2014; Delabaere et 
al., 2014), and had no evidence of neurological abnormalities during autopsy for the four that 
could be examined. There were three (1.2%) further cases of foetal demise in the prospective 
cohort, which were all medically indicated terminations of pregnancy due to ultrasound 
detection of severe structural brain abnormalities with microcephaly.12 If combining the severe 
neurological abnormalities in foetuses from medically terminated pregnancies (n=3) and live 
born infants (n=1) our new adjusted estimate of birth defects that could be attributed to ZIKV 
exposure in Guadeloupe would be 1.6% (95%CI: 0.4-4.1%) (See Figure 4). This would 
translate to a 4.1% (95%CI: 0.9-11.5%), 0.8% (95%CI: 0.02-4.6%), and 0% (one-sided 
97.5%CI:0–6.3%) risk of birth defects per first, second, and third trimester, respectively. 
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Figure 4: Determination of excess risk of birth defects associated with ZIKV infection, 
based on autopsy findings and comparison with the ZIKV non-infected group  
 
This is the largest study of ZIKV non-infected women from a defined epidemic region 
that has been used as a comparative control group against ZIKV-infected pregnant women 
followed up during pregnancy. This study was conducted in a resource-rich setting where the 
standard of care for pregnant women is high. The exposure statuses of each of the two groups 
included in this study were well defined. The ZIKV infected women from Guadeloupe were 
confirmed via RT-PCR within days of infection (Hoen et al., 2018), and the ZIKV non-
infected group was defined so based on the absence of IgG at the time of delivery. Recent 
studies support a rapid appearance of ZIKV IgG after infection; it was 100% detectable within 
11 days following infection for 15 subjects in Guadeloupe and within 26 days following 
infection for 29 returned travelers to the United States of America (Pasquier et al., 2018; 
Barzon et al., 2018). The Guadeloupe study also showed consistently positive IgG results 
throughout follow-up for all subjects, which was up to at least 120 days for around 90% of 
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subjects included. This evidence suggests that subjects infected with ZIKV, even early in 
pregnancy, would still have detectable IgG at delivery and would have been excluded from 
our ZIKV non-infected control group. 
This study has several limitations. As we had no directly comparable prospective 
cohort to that of recently published ZIKV confirmed infected women, we used a group of 
ZIKV non-infected women delivering at the same hospitals and in the same time period. The 
prevalence of TORCH infections did not differ significantly between the two groups and in 
terms of most baseline characteristics, the two groups were similar, although ZIKV non-
infected women were more likely to be unemployed, and ZIKV infected women were more 
likely to report smoking during pregnancy. This may reflect recall ability and employment 
situation differences according to the timing of data collection, as ZIKV non-infected women 
were all recruited at the time of delivery and ZIKV infected women were recruited at various 
earlier time points during their pregnancy. Furthermore, the quality of follow-up and 
collection of data on the course of pregnancy was likely of a higher quality in the ZIKV-
exposed group as this was a prospective cohort where women had been symptomatic during 
pregnancy. Highlighting this is the fact that the study team was able to retrieve ultrasound 
records for 88.4% of ZIKV infected women and only 51.6% for ZIKV non-infected women. 
However, such a difference would only lead to an underestimation of birth defects in the 
ZIKV non-infected group. Furthermore, the completeness of data at the time of delivery for 
live births, which was used to determine anthropometric and clinically apparent abnormalities, 
was very high in both ZIKV-exposed (97.9%) and non-exposed (98.8%) infants. Recruitment 
of ZIKV non-exposed pregnant women at delivery also prevented us from determining the 
number of expected miscarriages, stillbirths, and abortions that may occur in the ‘baseline’ 
population, but this also indicates a potential under rather than over-estimation of birth defects 
in this group.  
Most of the originally reported ‘potentially linked to ZIKV’ abnormalities seen in both 
the exposed and non-exposed pregnancies of our study represent identification of 
microcephaly in live births; these cases were defined based only on anthropometric 
measurements, with known clinical and radiological findings for each infant being normal. 
This diagnostic approach to microcephaly, which does not require clinician judgment on the 
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appearance of microcephaly, but relies solely on the comparison of a head circumference 
measurement against a normalized birth curve, has been used in all of the cohort studies 
describing the risk of birth defects following maternal ZIKV exposure during pregnancy, to 
date (Adhikari et al., 2017; Brasil et al., 2016; Hoen et al., 2018; Pomar et al., 2017; 
Rodriguez-Morales et al., 2018; Shapiro-Mendoza et al., 2017). However, defining 
microcephaly based on ‘metrics’ does not reflect the real-life clinical diagnosis of this 
condition, and can lead to a false surge in cases if applied to an entire population for 
surveillance purposes (Orioli et al., 2017). Registries using more stringent definitions (e.g. -
3SD) and/or clinician specific criteria indicate that true disease-related microcephaly is very 
rare; the European Surveillance of Congenital Anomalies (EUROCAT) recently estimated the 
prevalence of microcephaly in Europe to be 1.53 per 10,000 births (~0.02%) with data from 
2012-2016 (Morris et al., 2016). However, as infant growth is approximately normally 
distributed, the INTERGROWTH-21st study itself prescribes that approximately 2% and 0.1% 
of healthy infants should have a head circumference at birth that falls below -2 and -3SD, 
respectively (Villar et al., 2014). Corroborating this, a recent study applying this definition of 
microcephaly to birth cohorts from two Brazilian cities, Ribeirão Preto! and São Luís, 
estimated the baseline prevalence of microcephaly in 2010 to be of 2.5% and 3.5%, 
respectively (Silva et al., 2018). Our own estimates of the prevalence of moderate and severe 
microcephaly and small weight for gestational age in ZIKV exposed infants was similar to that 
which the INTERGROWTH-21st standards prescribes. However, in our larger ZIKV non-
infected control group, our estimates for each of these anthropometric abnormalities, while not 
different from those in the ZIKV-exposed cohort, were higher than what is prescribed by the 
INTERGROWTH-21st growth standards. This may be due to a ‘non-perfect-fit’ of the 
Guadeloupian population to this international pooled growth standard. Other authors (Albert 
and Grantz, 2014; Cheng et al., 2016; Liu et al., 2017), as well as the INTERGROWTH-21st 
study themselves (Villar et al., 2014), have noted varying levels of fit for individual 
populations when compared to this pooled standard.  
This study highlights the importance of a control group to estimate the baseline risk of 
anthropometric and other birth defects when determining the risk of severe congenital 
abnormalities that can be attributed to a given infection during pregnancy. This is particularly 
true for anthropometric measurements where regional variations may exist (Albert and Grantz, 
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2014; Cheng et al., 2016; Liu et al., 2017; Villar et al., 2014). Pre-Zika microcephaly baseline 
prevalence estimates are increasingly being reported (de Magalhaes-Barbosa et al., 2017; Hoyt 
et al., 2018; Orioli et al., 2017; Rick et al., 2017; Silva et al., 2018). While such reports can be 
used to give general clues as to the magnitude of birth defects seen through cohort studies that 
can be attributed to ZIKV infection, the definition of microcephaly and CZS used, and 
whether or not clinician expertise was considered, will be key to their interpretation.  As with 
other congenital infections that cause neurological abnormalities, such as cytomegalovirus and 
rubella (De Santis et al., 2006; Manicklal et al., 2013), longer-term studies that postnatally 
follow-up infants that are exposed to ZIKV in-utero but who are apparently healthy at birth are 
needed in order to understand the true overall risk of defects. However, in terms of the risk of 
immediate severe congenital defects that are potentially linked to ZIKV infection during 
pregnancy, and that may impact pregnancy outcome, our findings have further diminished our 
own estimate for pregnant women in Guadeloupe from 7.2% to 1.6% overall. Communication 
of the most possibly accurate estimate of the risk of severe birth defects linked to this 
infectious exposure, as well as the likelihood that such abnormalities will be detected early in 
pregnancy, will have an important influence on the family planning decisions of pregnant 
women with ZIKV-positive test results.  
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2.3 ZIKV-related birth defects in sub-Saharan Africa and Asia 
2.3.1 The “Surveillance of ZIKV-related microcephaly in sub-Saharan Africa and Asia” 
study 
• Background 
As discussed in the introduction to this thesis, after its discovery in Uganda in the late 
1940’s, seroprevalence surveys indicate that ZIKV seems to have circulated for decades in 
sub-Saharan Africa and Asia. However, until very recently there has been no reported excess 
of ZIKV-related complications, e.g., microcephaly and GBS in these regions (Chu et al., 2018; 
Rosenstierne et al., 2018; Sassetti et al., 2018; Wongsurawat et al., 2018). This may be related 
to a historically low circulation of the virus in these regions, a lack of systematic testing for 
the virus when those complications occurred, or possibly recent mutations in the virus that 
have increased its pathogenicity. As interventions against ZIKV and its complications are 
being developed (e.g., vaccine, vector control), we consider it important to document the 
public health impact of ZIKV in these regions of the world through improved surveillance of 
its main complication: microcephaly.  
 
• Objectives 
This study will explore whether ZIKV is currently responsible for neurological 
complications, and particularly microcephaly, in Aedes-infested regions of sub-Saharan Africa 
and Asia. This may inform regional public health strategies, such as vaccination of women of 
childbearing age. It will also demonstrate the public health impact of ZIKV infection and 
increase understanding of other regional infectious (e.g. CMV) causes of microcephaly.  
 
• Study design 
This study will last for 2 years, and will include only new cases of microcephaly. 
Surveillance will take place in large maternities in urban areas (see Table 9). In each city, 
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approximately 3000 live births per month will be monitored, so that on average one disease-
related microcephaly case will be diagnosed per month per city (i.e., 24 per city in 2 years); 
this is based on estimates from birth defects registries, with allowance for a possible increased 
proportion due to differences in nutritional and environmental factors as well as variation in 
circulation of infectious agents (e.g. rubella).  
 
Table 9: Participating maternities with estimated number of births per day that will be 
examined for microcephaly 
Country City Maternities # Births/day 
Cameroun Yaoundé 
Central Hospital Maternity 11 
Essos Hospital Centre Maternity 7 
China Guangzhou Guangzhou Women and Children's Medical Centre 55 
  
Guangzhou Liwan Maternal and Child Health Hospital 9 
  Guangzhou Huadu Maternal and Child Health Hospital 22 
Côte 
d’Ivoire 
Abidjan 
General Hospital of Yopougon-Attie 37 
General Hospital Abobo-Sud 17 
Sri Lanka Colombo 
Castle Street Hospital for Women (CSHW) 35 
De Soyza Hospital for Women (DSHW) 20 
Vietnam 
Ho Chi 
Minh City 
Tu Du Hospital 180-200 
 
For the purpose of this study, microcephaly will be defined as a head circumference of 
less than -3SD, according to the INTERGROWTH-21st standards for gestational age and sex 
AND having an abnormal pre or postnatal ultrasound and/or clinical examination. If an infant 
is disproportional in terms of its weight and/or length by greater than 2SD when compared to 
its head circumference Z score, this will be considered a clinical examination abnormality. 
Exclusion criteria include the mother being less than 18 years of age and 
unwillingness/inability to provide informed consent.  
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Note: Originally, in September 2016, the microcephaly case definition that we 
envisaged for this study was simply having a head circumference of less than -2SD according 
to the INTERGROWTH-21st standards for gestational age and sex. However, due to 
preliminary results from surveillance using this definition in four of the study sites, as will be 
presented, this definition was refined to be more specific.  
 
• Data collection  
A questionnaire that collects information on demographic characteristics, teratogenic 
exposures, and historical and current pregnancy details will be administered to all mothers 
whose infants have met the case definition for microcephaly.  
 
• Laboratory testing and clinical examination 
Various biological samples (e.g. blood, placenta) will be collected from mothers and 
newborns/fetuses and tested for presence of ZIKV, and for other infectious (e.g. rubella, 
cytomegalovirus) causes of microcephaly. Table 10 provides an example of this testing for 
live born infants. In the case of a stillborn infant or a microcephaly case detected via prenatal 
ultrasound where the pregnancy outcome is termination, the samples collected will differ 
slightly. Physical, neurological, hearing and visual examinations for all live births will be 
performed where possible in the first week of life.  
 
• Study partners 
This study has been designed and implemented in partnership with each participating 
country/organization, including:  
o Paris, France: Emerging Disease Epidemiology Unit, Institut Pasteur 
o Lausanne, Switzerland: University Hospital of Lausanne  
o Yaoundé, Cameroon: Institut Pasteur of Cameroon 
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o Abidjan, Cote d’Ivoire: Institut Pasteur of Cote d’Ivoire 
o Guangzhou, China: Guangzhou Women’s and Children’s Hospital 
o Ho Chi Minh City, Vietnam: Tu Du Hospital; Institut Pasteur of Ho Chi Minh City 
o Colombo, Sri Lanka: Perinatal Society of Sri Lanka 
 
Table 10: Laboratory examinations for live born cases 
 Zika virus Cytomegalovirus Rubella Toxoplasmosis 
Serological testing for all infectious agents on maternal sample 
Venous blood RT-PCR, IgG & IgM IgM IgM IgM 
If possible, testing should be performed on one sample below, depending on availability and hospital 
standard procedure*, in the preferred order as shown  
Cord blood RT-PCR PCR RT-PCR PCR 
Placenta RT-PCR PCR RT-PCR PCR 
Infant saliva  RT-PCR PCR RT-PCR PCR 
* In some countries CMV and Rubella viral load may need to be tested using urine sample. 
 
• Current study progress 
Although the first meeting with study partners from each country took place through a 
workshop in Paris in September 2016, the implementation of this research has been delayed 
due to various regulatory processes, mostly in France, but also sometimes in the study 
countries. As of September 2018, all regulatory procedures have been completed, and 
authorizations to officially start the study have been given, for two countries- China and Cote 
d’Ivoire. For two other study countries, Cameroon and Sri Lanka, all regulatory procedures 
have been completed besides final notice of local ethical approval, which should be completed 
by October 2018. In Vietnam, the study implementation has faced considerable delays and 
will likely start in early 2019. !
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2.3.2 Original research (full article): Surveillance of microcephaly in four cities of sub-
Saharan Africa and Asia 
 Prior to starting the study described above, we needed to understand how many cases 
of microcephaly we might eventually observe in each location; this would be important for 
budget and logistical considerations. At our disposal were recent estimates of a 0.02% 
prevalence at birth of microcephaly in Europe, published just days prior to our international 
study group meeting in Paris in late 2016 (Morris et al., 2016). We imagined we might find 
higher estimates than this, due to variance in environmental and infectious factors that may 
cause the condition – so then, perhaps 0.04% or 0.06%? At this point in our group meeting, 
one of our Chinese colleagues presented some preliminary data from a birth cohort in 
Guangzhou; if applying a -2SD cut-off with the INTERGROWTH-21st standards, about 1.4% 
of infants would be labeled as having microcephaly. This was our first experience with the 
perils of a ‘metric’ microcephaly definition.  
 Unsure of what this would look like in each collaborating country, each study partner 
returned home from Paris with the aim to conduct a ‘pilot’ microcephaly surveillance in 
participating hospitals in their region. This would be done, where possible, both by reviewing 
data for 3000 infants in birth registers retrospectively and then, using non-stretch headbands 
and reinforced methods, moving forward prospectively looking at 3000 births. The 
comparison of these two methods would give a further indication of data quality. The eventual 
proportion of both moderate and severe microcephaly would give us more guidance on which 
cut-off we should use for our over-arching study.  
At least, we expected to find around 2-3% of moderate microcephaly (<-2SD) and 
<0.05% (<-3SD) of severe microcephaly, as predicted by the normal distribution under the 
INTERGROWTH-21st growth standards. In this case, we could go with a more specific 
definition of microcephaly (i.e. severe microcephaly) for our study and, possibly with need for 
consideration of imaging and clinical evaluations for each infant. Our actual results showed 
highly varied proportions of both moderate and severe microcephaly by region. We also were 
able to see that the data we had collected produced head circumference Z-score distributions 
that were fairly normal, but shifted either right or left when compared to the reference 
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standard. These results highlighted a potentially more serious problem with a measurement-
based microcephaly definition – extreme variation by region, likely due to diverse 
socioeconomic and environmental factors common in real-life settings, when using a pooled 
international growth standard.  
At the time of submitting this thesis manuscript to the referees on October 17th, 2018, 
this article is submitted at Pediatrics. The PDF of this article can be found in Appendix 5. 
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Microcephaly surveillance in Africa and Asia using a -2SD cut-off and international 
growth charts 
Anna L Funk, Man-Koumba Soumahoro, Kapila Jayaratne, Mathurin Cyrille Tejiokem, Xiu 
Qiu, Lahanda Purage C Saman Kumara, Anne E Njom Nlend, Wanqing Xiao, Rémy Konan-
Blé, Nalin I Gamaathige, Jianrong He, Fouelifack Ymele Florent, N'Guessan Pierre Oura, 
Kouadio Narcisse Tano, Amber Kunkel, M Nishani Lucas, Gabriel M Leung, Arnaud 
Fontanet 
 
• Abstract 
Background and Objectives: Little data on microcephaly baseline estimates exists in 
sub-Saharan Africa and Asia. We aimed to estimate the proportion of live births with 
microcephaly from four cities in sub-Saharan Africa and Asia using the INTERGROWTH-21st 
growth charts and a -2 standard deviation (SD) cut-off. Methods: Large maternities in 
Yaoundé (Cameroon), Abidjan (Ivory Coast), Colombo (Sri Lanka) and Guangzhou (China) 
collected data for live born infants through retrospective and/or prospective surveillance, as 
feasible in each setting. Head circumference, gestational age, and sex were compared to the 
INTERGROWTH-21st standards to obtain head circumference Z-scores (HCZ) for each infant. 
Moderate and severe microcephaly were defined as between -2 and -3SD, and less than -3SD, 
respectively. Results: Sufficient data for 19914 live births across all study sites were analysed. 
The proportion of infants with microcephaly, according to the definition, was between 2.9% 
and 34.8% through retrospective surveillance in three countries. Prospective surveillance in 
Guangzhou, Colombo, and Abidjan, labelled 3.8%, 7.5%, and 18.6% of infants as having 
microcephaly, respectively. The retrospective data from Abidjan differed the most from the 
INTERGROWTH-21st distribution, with a shifted mean HCZ -1.41 SD, whereas the HCZ for 
infants from Guangzhou, following prospective surveillance, differed the least (mean HCZ -
0.02SD). Conclusions: A cut-off of -2SD will most likely lead to labelling large numbers of 
healthy babies as having microcephaly, with important regional variations.  For the purpose of 
microcephaly surveillance, we suggest using regional growth charts, increasing consideration 
of infant body size, and defining the cut-off at -3SD (severe microcephaly).  
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• What’s known on this subject?  
In sub-Saharan African and Asian regions suitable for Zika transmission, little 
information on the baseline prevalence of microcephaly in live born infants is available. 
However, the prevalence in Europe and the United States was recently estimated at less than 
0.1%.  
 
• What this study adds? 
A -2SD cut-off with pooled international growth standards classifies many infants (3 to 
35%) as having microcephaly in sub-Saharan Africa and Asia. Consideration of infant body 
size and regional growth differences are needed in the microcephaly definition used for 
surveillance.  
 
• Introduction 
Microcephaly is a congenital anomaly that can appear in neonates following abnormal 
brain development due to infectious, genetic or environmental causes (Gilmore and Walsh, 
2013; von der Hagen et al., 2014). This birth defect has attracted increased attention recently, 
following the rapid spread of Zika Virus (ZIKV) throughout the Americas in 2015-2016 and 
the realisation that microcephaly due to abnormal brain development can occur in the infants 
of women infected with ZIKV during pregnancy (de Araújo et al., 2016). Although few recent 
cases have been reported so far outside of the South-Pacific and Americas, a large proportion 
of sub-Saharan Africa and Asia is equally suitable for ZIKV transmission (Messina et al., 
2016). The lack of understanding of the effects of current or impending transmission of ZIKV 
in these latter regions further emphasizes the need for strong surveillance systems and clear 
case definitions for microcephaly (Wetsman, 2017).  
From 2003 to 2012, the European Surveillance of Congenital Anomalies (EUROCAT) 
registry estimated the prevalence of microcephaly in Europe to be 1.5 per 10,000 births 
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(~0.02%) (Morris et al., 2016). In the United States, between 2009 and 2012, pooled results 
from 30 birth defects registries, estimated the prevalence of microcephaly to be 9 per 10,000 
births (0.09%) (Cragan et al., 2016).To our knowledge, there are no recent microcephaly 
registries or causality profiles for most regions of sub-Saharan Africa and Asia. In these 
regions we may expect different figures than in Europe due to environmental factors, 
differences in nutrition, and increased circulation of and lower vaccine coverage for infectious 
agents such as rubella. For the purpose of screening live neonates born to women at risk of 
ZIKV exposure during pregnancy, at the beginning of the recent outbreak in the Americas, the 
Centres for Disease Control and Prevention (CDC) (2016) and the World Health Organisation 
(WHO) (2016f) recommended defining moderate and severe microcephaly as a head size of 
less than -2SD (or < 3rd percentile) and -3SD, respectively, for gestational age and sex using 
the INTERGROWTH-21st or WHO growth standards. The same definition has been used by 
many of the key cohort and case-control studies defining Zika related birth defects (Brasil et 
al., 2016; de Araújo et al., 2016; Hoen et al., 2018; Shapiro-Mendoza et al., 2017), as well as 
in some recent estimations of the pre-Zika (i.e. <2015) microcephaly prevalence in South 
America (de Magalhaes-Barbosa et al., 2017; Rick et al., 2017; Silva et al., 2018). Therefore, 
we sought to understand the distribution of newborn head sizes, and in particular the 
prevalence of microcephaly at birth, that could be expected using data from real-life settings in 
sub-Saharan Africa and Asia, according to a -2SD cut-off with a pooled international growth 
standard. Such results could be used as a baseline reference in these regions, for interpretation 
of disease-related microcephaly surveillance following a Zika epidemic.  
 
• Methods 
Eight hospitals across four countries, two in sub-Saharan Africa and two in Asia, 
participated: Essos Hospital Maternity in Yaoundé, Cameroon; the General Hospitals of 
Yopougon-Attie and Abobo-Sud in Abidjan, Ivory Coast; Guangzhou Women and Children’s 
Medical Center, Guangzhou Huadu Women and Children Health Care Hospital and 
Guangzhou Liwan Women and Children Health Care Hospital; the Castle Street and De Soyza 
Hospitals for Women in Colombo, Sri Lanka. These are large hospitals in urban areas suitable 
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for ZIKV transmission (Messina et al., 2016),  and have many births per day (mean: 22, range: 
7-55) in relation to other regional hospitals. Most regions in which the study sites are situated 
would be considered low-income, besides Guangzhou.  
Data from birth registers was collected retrospectively, with an aim to record data for 
at least 3000 births consecutively moving back from the day at which the collection started, in 
the participating hospitals in Yaoundé (January 1st 2015 – December 31st 2016), Abidjan 
(August 14th, 2016 – November 2nd 2016), and Colombo (June 13th 2016 –December 14th 
2016). Head circumference in these maternities is measured within the first 24 hours of life 
using vinyl-measuring tapes which are crossed over at the front of the head to get a reading of 
the head circumference. Birth register entries that were missing one or more data points were 
equally recorded and missing values noted in the data collection form.  
In Guangzhou (February 10th 2017 to March 13th 2017), Colombo (December 15th 
2016 to April 5th 2017), and Abidjan (April 4th 2018 to 14th July 2018), the participating 
maternities collected data prospectively with the aim to review 3000 consecutive births 
moving forward from the date of the collection start. Prior to this prospective data collection, 
the participating maternities reinforced their standard procedures for head measurement and 
birth register data collection (Harris, 2015). They also introduced use of non-stretch Teflon 
seca 212 head measuring bands, which remain in a loop format with a viewing window in 
order to read head circumference measurements to the nearest millimetre 
(https://us.secashop.com/products/pediatric-measuring-systems/seca-212).   
 
Gestational age calculation 
According to standard procedure at each participating maternity, gestational age is 
calculated based on the first date of the last menstrual period; for varying proportions of 
patients within each country, this estimate is confirmed using ultrasound examination carried 
out in the first trimester of pregnancy. In Ivory Coast, women frequently first present at the 
hospital at a stage very late in pregnancy (e.g. onset of labour or first prenatal visit in the third 
! 94!
trimester); in this case, the calculation of gestational age based on the date of last menstruation 
is still attempted and is often complemented by symphysis fundal height. 
 
Data analysis 
A newborn was included in the analysis if they had all of sex, gestational age and head 
circumference recorded in the birth register; this data is needed to calculate the infant’s head 
circumference Z-score (HCZ). Moderate microcephaly was considered as having a HCZ of 
less than or equal to -2SD & greater than -3SD and severe microcephaly was considered as 
having a HCZ of less than or equal to -3SD (Brasil et al., 2016; CDC, 2016; de Araújo et al., 
2016; Hoen et al., 2018; Shapiro-Mendoza et al., 2017; WHO, 2016f;). Data was uploaded 
into the open access INTERGROWTH-21st online application retrieved at: 
http://intergrowth21.ndog.ox.ac.uk, which gave an exportable HCZ for each infant. We 
calculated a mean HCZ for each country, by type (retrospective/prospective) of data 
collection, to compare with the pooled mean from the INTERGROWTH-21st standards (i.e. 
0SD). The Student’s t-test and the Chi-squared test were used to compare continuous data and 
categorical data, respectively. We excluded stillborn and very preterm (< 33 weeks gestational 
age) measurements as these were excluded in the elaboration of the growth standards (Villar et 
al., 2013; Villar et al., 2014). To facilitate the visual comparison between our data and the 
INTERGROWTH-21st standards for Figure 5, we recreated the distributions of newborn head 
circumferences by sex of the INTERGROWTH-21st charts (see PDF of submitted article in 
Appendix 5). Data analysis and graphics were produced using R version 3.4.0.  
 
Ethical considerations 
In Sri Lanka and Ivory Coast, national ethical committee approval was not required in 
order to publish the aggregated results of the routinely collected data used for this analysis, 
however, institutional approval from participating hospitals was obtained. In Cameroon and 
China, institutional ethics committee clearance and approval of hospital authorities was 
obtained. 
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• 
R
esults 
In total, data w
as collected for 21426 births that occurred betw
een January 2015 and July 2018 across eight hospitals in the 
four participating countries. A
fter exclusion of stillbirths (n=298, 1.4%
), very preterm
 births (n=472, 2.2%
), and birth records w
ith 
m
issing variables (n=742, 3.5%
), data from
 19914 (92.9%
) live births w
as analyzed (Table 11).  
  T
able 11: N
um
ber of births collected and used in this analysis by participating country   
 
C
am
eroon 
Ivory C
oast 
Sri L
anka 
C
hina 
D
ata collection m
ethod 
R
etrospective 
R
etrospectiv
e 
Prospective 
R
etrospective 
Prospective 
Prospective 
T
otal births recorded 
5031 
3212 
3526 
3147 
3281 
3229 
Still births 
84 (1.7%
) 
83 (2.6%
) 
112 (3.2%
) 
3 (0.1%
) 
4 (0.1%
) 
12 (0.4%
) 
V
ery preterm
 (<33 w
eeks 
gestation) 
208 (4.1%
) 
14 (0.4%
) 
26 (0.7%
) 
74 (2.4%
) 
114 (3.5%
) 
36 (1.1%
) 
Live births (m
issing data) 
312 (6.2%
) 
158 (4.9%
) 
81 (2.3%
) 
11 (0.3%
) 
21 (0.6%
) 
159 (4.9%
) 
Live births (sufficient data
a) 
4427 (88.0%
) 
2957 (92.1%
) 
3307 (93.8%
) 
3059 (97.2%
) 
3142 (95.8%
) 
3022 (93.6%
) 
of w
hich w
ere m
ale
b  
2242 (50.6%
) 
1542 (52.1%
) 
1698 (51.3%
) 
1592 (52.0%
) 
1561 (49.7%
) 
1621 (53.6%
) 
aW
ith sufficient data for analysis, including sex, gestational age estim
ation, head circum
ference m
easurem
ent bPercentage of live births w
ith sufficient data  
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The distribution of HCZ from each country differed from that of the 
INTERGROWTH-21st standards by varying degrees (see Table 12). Figure 5 compares 
the HCZ distribution for each country with the HCZ distribution that would be expected 
based on the INTERGROWTH-21st standards. The prospective data from Guangzhou was 
the most similar (mean HCZ = -0.02SD, 95%CI: -0.06 – 0.02) to the INTERGROWTH-
21st standards, whereas the retrospective data from Abidjan was the least similar (mean 
HCZ = -1.41SD, 95%CI: -1.45 - -1.37). We found a significant difference in mean HCZ 
between male and female infants in the retrospectively collected data in Cameroon and 
Ivory Coast, as well as in the prospectively collected data in Ivory Coast and Sri Lanka 
(Table 12, Figure 5).  
Overall, in the retrospectively collected data, the prevalence of moderate 
microcephaly ranged from 2.4% (Cameroon, 95%CI: 2.0-2.9%) to 25.8% (Ivory Coast, 
95%CI: 24.2-27.4%), and the prevalence of severe microcephaly ranged from 0.5% 
(Cameroon, 95%CI: 0.3-0.8%) to 9.0% (Ivory Coast, 95%CI: 8.0-10.1%). In the 
prospectively collected data, the prevalence of moderate microcephaly ranged from 3.6% 
(China, 95%CI: 2.9-4.3%) to 14.6% (Ivory Coast, 95%CI: 13.4-15.8%), and the 
prevalence of severe microcephaly ranged from 0.2% (China, 95%CI: 0.1-0.5%) to 4.1% 
(Ivory Coast, 95%CI: 3.4-4.8%) (See Table 12). 
In Abidjan, where the mean HCZ was the furthest from zero (HCZ=-1.41SD, 
95%CI: -1.45 -  -1.37), a sensitivity analysis demonstrated a more shifted HCZ 
distribution (i.e. disaccord with the INTERGROWTH-21st standards) when mothers 
presented late in pregnancy (62.4% of women) and uterine measurements were used to 
confirm the gestational age estimation, compared to when this was not needed: -1.48SD 
(95%CI: -1.53 - -1.42) vs -1.28SD (95%CI: -1.37 - -1.23, p<0.001). The prospectively 
collected data from the maternities in Colombo showed less microcephaly and a mean 
HCZ closer to 0 (-0.22SD, 95%CI: -0.26 - -0.18) when compared to the retrospectively 
collected data from the same site (-0.49SD, 95%CI: -0.54 - -0.44, p<0.001).  Similarly, 
the prospectively collected data from the maternities in Abidjan showed less 
microcephaly and a mean HCZ closer to 0 (-0.85SD, 95%CI: -0.89 - -0.81) when 
compared to the retrospectively collected data (-1.41SD, 95%CI: -1.45 - -1.37, p<0.001). !
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Figure 5: D
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T
able 12: M
ean head circum
ference Z
-score (H
C
Z
) &
 m
icrocephaly prevalence by study site, type of data collection, and sex. 
*D
enotes significant difference betw
een m
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ale m
ean H
C
Z *a p<0.001 *
b p=0.002 *
c p=0.007 !
 
M
ean H
C
Z 
 SD
 
Total m
icrocephaly 
(≤-2SD
) 
M
oderate m
icrocephaly 
≤-2SD
 &
 >
-3SD
 
Severe m
icrocephaly 
≤-3SD
 
R
E
T
R
O
SPE
C
T
IV
E
 D
A
T
A
 C
O
L
L
E
C
T
IO
N
 
 
 
 
C
am
eroon                                  
Total (n=4427) 
0.67 ± 1.33 
129 (2.9%
) 
105 (2.4%
) 
24 (0.5%
) 
M
ale (n=2242) 
0.61 ± 1.32
*a 
62 (2.8%
) 
49 (2.2%
) 
13 (0.6%
) 
Fem
ale (n=2185) 
0.74 ± 1.33
*a 
67 (3.1%
) 
56 (2.6%
) 
11 (0.5%
) 
Ivory C
oast  
Total (n= 2957) 
-1.41 ± 1.20 
1029 (34.8%
) 
762 (25.8%
) 
267 (9.0%
) 
M
ale (n=1542) 
-1.48 ± 1.16
*b 
632 (41.0%
) 
506 (32.8%
) 
126 (8.2%
) 
Fem
ale (n=1415) 
-1.33 ± 1.25
*b 
397 (28.1%
) 
256 (18.1%
) 
141 (10.0%
) 
Sri L
anka  
Total (n=3059) 
-0.49 ± 1.27 
335 (11.0%
) 
280 (9.2%
) 
55 (1.8%
) 
M
ale (n=1592) 
-0.52 ± 1.28 
193 (12.1%
) 
165 (10.4%
) 
28 (1.8%
) 
Fem
ale (n=1467) 
-0.46 ± 1.27 
132 (9.0%
) 
115 (7.8%
) 
27 (1.8%
) 
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Ivory C
oast 
Total (n=3307) 
-0.85 ± 1.24 
616 (18.6%
) 
482 (14.6%
) 
134 (4.1%
) 
M
ale (n=1698) 
-0.96 ± 1.20
*a 
341 (20.1%
) 
272 (16.0%
) 
69 (4.1%
) 
Fem
ale (n=1609) 
-0.74 ± 1.28
*a 
275 (17.1%
) 
210 (13.1%
) 
65 (4.0%
) 
Sri L
anka 
  Total (n=3142) 
-0.22 ± 1.24 
236 (7.5%
) 
203 (6.5%
) 
33 (1.1%
) 
M
ale (n=1561) 
-0.16 ± 1.25
*c 
126 (8.1%
) 
113 (7.2%
) 
13 (0.8%
) 
Fem
ale (n=1581) 
-0.28 ± 1.23
*c 
110 (7.0%
) 
90 (5.7%
) 
20 (1.3%
) 
C
hina                                        
Total (n= 3022) 
-0.02 ± 1.13 
115 (3.8%
) 
108 (3.6%
) 
7 (0.2%
) 
M
ale (n=1621) 
-0.06 ± 1.11 
60 (3.7%
) 
59 (3.6%
) 
1 (0.1%
) 
Fem
ale (n=1401) 
0.02 ± 1.16 
55 (3.9%
) 
49 (3.5%
) 
6 (0.4%
) 
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• Discussion 
Defining microcephaly strictly as less than -2SD according to the INTERGROWTH-
21st standards resulted in a prevalence at birth at our study sites in sub-Saharan Africa and 
Asia that far exceeded estimates observed in birth defect registries of Europe, the United 
States, and Latin America (Cragan et al., 2016; Morris et al., 2016; Orioli et al., 2017). These 
findings were in part expected, since the approximation of the distributions underlying these 
standards suggests that 2.2% of the healthy newborns included in the creation of the 
INTERGROWTH-21st standards would be classified as having at least moderate microcephaly 
given this definition (Altman and Ohuma, 2013). This prevalence would already be between 
25 and 125 times the proportion of microcephaly as estimated through recent reports from 
birth defects registries (Cragan et al., 2016; Morris et al., 2016; Orioli et al., 2017). Supporting 
this, the ECLAMC (Latin American Collaborative Study of Congenital Malformations) 
determined a pre-Zika hospital-based microcephaly baseline prevalence of 0.08% in Brazil 
(Orioli et al., 2017), whereas another study from Brazil that applied a standard definition (-
2SD according to the INTERGROWTH-21st standards) to two hospital populations, without 
other criteria, found that more than 2.5% of infants were labelled as having microcephaly 
(Silva et al., 2018). These differences are not surprising considering that microcephaly cases 
in birth defects registries are likely classified as so by clinicians who have considered 
additional factors such as proportionality of the infant, dysmorphic features, and regional 
norms.  
There are many limitations of determining the prevalence of microcephaly in real-life 
settings if using pooled international standards that reflect ideal growth under optimal 
conditions. These constraints may explain the variation in our own estimates, as well as some 
of the extreme estimates for some sites, such as Abidjan, that we obtained.  Certain clinical 
practices and tools are needed in order for newborn data to best be compared with growth 
standards, some of which are not always feasible in real-life settings of low-income countries. 
First, accurate measurement of the infant head circumference is needed, requiring multiple 
measurements using a non-stretch measuring tape with correct positioning on the neonate’s 
head. In the analysis we present, these methods were employed in a controlled fashion during 
the prospective surveillance in China, Sri Lanka and Ivory Coast, but not in the retrospective 
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data from birth registers. In both Sri Lanka and Ivory Coast, the prospectively collected data 
that followed reinforcement of head measurement techniques and introduction of standard 
non-stretch headbands demonstrated mean HCZ estimates closer to zero when compared to 
the retrospective data; this indicates that reduction of measurement error leads to increased, 
but not total, assimilation with the INTERGROWTH-21st standards.  Furthermore, estimation 
of gestational age, which is best done with an ultrasound assessment in the first trimester, or 
otherwise using the date of last menstruation (Villar et al., 2013; Villar et al., 2014), is a 
measure that is complex to determine for a high proportion of women in our two participating 
countries in sub-Saharan Africa. In Abidjan, around 60% of the women presented for the first 
time at the hospital towards the end of their pregnancy, leading to uterine measurements being 
used to help estimate the gestational age. In Guangzhou, which is not a low-income setting, 
women typically undergo 4-8 ultrasounds per pregnancy, allowing for precise determination 
of gestational age and early detection and abortion of infants with any abnormalities. This 
level of care and availability of tools may partially explain the similarity of the Guangzhou 
prospectively collected data to that of INTERGROWTH-21st standards.  
The differences observed between the populations in each of our study sites and the 
INTERGROWTH-21st standards likely also reflect regional differences in the head sizes of 
infants due to environmental and socioeconomic factors, such as poor nutrition and circulation 
of infectious agents. These factors are, by definition, limited as much as possible in the 
creation of prescriptive growth standards, but cannot be teased out when comparing real-life 
data to the standards on a large-scale for surveillance purposes. Some criteria employed in the 
creation of the INTERGROWTH-21st standards, such as that for maternal height and body 
mass index, led to exclusion of more than 10% of otherwise eligible women and 
disproportionately affected specific countries (Villar et al., 2014). In a real-life setting where 
factors influenced by environmental and socioeconomic factors (e.g. maternal height and 
weight) are not adjusted for, the distribution of infant head circumference Z scores may be 
shifted away the pooled standard, further exacerbating extreme microcephaly estimates when 
using a fixed cut-off.  For example, within our two sub-Saharan Africa sites, the included 
hospitals in Ivory Coast, whose HCZ are shifted left compared to the INTERGROWTH-21st 
distribution (mean HCZ -1.39SD with retrospective collection, -0.85SD with prospective 
collection), are public with low-income catchment areas, while the hospital in Cameroon, with 
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data shifted right with a mean HCZ 0.75SD (retrospective collection), is a semi-private 
institution with most patients coming from a higher socioeconomic status, and therefore likely 
with different environmental exposures.  
Variation in fetal growth has been noted recently across the 10 countries included in 
the creation of WHO fetal growth standards (Kiserud et al., 2017), as well as across the four 
ethnic groups included in the National Institute for Child Health and Human Development 
(NICHD) fetal growth study in the United States (Buck Louis et al., 2015). Even after strict 
inclusion criteria, the INTERGROWTH-21st study noted variance in the mean HCZ for each 
of their participating countries when compared to their eventual pooled standard, which they 
call the standardized site discrepancy (SSD). Their eventual range of SSD for head 
circumference at birth varied from as low as -0.55SD to as high as 0.42 SD depending on the 
study country (Villar et al., 2014), which was within their predetermined limits to justify a 
pooled growth standard.20 It was demonstrated by Albert and Grantz (2014) that this allowed 
variance means that the probability of falling below the 5th percentile of the 
INTERGROWTH-21st percentiles would be as high as 12.6% in a setting with an SSD of -0.5 
and as low as 1.6% in a setting with an SSD of 0.5. Applied to microcephaly surveillance, in 
the first case, such pooled standards could lead to over-diagnosis in healthy infants, and in the 
second, under-diagnosis of potential clinical cases. The mean HCZ (a measure similar to the 
INTERGROWTH-21st ‘SSD’) from our study sites had an even wider range, from –1.41 to 
0.67SD, which may explain the very high proportion of microcephaly classifications that we 
observed in some countries, such as Ivory Coast. Indeed some recent studies corroborate this, 
noting that replacement of regionally specific growth charts with the INTERGROWTH-21st 
growth standards would reclassify a significant proportion of infants/foetuses as having either 
macrocephaly or microcephaly in Canada and China, respectively (Cheng et al., 2016; Liu et 
al., 2017). A systematic review evaluating the WHO pooled international growth standards 
also corroborates this finding, with individual country means matching particularly poorly to 
the head circumference standards and leading to misdiagnosis of micro and macrocephaly 
(Natale et al., 2014). 
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• Conclusions 
Our study raises several issues regarding microcephaly surveillance. The use of a -2SD 
cut-off based on the INTERGROWTH-21st chart implies that by definition, around 2% of 
healthy newborns will be categorised as having microcephaly. As mentioned by Morris and 
colleagues (2016), this will result in a high proportion of babies labelled as microcephalic who 
will have no detectable neurological impairment, generating unnecessary additional diagnostic 
costs and anxiety. To this group will be added those who have underlying morbid or 
nutritional conditions associated with small body size, and who have been excluded from the 
elaboration of pooled prescriptive standards that describe ideal growth.  These conditions may 
be particularly common in poor settings of low-income countries.  Finally, in regions with 
high variation in head circumference size due to environmental and socioeconomic factors, the 
proportion of babies diagnosed with microcephaly may reach proportions so high that any 
surveillance or diagnostic work-up based on this definition would become very impractical.  
The Ivory Coast maternities sampled in our study, with 19% of babies diagnosed with 
microcephaly through reinforced prospective surveillance, may be one example of that 
situation.  
As the ZIKV epidemic has ended (PAHO, 2017b), the focus of surveillance shifts 
towards increased specificity in identifying neurological birth defects. As a result, a cut-off of 
-3SD for microcephaly surveillance should be reconsidered, to conform with EUROCAT as 
well as guidelines and a systematic review predating the ZIKV epidemic (ECLAMC, 2015; 
EUROCAT, 2017; WHO, 2014; Woods and Parker, 2013). The predictive value of 
developmental disabilities for infants with an at-birth head circumference Z-score of less than 
-3SD compared to the norm, as opposed to -2SD, is also much higher (Dolk, 1991), and this 
should be further validated using data from cohorts of infants with ZIKV exposure during 
pregnancy. In addition to a more specific cut-off, consideration of the proportionality of 
newborn head circumference length and/or weight should be considered; inclusion of these 
criteria will mimic the procedures of birth defects registries more closely, and is echoed in 
updated recommendations from the WHO and CDC (CDC, 2018b; WHO, 2016g). Finally, 
there is a need to perform further country-specific and regional studies to develop local 
standards for foetal and newborn head circumference that can be used on a large-scale for 
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surveillance purposes. A growing body of research, including our own study, challenges the 
idea that foetal and newborn growth across the world can be assessed with a ‘one size fits all’ 
standard (Buck Louis et al., 2015; Gaillard and Jaddoe, 2014; Kiserud et al., 2017; Natale et 
al., 2014). If the international definitions for microcephaly adapt to be considerate of this 
evidence, our global epidemiological understanding of this condition will benefit.  
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2.4 Discussion: Estimates and definitions of ZIKV-related birth defects  
 
In the largest prospective cohort of pregnancies with confirmed ZIKV exposure, we 
found a risk of 7.0% (95%CI: 5.0-9.5) birth defects possibly linked to ZIKV infection, which 
was reduced to approximately 1.6% (95%CI: 0.4-4.1) after consideration of a control group.  
The reason for the dramatic reduction in our estimate was the very high proportion of infants 
originally included who were labeled as having a ZIKV-related birth defect because of ‘metric 
microcephaly’; meaning microcephaly defined so based on head circumference measurements 
according to a normalized growth curve for gestational age and sex, rather than based on or 
supported by a clinician’s diagnosis (Orioli et al., 2017). Further supporting the non-
specificity and inappropriateness of defining disease-related microcephaly through only 
‘metrics’, were our findings from two sub-Saharan African and two Asian settings that 
demonstrated elevated and highly regionally-variable proportions of infants being labeled as 
having microcephaly when using such a definition.  These results, and our attempts to 
compare them to other contemporary studies on the same topic, highlight the difficulties in 
generating accurate estimates of disease burden following emerging disease events. Below I 
will discuss how, in the case of ZIKV-related birth defects, these complications may be arising 
due to incomparability in epidemiological studies, and use of non-specific case definitions.  
 
• Drawing a consensus on the risk of ZIKV-related birth defects  
At present, three key studies have estimated the risk of birth defects following ZIKV 
infection during pregnancy; these studies have been performed each in different settings and 
with slightly differing methodologies. In a prospective cohort study in Brazil, 125 women with 
rash at any moment during pregnancy were enrolled and followed until either pregnancy loss 
or up until one month after birth for live born infants (Brasil et al., 2016). In our prospective 
cohort study in the French Territories in the Americas (FTA), 546 women with any symptom 
of ZIKV infection at any moment during pregnancy were enrolled and followed until either 
pregnancy loss or until hospital discharge following birth for live born infants (Hoen et al., 
2018). In the United States territories, a registry based study compiled longitudinal 
information on the pregnancies of 1279 ZIKV symptomatic women until either pregnancy loss 
or hospital discharge for live born infants (Shapiro-Mendoza, 2017). In all of the figures 
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mentioned above and risk estimates further discussed below, only women with RT-PCR 
confirmed ZIKV infection are considered. Without adjustment of control groups (for now), the 
estimates from the FTA and the USZIPR are similar with 7.0% (95%CI: 4.0-9.5) and 4.9% 
(95%CI: 3.8-6.3), respectively, but are much lower than the 46.4% (95%CI: 37.4-55.5) 
observed in Brazil. The reason for the stark differences between these estimates is yet to be 
addressed formally, but may be due to differences in any of: study methodologies, the 
definitions of birth defects ‘possibly linked to ZIKV’ that were used, or biological mediating 
or interactive mechanisms that differ regionally.  
 
Methods and bias in studies addressing the risk of ZIKV-related birth defects 
The main methodological characteristics of the three prospective studies addressing the 
question of the risk of ZIKV-related birth defects following infection during pregnancy are 
summarized in Table 13. Enrollment was slightly different in each study. In Brazil and the 
FTA, only ZIKV symptomatic women who presented to hospital were included; in Brazil, the 
presence of rash was necessary for inclusion, while in the FTA any symptom of infection was 
allowed (e.g. fever, rash, conjunctivitis, etcetera). In both studies, inclusion of symptomatic 
women presenting to hospital is likely to select for pregnancies with more severe infection 
manifestations. In addition, it is possible that a specific selection for women presenting with 
rash may further increase the chance for severe symptomatic infection in the Brazilian study; 
although the presence of rash in 95% of our own participants makes this, as a reason for 
differences in estimates, seem unlikely (Brasil et al., 2016; Hoen et al., 2018). As mentioned 
by the authors of the study in the US Territories, inclusion through a registry-based study may 
either select for more symptomatic pregnant women and pregnancies with already detected 
abnormalities, or rather may lead to underreporting of birth defects in pregnancy losses 
(Reynolds et al., 2017); the former could lead to an overestimate and the latter an 
underestimate of birth defects possibly linked to ZIKV. Our own research shows that 
symptom severity may be linked to increased viral load (Pellerin et al., unpublished data); 
however, higher viral load has not necessarily been linked to an increase in Zika-related birth 
defects (Halai et al., 2017; Pellerin et al., unpublished data).  
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Still focusing on methodological differences, an alternative, more plausible, 
explanation for stark differences in study estimates between the FTA and US Territories, when 
compared to Brazil, may be in the imaging procedures and length of follow-up for each study. 
In Brazil, transfontenellar ultrasound was performed in all live born infants, with subsequent 
computed tomography (CT) and MRI examinations when any abnormality was detected 
(Brasil et al., 2016). In contrast, in the FTA only prenatal imaging was performed, with 
subsequent MRI if abnormalities were detected (Hoen et al., 2018). In the US Territories post-
natal imaging was performed in only 52% of live born infants (Honein et al., 2017; Reynolds 
et al., 2017; Shapiro-Mendoza et al., 2017). Another important methodological difference is an 
increased length of follow-up in live born infants from Brazil when compared to those in the 
FTA and US Territories; this was up to one month of age for Brazilian infants, whereas 
follow-up was only until hospital discharge in the FTA and United States Territories. 
Increased CT and MRI imaging may lead to the identification of subtle brain abnormalities not 
picked up by pre and postnatal ultrasound examination that could indicate future ZIKV-related 
developmental abnormalities, and a longer follow-up period allows for further evaluation of 
clinical signs of CNS dysfunction (e.g. tonicity, reflexes, irritability, swallowing ability) that 
may not easily be observed in the first few days of life.  Supporting this, the proportion of 
microcephaly at the time of birth was similar in Brazil and the FTA, with 3.8% and 5.4%, 
respectively, whereas findings related only to postnatal imaging and clinical signs of CNS 
dysfunction, with no abnormalities seen by prenatal ultrasound, physical examination at birth, 
or eye examinations, were 18.4% and 0.4%, respectively. On the other hand, the proportion of 
infants being admitted to intensive care was much higher in Brazil when compared to the FTA 
(21% vs. 1.3%), which does indicate that the infants in Brazil were in a worse overall health 
condition, irrespective of what detailed imaging was employed (Brasil et al., 2016; Hoen et al., 
2018).  In the data published from the US Territories, it is not possible to break down these 
estimates (Shapiro-Mendoza et al., 2017).  
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Table 13: Characteristics of studies following pregnancies with RT-PCR confirmed 
ZIKV exposure in symptomatic pregnant women 
Location Study design 
and inclusion  
Sample 
Size* 
Imaging Clinical exam after 
pregnancy outcome 
Control 
Group 
Brazil 
 
Brasil et al., 
2016 
Prospective 
cohort study, 
enrolling 
pregnant 
women 
presenting 
with rash 
125 Prenatal 
ultrasound (45%). 
Postnatal 
transfontanelar 
ultrasound offered 
to all ZIKV+ 
pregnancies, then 
recommended 
CT/MRI if 
abnormality 
detected. 
Examinations up 
until 1 month of life 
by multidisciplinary 
team (neonatologists, 
neurologists, 
infectious disease 
specialists, 
geneticists, 
ophthalmologists, 
physical therapists) 
Yes 
Postnatal 
imaging not 
performed in 
control group. 
Clinical 
examinations in 
control group 
not reported. 
Clinicians not 
blinded to 
ZIKV status of 
infants 
FTA 
 
Hoen et al., 
2018 
Prospective 
cohort study, 
enrolling 
pregnant 
women 
presenting 
with ZIKV 
symptoms 
546 Prenatal 
ultrasound (80%), 
then 
recommended 
CT/MRI if 
abnormality 
detected. 
Postnatal 
ultrasound only 
for those enrolled 
in infant cohort 
(not reported). 
Examinations by 
pediatrician at time 
of birth for all live 
born infants. Hearing 
and visual testing 
only for those 
enrolled in infant 
cohort (not reported). 
No 
ZIKV negative 
control group 
identified later. 
Prenatal 
imaging less 
common (52%) 
but post-birth 
clinical exam 
similar in 
control group. 
Clinicians not 
blinded to 
ZIKV status of 
infants. 
United 
States 
Territories 
(USZIPR) 
 
Shapiro-
Mendoza et 
al., 2017 
Registry-based 
compilation of 
prospective 
longitudinal 
data on ZIKV 
exposed 
pregnancies* 
1279 Proportion of 
infants with 
prenatal imaging 
results not 
reported.  
Postnatal imaging 
performed in 
52%.  
Clinical examination 
performed at time of 
birth in all infants. 
Hearing 
examinations in 79% 
of infants. 
No 
*Symptom data collected but not an inclusion criterion 
** Numbers reflect pregnant women with confirmed ZIKV infection by RT-PCR and symptomatic 
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Differences in defining and reporting on birth defects possibly linked to ZIKV 
Although more intensive brain imaging and clinical examinations could be the reason 
for a higher proportion of infant abnormalities linked to ZIKV in Brazil when compared to the 
USZIPR or FTA, the differences in estimates may be further exacerbated by differences in 
what is reported as ‘adverse pregnancy outcome’, with the implication of being potentially 
linked to ZIKV, in different studies. Of the 58 (46%) adverse pregnancy outcomes notified in 
Brazil, 9 (7%) were fetal losses without any indication of brain abnormalities by prenatal 
ultrasound or autopsy, 4 (3%) were infants either small for gestational age or with macrosomia 
due to maternal gestational diabetes with other linked or non-specific findings, and 13 (10%) 
are solitary non-specific MRI and other post-natal imaging findings that would typically 
require further follow-up to determine if an abnormality is present (Brasil et al., 2016). The 
remaining 32 (26%, 95%CI: 18.2-34.2) defects, significantly different than the reported 46%, 
may more closely represent conditions that would be considered as abnormalities in the 
studies performed in the FTA and United States Territories. This adapted risk estimate is still 
much higher than those of the latter two studies, but, if combined with the increased length of 
follow-up into the first month of life for observation of CNS dysfunction, the results of the 
three studies become more easily reconcilable. 
 
Regional differences that may lead to mediation or interaction  
Finally, there may be a biological mediating or interacting mechanism that comes 
between ZIKV infection during pregnancy and adverse fetal outcomes. If such a mechanism 
exists, it may differ regionally due to environmental exposures or genetic differences. Poor 
socioeconomic conditions have been linked to increased microcephaly cases in Brazil, though 
this may simply indicate an area with higher birth rates and slightly increased incidence of 
ZIKV infection due to vector control deficiencies (Souza et al., 2018). Previous dengue virus 
exposure has been indicated to enhance ZIKV infection in human serum (Castanha et al., 
2017), and increase adverse fetal outcomes in ZIKV infected pregnancies in mice (Rathore et 
al., 2018). In the Brazilian ZIKV infected pregnant women, 88% had previous exposure to 
dengue virus (Brasil et al., 2016); however, presence of DENV IgG was not associated with 
adverse pregnancy outcomes in their study (Halai et al., 2017). Although in very recent years 
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there has been minimal circulation of DENV in the FTA, especially in Guadeloupe and 
Martinique where most of the data from our work on ZIKV-related birth defects originates 
(INVS, 2015; 2016; 2017), there have been significant outbreaks in these regions in the past 
(L’Azou et al., 2014). Further work to evaluate the comparative proportion of pregnant 
women with past exposure to DENV in the FTA would be interesting for comparison to that in 
Brazil; in the participants in the USZIPR study, there may be very little previous DENV 
exposure. As with other congenital infections, maternal-foetal transmission does not occur in 
all ZIKV infected pregnancies, and the reasons for why it does happen in some cases, but not 
in others, deserves further study.  
 
 
• Defining ZIKV disease-related conditions 
Metric microcephaly 
In the three studies discussed above, as well as in other key studies that focus on 
defining ZIKV-related birth defects and their risk, a standardized definition of microcephaly 
with a set head circumference cut-off (less than either -2SD or the 3rd percentile) according to 
an international pooled growth chart for gestational age and sex has been used (Brasil et al., 
2016; de Araújo et al., 2016; Hoen et al., 2018; Honein et al., 2016; Reynolds et al., 2017; 
Shapiro-Mendoza et al., 2017). Standards used include the INTERGROWTH-21st Newborn 
Size at Birth Growth Charts, the WHO Child Growth Standards, and the revised Fenton 
growth chart (de Onis et al., 2004; Fenton and Kim, 2013; Villar et al., 2014); the former two 
are recommended by the CDC and WHO (CDC, 2016; WHO, 2016f). When this definition is 
used on its own to define a case, without needing clinician opinion or agreement that the infant 
is abnormal, it can be termed ‘metric’ microcephaly, as has been discussed by Orioli and 
colleagues (2017). Labeling an infant as having microcephaly based on measurement only 
does not reflect the real-life practice of diagnosis for this condition, outside of research and 
ZIKV-induced surveillance (Orioli et al., 2017).  For example, an infant with a head 
circumference of     -2.5 SD and length of -2.2 SD, according to a standardized growth chart, 
may not be flagged as possibly abnormal by a pediatrician, especially the infant has no 
dysmorphic features and the mother is 150cm tall. Alternatively, an infant with head 
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circumference of -1.9 SD with partially collapsed skull, excess scalp and a length of 0.2 SD 
according to a standardized growth chart, may be noted as having microcephaly with 
recommended further imaging. In both examples, the growth standards may be useful at an 
individual level to determine whether the infant needs a closer examination, but an expert 
clinical opinion decides the next steps in diagnosis and care.    
 
The use of one definition for a clinical condition in real-life and another for research 
purposes may lead to the perception of a highly distorted flux in cases if a focus on the 
manifestation suddenly increases due to an emerging disease event. In the case of 
microcephaly, this is obvious when we compare the reported pre-ZIKV prevalence of the 
condition, reported through birth defects registries, against the observed proportions when a 
‘metric microcephaly’ definition is applied across a population of infants either pre or post-
ZIKV. Table 14 demonstrates this, along with a further comparison to the proportion of 
microcephaly in studies in ZIKV exposed neonates, and the magnitude of increase that may 
then be perceived and reported. A key factor underlying this large difference is that, by 
definition, use of a cut-off at less than -2SD (or 3rd percentile) against a normally distributed 
standardized growth chart, should automatically implicate 2-3% of healthy infants as having 
microcephaly. Although this may seem obvious, high proportions of microcephaly seen in 
studies applying metric microcephaly definitions to hospital-based or other study populations 
have been interpreted as clinically relevant in the wake of the ZIKV epidemic. In Brazil and 
Guatemala, when high baseline microcephaly was observed using pre-ZIKV era data, the 
interpretations were ‘microcephaly was endemic… before circulation of the Zika virus’ and 
presence of ‘high background congenital microcephaly’, respectively, with recommendations 
to improve screening techniques (Rick et al., 2017; Silva et al., 2018). In one of the Brazilian 
hospitals studied by Silva and colleagues, the 2.5% prevalence of microcephaly seen should 
could alternatively be interpreted as “similar to the expected amount of infants with head 
circumference Z-scores less than -2SD according to the growth standard used”; the 
INTERGROWTH-21st newborn standards, used in that study, prescribe that 2.2% of healthy 
infants will have microcephaly (Villar et al., 2014). 
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Regional differences in growth  
            Misleading baseline proportions of microcephaly may be further exacerbated 
when regional growth norms do not match well with the recommended international 
pooled growth standards used to define metric microcephaly. This has been previously 
reported through a systematic review for the WHO child growth standards (Natale et al., 
2014). This was also clearly demonstrated through our own findings in four settings in 
sub-Saharan Africa and Asia, with as low as 3% and as high as 35% live born infants 
being labeled as having microcephaly using a -2SD cut-off according to the 
INTERGROWTH-21st newborn growth standards. Such variation should equally be 
considered when interpreting research on ZIKV-exposed populations in different settings.  
The INTERGROWTH-21st Newborn Size at Birth growth standards were created 
through a large population based study which included cities in eight countries: Pelotas 
(Brazil), Turin (Italy), Muscat (Oman), Oxford (UK), Seattle (USA); Shunyi County, 
Beijing (China); the central area of Nagpur (India); and the Parklands suburb of Nairobi 
(Kenya). The study enrolled pregnant women in each region who had optimum health, 
nutrition, education and socioeconomic status, who lacked any significant gynaecological 
or obstetric history, and who met other pre-specified study inclusion criteria (Villar et al., 
2013). In the case that the mother developed any severe condition during pregnancy, or in 
the event of a stillbirth, miscarriage, medical abortion, or live birth with congenital 
abnormalities, the participant was excluded. The INTERGROWTH-21st study group 
found that while skeletal indicators (including crown-rump length for early linear foetal 
size, and head circumference for foetal growth after 14 weeks gestation) differed across 
the eight countries, even after application of their strict inclusion criteria, the estimates 
were within a pre-specified degree high enough in order to justify pooling the findings 
(Villar et al., 2014; Altman and Ohuma, 2013). This allowed range of difference was 
0.5SD; meaning that for a key indicator, any one country’s growth distribution could 
differ by up to 0.5SD from the pooled standard. As mentioned in our paper, this allowed 
variance was criticized by some, who demonstrated that 13% of healthy infants could be 
labelled as abnormally small if the mean SD of a specific country sat at -0.5SD on the 
pooled standard (Albert and Grantz, 2014). !
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 Although it is controversial to suggest that ethnic variation and genetics may play a role in 
fetal growth, abstaining from entering into that conversation does not exclude the realization that 
we should expect (sometimes extreme) variance in head circumference and other growth Z score 
distributions when applying pooled standards to an entire newborn population in a given region 
of the world. In a real-life newborn population for which the proportion of microcephaly is of 
interest, there cannot be any selection based on criteria such as maternal height, nutrition and 
environmental conditions. This can explain, non-controversially, the variation seen in proportion 
of infants at baseline with microcephaly, or other conditions, in different regions. For example, in 
India, a criterion that mothers needed to be >153 cm tall, led to the exclusion of many otherwise 
eligible women (i.e. good nutritional and socioeconomic status, etcetera) in the 
INTERGROWTH-21st study (Villar et al., 2014). As the average female height in India has been 
estimated at around 152 cm, creation of a growth chart using this criterion is not nationally 
representative, and would no doubt lead to extreme results if it was applied nationwide for 
surveillance (Mamidi et al., 2011; Steer, 2014). Persons on either side of the debate for or against 
regionally specific growth standards are unlikely to argue that microcephaly surveillance of all 
newborns in a village in South Kivu may produce a very different estimate when compared to a 
private hospital in Manhattan, if using a pooled growth standard. In a setting with nutritional or 
socioeconomic deficiencies or excesses, the artificially high or low proportions of baseline 
microcephaly automatically implied when using a ‘metric microcephaly’ definition and 
international pooled growth charts will become very problematic when trying to identify a real 
change in disease-related cases should an epidemic of ZIKV occur.   
 
• Improving accuracy and comparability of ZIKV-related birth defects findings  
Avoidance of many of the issues I have raised above can be achieved by comparison with 
an appropriate ZIKV non-exposed control group that has had, as much as possible, the same 
investigations as a ZIKV exposed fetal/newborn population of interest. In our own case, 
comparison with a control group left us to deduce that only 1.6% of foetuses/infants born to 
women infected during pregnancy in Guadeloupe during the epidemic period had severe 
abnormalities linked to ZIKV at the time of birth. Even though in our original prospective cohort 
study we used a metric definition of microcephaly, even this likely inappropriate diagnostic for 
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the condition was teased out through comparison with a control group who had the same clinical 
examination at birth. Control groups may also help to speed up conclusions on non-specific 
imaging and clinical findings in the early neonatal stages; in this case, it would be necessary that 
clinicians are blinded as to ZIKV exposure and that the same intensity of imaging is done in 
control groups. This was not the case for the control group used in the Brazilian study examining 
the risk of ZIKV-related birth defects (Brasil et al., 2016). In the case of inability to identify a 
control group, shifting away from a measurement-based definition of some conditions, such as 
microcephaly, and towards more clinically relevant pathology-based definitions is needed.   
Transparency and clear communication between study authors can be a quick and easy 
way to deduce differences in study case definitions. In our own study on ZIKV-related birth 
defects, as well as that of Brasil and colleagues in Brazil, publishing of a supplementary appendix 
that clearly stated all the imaging and clinical findings of each infant diagnosed as ‘abnormal’ 
allows any person to compare what each research group has considered as a disease-related 
condition (Brasil et al., 2016; Hoen et al., 2018). Research groups addressing the topic of the risk 
of ZIKV-related birth defects in the future will ideally use the same approach, which, all together, 
will facilitate eventual meta-analyses.  
Determination of the most accurate possible results regarding the risk of ZIKV-related 
birth defects following infection during pregnancy has important policy implications, for 
example, for the eventual vaccination of women of childbearing age. Without a vaccine yet 
available, there is an more pressing importance in deciphering the true risk of ZIKV-related birth 
defects, and that is a clear and accurate communication with women who are positive for ZIKV 
during pregnancy. This will limit anxiety and guide follow-up and family planning decisions in 
countries where these services are available. In many South American countries where access to 
safe abortion is restricted, requests for pregnancy termination through an online telemedicine 
alternative increased significantly during the ZIKV epidemic period; these magnitudes may be 
underestimated as they do not take into account those who sought unsafe alternatives (Aiken et 
al., 2016). These women, on whom the social and economic burden of having an infant with a 
severe disability will largely fall, deserve our best collaborative efforts in estimating the risk of 
ZIKV-related birth defects.  
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In this section, I will focus on research related to the introduction of new highly effective 
direct acting antivirals (DAA) to treat Hepatitis C (HCV) in Egypt – this was the original topic of 
my thesis from October 2014 until mid-2016. During these two years, I made multiple visits to 
Cairo to prepare a cohort study following 7500 persons treated with these drugs through the 
National Treatment Program, and worked on moving the protocol through various regulatory 
bodies in France. Although the full cohort study was halted (the reason for my thesis topic 
switch), and has only just re-begun in early 2018, valuable collaborations with smaller associated 
research groups during this time led to my significant involvement in four published and two 
ongoing pieces of linked research over the past four years.  
 
I will start with some background information on HCV, with a specific focus on the 
evolution of available treatment options as well as the Egyptian context. The latter will include a 
brief description of a research article I worked on related to the prevalence of HCV in Egypt. I 
will then present two research articles that highlight the challenges in bringing together initial 
findings on potential adverse events of a new treatment after administration in real-life 
populations. A third article, a research letter, addresses a challenge of wide-scale introduction of 
new therapies for HCV – assuring retention of patients until the moment of cure to enable follow-
up of non-responders with potential resistance mutations as well thorough program evaluation. I 
will then briefly discuss further implications of our findings, potential explanations and solutions 
for addressing the challenges of interpretation of results following an event such as effective 
treatment introduction, and propose important next steps.  !
!  
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3.1 Background  
 
3.1.1 Discovery and Diagnosis of HCV 
 
In 1975, researchers realized that a high proportion of transfusion related hepatitis was 
caused by an elusive other agent, rather than the already identified hepatitis A and hepatitis B 
viruses (Alter et al., 1975; Alter, 1999; Fienstone et al., 1975). ‘Non-A, non-B hepatitis’ (NANB) 
was shown to lead to liver disease in a high proportion of patients, however, without being able to 
isolate the agent behind it, prevention efforts and specific blood screening tests were not possible 
(Hoofnagle & Alter, 1985).  In the 1980s, there were many unsuccessful attempts to isolate the 
pathogen causing NANB in vitro using traditional methods on blood from patients. Then, more 
than 10 years after the discovery of NANB, a research group headed by Michael Houghton from 
Chiron Corporation laboratories, with the support from the Centers for Disease Control and 
Prevention, were able to isolate a cDNA clone of derived from a virus after screening large 
amounts of blood from experimentally infected chimpanzees (Alter, 1999; Houghton, 2009). It 
was a flavivirus, a member of the family Flaviviridae, and was thereafter called the “Hepatitis C 
virus” (Choo et al, 1989).  Rapid work that followed saw the identification of several HCV 
genotypes (up to seven), development of assays for detection of HCV antibodies and HCV RNA, 
and an epidemiological understanding that this virus had been the main cause of blood-
transmitted NANB hepatitis (Alter, 1999; Kuo et al, 1989).  In the United States, it quickly 
became standard procedure to test donated blood for antibodies against the pathogen, and with 
further improved enzyme immunoassays (EIA) in the early 1990s, transfusion-associated HCV 
was practically eliminated in high-income nations within a few years (Alter, 1999).  
 
At present, HCV antibodies (anti-HCV) can be detected in oral fluid or blood within a 
few weeks of infection using the third generation enzyme immunoassays (EIA-3) in laboratory 
conditions, with sensitivities and specificities up to 98% and 100%, respectively. Rapid tests for 
anti-HCV are also available; for detection in blood with sensitivities and specificities reaching 98 
and 100%, respectively, and for detection in oral fluid with sensitivities and specificities reaching 
94 and 100%, respectively (Tang et al., 2017). Presence of anti-HCV indicates qualitatively 
whether or not a person has ever been infected, but is unable to distinguish between current (i.e. 
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active) and former infection. Nucleic acid tests are used to detect and quantify HCV RNA, 
expressed in ‘units international’ per ml (UI/ml), and are commonly carried out using PCR 
techniques (Chevaliez, 2011; Pawlotsky, 2003). Presence of HCV RNA indicates an active 
infection with ongoing viral replication. Rapid tests for detection of HCV RNA using venous 
blood are currently being evaluated, with demonstrated sensitivities and specificities of up to 
100%, and the possibility of eventually using capillary blood (finger prick testing) (Grebely et al., 
2017; Lamoury et al., 2018; Llibre et al., 2018).   
 
 
3.1.2 Natural history of HCV infection 
Following acute infection with HCV, between 15 and 40% of individuals clear the virus 
spontaneously with 6 months time (Westbrook & Dusheiko, 2014); this clearance is associated 
with various genetic factors, including presence of variants of the interleukin 28B (IL28B) gene, 
as well as the DQB1⁄0301 allele of the major histocompatibility complex class II (Alric et al., 
1997; Ge et al., 2009; Thomas et al., 2009).  While most persons with acute infection will be 
asymptomatic, a minority will have flu-like symptoms with more severe symptoms such as 
jaundice, abdominal pain, and lack of appetite (Westbrook & Dusheiko, 2014); this lack of 
symptoms makes studies on acute HCV infection complex to carry out. The most common 
complication of acute infection is progression to chronic infection and hepatitis, however, for 
those who do clear the virus spontaneously, long-term impact on the liver is very rare. It is 
important to note that clearance of HCV, either spontaneously or via treatment, does not preclude 
re-infection (Westbrook & Dusheiko, 2014). 
For the majority of persons with acute infection, chronicity occurs, marked by continual 
hepatic inflammation. After 20 years and 30 years, chronic HCV infection has been seen to lead 
to cirrhosis in around 15% and 40% of persons, respectively (Thein et al., 2008; Westbrook & 
Dusheiko, 2014). Cirrhosis is caused by progressive fibrosis (scarring), of the liver, which is a 
result of chronic inflammation and perpetually elevated liver enzymes. Fibrosis is evaluated in 
stages, best diagnosed by liver biopsy, which relates to the level of scarring of the liver using the 
Metavir score: F0 indicates a lack of fibrosis, and F1-F2 mild-moderate fibrosis, F3 is moderate-
severe fibrosis without cirrhosis, and F4 is cirrhosis. Cirrhosis indicates that scarring has 
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encompassed the liver to such a degree that it is unable to perform its usual functions. The timing 
by which each patient develops and then moves towards increased fibrosis levels differs and is 
not necessarily linear; it is influenced by the virus itself, the individual, and the environment 
(Datz et al., 1999; Westbrook & Dusheiko, 2014; Yi et al., 2004).   
For those with cirrhosis, the yearly incidence risk for hepatocellular carcinoma (HCC) is 
between 1 and 4% (El-Serag et al., 2006; Goodgame et al., 2003). If presence of HCC lesions are 
caught at an early stage, then local ablation or surgical resection procedures can successfully be 
used as treatment, with up to 70% of patients having 5-year survival following this therapy (Lin 
et al., 2012). If detected at an intermediate stage, transarterial therapies, such as transarterial 
chemoebolization (TACE), are usually recommended to treat HCC, however, studies evaluating 
whether or not this intervention increases average survival time have varying conclusions 
(Oliveri et al., 2011).  Surgery is another option for persons with intermediate stage HCC, but 
with 5-year survival estimated at less than 20% (Chen et al., 2006). At late or terminal stages of 
HCC, oral sorafenib can be given, sometimes in addition to transarterial therapy, with median 
survival being typically less than a year (Bruix & Sherman, 2011; Qu et al., 2012). Unless a 
person is at the very earliest stages of this cancer, liver transplantation is also an option for 
treatment. With liver transplantation, the chance of 5-year survival for persons with HCC 
increases up to 80% (Mazzaferro et al., 2009; Poon et al., 2007). This success rate is due to the 
fact that liver transplantation not only removes the cancer, but also eliminates all previous liver 
damage. Unfortunately, the feasibility of transplantation is low due to a shortage of donors and 
strict eligibility criteria (Lin et al., 2012). Influencing survival, the 5-year risk of HCC recurrence 
after successful treatment, of even some of the earliest stages, is up to 70% (Hanazaki et al., 
2000; Poon et al., 2002; Portolani et al., 2006).  
An alternative risk for persons with cirrhosis, occurring in 3-6% of persons annually, is 
decompensation - defined as the occurrence of variceal haemorrhages, ascites and 
encephalopathy (Westbrook & Dusheiko, 2014). One-fifth of persons having a decompensation 
event will not survive until the following year (Thein et al., 2008).  
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3.1.3 Treatments for HCV  
• The Interferon-Era (1990 – 2014) 
Interferons (IFN) are proteins that occur naturally in the human body and have a wide 
range of actions. Various types of IFN are commercially produced for use in treating disease. In 
the case of hepatitis C, both IFN-α2a and IFN- α2b, subtypes of IFN- α that differ only by one 
amino acid, are active. Use of IFN-α to treat HCV began shortly after discovery of the virus, in 
1990 (Poordad & Dieterich, 2012). Original treatment regimens that prescribed injected doses of 
IFN-α for six months to one year led to a sustained virological response (SVR) in between 10 and 
20% of patients (Carithers & Emerson, 1997; Haria & Benfield, 1995; Poynard et al, 1996; 
Saracco & Rizzetto, 1995). In the case of HCV, SVR indicate successful clearance of the virus, 
and is assessed 24 weeks (SVR24; used in the IFN-era) or 12 weeks (SVR12; used with more 
recent regimens) after the end of treatment. In the decade or so to follow, some improvements to 
treatment with IFN-α included addition of another anti-viral, ribavirin (RBV), as well as 
pegylation of IFN (i.e. peg-IFN), a process that allows for an increased half-life of, and tolerance 
to, the molecule. Combination therapy of parenteral peg-IFN-α and orally administered RBV 
could typically lead to SVR in around 40 and 50% of chronic hepatitis C patients with genotypes 
1 or 4 (G1, G4) if given for 48 weeks, and between 70 and 80% for those with genotypes 2 or 3 
(G2, G3) if given for 24 weeks (Brok et al, 2005; Fried et al, 2002; Hadziyannis et al, 2004; 
Kjaergard et al, 2001; Manns et al, 2001; Simin et al, 2007; Zayed et al, 2016).  
IFN is not a well-tolerated treatment, and is contraindicated in persons with advanced 
liver disease. Although severe side effects were rare for persons undergoing HCV therapy with 
IFN-α, almost all patients experience some mild-moderate symptoms. A ‘flu-like’ syndrome (i.e. 
fatigue, nausea, etcetera) is seen in almost all persons taking this therapy- the severity of this side 
effect is reduced with increased time on treatment for most patients (Dusheiko, 1997). Psychiatric 
side effects, such as depressive episodes and cognitive disorders are seen frequently, in around a 
quarter of patients (Dusheiko 1997; Udina et al, 2012). Such side effects have a negative impact 
on quality of life early on in treatment, and have led to discontinuation and dosage changes in up 
to 30% of patients (Bonkovsky et al, 1999; Dusheiko, 1997; Hunt et al, 1997; Ware et al, 1999; 
Zeuzem et al, 2000).  
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• Direct acting antivirals (2014 to present) 
Direct acting antivirals (DAAs) are agents that act on parts of the viral life cycle that are 
specific to HCV itself. Advances in the in-vitro cultivation of HCV in the last decade or so have 
allowed for identification of many potential targets for such treatments. The class names of the 
DAAs reflect the part of the viral genome that is suppressed by their action: NS3/4A protease 
inhibitors block the ability of the virus to protect itself and cause damage to the host liver cell, 
NS5B nucleoside and non-nucleoside inhibitors block the ability of HCV to replicate itself, 
NS5A inhibitors block viral replication and the ability of HCV to interfere with host-cell immune 
defenses (Poordad & Dieterich, 2012).  
In 2011, the FDA approved the first DAAs against HCV (FDA, 2011a; FDA, 2011b). 
These two agents, called boceprevir and telaprevir, are protease inhibitors that had demonstrated 
achievement of SVR in around 75% of treatment-naïve patients, and 65% of treatment-
experienced patients in clinical trials when given in combination with IFN and RBV (Park et al., 
2014). However, this triple therapy was associated with higher discontinuation of treatment due 
to adverse events when compared to IFN + RBV therapy alone; more common side effects 
included anemia, rash and itching, nausea, and taste distortion (Cooper et al., 2012; Dang et al., 
2011; Park et al., 2014). In addition, development of resistance was a common reason for patients 
to fail treatment (Macartney et al., 2014; Wyles, 2012).  
 In 2013, a NS5B inhibitor called sofosbuvir (SOF), manufactured by Gilead Sciences 
under the name Sovaldi®, was approved for treatment of G1-4 of HCV by the FDA (FDA, 2013).  
This second generation DAA led to SVR in 90% of treatment-naïve HCV patients, with any of 
the four main genotypes, when given in combination with peg-IFN & RBV for 12 weeks of 
treatment (Kowdley et al., 2013; Lawitz and Lalezari et al., 2013; Lawitz and Mangia et al., 
2013).  In addition, for historically ‘difficult to treat’ populations (e.g. treatment non-responders, 
cirrhotics), dual therapy of SOF plus RBV for 24 weeks demonstrated SVR in up to 70% of 
persons enrolled in clinical trials (Osinusi et al., 2013). Swiftly following the approval to treat 
persons with HCV with SOF using dual or triple therapy, other DAAs were released by Gilead 
Sciences, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, and Merck (FDA, 2017).  
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For chronic HCV patients of all genotypes and regardless of treatment experience, there 
are now many all-oral treatment options available, many given as a single tablet containing 
multiple fixed dose DAAs. Recommended treatment durations are currently from 8-12 weeks for 
non-cirrhotic patients and 12-16 weeks for patients with compensated cirrhosis. In this case, 
treatment experience refers to therapy with peg-IFN plus RBV with or without SOF, or SOF plus 
RBV (EASL, 2018). Clinical trial and real-life evaluations of these treatment regimens show 
similar cure rates of  > 95% in these populations with all-oral regimens (Afdhal and Reddy et al., 
2014; Afdhal and Zeuzem et al., 2014; Asselah et al., 2018; Feld et al., 2015; Ferenci et al., 2014; 
Forns et al., 2017; Jacobson et al., 2017; Kohli et al., 2015; Kowdley et al., 2014; Krishnan et al., 
2017; Landis et al., 2017; Naggie et al., 2015; Rockstroh et al., 2015; Toyoda et al., 2018; Tsai et 
al., 2017; Wei et al., 2016; Welzel et al., 2016; Zeuzem et al., 2015; Zeuzem et al., 2018). In 
patients with severe liver disease (i.e. decompensated cirrhosis) and those who have received 
liver transplantation, there now are also treatment options, however, DAAs that act as protease 
inhibitors are not recommended (EASL, 2018).  For this population, real-world evaluations and 
clinical trials demonstrate cure rates of >85% for persons with moderate decompensation, and up 
to 80% in those with severe decompensation with HCV genotypes 1 and 4  (Charlton et al., 2015; 
Manns et al., 2016; Foster et al., 2016, EASL, 2018).   
The adverse events experienced using second generation DAAs are considerably milder 
when compared to IFN containing regimens, and lead to treatment discontinuation in only around 
1% of patients. Typical side effects include fatigue, headache, nausea, benign diarrhea, and for 
some regimens, dermatological manifestations such as itching and rash (Dufour et al., 2017; 
EASL, 2018; Jacobson et al., 2017). Rare severe adverse events have included episodes of severe 
pulmonary arterial hypertension and cardiac arrhythmias, the latter due to contraindication with 
other treatments (EASL, 2018; Renard et al., 2016; Renet et al., 2015).  Persons with 
decompensated cirrhosis are more likely to experience severe adverse events to treatment (EASL, 
2018). While the new DAAs have higher barriers to resistance than the first generation ones, 
resistant-mutations have been detected in persons not responding to treatment, and this confers a 
lower likelihood of achieving SVR (Pawlotsky, 2016). Further research and monitoring in the 
area of DAA resistance is needed.  
 
! 123!
• Benefits of achieving an SVR 
 Achievement of SVR for patients with mild to moderate liver damage is associated with 
reversal of liver damage, reduction in incidence of HCC, and overall increased survival 
(D’Ambrosio et al., 2012; George et al., 2009; Morgan et al., 2012; Poynard et al., 2002; van der 
Meer et al., 2012; Veldt et al., 2007;) In similar patients treated with all-oral DAAs, 
improvements in hepatic function and overall mortality have been seen (Backus et al., 2018; 
Mandorfer et al., 2016; van der Meer & Berenguer, 2016). However, more time will be needed to 
fully quantify long-term benefits and improvement in liver function (van der Meer & Berenguer, 
2016). In addition, for one-third to one-half of persons with moderate and severe decompensation 
that are treated with DAAs, achievement of SVR has been associated with improvement in liver 
function scores in both clinical trials and real-world evaluations; longer-term studies will be 
needed to determine if overall liver function and survival is improved (EASL, 2018; van der 
Meer & Berenguer, 2016). Achieving SVR also has a positive impact on patients’ health-related 
quality of life, regardless of type of regimen this is achieved by (Bernstein et al., 2002; Younossi 
et al., 2018).   
 
• The cost of the miracle drugs 
The release of Sovaldi® (i.e. SOF) by Gilead Sciences was not met with unbridled joy in 
the international community, even considering its huge perceived benefits according to published 
clinical trials. The cost of a 12-week supply of the drug was marketed originally at 84000 United 
States dollars (USD) - about 1000 USD a pill (Reuters, 2014a). The backlash to this included 
protests, such as a ‘death-in’ staged at an event hosted by Gilead Sciences, condemnation from 
various health organizations, and legal movements for patent opposition (Treatment Action 
Group, 2014; The New York Times, 2014; MSF, 2017).  
As of 2018, some middle-income countries such as India, Egypt, and Brazil, have refused 
the patent or have successfully applied for exceptions with Gilead Sciences and other 
pharmaceutical companies in order to produce generic versions of the drug (Gilead Sciences Inc, 
2015; The New York Times, 2015; Pharmaceutical-Technology News, 2018; Douglass et al., 
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2018). Further, many middle and high-income nations have successfully negotiated down the 
prices for DAA regimens with Gilead and other pharmaceutical companies. However, in some 
countries such as the United States, Denmark, and Poland, treatment costs remain very high and 
lead to patient eligibility selection (e.g. based on fibrosis level) that is not mandated by the 
treatments themselves (Douglass et al., 2018).  
 
3.1.4 Global epidemiology of HCV  
The adult global prevalence of anti-HCV was estimated to be 2.5% in 2016 using data 
from 138 countries collected between the years 2000 and 2015. Of this, it was estimated that 
approximately 67% of persons are viraemic, signifying around 120 million chronic HCV 
infections globally (Petruziello et al., 2016).  The most predominant genotype is 1 (G1), 
estimated to have a global prevalence of 46-49%, followed by G3 (18-30%), G4 (13-17%), and 
G2 (11-13%) (Gower et al., 2014; Messina et al., 2015; Petruziello et al., 2016). By region, the 
proportion of persons with chronic infection, and the predominant genotype, vary greatly (see 
Table 15).  Associated with the differences in prevalence per region are variations in the most 
common modes of transmission as well as locally available resources for prevention, testing, and 
treating. HCV is a blood-borne pathogen, and the most common methods of transmission include 
unsafe medical injections and surgical procedures, illicit injection drug use, and blood transfusion 
(Shepherd et al., 2005). In low-middle income countries, transmission has occurred mainly 
through exposure to unsafe medical procedures and a lack of injection safety (El-Ghitany et al., 
2015; Eze et al., 2014; Malhotra et al., 2015; Rerambiah et al., 2014); however, it is estimated 
that the number of new healthcare associated cases has decreased by more than 80% in these 
settings since the year 2000 (Kane et al., 1999; Pepin et al., 2014). In high-income countries, 
injection drug use is the main risk factor for transmission; this accounts for up to 80% of new 
HCV cases in many European countries as well as in North America and Australia (Alter, 2002; 
Dore et al., 2003; Judd et al., 2005; Mele et al., 2000; Negro, 2014; Suryaprasad et al., 2014; 
Thorpe et al., 2002).  
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Blood transfusion is considered to have been the biggest driver of HCV transmission, but 
dropped drastically as a contributor to incident infections in high-income countries with the 
implementation of ‘all-volunteer’ blood donation programs in the 1970s and 80s as well as 
screening of blood products in the early 1990s after discovery of the virus (Alter et al., 1972; 
Doman, 1995). Unfortunately, in many low-income settings, blood donor and blood product 
screening is not enforced universally and so transmission through this pathway is still a risk 
factor (Marwaha and Sachdev, 2014). Vertical transmission of HCV infection, from mother to 
child, is estimated to occur in 3-8% of infected pregnancies, with increased risk if the mother is 
co-infected with human immunodeficiency virus (Dal Molin et al., 2002; Ferrero et al., 2003; 
Thomas et al., 1998; Yeung et al., 2001). Sexual transmission of HCV is also possible, but is 
extremely rare in heterosexual single-partner relationships, and more common for multiple-
partner and higher-risk sexual behaviours (e.g. anal sex); the latter is true especially if co-infected 
with HIV (Alter et al., 1989; McFaul et al., 2015; Terrault et al., 2013; Vanhommerig et al., 
2015).  
Recent research suggests that the worldwide prevalence of HCV is decreasing, from 
approximately 2.8% estimated from data collected up until 2005, down to 2-2.5% in data 
collected up until 2015 (Petruziello et al., 2016). However, these trends, and an accurate 
estimation of their magnitude, may be nuanced by changes in sensitivity and specificity of 
diagnostic tests, as well as differences in data availability, over the past 25 years.  
 
3.1.5 HCV in Egypt 
From ancient times until quite recently, schistosomiasis (or Bilharzia), caused by the 
parasites S. haematobium and S. mansoni, was a major public health problem and the main cause 
of liver disease in Egypt (Abdel-Wahab et al, 1980; Abdel-Wahab, 1982; Scott 1937) Although 
an effective oral treatment for schistosomiasis (i.e. praziquantel) is now available, for most of the 
last century the recommended therapy was repeated injections of tartar emetic (Strickland & 
Ramirez, 2000). To tackle the large national prevalence of schistosomiasis, the Egyptian Ministry 
of Health and Population (MoHP) employed this latter treatment in countrywide campaigns as 
early as the 1920s and with increasing intensity up until the early 1980s (Frank et al, 2000; 
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Strickland, 2006). At that time, the dangers of blood-transmitted pathogens were still 
underestimated and glass-syringes were used repeatedly with insufficient sterilization over large 
groups of persons receiving treatment.  
HCV seroprevalence studies taking place in the Egypt in the early 1990s indicated that a 
very high proportion of the adult population had been exposed to the virus, with estimates of 
around 10-25% anti-HCV in blood donors from urban areas, and 15-40% in non-blood donor 
populations living in rural areas (Abdel-Wahab et al, 1994; Arthur et al, 1997; Darwish et al, 
1993; Darwish et al, 1996; Darwish et al, 2001; El Gohary et al, 1995; Kamel et al, 1992; Kamel 
et al, 1994; Mahamoud et al, 2013; Quinti et al, 1995). In 1995-96, a representative survey of 
8499 Egyptians between 10 and 50 years of age demonstrated a national seroprevalence of 21.9% 
(95% CI: 21.0-22.8), with analyses confirming an association between presence of anti-HCV and 
parenteral therapy for schistosomiasis (Frank et al., 2000).  Later, in 2008, a representative 
demographic health survey in 11126 Egyptians aged 15-59 years old demonstrated an updated 
seroprevalence of 14.7% (95% CI: 13.9-15.5) (Guerra et al, 2012). It is estimated that more than 
90% of the HCV infection in Egypt is due to G4, which is rare in other parts of the world (Gower 
et al., 2014; Ray et al., 2000).  
Although oral praziquantel is now used for treatment of schistosomiasis in Egypt, a high 
incidence of infection persists through unsafe medical injections and other surgical procedures, 
facilitated by the large HCV reservoir (Arafa et al., 2005; Mohsen et al., 2015; Paez Jimenez et 
al., 2009; Paez-Jimenez et al., 2010;). The incidence was estimated at approximately 150 000 
infections annually by a modeling study performed using data from cohort studies in 2012 
(Breban et al., 2013).  !
• Original research (short description): Hepatitis C prevalence in Egypt, 2014-2015 
The Egyptian Demogaphic Health Survey (EDHS) took place again in 2014, this time 
under the name of Egyptian Health Issues Survey (EHIS). Both of the national surveys in 2008 
and 2015 were cross-sectional household surveys, conducted by El-Zanaty and Associates with 
support from the United States Aid of International Development-sponsored DHS-7 project. In 
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these surveys sampling weights were used to provide estimates considered representative of the 
Egyptian population on the basis of a complex, three-stage probability sampling approach (El-
Zenati & Way, 2008; Ministry of Health Egypt, 2015). The surveys provide estimates of HCV 
prevalence in Egypt for the country as a whole as well as broken down for the major 
administrative regions (Urban Governorates, Lower Egypt, Upper Egypt and the Frontier 
Governorates). In both EDHS 2008 and EHIS 2015, those aged 15– 59 years were invited to 
participate, however, in 2015, children aged 6 months to 14 years were also included. The 
preliminary analysis of the EHIS 2015 demonstrated a new seroprevalence of 10.0% (95%CI: 9.5–10.5). When compared to the 14.7% (95% CI: 13.9-15.5) seroprevalence seen in 2008, this 
significant decline raised questions of whether or not the nationwide prevention and treatment 
efforts could be credited. At this point, we began some collaborative work with the MoHP in 
order to compare and interpret the differences between the 2008 and 2015 surveys.   
We found that, in the 15–59-year age groups, the prevalence of HCV antibody was found 
to be 10.0% (95% CI 9.5–10.5) and that of HCV RNA to be 7.0% (95% CI 6.6–7.4). In children, 
1–14 years old, the prevalence of anti-HCV and HCV RNA were 0.4% (95% CI 0.3–0.5) and 
0.2% (95% CI 0.1–0.3), respectively. For both antibodies and HCV RNA, the prevalence was 
increasing by age group. Extrapolated, this would mean that 3.7 million persons have chronic 
HCV infection in the age group 15–59 in 2015 in Egypt. For chronic infection (presence of HCV 
RNA), when the 2015 results were compared to the 9.9% (95%CI: 9.3-10.5) of persons with 
HCV RNA in the EDHS of 2008, a 29% reduction was indicated. We then deduced that this 
apparent decrease was mostly due to the ‘cohort effect’ rather than prevention or treatment 
efforts; age groups with very high prevalence of infection were growing older and shifting out of 
the age range captured by the survey (Figure 6).   
To estimate whether or not the effect of widely employed prevention efforts, such as 
infection control and needle safety programs, could be seen through the national surveys, we 
looked to the younger age groups, where seroprevalence reflects the cumulative incidence of the 
past years in the absence of mortality. In 2008 and 2015, the prevalence of HCV antibodies in 
those aged 15– 19 years was 4.1 and 1.0%, respectively; the percentage of relative risk reduction 
was 75% (95% CI 64–85), implying a very substantial reduction in HCV incidence in the past 20 
years in this age group. However, we were not yet able to visualize any effect of the nationwide 
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HCV treatment program (to be described further below), in the reduction of the proportion of 
persons with HCV RNA compared to the proportion of persons with evidence of ever having 
been infected (anti-HCV).  
In order to better estimate the prevalence of HCV in Egypt, and to further visualize both 
the cohort effect and the impact of HCV treatment, the next EHIS survey, likely to take place 
around 2020, will need to adapt to include older age groups. The PDF of this article can be found 
in Appendix 5. 
 
!
 
 
Figure 6. (A) Age-specific prevalence of hepatitis C virus (HCV) antibody-positive persons 
in 2008 and 2015 (left), then shifted (by 7 years) 2008 and 2015 (right). (B) Age-specific 
prevalence of HCV RNA-positive persons in 2008 and 2015 (left), then shifted (by 7 years) 
2008 and 2015 (right). 
 
! 130!
• National Treatment Program for HCV in Egypt 
In response to the high national HCV prevalence and associated disease burden, the 
Egyptian MoHP launched the National Committee for the Control of Viral Hepatitis (NCCVH) in 
2006. This committee is composed of expert Egyptian hepatologists, an MoHP representative, 
and a few ad-hoc international experts. The key initial priority of the NCCVH was to promote 
access to care and treatment for persons infected with HCV, and they therefore quickly 
established an Egyptian National Treatment Program (NTP). In 2007, the first national HCV 
treatment centers were founded, distributed equally throughout the country based on population 
density as well as controlling for a feasible maximum distance of travel (i.e. < 50 kilometers) for 
patients seeking treatment. By the time that DAAs were introduced in late 2014, the National 
Treatment Program comprised 26 centers, and now, in 2018, it has expanded to include 74 
centers nationwide (see Figure 7) (El Akel et al, 2017).  From 2007- 2014, the regimen provided 
by the National Treatment Program was combined peg-IFN-α2a or 2b with ribavirin over a 
period of 48 weeks. More than 350000 persons were treated with these regimens in Egypt 
between 2007 and 2014, with cure rates of approximately 50% (El Raziky et al, 2013; Waked et 
al, 2014). In 2014, an agreement was signed between the NCCVH and Gilead Sciences for the 
purchase of SOF at the cost of 900 USD for the full 12 weeks treatment course – a 99% reduction 
from the 84000 USD price for the same treatment in the United States. This deal fit within 
Gilead’s tiered ‘global pricing programme’ that considers the national income of each country as 
well as negotiations based on other country-specific conditions, such as the very high prevalence 
of HCV in Egypt (El Akel et al., 2017; Reuters, 2014b).   
In October 2014, the first DAA-containing regimen used in Egypt was SOF in 
combination with peg-IFN and RBV for 12 weeks; this regimen could be given to so-called ‘easy 
to treat’ patients, without a prior history of treatment or current comorbidities. This was quickly 
followed by introduction of 24 weeks of SOF and RBV for those ineligible for IFN-containing 
regimens. Due to high demand for treatment, DAA regimens were initially given in priority to 
patients with bridging fibrosis (F3) and compensated cirrhosis (F4). Since 2014, many other 
branded oral IFN-free regimens have been introduced into the country, with equally low prices, 
primed by the climate of the original deal with Gilead for SOF. In addition, generic versions of 
many of these molecules are now being produced locally in Egypt, further lowering the prices for 
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each patient’s regimen down to 74 USD for a 12-week SOF-daclatasvir combination (El Akel et 
al, 2017). As of September 2018, regimens that are being used for ‘easy-to-treat’ patients (i.e. 
treatment naïve, low level of liver disease) include SOF with daclatasvir or paritaprevir-
r/ombitasvir with RBV, each for 12 weeks. The regimen given to ‘difficult-to-treat’ patients (i.e. 
treatment experienced and/or moderate levels of liver disease) is SOF with daclatasvir and RBV. 
Special populations, such as those with failure to DAA regimens, advanced liver disease, co-
infection with hepatitis B virus (HBV), chronic kidney disease, and post-transplant, can also be 
treated through the program through a variety of other available DAA regimens – these patients 
are often referred to specialized centers for follow-up (NCCVH, 2016).  
 It is estimated that now more than 1.5 million persons have received DAAs in Egypt 
through the National Treatment Program (El Kassas, Pers Comm), with real-life efficacy rates 
above 90% for easy to treat and above 80% in difficult to treat patients (Eletreby et al, 2017; 
Elsharkaway et al, 2017; Nagaty and Abd El-Wahab, 2017; El Kassas, Alboraie et al., 2018). 
                 
     Figure 7: Location of the 74 National Treatment Centers for HCV in Egypt, 2018 
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• The Egyptian “model of care” for treating HCV with DAAs The! flow! of! each! HCV! patient! through! the! National! Treatment! Program! has! been!thoroughly!described!by!our!colleagues! from!the!NCCVH! in! their!2017!publication!on! the!same! topic,! from!which! I! borrow! the! name! for! this! small! section! (ElKAkel! et! al,! 2017).! ! I!summarize!it!here!briefly,!based!on!my!discussions!with!them!as!well!as!their!publication.!!In!anticipation!of! the!many!persons!with!HCV!wishing! to!be! treated!with!DAAs,! in!2014,! in!addition!to!opening!up!further!treatment!centers,! the!NCCVH!also!commissioned!an! online! portal! with! which! persons! from! anywhere! in! the! country! could! register! for! a!treatment! assessment.! After! entering! in! some! basic! information! online,! including!information! on! address,! each! person! would! be! referred! to! a! treatment! center! in! close!proximity! to!him!or!her!with!a!specific!appointment!date.!Using! this!online!system,!more!than!300000!persons!registered!within!the!first!week.!The!patient!then!attends!their! first!appointment,! usually! bringing! along! some! preKspecified! laboratory! results.! If! sufficient!clinical!and!laboratory!data!are!available!during!this! first!visit,!hepatologists!at!the!center!will!make!a!treatment!decision!for!the!patient,!which!should!be!confirmed!by!the!NCCVH,!or!alternatively,!refer!the!patient!for!further!laboratory!testing.!In!either!situation,!a!followKup!appointment! for! the! patient! is! determined.!When! ready,! the! patient! starts! their! assigned!treatment,!returning!every!2K4!weeks!for!monitoring!visits!until! the!end!of!their!12!or!24!week!regimen.!Clinical!indicators,!laboratory!results,!and!adverse!events!are!evaluated!and!recorded!at!each!patient!monitoring!visit,!and!specific!efforts!are!made!to!ensure!that!the!patient! sees! the! same! hepatologist! throughout! their! treatment.! Following! completion! of!treatment,!the!patient!is!requested!to!return!to!the!center!12!weeks!later!for!evaluation!of!SVR.! Initially,! almost! 40%! of! patients! did! not! return! for! this! final! visit,! with! negative!implications!for!patient!referral!and!program!monitoring;!the!National!Treatment!Program!then!started!issuing!‘cure!certificates’.!Due!to!the!stigma!surrounding!HCV!infection,!and!the!fact! that! confirmation! of! HCV! negativity! is! sometimes! required! for! employment! and!marriage!contracts,!this!intervention!greatly!improved!patient!retention!until!SVR.!!Patient!data! from!the!baseline,!monitoring,!and!SVR!visits!are!entered! into!a! standardized!online!data!management!system!that!is!centralized!in!Cairo!(El!Akel!et!al,!2017).!!
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3.2 Collaborative epidemiological investigations within the National 
Treatment Program for HCV in Egypt 
• The ANRS 12332 ‘HepNile’ Cohort Study 
This cohort study, entitled “Evaluation of the ‘real-life’ efficacy and safety of antiviral 
treatments including new Direct Acting Antiviral agents among patients treated for chronic 
hepatitis C in three National Treatment Centres in Cairo”, was first funded by the French Agence 
nationale de recherche sur le Sida et les hépatites virales (ANRS) in early 2014, and was set to 
begin in early 2015. This is a prospective, non-interventional cohort study to monitor and further 
describe the “real life” efficacy and tolerance of DAA regimens among 7500 HCV patients at 
three National Treatment Centres in Cairo, over the period of 3 years. The only deviation of this 
cohort study from the standard care received through the National Treatment Program is 
establishment of a biobank for resistance studies - blood will be taken at baseline and end of 
treatment for all patients, and SVR12 visits for patients failing treatment.  
 The experience of setting up and running this cohort study, then analysing and 
interpreting the data collected through it, was originally meant to comprise my thesis project. 
However, between 2014 and 2015, the project experienced many regulatory delays. Despite this, 
we made many field visits to Cairo and made small steps forward with the protocol and study set-
up procedures. Finally, on the brink of enrolling our first patients in January 2016, the project 
was halted indefinitely due to internal-political reasons outside of our control. About two years 
later, in November 2017, the NCCVH and the ANRS re-evaluated the interest of starting the 
project, and in January 2018, the cohort began enrolling its first participants. As of September 
2018, more than 1500 patients have been enrolled into the cohort.  
 
• Research Collaboration with New Cairo Treatment Centre 
In one of the three collaborating centres within the HepNile cohort, New Cairo Hospital, the 
clinicians have formed a research group for conducting observational studies using data on 
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special populations and/or topics within the National Treatment Program. In 2015, we began 
collaborating with them on various subjects, including:  
1. Evaluation of the validity of an earlier time point four weeks following the end of 
treatment rather than 12, for assessment of HCV cure (i.e. SVR) 
2. Patient outcomes, and specifically, risk of recurrence, for persons with a history of 
hepatocellular carcinoma  
3. Risk of reactivation for persons receiving direct acting antivirals for HCV who are co-
infected with Hepatitis B virus  
4. Safety, efficacy, and quality of life outcomes in elderly patients (>65 years old) being 
treated with direct acting antivirals 
5. Validity of the PROQOL-HCV questionnaire for use in Egypt in Arabic.  
6. Efficacy and safety of direct acting antivirals in liver transplant patients 
The first three subjects listed above are completed and published, and are those that I will 
present in this section. The fourth and fifth topics, related to quality of life of persons taking 
DAAs, are on-going, and some preliminary results and implications will be mentioned in the 
discussion of this chapter. The final topic, regarding liver transplantation, is currently on hold.  
 
 
 
 
 
 
 
 
 
 
! 135!
3.2.1 Original research (full article): HCC recurrence after DAAs 
!! In early 2016, a research group in Spain published a report signaling a ‘higher than 
expected’ incidence of hepatocellular carcinoma (HCC) recurrence for persons being treated with 
DAAs.  Persons infected with HCV and having had successful ablation of HCC tumors (or 
lesions) in the past, comprise a special population that was, in the IFN-era of treatment, largely 
excluded from therapy. Linked to this, it is also a population who were little or not-at-all included 
in clinical trials testing the DAAs. Therefore, this report from Spain generated considerable 
concern and rapid attempts by clinical research groups to evaluate the same topic in their settings.  
 With our colleagues from the New Cairo Hospital HCV Treatment Centre in Egypt, we 
decided to weigh in on this question. The coordinator of this centre, our collaborator Pr. 
Mohamed El Kassas, also ran a HCC treatment centre in Cairo, dealing exclusively with patients 
having early stage tumors where simple ablation and surgical techniques are practiced. Following 
successful tumor removal, patients are continually followed up at this centre every three to six 
months and some will eventually commence treatment for HCV with DAAs. Due to the unique 
context of a centralized National Treatment Program for HCV and the involvement of our 
collaborator in it, we were also able to obtain longitudinal information about each person’s DAA 
treatment. Therefore, we could perform a survival analysis, using as our base population all the 
patients treated at one HCC centre, then followed from the time of successful HCC ablation, 
factoring in the time of DAA administration in some of those patients while not in others, and 
finally observing the difference in their outcome – either recurrence, or censoring, within a two 
year period. In addition, considering that the reason for international concern on this topic was 
the possibility of causality (i.e. that it was the indeed the DAAs causing increased recurrence), we 
took care to implement specific inclusion and exclusion criteria for who could be included in the 
analysis; we tried our best to imagine the ideal patients included in and analysis conducted on a 
randomized controlled trial, according to the principals of causal inference research using 
observational data. At the time we performed this analysis, only one survival analysis that also 
treated DAAs as a time-varying exposure had been published, but this study was not able to 
follow patients from the time of original HCC ablation. In addition, most results that had been 
reported were percentages of recurrence in persons with former HCC treated with DAAs without 
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ability to compare with those not-treated with DAAs; in this case, it is indeed complicated to find 
an appropriate control group and often, historical figures are used for comparison instead.  
In the paper that follows, you will see a more detailed description of the population 
included, analysis performed, results obtained, and finally a discussion that shows the difficulties 
we faced in interpreting our findings in relation with the others that had been already published.  
The PDF of this article can be found in Appendix 5. 
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Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C 
infected Egyptian cohort: a comparative analysis 
Mohamed El Kassas*, Anna L Funk*, Mohamed Salaheldin, Yusuke Shimakawa, Mohammed 
ElTabbakh, Kévin Jean, Adel El Tahan, Ahmad T Sweedy, Shimaa Afify, Naglaa FA Youssef, 
Gamal Esmat, Arnaud Fontanet 
*These authors contributed equally 
 
• Abstract 
Background: In Egypt, hepatocellular carcinoma (HCC) is the most common form of 
cancer and direct acting antivirals (DAAs) are administered on a large scale. In this unique 
setting, we aimed to determine the association of DAA exposure with early phase HCC 
recurrence in patients with a history of hepatitis C (HCV)-related liver cancer. Methods: A 
prospective cohort study of an HCV infected population from one Egyptian specialized HCC 
management center starting from the time of successful HCC intervention. The incidence rates of 
HCC recurrence between DAA exposed and non-exposed patients were compared, starting from 
date of HCC complete radiological response and censoring after two years.  DAA exposure was 
treated as time-varying. Two Poisson regressions models were used to control for potential 
differences in the exposed and non-exposed group; multivariable adjustment and balancing using 
inverse probability of treatment weighting (IPTW). Results: We included 116 patients: 53 treated 
with DAAs and 63 not treated with DAAs. There was 37.7% and 25.4% recurrence in each group 
after a median of 16.0 and 23.0 months follow up, respectively. Poisson regression using IPTW 
demonstrated an association between DAAs and HCC recurrence with an incidence rate ratio of 
3.83 (95% CI: 2.02-7.25), which was similar in the multivariable adjusted model and various 
sensitivity analyses. Conclusion: These results add important evidence towards the probable role 
of DAAs in HCC recurrence and stress the need for further mechanistic studies and clinical trials 
to accurately confirm this role and to identify patient characteristics that may be associated with 
this disconsolate event. 
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• Introduction 
Several studies and meta-analyses have concluded that eradication of HCV with antiviral 
therapy would reduce the risk of HCC in patients with chronic HCV, independent of their fibrosis 
stage (Morgan et al., 2013). During the era of interferon-based therapy, patients with a sustained 
virological response (SVR) including those on combination therapy with pegylated-interferon 
(peg-IFN) and ribavirin (RBV), showed both histological improvement through HCV eradication 
as well as a decrease in the risk of HCC development (Ikeda et al, 1999).  Other research 
concluded that patients achieving SVR through interferon-based therapies who had previously 
received curative HCC treatment, including local ablation therapy and hepatic resection, had 
favorable outcomes compared with non-SVR patients. The introduction of the new wave of 
DAAs in 2014, with increased tolerance and effectiveness, was seen as a continuing step forward 
in the treatment of persons with a history of HCC and improvement in their overall prognosis.  
The new, highly effective DAAs were expected to dramatically decrease HCV related 
liver disease progression to end-stage liver disease and HCC; however, these optimistic 
expectations were questioned by an initial report from Spain in 2016. Reig and colleagues (2016) 
reported a ‘more than expected’ early recurrence rate (27.6%) in patients with HCC who received 
DAA treatment after an initial good response to HCC treatment. This report represented a red 
flag and opened the door for a debate about the relationship between DAA treatment and HCC 
recurrence. Reports from Italy and the United States, both demonstrating and refuting any 
increase in recurrence following DAAs in varying groups were released soon after (Conti et al., 
2017; Torres et al., 2016; Yang et al., 2016; Zavaglia et al., 2017). These initial reports lacked 
any form of comparative survival analysis between DAA exposed and non-exposed groups. 
Subsequently, a comparison of DAA exposed and non-exposed groups from French cohort, 
reported by Pol and colleagues (2016), treated DAA exposure as time varying and found no 
increased risk of recurrence in those exposed to DAAs (HR: 1.21, 95%CI 0.62–2.34). However, 
this cohort started following eventually DAA-exposed patients from a median 23 months after the 
original HCC diagnosis and was criticized for possible underreporting of HCC recurrence (Reig, 
Boix, and Bruix, 2017). A recent review by Reig, Boix, Marino and colleagues (2017) presents 
an overview of the conflicting evidence that has been presented so far in this debate; the types of 
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studies conducted, heterogeneity in the populations included, and variability in the analytical 
methods used, means that no firm conclusions have yet been drawn on this topic. 
HCC is the most common cancer in Egypt (Ibrahim et al., 2014), largely due to the 
country having the highest global prevalence of HCV (Kandeel et al., 2016). Due to the 
availability of low-cost branded and generic DAAs, the Egyptian Ministry of Health and the 
National Committee for the Control of Viral Hepatitis have treated approximately one million 
Egyptian patients since 2014, with cure rates over 90% using various DAA combinations (El-
Akel et al., 2017). Therefore, we examined HCC recurrence within two years of initial HCC 
complete radiological response in an HCV infected Egyptian cohort, for those who either were or 
were not given DAAs through use of comparative time-dependent analysis and propensity 
scoring.   
 
• Materials And Methods 
Study design and participants 
This study was carried out at one HCC treatment center in Cairo, Egypt. Patients of all 
Barcelona Clinic Liver Cancer (BCLC) stages and prognoses were consulted at this center 
through clinical and imaging examinations and those with BCLC stages 0 and A were treated 
through local ablation procedures; these patients had a maximum of three cancerous lesions, with 
the largest lesion being <5cm in diameter. Local ablative procedures available at this center 
included: radiofrequency ablation (RFA), microwave ablation (MWA), percutaneous ethanol 
injection (PEI), surgical resection, and transarterial chemoembolization (TACE). Following the 
ablative procedure, patients were followed up after one and three months with dynamic 
computerized tomography (CT) and ultrasound imaging to assess tumor response. After complete 
radiological response according to modified response evaluation criteria for solid tumors  
(RECIST) (hereafter referred to as ‘complete radiological response’) had been confirmed by a 
senior radiologist using the mentioned imaging techniques at both month one and months three 
visits, the patients returned for follow-up imaging every three to six months, for continued 
confirmation of complete radiological response until death or loss-to-follow-up. HCC follow-up 
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imaging at these time intervals was the same for patients both eventually treated and not treated 
with DAAs.  
Following HCC complete radiological response, patients were referred back to local 
hepatologists at varying National HCV Treatment Centers where they were examined for DAA 
treatment eligibility. If the patient’s clinical indicators fit within the national HCV treatment 
guidelines, they were given, free of charge, either a three or six-month regimen of DAA. These 
patients’ viral loads were assessed at the end of their DAA treatment period (EOT) as well as 12 
weeks post-treatment in order to establish whether or not there has been a sustained virological 
response (SVR12). The choice of whether or not a patient with a history of HCC will receive 
DAAs was dependent on the patient decision to seek treatment and the decision of the consulting 
hepatologist at the HCV treatment center. Patient eligibility, in the Egyptian context, refers to the 
patient having no contraindication to DAAs, a good prognosis, and limited liver damage; during 
the first wave of DAA introduction this meant that patients with Child-Pugh scores greater than 6 
were not eligible for DAA treatment, nor those greater than 65 years of age. The decisions of a 
consulting hepatologist to either treat immediately, wait to treat, or never treat, a patient with a 
history of HCC was either based on treatment ineligibility or their own personal practice 
methods; some hepatologists recommended waiting during the first two years post HCC complete 
radiological response as this is a period when recurrence is common.  
According to the current Egyptian national treatment guidelines, all-oral DAAs can be 
given as soon as one month following the HCC ablative maneuver, as long as the patient was 
seen to have a complete radiological response through dynamic CT and ultrasound during this 
visit. Patients with a history of HCC being examined for DAA treatment eligibility need to have 
had a dynamic CT scan and ultrasound confirming lack of HCC recurrence in the 3 months prior 
to the DAA start date; any patient who has not had this imaging performed within this time frame 
through their regular visits at the HCC Treatment Center, was required to return to the center to 
do so.  
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Procedures 
For the presented analysis, we applied various inclusion and exclusion criteria to the total 
population of BCLC A and 0 patients who visited the HCC treatment center for local ablation 
between January 2013 and March 2016 (Figure 8).  
We consecutively included patients who achieved HCC complete radiological response 
according to modified RECIST criteria between 2013 and 2016. All patients needed to be HCV 
positive and not co-infected with HBV or HIV. HCV genotype was not specified for inclusion 
and indeed genotyping was not done on all patients, however, most HCV infection in Egypt is 
with genotype 4 (Abdel-Hamid et al., 2007). All included patients were treated for their HCC 
with local ablative procedures including: RFA, MWA, PEI, and surgical resection.  
We excluded patients who were treated using TACE, as this maneuver can be considered 
palliative.  For those who were treated with DAAs during the two-year analysis window, we 
excluded any patients who had received interferon-containing DAA regimens (i.e. 
Sofosbuvir/Interferon/RBV). We also excluded any patients with early recurrence within three 
months of the date of complete radiological response, in order to further ensure that newly 
detected tumors represented true recurrence, and were not residual but previously undetected 
(Torres et al., 2016).  
This study obtained ethical approval by the Institutional Review Board for Human 
Subject Research at the National Hepatology and Tropical Medicine Research Institute in Cairo, 
Egypt, which is organized and operated according to the Declaration of Helsinki for Human 
Subject Research (2013). All patients provided written informed consent to have their data 
included in this analysis.  
 
Statistical analysis 
After applying the stated inclusion and exclusion criteria to our original population, 
persons eventually treated or not-treated with DAAs within the two-year follow-up period were 
compared for their baseline characteristics (i.e. at the time of HCC ablative maneuver) using the 
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Student’s t-test for continuous variables and chi-square or Fisher’s exact test for categorical 
variables. For time-dependent analysis, Poisson regression models were preferred to Cox models 
because they allow the estimation of incidence rates according to DAA exposure (or non-
exposure). Censoring was done when a patient died, was lost to follow-up, or was at the end of 
their two-year follow-up period. For the main analysis, DAA treatment was treated as time 
varying, with exposure starting from the date of DAA start and ending at the endpoint/censoring 
(thus reflecting a current or past exposure to DAA).  
Incidence rate ratio for DAA treatment exposure was estimated using univariable and 
multivariable Poisson regression models. Covariates included in the multivariable model were: 
time since entry into the cohort (<8 months, 8-16 months, 16-24 months), sex, age (categorized 
as < or ≥65 years old), baseline Child-Pugh score (categorized as ≤ or >6) and whether or not the 
patient had ever had gastroesophageal varices (a possible indicator of portal hyptertension). 
Furthermore, in order to minimize the effect of confounding by treatment indication, we used 
inverse probability of treatment weighting (IPTW) using propensity scores (Austin, 2014). The 
probability of receiving DAA treatment was modelled based on time since entry into the cohort, 
sex, age, baseline Child-Pugh score, and history of gastroesophageal varices, and stabilized 
weights were calculated using the R package “ipw” (van der Wal & Geskus, 2011) The average 
treatment effect was estimated using a robust variance estimator in order to account for the 
weighted nature of the sample. IPTW diagnostics were conducted as recommended by Austin and 
Stuart (2015). 
A sensitivity analysis removed all patients with Child-Pugh score 7 and over the age of 
65, as these were DAA treatment ineligibility criteria during the first phase of DAA introduction 
in Egypt. For a sub-analysis, DAA-treatment exposure, still treated as time varying, was broken 
down into three periods: no treatment, the first six months after start of DAA treatment, and six 
months after the start of DAA treatment. A further sub-analysis examined the difference between 
exposure to three and six-month DAA treatment regimens. All statistical analyses were 
conducted using R.  
! 143!
!
Figure 8: Application of inclusion and exclusion criteria to study population with basic 
recurrence proportions !!
• Results 
Between January 2013 and May 2016, 129 HCV-infected HCC patients, all BCLC stage 
A or 0, were consulted and treated with local ablation procedures at the HCC Treatment Center in 
Cairo, Egypt.  Of these, we excluded: two patients who were treated with TACE; two patients 
who never achieved a complete radiological response; six patients who had early recurrence of 
HCC (two of these were already taking DAAs); three patients who were eventually treated with 
DAA regimens containing Interferon. This left us with a total of 116 patients, 53 of whom 
eventually received DAAs during the two year analysis follow-up period and 63 who did not 
(Figure 8, links 2 & 3 in Appendix 4). 
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Table 16: Baseline characteristics, at the time of HCC complete radiological response, for 
patients eventually treated and not treated with DAAs 
Baseline Characteristic DAA Treated  (N=53) 
Not DAA Treated 
(N=63) p-value 
Male, # (%) 35 (66.0) 41 (65.1) 0.91 
Age, mean (P25-P75) 56.7 (52-62) 57.3 (51-62) 0.70 
Diabetes, # (%) 17 (32.1) 16 (25.4) 0.43 
Child-Pugh score   0.006* 
5 26 (49.1) 30 (47.6)  
6 26 (49.1) 22 (34.9)  
7 1 (1.9) 11 (17.5)  
# Hepatic focal lesions [HFL]   0.06 
1 50 (94.3) 57 (90.5)  
2 1 (1.9) 6 (9.5)  
3 2 (3.8) 0  
History of gastroesophageal varices  30 (56.6%) 42 (66.7%) 0.34 
Largest HFL in cm, median (P25-P75) 2.3 (2.0-3.0) 2.5 (2.0-3.0) 0.50 
HCC Treatment Maneuver, # (%)   0.30 
RFA 31 (58.5) 48 (76.2)  
PEI or PEI/RFA 13 (24.5) 7 (11.1)  
MWA 7 (13.2) 6 (9.5)  
Surgical Resection 2 (3.8) 2 (3.2)  
* Child-Pugh score 5 and 6 against Child-Pugh score 
 
The DAA exposed and non-exposed groups were similar in terms of sex, age, and 
diabetes as well as their number of hepatic focal lesions and size of their largest lesion at baseline 
(Table 16). No patients in our cohort were alcoholic or had a history of alcoholism.  
The Child-Pugh score was lower in those treated with DAAs; 1.9% of the DAA-exposed 
group had a score of 7 whilst the DAA non-exposed had 17.5% (p=0.006). The ablative 
maneuvers performed on patients in both groups were similar; the majority of patients in both 
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groups underwent radiofrequency ablation.  The DAA exposed group received varying all-oral 
regimens for either three or six-month periods. SVR12 was confirmed in 77.4% of the DAA 
treated patients overall, and in 89.2% of patients when excluding those treated with 
Sofosbuvir/RBV (Table 17).  
 
Table 17: DAA treatment regimens, end of treatment and SVR12 proportions in the DAA 
exposed group (N=53) 
DAA Treatment 
Regimen 
Duration of 
Treatment 
(months) 
# Treated % EOT % SVR12 
SOF/RBV 6 16 (30.2) 75.0 50.0 
SIM/SOF 3 9 (17.0) 100 88.9 
SOF/DCV/RBV 3 8 (15.1) 100 100 
 6 1 (1.9) 100 100 
SOF/DCV 3 11 (20.8) 90.9 81.8 
 6 4 (7.5) 100 75.0 
SOF/LDV/RBV 6 2 (3.8) 100 100 
SOF/LDV 6 2 (3.8) 100 100 
Total - 53 (100) 90.6 77.4 
Note: EOT= undetectable viremia at end of DAA treatment, SVR12 = sustained virological response 12 weeks after 
the end of DAA treatment 
 
Among the 53 patients treated with DAAs, we observed 37.7% recurrence after a median 
of 16.0 months follow up. Among the 63 patients not treated with DAAs we observed a 25.4% 
recurrence after a median 23.0 months follow up. The association between DAA exposure and 
recurrence can be seen in Table 18. The unadjusted rate, per 100 person-months, of recurrence 
was 1.00 (95% Confidence Interval, CI: 0.51-1.49) in the DAA non-exposed group versus 4.06 
(95% CI: 2.30-5.85) in the DAA exposed group, representing a crude Incidence Rate Ratio (IRR) 
of 4.08 (95% CI: 2.14-7.76) associated with DAA treatment. After controlling for time since 
HCC complete radiological response (i.e. time in cohort) as well as sex, age, Child-Pugh score, 
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and history of gastroesophageal varices using IPTW, exposure to DAA treatment was associated 
with a significantly increased risk of recurrence of 3.82 (95% CI: 2.00-7.30), consistently with 
results found in the multivariate analysis (Table 18). The results of IPTW diagnostics can be 
found by following link 4 in Appendix 4.  
For patients with recurrence, the location of cancerous lesions was found in a new site for 
15 (93.8%) of those not treated with DAAs and 19 (95.0%) of those treated with DAAs. In 
examination of whether or not patients treated with DAAs had a more aggressive recurrence 
compared to their non-DAA exposed counterparts, we observed that six (30.0%) of the recurring 
patients with DAA exposure had greater than three hepatic focal lesions, but we did not have 
enough statistical power to show whether or not this was higher than the two (18.0%) patients 
with this characteristic in the DAA non-exposed recurring population. Among the DAA treated 
group, the incidence of recurrence was not different among those who did achieve SRV12 as 
compared to those who did not (unadjusted IRR = 1.64, 95% IC: 0.64 – 4.20). Although three 
(2.6%) patients were censored due to being lost to follow-up, there was no censorship due to 
death within the 2 years following inclusion in the study for patients without recurrence. No 
patients underwent liver transplantation.  
When excluding patients who did not achieve SVR12 (n=12), the recurrence IRR was 
4.18 (95% CI=1.64-10.69). The results were consistent when considering only patients treated 
with six-month DAA regimens (IRR=3.39; 95% CI=1.56-7.37) or when considering only patients 
treated with three-month regimens (IRR=3.66; 95% CI=1.73-7.76). A sensitivity analysis using 
IPTW and excluding all patients with Child-Pugh score of 7 and aged >65 demonstrated a 
recurrence IRR of 5.62 (95% CI= 2.52-12.18) for DAA exposed vs non-exposed patients. A 
second sensitivity analysis split DAA exposure into two periods: the first six months after the 
start of DAAs and the time following six months after start of DAAs. Using multivariable 
Poisson regression (non-dichotomous nature of this exposure variable prevented the use of 
IPTW), we found an adjusted recurrence IRR of 3.24 (95% CI=1.50-7.01) in the first six months 
of DAA exposure and 4.17 (95% CI=1.73-10.05) in the post six-month DAA exposed groups 
respectively.   
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• Discussion 
Our data point to a highly (i.e. almost 4 times) increased rate of recurrence after DAA 
treatment for patients with a history of successfully treated HCC, when compared to similar 
patients who were not given DAAs. This significantly higher rate of recurrence in the DAA-
exposed group remained after adjustment for baseline factors and time since HCC complete 
radiological response through inverse probability weighting, as well as across the sensitivity 
analyses performed. As far as we know, this is the first propensity scored comparative time-
dependent analysis for DAA exposed and non-exposed patients followed from the moment of 
HCC complete radiological response. 
It has been suggested that rapid changes to the immune surveillance system and/or anti-
tumor response following DAA treatment could be the reason for the apparent increase in HCC 
recurrence (Nault & Colombo, 2016). A recent observational study by Villani et al (2016), 
supported this idea through demonstration that during treatment with DAAs, an angiogenesis 
inducer called vascular endothelial growth factor, which supports tumor development, increases 
significantly and can remain high until 3 months after DAA treatment.  However, our own results 
showed a similar association between DAAs and HCC recurrence for those with longer (6 month) 
vs. shorter (3 month) DAA exposures (IRR 3.39 vs. 3.66, respectively).  
The necessary assumption of this comparative analysis is that DAA-exposed and non-
exposed patients are similar. However, it can be argued that in an era of highly expensive DAA 
treatments for HCV, it is possible that clinicians systematically choose to treat patients with 
certain clinical indicators over others; for example, in Egypt, treating patients with better 
prognoses has been estimated as more cost-effective based on quality-adjusted life expectancy 
outcomes (Obach et al., 2014). Our inclusion criteria, especially treatment initiation from 2013 
onwards and rapid complete radiological response in response to initial HCC treatment (i.e. seen 
already at one month post-ablative maneuver), were specifically chosen to improve comparability 
between treated and untreated patients. As a result, baseline characteristics of the DAA exposed 
and DAA non-exposed groups in the study presented here appeared to be balanced, except for 
baseline Child-Pugh score. 
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It is possible that there are other confounding factors that were not collected as 
part of this study. Indeed, although baseline characteristics are similar for all patients in 
our study, we do not have updated records of liver enzyme changes at each imaging 
follow-up visit. We argue, though, that we can assume that any selection bias in DAA 
administration would trend towards the treatment of those with better prognosis (e.g. 
younger age, limited liver damage), at least in the case of patients with a history of HCC 
in Egypt. Within the Egyptian National Treatment Program, a patient with a history of 
HCC would not be given DAAs immediately following HCC complete radiological 
response because of either ineligibility for treatment according to the Egyptian national 
treatment guidelines, or due to the personal opinion of the attending hepatologist 
regarding the need to wait to make sure the cancer is truly gone first.  Ineligibility for 
treatment in this case relates mainly to when a patient had a worse prognosis (e.g. older 
age, more deteriorated liver function); this was the case for 11 of our patients who had 
Child-Pugh score 7, and two patients who were too old (>65 years), who did not receive 
DAAs according to the applied treatment protocol at that time.  For the remaining 50 
patients who did not receive DAAs within our two-year analysis period, 14 eventually 
received DAAs afterwards, 15 had recurrence within this time and were therefore not 
eligible and for 21 the attending hepatologist decided not to recommend treatment at all 
within the viewed follow-up period.  Although our results cannot approximate a clinical 
trial in terms of random treatment assignment, we do assess that any underlying differing 
factors between the groups would likely be negative confounders; we would expect 
patients with a better prognosis to be treated with DAAs.  
One of the biggest strengths of this study was our ability to follow, and analyze 
recurrence depending on eventual DAA exposure in an entire cohort of HCV positive 
patients from the moment of HCC complete radiological response. This has not yet been 
done in any other robust study; the survival analysis performed by Pol et al followed 
patients from time of ‘cohort inclusion’; this was a median 1.9 and 1.6 years after HCC 
diagnosis for DAA exposed and unexposed groups respectively (Pol et al., 2016). All 
other currently published papers on this subject report recurrence in DAA exposed groups 
after varying median number of months following their HCC complete radiological 
response. A demonstration of these differences, using some of the first studies published 
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within this debate, can be seen in Table 19. The issue with a delayed observation window 
in these populations is two-fold: 1. The biological mechanisms behind early (within two 
years) and late (> two years) phase recurrence have been reported to differ (Imamura et 
al., 2003), and 2. All patients with recurrence or death prior to the observation window 
are inherently excluded from the analysis and final recurrence rates. The former indicates 
that studies observing recurrence in the first two years since HCC complete radiological 
response, such as the study we present here or that of Reig (2016) or Conti (2016) are not 
comparable to those of Pol (2016) or Zavaglia (2017). The latter means that some studies, 
such as that of Pol (2016) and Zavaglia (2017), who have reported ‘no apparent effect of 
DAAs’, have done so in survivor populations. Recurrence in the first two years since 
HCC complete radiological response has been linked to microscopic vascular invasion, 
high serum AFP levels and having had non-anatomical resection, whereas after two years 
since HCC complete radiological response, tumors can be considered de novo and are 
linked to the grade of hepatitis activity, tumor nodule multiplicity and gross tumor 
classification (Imamura et al., 2003).   
In order to draw any interim guidance from the currently published data on this 
subject, the findings that have been put forth to date should be considered and grouped 
according to the population included, analysis methods used and the time-window of 
observation for the included patients. Perhaps DAA treatment of surviving patients 
without any recurrence two years after HCC complete radiological response poses no 
additional risk, whereas administration of DAAs to patients in the first two years after 
HCC complete radiological response should be avoided until clinical trials provide more 
concrete evidence of their benefit.  ! !
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3.2.2 Original research (short description): HBV reactivation following DAAs 
Following the introduction of DAAs, several published case reports signalled a 
risk of HBV reactivation and HBV-related hepatitis during the course of treatment in 
patients with chronic HCV infection co-infected with chronic HBV (presence of HBV 
surface antigen - HBsAg) as well as those with past or resolved HBV infection (presence 
of hepatitis B core antigen anti-HBc) (Collins et al., 2015; Ende et al., 2015; Takayama et 
al., 2016). This led to guidelines by the American (AASLD) and European (EASL) 
Associations for the Study of Liver Disease for the monitoring and treatment of patients 
showing signs of reactivation (AASLD, 2017; EASL, 2017a; EASL, 2017b); however, 
large discrepancies in these recommendations highlighted the lack of robust evidence on 
this topic. Few cohort studies had been performed evaluating the magnitude of the risk of 
reactivation, and these studies were limited due to heterogeneity in study participants 
(inclusion of patients under HBV antiviral treatment), varying criteria for HBV 
reactivation, and small sample sizes in estimates for concurrent HBV infection (Gane et 
al., 2016; Liu et al., 2017; Londono et al., 2017; Wang et al., 2017; Yeh et al., 2017). 
Therefore, in Egypt, we prospectively followed HBsAg-positive persons 
undergoing interferon-free DAAs through the National Treatment Program, to estimate 
the risk of HBV reactivation and HBV-related hepatitis. In addition, we conducted a 
meta-analysis to estimate the reactivation risk using published data obtained from a 
systematic review of PubMed/Embase, in addition to our Egyptian data. We applied a 
standard definition of HBV reactivation and hepatitis proposed by two international 
associations for the study of the liver, the AASLD and the Asian Pacific Association 
(APASL) (AASLD, 2017; Sarin et al., 2017) 
Of 4471 patients with chronic HCV being treated in the National Treatment 
Program in Egypt, 35 HBsAg-positive patients started interferon-free DAAs without 
HBV nucleos(t)ide analogues. Ten experienced HBV reactivation (28.6%), of whom 1 
developed hepatitis (10.0%). The systematic review we did identified 18 eligible studies. 
The meta-analysis then showed that the pooled reactivation risk in HBsAg-positive 
patients was 18.2% (95% CI: 7.9%-30.7%) without HBV therapy (see Figure 9) and 
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0.0% (95% CI: 0.0%-0.0%) with HBV nucleos(t)ide analogues. The pooled risk of 
hepatitis in those with HBV reactivation was 12.6% (95% CI: 0.0%-34.7%). The pooled 
reactivation risk in HBsAg-negative, antibody to HBV core antigen-positive (anti-HBc-
positive) patients was negligible (0.1%, 95% CI: 0.0%-0.3%), irrespective of the presence 
of antibody to HBsAg (anti-HBs).   
 
Figure 9: Pooled risk of HBV reactivation in HBsAg-positive patients without 
concomitant anti-HBV nucleos(t)ide analogue therapy 
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Our study confirmed the importance of screening for HBsAg and anti-HBc in 
patients undergoing DAA therapy. For those negative for HBsAg but positive for anti-
HBc, the European (EASL) recommendation of monitoring and testing for HBV DNA in 
case of ALT elevation seems reasonable as HBV reactivation and particularly HBV-
related hepatitis are rare in this group (EASL, 2017a; EASL, 2017b). For those positive 
for HBsAg, we concluded that further studies are needed to determine the best strategy 
between systematic nucelos(t)ide analogue prophylaxis or, rather, “on-demand” HBV 
therapy implemented only when HBV DNA levels become elevated during the course of 
DAA treatment.  
The PDF of this article can be found in Appendix 5. 
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3.2.3 Original research (full article): Validity of earlier SVR testing after DAAs 
 
With the introduction of DAAs, the duration of a person’s HCV treatment went 
from almost one year, to only 2-3 months, in a very short period of time. However, the 
wait time to find out if the person had achieved SVR remained recommended at 3 months 
following treatment. This long gap between the last visit at which a patient receives 
treatment and the visit where they understand whether or not a cure was achieved, is 
problematic in the context of the large, centralized National Treatment Program in Egypt. 
Many patients are lost to follow-up between the end of treatment and the SVR12 visit and 
this leads to a lack of proper referral and resistance testing for patients failing treatment, 
as well as a high proportion of missing data inhibiting ‘real-world’ efficacy and program 
evaluations.  
 
Using data from a cohort of patients treated at New Cairo Hospital Treatment 
Centre, we attempted to see whether or not an earlier time point for assessment of SVR, 
four weeks after the end of treatment rather than 12, would provide adequate sensitivity 
for observing all true treatment failures.  This is biologically plausible considering the use 
of new highly potent treatments. Regardless of the result, this would inform the policy of 
the Egyptian National Treatment Program, and, if positive, would possibly allow for an 
alleviation of the logistical hurdle faced when attempting to retaining the very large 
volume of patients applying to be treated with the newly introduced DAAs.  
 
The PDF of this article can be found in Appendix 5. 
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Letter: Concordance of SVR4 and SVR12 following direct acting antiviral 
treatment in Egypt. 
Mohamed El Kassas*, Anna L Funk*, Yasmeen Abd El Latif, Anca Vasiliu, Ahmed 
Sherief, Yusuke Shimakawa, Naglaa Youssef, Adel El Tahan, Mohamed Elbadry, Amir 
M Farid, Yehia El Shazly, Wahid Doss, Gamal Esmat, Arnaud Fontanet.  
* Mohamed El Kassas and Anna L Funk should be considered joint first authors 
!
In your recently published paper by Omar and colleagues (2018), we are 
presented with the results of 18,378 patients treated for chronic hepatitis C (HCV) with 
direct acting antivirals (DAAs) through the Egyptian National Treatment Program.  
During the same time period within the program, retention of patients until the 
assessment of sustained virological response (SVR12) posed a significant logistical 
hurdle, and led to 29-40% of patients being lost-to-follow-up (El-Akel et al., 2017; 
Elsharkawy et al., 2017).  Use of a more prompt endpoint, 4 weeks after the end of 
treatment (SVR4), could potentially lower these proportions and subsequently support 
evaluations of Egyptian and other national treatment programs administering DAAs; 
however, SVR4 has previously shown to be inadequate (Burgess et al., 2016). 
 
To compare SVR4 to the conventional endpoint, SVR12, in a real-life setting, the 
program carried out a prospective, observational cohort study of patients receiving 
interferon-free DAAs at the New Cairo Hospital treatment centre in Cairo, Egypt, 
between September 2014 and December 2016. All patients eligible for treatment 
according to the Egyptian National Guidelines were invited to participate. Participants 
received two vouchers for free quantitative HCV RNA testing 4 and 12 weeks post-
treatment and real-time PCR was done at the centre’s laboratory or other selected 
national laboratories. Patients had clinical follow-up at the centre every four weeks until 
the end of treatment, then at 4 and 12 weeks post-treatment.  
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Of the 2899 patients treated at the centre who agreed to participate, 233 (8.0%) 
were treated with IFN containing DAA regimens, and 196 (6.8%) were lost to follow-up, 
leaving 2470 (85.2%) eligible for analysis. Patient characteristics are described in Table 
20. The DAAs administered include: sofosbuvir and daclatasvir with or without ribavirin 
(n=1559, 63.1%), sofosbuvir and simeprevir (n=586, 23.7%), sofosbuvir with ribavirin 
(n=285, 11.5%), ombitasvir/paritaprevir with ribavirin (n=40, 1.6%). Five and 15 patients 
had detectable HCV RNA at four and 12 weeks post-treatment, leading to an estimation 
of SVR4 and SVR12 as 99.8% (95%CI: 99.5%-99.9%) and 99.4% (95%CI: 99.0%-
99.7%), respectively. The sensitivity of viral load testing at 4 compared to 12 weeks post-
treatment was 33.3% (5/15, 95%CI: 11.8%-61.6%) and the specificity was 100% 
(2455/2455; one-sided 97.5%CI: 99.9%-100%). The negative and positive predictive 
values were 99.6%, (2455/2465, 95%CI: 99.3%-99.8%) and 100% (5/5, one-sided 
97.5%CI: 47.8%-100%), respectively. 
 
In this study, viral load testing four weeks post-treatment misclassified a small 
number of individuals (i.e. 10/2470, 0.4%), but did not identify the majority (66.6%) of 
eventual treatment failures. Practically, within the Egyptian National Treatment Program, 
which aims to treat 350,000 persons annually, this would leave 1400 viremic persons 
returning to their communities as transmitters, with a higher risk of complications, and 
without a referral for further DAA treatment (Dieperink et al., 2014; van der Meer et al., 
2012; Waked et al., 2014). Evaluations of other intermediate endpoints, such as SVR8, as 
well as studies examining patient factors contributing to relapse between the end of 
treatment and SVR12, are needed.  In the meantime, various other measures have been 
employed in Egypt to ensure higher proportions of patients undertake viral load testing at 
SVR12, including text message and phone call reminders, as well as delivery of ‘cure’ 
certificates upon demonstration of SVR12 results (El Akel et al., 2017; Gomaa et al, 
2017).  
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Table 20: Baseline characteristics and viral load dynamics for treatment failing 
discordant and concordant patients, with summary baseline characteristics for all 
study patients.  
Baseline Evaluation SVR4 SVR12 
Sex Age Viral  
load 
log10 IU/ml 
Past HCV 
treatment 
DAA Regimen/ 
Duration in wks 
Fib4 
scor
e 
Viral  
load* 
log10 IU/ml 
Viral  
load* 
log10 IU/ml 
Discordant treatment failures (n=10), summary: male=7 (70.0); age=55.4 (11.4); viral load in 
log10IU/ml =13.1 (1.5); treatment experienced=0; fib4 score=6.6 (4.9) 
F 64 14.3 No SOF/DCV/RBV; 
12 
5.7 Not detected 9.8 
M 67 10.8 No SOF/RBV; 24 14.4 Not detected Detected;UA 
M 61 14.7 No SOF/DCV/RBV; 
12 
15.8 Not detected 10.7 
M 47 12.5 No SOF/SIM; 12 2.3 Not detected 11.2 
M 29 11.5 No SOF/DCV; 12 0.6 Not detected 11.0 
F 57 13.1 No SOF/DCV/RBV; 
12 
4.8 Not detected 11.4 
M 58 12.9 No SOF/RBV; 24 5.4 Not detected Detected;UA 
M 59 13.9 No SOF/SIM; 12 8.8 Not detected 13.2 
M 47 15.3 No SOF/DCV/RBV; 
12 
4.8 Not detected 10.6 
F 65 12.0 No SOF/SIM; 12 3.9 Not detected 11.7 
Concordant treatment failures (n=5), summary: male=2 (40.0); age=56.0 (7.8); viral load in 
log10IU/ml = 13.0 (0.9); treatment experienced=2 (20.0); fib4 score=7.6 (5.8) 
M 59 13.7 No SOF/RBV; 24 4.9 Detected;UA 13.7 
F 68 13.0 No SOF/RBV; 24 17.7 14.0 Detected;UA 
F 53 11.8 IFN/RB
V 
SOF/SIM; 12 7.3 6.9 6.9 
M 52 12.2 IFN/RB
V 
SOF/RBV; 24 4.6 Detected;UA Detected;UA 
F 48 14.0 No SOF/RBV; 24 3.7 Detected;UA 11.1 
Concordant treatment successes (n=2455), summary: male=1045 (42.6 %); age=51.8 (11.3); 
viral load in log10IU/ml =13.0 (1.9); treatment experience=249 (10.1); fib4 score=2.4 (2.2) 
ALL PATIENTS (N=2470), summary: male=1054 (42.7); age=51.8 (11.3); viral load in 
log10IU/ml =13.0 (1.9); treatment experience=251 (10.2); fib4 score=2.5 (2.3) 
*UA indicates a detected viral load, but quantitative value unavailable.  Note: summary statistics are 
presented as n (%) or mean (SD) for categorical and continuous variables, respectively.  
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3.3 Discussion: Evaluating the introduction of DAAs in Egypt 
The introduction of DAAs is a game-changer for the control of HCV, and 
increased access to these treatments, through availability of generics and expansion of 
treatment programs, will enable drastic reductions in each nation’s prevalence of chronic 
infections, possibly to the point of disease elimination in the near future (Anonymous, 
2015; Ippolito et al., 2015; Polaris Observatory, 2017; WHO, 2016). Although the safety 
and efficacy of DAAs were evaluated in depth in clinical trials prior to approval, 
administration of the treatments to real-life populations in Egypt, and equally in other 
regions of the world, brought with it some unexpected questions and concerns. Using 
data from a very specific context – mass administration of the treatments through a 
centralized national treatment program in the country with the highest prevalence of 
HCV, we weighed in on some of the pressing questions that accompanied DAA 
introduction. Through this, we were also privy to the difficulties of bringing together and 
making conclusions from findings in the immediate time period following this emerging 
disease event; here, these challenges were due to lags in standardization of recommended 
study designs, analysis methods, and case definitions.  
 
• Monitoring adverse events in special populations after DAA introduction 
Two of the research topics we worked on related to the evaluation of adverse events 
in special populations of persons with HCV following treatment with DAAs; persons 
from these groups had not been included extensively in clinical trials. These adverse 
events were: recurrence of liver cancer, and reactivation of HBV. As neither of these side 
effects was explicitly expected based on experiences during the IFN-era, the first 
epidemiological studies describing them were conducted and reported in ways that did 
not necessarily facilitate comparability. Increased HCC recurrence, as an adverse event to 
HCV treatment, was unobservable prior to the advent of DAAs due to the fact that 
persons with advanced liver disease were contraindicated for treatment with IFN-based 
regimens. The causal effect of DAAs on an increase in recurrence is still under debate. 
Alternatively, reactivation of HBV infection after treatment for other diseases, such as 
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cancer, is well known (Hoofnagle, 2009), and it has also been previously reported in 
patients co-infected with HBV and HCV who were treated with IFN and RBV (Liu et al., 
2012). Whether or not reactivation would occur with the new DAAs, and to what extent, 
was unknown prior to their introduction. Here I will discuss the implications that this 
context, the conditions in which initial reports of these adverse events surfaced, have had 
on the types of studies conducted and reports produced surrounding them, and what that 
has meant for bringing them together to draw conclusions.  
 
HCC recurrence 
In epidemiology, we shy away from overtly stating, especially in writing, that we 
are trying our best to understand causal effects. However, after painstakingly planning 
out sampling strategies and study designs, fretting over loss-to-follow-up, carefully 
choosing our analysis model, and adjusting for confounders, we discredit ourselves by 
not admitting that this is indeed what we are attempting to approximate (Hernan, 2018a; 
Hernan, 2018b). For the many public health topics for which it will always be highly 
unfeasible, if not impossible, to conduct a randomized controlled trial, we can eventually 
consider accumulation of non-randomized observational studies, weighing reports with 
‘stronger’ versus ‘weaker’ study designs differently, to make causal conclusions with 
policy implications. For example, the fact that there has been no randomized controlled 
trials observing the effect of smoking on lung cancer incidence has not prevented 
worldwide cigarette taxes and legislation on smoking in public spaces. In attempting to 
understand whether or not DAAs lead to increased recurrence of HCC, if we could, we 
would draw consensus from randomized trials. However, even if ethically and logistically 
it is eventually possible to carry out a randomized trial, it will be many years before we 
have mid-long term comparative survival data for exposed and non-exposed patients. In 
the meantime, what we can do is try our best to use the cohorts and the data we have to 
approximate the ideal trials we would conduct (Hernan, 2018a; Hernan, 2018b).  
Hypothetically, if we could, we would follow a group of patients from the time of their 
original HCC cure (i.e. the moment when recurrence risk starts), assign them randomly to 
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either receive DAA treatment at a certain time or not, and then perform frequent and 
regulated imaging to check for signs of recurring cancer. In the real-world, with the data 
we have from Egypt, the best way we found to mimic this was following an entire group 
of persons treated for HCC from the time of their successful ablation, use inverse 
probability weighting with measured confounders in our analysis to approximate 
randomized treatment assignment, and treat DAA initiation as a time-dependent 
exposure, censoring our analysis after two years. After doing this, we found a highly 
significant increase in the risk of recurrence for those treated with DAAs (IRR: 3.82, 
95%CI: 2.00-7.30).  
Our methods and reporting differed greatly from many of the other groups who had 
already published at that time. The original harbingers of increased HCC recurrence due 
to DAAs tended to report percentages of persons with recurrence, which were interpreted 
as either high or low compared to historical estimates in groups of persons treated with 
the new regimens (Conti et al., 2016; Reig et al., 2016; Zavaglia et al., 2016). While these 
reports were useful in starting debate and prompting other groups to signal similar or 
contrary experiences, such study designs and reported figures, without identifying a 
control group or employing survival analysis, did not provide us with risk-ratios for 
comparison and discussion against our own findings. One other survival analysis with a 
control group had been performed at the time we were working on ours; this French study 
concluded no effect of DAAs on recurrence (HR: 1.21, 95%CI 0.62–2.34) (Pol et al., 
2016). However, as we mentioned in the discussion of our paper, our results are possibly 
not appropriately compared with those of this French cohort as the follow-up starting 
points and median time after original HCC cure at which DAA administration, differed. 
In the discussion of our paper we mentioned that this could lead to a different 
interpretation of each our own and the French study, rather than indicating conflicting 
results; the French study shows no increased risk of recurrence if persons who have 
survived for two years after original HCC cure and ours shows increased risk of 
recurrence if DAAs are administered within a few months of tumor ablation. In other 
words, the design and analysis of each of our studies emulated different trials, and 
therefore, the results of each should not be considered together, just as they wouldn’t be 
had they actually been reported from randomized studies with different populations and 
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protocols. Alternatively, and very importantly, interpreting any estimates as 
demonstrating causality, even when it seems a trial has been well imitated, comes with 
the very important assumption that there are no significant unmeasured confounders 
(Hernan, 2018a; Hernan, 2018b).  If eventually deemed ethical, a randomized trial 
comparing early versus late DAA treatment (e.g. within six months of cancer cure or 
after) for persons with a history of liver cancer would respond well to the question I have 
posed above.  
In the time since our analysis has been carried out on recurrence of HCC, there 
have been many further studies, including some survival analyses with control groups, 
reported. There have also been reviews and meta-analyses attempting to bring these 
findings together; for many of these, the general conclusion is that there can still be no 
conclusion, and that further well designed studies are needed (Butt, Sharif, et al., 2018; 
Guarino et al., 2018; Saraiya et al., 2018; Waziry et al., 2017).  The first red flags for this 
adverse event were reported just shortly after DAAs started to be used in this special 
population of persons with former liver cancer, and in that setting, consideration of all 
study designs and reported figures as possible evidence for or against this side effect may 
be beneficial. However, in late 2018, an increased emphasis by researchers, as well as the 
journals that accept their reports, should be put on how the data we have can be used to 
generate policy implications in the absence of a real, and maybe never to be realized, 
randomized controlled trial. This could include recommendations and ‘calls’ by liver 
associations for the types of analyses that can be performed using non-randomized 
observational data, and/or eventual differential weighting in meta-analyses based on 
study and analysis design.  
As a follow-up to this work on HCC recurrence, we are currently undertaking an 
updated survival analysis comparing the risk of overall mortality over a further extended 
time period for those receiving and not receiving DAAs. Our preliminary results 
demonstrate an eventual increased risk of death for persons receiving DAAs, but which 
seems to be entirely mediated by whether or not there has been recurrence. If 
corroborated by others, this finding would indicate a lack of benefit in giving these 
treatments to some populations of persons with a history of liver cancer.  
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HBV reactivation 
HBV reactivation can be triggered by health events such as onset or, alternatively, 
treatment of other diseases, such as cancer chemotherapy (Hoofnagle, 2009), and had 
previously been seen in co-infected patients treated with IFN and RBV (Liu et al., 2012). 
Therefore, after case reports surfaces indicated that this event had occurred in persons 
taking DAAs, causality of the two events was not debated. In order to inform policy on 
monitoring and treatment in this case, a cohort study following patients with evidence of 
current or past infection with HBV through their DAA treatment and until the moment of 
cure assessment, will address the question of the magnitude of risk and consequences of 
this adverse event. We found two challenges in bringing together the findings from our 
own cohort study on this topic with others through a meta-analysis; non-consensus on the 
definition of HBV reactivation used in studies, and risk of bias in reported studies. 
Timing may play a role in the former; either that research is conducted and published 
rapidly following initial reports of an adverse event leading to non-consideration of 
eventual comparability, or alternatively, studies are conducted in the lag time prior to 
official recommendation of case definitions by reference associations (e.g. the American 
or European associations for the study of liver disease). Another challenge that we 
observed, while trying to bring findings together with our own through a meta-analysis 
was a high risk of bias in some studies. For example, we excluded some studies in 
populations of veterans in the United States who stated high original sample sizes, but 
also had very high losses-to-follow-up; in these two studies the final reported risk of 
reactivation used the original denominator of patients included and patients were not 
stratified on whether or not they received concomitant therapy against HBV (Belperio et 
al., 2017; Butt, Yan, et al. 2018). Inclusion of such studies could inaccurately sway meta-
analyses. Criteria for risk of bias, and exclusion of studies with such characteristics is 
therefore necessary and possibly requires increased attention in investigations that 
immediately follow emerging disease events.  
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• Ameliorating logistical hurdles linked to high uptake of DAAs  
Some challenges linked to an introduction of a new, highly effective treatment need 
not be negative from all sides, such as the appearance of unexpected adverse events. In 
the case of Egypt, an initial high uptake of persons into the large centralized national 
treatment program to administer DAAs quickly led to difficulties in retaining patients 
until the moment of their cure evaluation, with up to 40% of patients not returning with 
their SVR12 results (El Akel et al., 2017). In response to this, we examined whether or 
not an earlier time point, four weeks following the end of treatment (rather than 12 
weeks), could equally identify most treatment failures. This is biologically plausible 
considering that the new treatments are highly potent and lead to rapid responses in most 
patients (EASL, 2018). We found that only one-third of eventual treatment failures were 
caught using this earlier endpoint, and recommended to remain using SVR12 in order to 
ensure adequate referral of patients with possible resistance. Few studies have looked into 
this question but further evaluations would be interesting, especially considering that 
even newer and more potent DAAs are being released, with proportions of patients 
achieving SVR12 reaching up to 100% (EASL, 2018). In the case of Egypt, for now, 
other methods are being used to retain patients, such as delivery of ‘cure’ certificates, 
which has been found effective in a context where infection with HCV is highly 
stigmatizing and proof of being infection-free is sometimes needed for work and 
marriage (El Akel et al., 2017).  
Another important challenge, that has not been addressed by any of my research, and 
that has directly arisen from introduction of the highly effective DAAs and scale-up of 
treatment programs, is eventual diminution of persons applying to be treated. As 
discussed extensively in this chapter, in Egypt and many other countries, DAAs are 
becoming more accessible through generic production, and more widely used in persons 
infected due to tolerability and access to treatment programs. However, in a country 
where it is estimated that almost 6 million adult persons are infected, it is also estimated 
that the majority are not knowledgeable of their infection status (El Kassas, Elbaz et al., 
2018). As a result, after treating approximately 1.5 million persons over the past 4 years 
through the National Treatment Program in Egypt, the waiting lists at the 74 treatment 
! 165!
centres, and the numbers of persons being treated per month have dwindled. Although 
screening of university students and health workers is now taking place mass testing of 
high-risk groups in Egypt, such as those in rural areas, is needed to continue addressing 
the need (El Kassa, Elbaz, et al., 2018). Further facilitating mass screening efforts will be 
availability of a robust and field-friendly rapid point-of-care test for active infections  
(i.e. detecting HCV RNA). Such tests are currently being developed and tested (Grebely 
et al., 2017; Lamoury et al., 2018; Llibre et al., 2018). Without improving this part of the 
care cascade, both in Egypt and worldwide, HCV elimination in the near future will not 
be possible.  
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This section is meant to serve as a brief and general conclusion to my thesis 
manuscript. It includes a few strategies for the initial organization of epidemiological 
investigations following emerging disease events, which may aid in developing research 
priorities and eventually reconciling findings. This will not be an exhaustive description 
of such methods, but rather will draw on a few examples from my own experiences 
during the thesis period.  
 
I will start by discussing the utility of research consortiums and protocol 
standardization. I will then present expert opinion elicitation as a method for focusing 
hypotheses, and providing rapid information for policy makers; here I will present, as an 
example of such methods, an article that describes my use of this technique to identify 
exposure pathways for Middle East respiratory syndrome coronavirus (MERS-CoV).  
 
Finally, I will give my concluding thoughts on my thesis work and the implication 
these findings have for persons affected by emerging disease events. 
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4.1 Research consortiums 
Establishment of diverse research partnerships for infectious disease topics has 
many benefits and is being increasingly recommended and utilized. These consortia are 
seen to lead to streamlined and robust answers to pressing emerging disease questions, 
reduction of duplicity in efforts, and generation of new hypotheses through stimulating 
inter-group discussions (Dockrell, 2010).  In addition, when those included in the 
consortium are from varied settings and types of expertise, this can lead to cross-group 
capacity building, and development of new regional partnerships where the disease in 
question has an impact. Many such research partnerships are composed of scientists from 
both high-income and low-middle income, settings; an additional benefit in this case can 
be the eventual diminution of global health inequalities, as long as the consortia have 
carefully thought out, shared governance (Global Ministerial Forum on Research for 
Health, 2008; Pratt and Hyder, 2016). 
Both of the research studies on ZIKV-related birth defects that I have been 
involved with (i.e. the ZIKA-DFA-FE cohort study, and the ZIKV-related microcephaly 
surveillance study) are part of the ZIKAlliance consortium supported through the 
European Union’s Horizon 2020 grant. This research consortium is composed of 54 
partners across 18 countries worldwide, and 9 work packages. Information on this 
consortium can be found here: https://zikalliance.tghn.org. Within the first work package 
of this research network, is the aim to demonstrate the impact of ZIKV infection on 
fetuses/infants when the mother is infected during pregnancy. In terms of clinical and 
epidemiological studies, this is being approached through cohort studies of women 
infected with ZIKV during pregnancy; both the Brazilian cohort study and our own 
cohort study in the FTA are part of this group, in addition to a further multi-country 
cohort study with a standardized protocol that takes place across South America.  
The clear benefit of having these varied cohort studies all involved in the same 
consortium is that it allows for presentations by, and discussions between, investigators at 
the multi-annual group meetings, therefore permitting eventual understanding of where 
methodological differences may lie between study protocols. Although not yet being 
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done, it could also eventually allow for collaboration between investigators and pooling 
of raw data, creating higher powered studies that may showcase regional variation, but 
also highlight why these differences may have been found. In addition, as this 
consortium, as with many of the others that have been put together to tackle ZIKV-
related research topics, follow a ‘one health’ approach (i.e. combining investigators 
across epidemiological, clinical, microbiological, animal/vector and social sciences 
fields), there is the possibility to easily share and have input on hypotheses on biological 
reasons for regional variation when methodological differences do not explain all.  
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4.2 Protocol standardization 
When comparing observational research studies, we are often unsure of whether 
or not the differences in results are due to underlying true variation by populations or 
simply to dissimilarities in the methods used or the data collected. This has been 
discussed as a possible reason for the present difficulty in drawing a consensus from 
findings on the risk of ZIKV-related birth defects as well as on the association between 
direct acting antivirals for HCV and recurrence of liver cancer, in this thesis. Use of 
harmonized research methods for certain study types and following guidelines on 
reporting can be used to ensure that a consensus can be drawn, as quickly as possible, 
from the studies that have been performed on an important emerging disease topic. The 
need for such standardization was highlighted following recent novel influenza epidemics 
and pandemics, after which two important consortiums, the International Severe Acute 
Respiratory and Emerging Infection Consortium (ISARIC) and the Consortium for the 
Standardization of Influenza Seroepidemiology (CONSISE) have been collaboratively 
developing and promoting standardized research protocols with the WHO (Van 
Kerkhove, 2013; Van Kerkhove, 2016).  
In 2016, the WHO also endorsed the creation and dissemination of standardized 
protocols for various types of ZIKV studies, including case-control studies for the 
association between ZIKV with microcephaly and ZIKV with Guillain-Barre Syndrome; 
cohort studies of ZIKV infected pregnant women and infants with ZIKV exposure in-
utero; persistence of ZIKV in body fluids; and ZIKV seroprevalence studies.  Personally, 
I participated in the drafting of the protocol for follow-up of infants born to women 
infected with ZIKV during pregnancy; this was done through review and combination of 
existing protocols for similar studies as well as through input and editing from experts. In 
June 2016, a meeting was held in Mexico City with researchers from across South 
America and Europe to discuss drafted versions of these protocols and agree on aspects 
that should be standardized across countries (Van Kerkhove et al., 2016).  These 
protocols can be found at: http://www.who.int/reproductivehealth/zika/zika-virus-
research-agenda/en/. While not all scientists will choose to adopt these prefabricated 
protocols, they can be used as guidance by well-established research groups and as a 
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protocol model for smaller groups with limited research experience in regions affected by 
the emerging disease.   
The CONsolidated Standards Of Reporting Trials (CONSORT) statement, was 
first conceptualized in 1993 when a diverse set of epidemiologists and methodologists 
came together to develop a scale for the assessment of clinical trials, and realized that 
many key indicators were poorly reported (CONSORT, 2010). This was a finding 
supported by contemporary literature (Altman and Dore, 1990; Pocock et al, 1987). Other 
meetings and gatherings to follow, led to the CONSORT 2001 and, eventually, the 
CONSORT 2010, checklists for reporting of clinical trial results (Moher et al., 2001; 
Schulz et al., 2010). Along the same lines, the STrengthening the Reporting of 
OBservational studies in Epidemiology (STROBE) checklists, which exist for all of case-
control, cross-sectional, and cohort studies, were first published in 2007 (Vandenbrouke 
et al., 2007; von Elm et al., 2007). Increasingly, and importantly, peer-reviewed journals 
require authors to fill out and submit these checklists along with their manuscript prior to 
its review. This fairly recent advancement, and the further adoption of this requirement 
by other journals in the future, will surely lead to increased comparability of published 
research findings and allow for merging of findings in robust meta-analyses.  
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4.3 Expert opinion elicitation 
 Expert opinion elicitation (EOE) is a tool that gathers inputs, from persons with 
relevant experience, regarding event probabilities, magnitude predictions, and relative 
importance of risks where empirical evidence is lacking. This has been employed in 
many scientific domains, such as, but not limited to, technology development, climate 
change forecasts, environmental health exposure impact, and emerging infectious disease 
risks (Cox et al., 2012; Gale et al., 2010; Goutard et al., 2012; Horst et al., 1998; Morgan, 
2014; Syed et al., 2010). Specifically with regards to emerging diseases, this method can 
be useful in generating rapid ‘best guess’ assessments that inform necessary policy 
actions, prior to the planning and conduct of appropriate research studies (Russell et al., 
2017).  
While EOE studies can be seen as a quick way of gathering information, it is still 
necessary to conduct them with a carefully thought out methodology, to avoid misleading 
results. The first consideration is the choice of relevant experts. This can be done either 
through informal methods, such as identification of potential participants by the study 
coordinators, who are normally also experts in the field, based on who they know to be 
knowledgeable and willing. To expand on this, ‘snowball’ recruitment can be done where 
an initial group of experts chosen by the study coordinators are asked to refer their 
colleagues who would be interested and appropriate. Alternatively, a less subjective 
method, such as a systematic search of articles on related subjects and identification and 
proposal of the study to the most frequently appearing authors, can be done (Morgan, 
2014).  
 Prior to commencing the elicitation activity, it is recommended that experts be 
given a thorough summary of existing evidence on the subject of interest; this will limit 
the chance that the expert will be biased by ‘availability’ and make their judgment only 
based on information they have recently been confronted with (Tversky and Kahneman, 
1974). This is typically done through provision of a recent and robust systematic review 
(Morgan, 2014). Following this, experts will respond to qualitative and quantitative 
questions on the likelihood and magnitude of certain risks associated with the emerging 
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disease topic at hand. Ideally, this is done through a well-designed questionnaire that is 
given to the expert in person through a face-to-face interview. However, use of 
technological aids, such as online software and questionnaires can also be used to deliver 
the questions to the participants. Eventually, for analysis of the results, it may be 
necessary to weight more heavily some expert opinions over others, as some persons will 
be more knowledgeable and/or certain in their answers than others. Here, calibration is an 
ideal method to understand the quality of each expert opinion; this includes asking a few 
‘seed’ questions for which there actually is empirical evidence, and that the expert’s 
answers can be compared to (Cooke, 1991; Cooke and Goossens, 2008). In addition, and 
especially when little to no already quantified risk estimates exist on a subject, experts 
can be asked for their personally assessed level of certainty in their own answer, for 
example on a scale of 1 (not confident) to 5 (very confident) (Morgan, 2014).  
 Finally, the results from each expert needs to be combined, either with the goal of 
drawing a consensus across those participating, or rather to present the range of possible 
expert answers and opinions on a subject. One well-known consensus method is the 
‘Delphi’ technique, which was first employed in decision making by the United States 
Air Force in the 1950s (Dalkey and Helmer, 1972). When applied to gathering expert 
opinions in scientific fields, the Delphi technique requires multiple rounds of the 
elicitation exercise.  The first round proceeds as I have described above, followed by a 
presentation, to a given expert, of how their answers compared to the responses of their 
colleagues. The expert is then given the chance to revise their response, and typically a 
second round where experts can discuss and justify their results together, with a final 
group decision on a ‘consensus’ result, is produced (Dalkey, 1962; Linstone and Turoff; 
1975). Alternative to the Delphi method, in certain fields such as climate science, 
investigators may want to understand the full range of risks and predictions that experts 
believe possible (Oppenheimer et al., 2007). This second approach, where consensus is 
not sought, is seen to be an advantage of EOE methods by many (Aspinall, 2010; 
Oppenheimer et al., 2007; US Environmental Protection Agency, 2011). 
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4.3.1 Original research (full article): MERS-CoV expert opinion elicitation 
 MERS is caused by a coronavirus that was discovered in 2012 in Saudi Arabia. 
Infection with the virus can lead to severe respiratory illness, including pneumonia, and 
an estimated fatality of up to 35% (WHO, 2018). However, since it was first identified 
six years ago, few disease parameters have been solidly quantified. For example, direct 
and indirect contact with camels is a clear risk factor for infection (Alraddadi et al., 
2016), however, whether or not camels also play the role of the main reservoir for this 
virus, is not yet well understood.  
 To follow will be the description of an expert opinion elicitation study that I 
performed in collaboration with colleagues from the Institut Pasteur (and international 
network partners) and the International Centre for Cooperation in Agronomical Research 
for Development (CIRAD), on the topic of exposure pathways for MERS-CoV. 
Originally, senior scientists from these institutions aimed to perform a risk assessment, 
including known disease parameters and supplementing them with inputs from EOE. 
However, due to a lack of quantified risks, such a study was not possible. This led us to 
focus on the EOE alone, hoping that it would give guidance for further robust studies.   
 This article is being presented, not to focus on MERS-CoV as an emerging 
disease example (this is outside the breadth of this thesis), but rather to showcase the use 
and limitations of a method such as EOE in demonstrating the range of predicted risks for 
an emerging disease, and in narrowing hypotheses for recommended research.  
The PDF of this article can be found in Appendix 5. 
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MERS-CoV at the animal–human interface: inputs on exposure pathways from an 
expert-opinion elicitation 
Anna L. Funk, Flavie Luce Goutard, Eve Miguel, Mathieu Bourgarel, Veronique 
Chevalier, Bernard Faye, J. S. Malik Peiris, Maria D. Van Kerkhove and Francois Louis 
Roger  
 
• Abstract 
Nearly 4 years after the first report of the emergence of Middle-East respiratory 
syndrome Coronavirus (MERS-CoV) and nearly 1800 human cases later, the ecology of 
MERS-CoV, its epidemiology, and more than risk factors of MERS-CoV transmission 
between camels are poorly understood. Knowledge about the pathways and mechanisms 
of transmission from animals to humans is limited; as of yet, transmission risks have not 
been quantified. Moreover the divergent sanitary situations and exposures to animals 
among populations in the Arabian Peninsula, where human primary cases appear to 
dominate, vs. other regions in the Middle East and Africa, with no reported human 
clinical cases and where the virus has been detected only in dromedaries, represents huge 
scientific and health challenges. Here, we have used expert-opinion elicitation in order to 
obtain ideas on relative importance of MERS-CoV risk factors and estimates of 
transmission risks from various types of contact between humans and dromedaries. 
Fourteen experts with diverse and extensive experience in MERS-CoV relevant fields 
were enrolled and completed an online questionnaire that examined pathways based on 
several scenarios, e.g., camels–camels, camels–human, bats/other species to camels/ 
humans, and the role of diverse biological substances (milk, urine, etc.) and potential 
fomites. Experts believed that dromedary camels play the largest role in MERS-CoV 
infection of other dromedaries; however, they also indicated a significant influence of the 
season (i.e. calving or weaning periods) on transmission risk. All experts thought that 
MERS-CoV-infected dromedaries and asymptomatic humans play the most important 
role in infection of humans, with bats and other species presenting a possible, but yet 
undefined, risk. Direct and indirect contact of humans with dromedary camels were 
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identified as the most risky types of contact, when compared to consumption of various 
camel products, with estimated “most likely” incidence risks of at least 22 and 13% for 
direct and indirect contact, respectively. The results of our study are consistent with 
available, yet very limited, published data regarding the potential pathways of 
transmission of MERS-CoV at the animal–human interface. These results identify key 
knowledge gaps and highlight the need for more comprehensive, yet focused research to 
be conducted to better understand transmission between dromedaries and humans. 
 
• Introduction 
Nearly 4 years after the first report of the emergence of Middle- East respiratory 
syndrome Coronavirus (MERS-CoV) in humans and more than 1800 human cases later 
(WHO, 2016), mainly in Saudi Arabia (~75% of cases and almost all of the primary 
cases), the ecology of MERS-CoV and its epidemiology remain poorly understood 
(Embarek and Van Kerkhove, 2015). Human-to-human transmission of MERS-CoV 
accounts for approximately half of all the MERS-CoV cases reported to date (Embarek et 
al., 2015). Inter-human transmission has been well documented in health care-associated 
outbreaks in the Middle East and Korea (Assiri et al., 2013; Drosten et al., 2015; Ki et al., 
2015), and there appears to be limited inter-human transmission in household settings 
(Drosten et al., 2014).  
Many studies have now identified dromedary camels (Camelus dromedarius; 
dromedaries) as a natural host for MERS-CoV, and there appears to be ample evidence of 
widespread infection (either past or present) in dromedaries in the Middle East (Azhar et 
al., 2014; Hemida et al., 2015; Hemida, Perera et al., 2014; Nowotny and Kolodziejek, 
2014), and in many parts of Africa (Deem et al., 2015; Müller et al., 2014; Perera et al., 
2013; Reusken, Haagmans, et al., 2013; Reusken, Messadi et al., 2014). High levels of 
MERS-CoV specific seroprevalence have been observed in dromedaries, ranging from 
0% in Central Asia to as much as 100% in Africa and the Arabian Peninsula (Azhar et al., 
2014; Deem et al., 2015; Hemida et al., 2015; Hemida, Perera et al., 2014; Miguel, El 
Idrissi et al., 2016; Miguel, Perera et al., 2016; Müller et al., 2014; Nowotny and 
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Kolodziejek, 2014; Perera et al., 2013; Reusken, Haagmans, et al., 2013; Reusken, 
Messadi et al., 2014) (see Figure 10). MERS-CoV strains isolated from dromedaries are 
genetically and phenotypically very similar or identical to those infecting humans (Chan 
et al., 2014; Farag et al., 2015).  
 
Figure 10: Review of MERS-CoV exposure pathways for animal-to-animal 
transmission and animal-to-human transmission based on literature evidence and 
the expert opinions elicited in this study!!
Note: As it is not possible to further adapt this figure, the references are as follows #1 is WHO, 2016; #6 is 
Drosten et al., 2014; #13 is Perera et al., 2013; #16 is Miguel, El Idrissi et al., 2016; #17 is Miguel, Perera 
et al., 2016; #21 is Gossner et al., 2014; #23 is Hemida et al., 2013; #24 is Reusken, Ababneh et al., 2013; 
#25 is Reusken et al., 2016; #27 is; #28 is Ithete et al., 2013; #29 is Memish et al., 2013; #31 is Alraddadi 
et al., 2016; #32 is Müller et al., 2015; #49 is Hemida, Chu et al., 2014; #51 is van Doremalen et al., 2013; 
#52 is Khalafalla et al., 2015; #67 is Adney et al., 2014; #68 is Drosten et al., 2013; #69 is Munster et al., 
2016; #70 is Corman, Jores et al., 2014; #71 is Al-Tawfiq and Memish, 2014.  
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Since the beginning of the MERS-CoV outbreak, animals and specifically 
dromedaries, have been suspected of playing a role in transmission. The global camel 
population has more than doubled in the past 50 years, reaching ~30 million today, 95% 
of which are dromedaries. Approximately 60% of camels are found in East African 
countries, which are important exporters to the Arabian Peninsula and Egypt (Faye, 
2013). Camels play a major role in socio-cultural traditions in Saudi Arabia; a place 
where the camel population has increased from 80,000 to 200,000 heads over the last 50 
years; a number which some experts estimate is actually closer to 800,000 heads 
(Gossner et al., 2014). In parallel, a drastic decrease (from 10 to 1.5%) of nomadic camel 
populations has been observed over this time period in favor of permanent (or semi-
permanent) settlements often at the borders of cities (Gossner et al., 2014). It is possible 
that the mentioned changes in global dromedary population dynamics have led to an 
increased spread and heightened detection of MERS-CoV in this species, both of which 
have made dromedaries the focus of most of the research conducted on MERS-CoV to 
date.  
While coronaviruses are widespread in the animal kingdom (Woo et al., 2012), 
MERS-CoV seems to have a narrow host range. In the last few years, a large spectrum of 
domestic species have been negative after MERS-CoV serology tests, including horses, 
cattle, pig, water buffalo, chickens, goats, and Bactrian camels (Hemida et al., 2013; 
Miguel, Perera et al., 2016; Perera et al., 2013; Reusken, Ababneh et al., 2013; Reusken, 
Haagmans et al., 2013;;). An exception was published recently when antibodies were 
detected in Alpaca (Vicugna pacos) in Qatar; this is notably in a specific region where 
MERS-CoV is already endemic in dromedary camels (Reusken et al., 2016) (Figure 10).  
A number of studies on wild birds and swine in Hong Kong, feral camels in 
Australia and bats in several countries have not identified MERS-CoV in these species 
(Crameri et al., 2015; Perera et al., 2013) (Figure 10). Putative precursors of MERS-CoV 
have been detected in species of African bats (Ithete et al., 2013), and Corman, Ithete and 
colleagues (2014) raised hypotheses on the emergence of MERS-CoV from other animal 
species. They characterized the full genome of an African bat virus closely related to 
MERS-CoV and showed that human, camel, and bat viruses have phylogenetic 
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relationships although these bat viruses are not closely similar to MERS-CoV. They 
suggest that, according to available serologic data on camels and humans since 2012 and 
molecular investigations of known cases, MERS-CoV moved from bats to camels in sub-
Saharan Africa. They also suggest that camelids could be “mixing vessels for MERS-
CoV and other mammalian CoVs” and that the virus can be transmitted between humans 
and camels (Corman, Ithete et al., 2014). Up to now, MERS-CoV-like viruses have not 
been detected in any species other than camels, with the exception of an unconfirmed 
report of the detection of a very small fragment of MERS-CoV-like RNA in a specimen 
from a Taphozous perforatus bat collected in Saudi Arabia (Memish et al., 2013). T. 
perforates and other bat species sampled in Egypt and Lebanon did not reveal MERS-
CoV like viruses, although other coronaviruses were detected (Shehata et al., 2016).  
However, after more than 1800 reported cases over the past 4 years from 27 
countries, only one case–control study evaluating non-human risk factors for infection 
has been performed and published. This study, which included 30 primary cases and 116 
age, sex, and neighborhood-matched controls, confirmed suspicions that direct and 
indirect exposure to dromedary camels in the 14 days prior to symptom onset are risk 
factors for infection. This study also found that advanced age (>60 years old), being 
male, and having certain underlying chronic health conditions, such as diabetes, heart 
conditions, and chronic lung disease, were independent risk factors for disease (Alraddadi 
et al., 2016). Several other seroprevalence studies evaluating the extent of MERS-CoV 
infection in occupationally exposed persons (e.g., farmers, herders, slaughterhouse 
workers) have identified that these populations have a higher levels of seroprevalence 
when compared to the general population (Müller et al., 2015; Reusken et al., 2015) (see 
Figure 10).  
What is currently unclear is why all primary human MERS- CoV cases have been 
reported from the Arabian Peninsula (Embarek and Van Kerhove, 2015). Given that there 
is evidence of MERS-CoV circulation in dromedaries across large parts of Africa (Deem 
et al., 2015; Müller et al., 2014; Perera et al., 2013; Reusken, Haagmans et al., 2013; 
Reusken, Messadi et al., 2014), it is likely that cases of MERS-CoV in humans have been 
missed. There are several potential hypotheses to explain this. First, surveillance for 
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MERS-CoV in human populations focuses mostly on severe disease and on travelers 
returning from the Arabian Peninsula rather than on patients without a history of travel. 
Moreover, on-going surveillance in Saudi Arabia is now very intensive (Saudi Arabia 
Ministry of Health, 2013). Second, the prevalence of chronic underlying medical 
conditions in many countries in Africa is far lower than in the Middle East, with high 
rates of heart disease, diabetes, and obesity; third, it is likely that asymptomatic, mild or 
sub-clinical cases are missed with even the most robust surveillance systems. Fourth, the 
nature of contact with and the use of dromedary products differ between countries and 
cultures. Lastly, the viruses circulating in the Arabian Peninsula may be different. 
Although MERS-CoV in Africa are >99% identical at the nucleotide level with those in 
the Arabian Peninsula (Chu et al., 2015), it is conceivable that a few key amino- acid 
differences may make a major change in transmissibility and virulence.  
In the case of MERS-CoV transmission, there is a large uncertainty about the 
various exposure pathways associated with new dromedary camel or human cases, and, 
although published research on MERS-CoV is actively increasing (Zyoud, 2016), few 
transmission risks have yet been quantified. There is an obvious need to collect more 
critical information from virological and eco-epidemiological studies, but also from 
social sciences (anthropology, sociology) studies about camel–human relationships, 
including behaviors at the interface. These studies can evaluate contact patterns, modes of 
transmission, viral shedding from animals, virus persistence in different environments, 
and biological samples. In view of all that remains to be done, we advocate a risk-ranking 
approach based on exposure pathways to guide allocation of resources for future data 
collection on the main sources of transmission of MERS-Cov. Risk assessment is a 
powerful modeling tool that enables decision-makers to determine the likelihood of 
disease occurrence and the magnitude of its consequences, which, in turn, allows 
identification of key steps and appropriate management measures to take. It is a 
structured and a systematic process that helps in the gathering of diverse and disparate 
information and data. However, when data are scarce and knowledge gaps are highly 
prevalent, such as with the recently identified MERS-CoV, too many transmission 
pathways would have been presented for the risk analysis. This is why we proposed, as a 
preliminary step, to call upon experts using expert- opinion elicitation (EOE), to explore 
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scenarios and hypotheses of transmission among animal(s), fomites, and humans. From 
the EOE outputs, a qualitative and/or quantitative risk assessment model could then be 
implemented. Expert-opinion elicitation has proven to be useful in other zoonotic disease 
risk assessments, especially in cases where little quantitative information for the disease 
is already known (Goutard et al., 2012; Horst et al., 1998). The aim of this work is to 
allow for a triage of highly likely and unlikely pathways, and highlight areas that deserve 
increased attention for field surveys and studies. 
 
• Materials and Methods 
In our study, experts were defined as being persons with relevant experience on 
the topic, including having extensive technical experience in epidemiological or 
virological research through MERS-CoV or related animal and/or human studies. 
Considering the recent emergence of the virus as a cause for human disease, extensive 
experience in MERS-CoV research itself was not an inclusion criteria; however, all 
included experts needed to have some experience working on MERS-CoV and/ or camel 
research topics within North Africa and the Arabian Peninsula, if not elsewhere. 
Furthermore, the experts’ publications and professional affiliations should have been 
significant enough to reflect this expertise. Recruitment was done first through relevance 
screening, where the researchers chose persons based on their own judgment. Following 
this original recruitment, “snowball” recruitment was used; experts who chose to 
participate were asked to recommend other experts to fill out the questionnaire. We 
aimed to enroll at least 10 experts, with extensive experience in relevant fields, for the 
exercise and, therefore, started by emailing invitations to 13 persons. All persons 
recommended by the first group of experts were invited to participate if their expertise 
was judged relevant for our study. All experts gave an informed consent before starting 
their participation in the survey. Written consent was not necessary for this type of study; 
experts could withdraw themselves from the study at any time and all opinion “results” 
would be presented in an anonymous fashion.  
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Searching into MERS-CoV literature and meeting reports allowed us to identify 
potential pathways and risk factors needed for designing the EOE (FAO, 2016; Shapiro et 
al., 2016; Zyoud et al., 2016) (Figure 10).  
The questionnaire was designed online using the tool Survey Monkey 
(www.surveymonkey.com). A pilot survey was sent to the team members in order to test 
the survey and optimize the consistency of the questions. A clear description of the study 
objectives and of what was expected for their participation was provided to experts in the 
invitation email. Following their acceptance to participate, the experts were emailed a 
link to the online survey. The beginning of the online survey included instructions, 
examples, and contact information of the administering researchers.  
The questionnaire was designed to take about 30–40 min, and be filled in by 
experts individually using a link to online software (see link 5 in Appendix 4). It 
consisted of expertise questions, relative importance of risk factor questions, transmission 
risk estimations, and open-ended responses, in that order, all of which will be described 
in more detail below.  
The analytical hierarchy process (AHP) is widely used in marketing research and 
has more recently been introduced as a tool in veterinary epidemiology (Horst et al., 
1996; Horst et al., 1998; Saaty, 1980; Saaty, 1987; Wind and Saaty, 1980). AHP obtains 
opinions on the weight of the relative importance of one attribute of an object or event 
over another, through pair-wise comparisons. In our questionnaire, we used the technique 
to obtain experts opinions about the most relevant exposure pathways and their relative 
importance for five different animal–animal or animal–human transmission scenarios. 
Where appropriate, simple transmission diagrams were used to explain the potential 
exposure pathways in question. Experts were first asked to identify which exposure 
pathway they “believed in” out of a provided list, always with the opportunity to specify 
“other.” They were then asked to do pair-wise comparisons of each exposure pathway, 
comparing the risk factors of transmission, using the Saaty scale (Saaty, 1987) (Figure 
11).  
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Figure 11:!Simplified Saaty scale used for comparing risk factors in the analytical 
hierarchy process. 
 
In order to obtain quantitative estimates on the transmission risks from 
dromedaries to humans, we asked experts for their 3-point estimation (minimum, most 
likely, and maximum) considering different types of exposure between 10 susceptible 
camel workers and dromedaries. Exposures included consumption of camel products 
(e.g., milk, urine, meat), direct and indirect contact; separate estimations were asked for 
different scenarios of younger (≤50 years) or older (>50 years) camel workers and adult 
or juvenile dromedaries. Using the same method, experts were also asked their estimates 
for transmission between potentially asymptomatic camel workers and family contacts.  
Finally, a few open-ended questions on factors that may increase or decrease 
transmission and were posed to experts. The survey was not anonymous in order to be 
able to come back to the experts in case of inconsistency in their answers. For every 
question, the experts were asked to respond not only expressing their opinion but also to 
assess their own confidence in their answers for each question, with a score from 1 to 5.  
The analytical hierarchy process allowed us to weight each exposure pathway 
according to the level of importance given to it by each expert. Additional weight was 
attributed to each answer according to the level of confidence given by the expert. Then, 
for each pathway, a weighted aggregation of all expert answers was generated. An 
expert’s data were excluded from the combined estimates in case of any of the following 
criteria: <30% consistency ratio, obvious erroneous entry, missing data for part of or the 
entire question. In this case, a 30% consistency ratio cut-off, taking into consideration 
that the historically recommended 10% cut-off is shown to be too severe for comparison 
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matrices that have >3 variables and that the cut-off should increase with number of 
variables (Golden and Wang, 1989; Peláez, 2003); our questions introduced up to eight 
variables for each matrix. The overall level of agreement across experts in their ranking 
of the selected risk factors was calculated using the Kendall’s W coefficient. The average 
weighted minimum, most likely and maximum transmission risk for each of the 3-point 
estimation questions was also generated using a similar weighting mechanism. An 
expert’s data was excluded from the 3-point distribution combined estimates in case of 
consistently highly outlying estimates or missing data for part of or the entire distribution. 
Outliers were defined as estimated risks that were consistently greater than twice the 
estimates of all other experts. When possible, for missing or erroneous data, experts were 
re-contacted by email to clarify. The mean confidence level, across all included experts, 
was calculated for each pair-wise comparison and 3-point distribution question. Open-
ended responses were summarized qualitatively. 
 
• Results 
Overall, 18 experts were contacted to take part in the questionnaire. Of these, 16 
responded to the invitation, and 14 filled out the questionnaire in full, contributing data to 
this study. All respondents, except 1, had expertise in either MERS-CoV epidemiology 
and/or virology; the remaining expert had significant experience in camel production and 
husbandry and general epidemiology. Six and three respondents had experience in 
conducting studies of camels and bats, respectively. A detailed description of each 
participant’s expertise can be found in Table 21.  
 
MERS-CoV Infection of Dromedary Camels  
On the topic of how dromedaries become infected with MERS-CoV, the 
following exposure pathways were presented to experts: infestation of infected bats in 
close proximity, daily close contact with infected camel workers (both ≤50 and >50 years 
old), short-term contact with an infected dromedary herd, short-term contact with a non-
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dromedary species infected with MERS-CoV, and infection occurring during dromedary 
calving season. All of the above risk factors were selected by at least 5/14 experts. 
However, the most highly selected and importantly weighted exposures were “short-term 
contact with an infected dromedary herd” and “timing coinciding with dromedary calving 
season” (Figure 12). Two experts selected the “other” option and specified the most risky 
season is dromedary-weaning season. Furthermore, one expert selected “other” and 
included the possible risk associated with contaminated camel feed.  
 
Table 21. Included Expert Profiles 
 Degree Epidemiology Virology Camel 
Studies 
Risk 
Analysis 
Chiropter-
ology (bats) 
1 MD ✓* 1-5 yrs ✓* 1-5 yrs       
2 DVM ✓* 10+ yrs ✓* 10+ yrs ✓ 10+ yrs     
3 MD ✓* 10+ yrs ✓* 10+ yrs       
4 MPH ✓* 6-10 yrs   ✓ 1-5 yrs ✓ 1-5 yrs   
5 PhD ✓* 10+ yrs ✓ 1-5 yrs   ✓ 6-10 yrs   
6 DVM ✓* 10+ yrs ✓* 10+ yrs ✓ 10+ yrs ✓ 6-10 yrs ✓ 10+ yrs 
7 DVM ✓ 10+ yrs ✓* 10+ yrs       
8 DVM ✓* 1-5 yrs         
9 PhD ✓* 1-5 yrs ✓* 6-10 yrs   ✓ 10+ yrs   
10 DVM ✓ 10+ yrs   ✓ 10+ yrs     
11 DVM ✓* 10+ yrs     ✓ 6-10 yrs   
12 PhD ✓* 1-5 yrs   ✓ 1-5 yrs ✓ 1-5 yrs   
13 MD ✓* 6-10 yrs ✓* 10+ yrs     ✓ 6-10 yrs 
14 DVM ✓* 10+ yrs ✓* 10+ yrs ✓ 1-5 yrs ✓ 6-10 yrs ✓ 1-5 yrs 
* Including MERS-CoV specific 
 
MERS–CoV Infection between Dromedary Herds 
Risk factors that were presented to experts, when asking about the possibility of 
dromedaries from different herds infecting each other, were: nomadic dromedary herds, 
introduction of a new dromedary into the herd, high dromedary density area, dromedaries 
taken to racetracks, dromedaries entered into/taken to beauty contests, dromedaries 
brought to communal water- points, dromedaries brought to/sold at markets, dromedaries 
pass through border points. Each factor was considered risky by at least 5 (36%) of the 14 
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experts, and no additional risk factors from experts were provided. The most highly 
selected (i.e., >70% of experts) risk factors, in order of weighted importance, were: 
bringing dromedaries to markets, introduction of a new dromedary into the herd, high 
dromedary density area, and bringing dromedaries to communal water-points. The first 
three of these risk factors were given similar weights by experts, while the last 
(communal water-points) was thought to only be half as important as them. Experts had 
sufficient agreement on their ranking of risk factors (Kendalls W = 0.25, p = 0.003), and 
had a mean response certainty of 3.9 and 3.8 (out of 5) for choosing risk factors and the 
subsequent rankings, respectively.  
 
MERS -CoV Primary Infection in Humans  
Exposure pathways for human primary case occurrence included: infestation of 
MERS CoV infected bats in close proximity to human populations, contact with a 
MERS-CoV infected herd of dromedaries, contact with a non-dromedary MERS-CoV 
infected species, blood-biting pests (e.g., fleas, ticks) on an infected animal species or on 
humans, contact with another human who is asymptomatically infected with MERS-CoV. 
All experts agreed that contact with infected dromedaries or asymptomatic humans were 
major risks for disease transmission, with the former being of higher risk (Figure 12). 
About a third of experts (29–36%) thought that contact with MERS-CoV infected species 
other than dromedaries or bats may also play a role in human infection. Only one expert 
considered the possibility of blood-biting pests transmitting infection between 
dromedaries or other species and humans. Experts suggested no “other” risk factors. 
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Transmission from Asymptomatic MERS -CoV Cases to Contacts 
Experts were asked to estimate the risk of transmission from an asymptomatic 
infected individual to other individuals in close contact. The estimated “most likely” risk 
of transmission if the potentially asymptomatic camel workers were either ≤50 years or 
>50 years old was 9%. The experts had a mean confidence of 2.8 (out of 5) for their 
answers for both age groups. 
                                                
 
Figure 13: Exposure pathways and relative weights of risk factors for types of 
transmission between dromedaries and camel workers. ^p < 0.01. *Mean confidence for 
choice of risk factors for this question with a scale of confidence between 1 (not confident) and 5 (very 
confident)!!
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Risk Factors for Symptomatic MERS -CoV Infection in Humans 
At least 10 of the 14 experts agreed that older age (>50 years), being 
immunocompromised, and the amount of viral dose transmitted, increases the chances 
that infected camel workers or other persons will become symptomatic after MERS-CoV 
infection. Being immunocompromised was given the highest overall comparative weight 
as a risk factor, followed by amount of viral dose transmitted. Also, genetic susceptibility 
and recent occurrence of an epidemic period for another disease (e.g., Influenza) were 
identified as risky by three and four experts, respectively. Experts had a good level of 
agreement on their ranking of the selected risk factors (Kendalls W = 0.61, p < 0.01), and 
had a mean response certainty of 3.4 and 3.3 (out of 5) for choosing risk factors and the 
subsequent rankings, respectively. 
 
Responses to Open-Ended Questions on Transmission Dynamics 
Experts were asked which factors led to increase viral shedding in MERS-CoV 
infected dromedaries. The most highly suggested items included: juvenile dromedaries 
lacking antibody immunity (n = 4), immunosuppressive conditions and secondary disease 
(n = 4), animal density (n = 2) and stressful environments for the animals (e.g., at 
slaughterhouses, markets) (n = 2). Experts believed factors that may lead to increased or 
more efficient transmission between MERS-CoV infected dromedaries and humans 
include repeated close contact with dromedaries with the chance of contact with 
respiratory secretions (n = 3), host susceptibility or immune status (n = 2), increased 
virulence of the virus through genetic recombination or other (n = 2), and environmental 
contamination of camel-visited areas (n = 2). Experts were also asked whether or not they 
thought any other viruses might cross-immunize with MERS-CoV for either dromedaries 
or humans. Of the 12 experts who answered this question, 3 said “No,” while 6 were 
unsure or thought this was possible, and 3 experts believed that other coronaviruses might 
cross-immunize with MERS-CoV. 
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• Discussion 
Our results use expert opinion to weigh the different transmission risks of MERS-
CoV between animals and from animals to humans. Despite a lack of quantitative data, 
our results are supported by growing evidence from research published from MERS-CoV 
affected countries. Risk assessment is a tool that allows for the gathering of accessible 
data and information (e.g., expert opinion). The preliminary approach proposed in this 
paper synthesized available evidence regarding primary MERS-CoV transmission to 
humans. Our results highlight a general consensus in the order/rank of pathways, as well 
as for potential drivers and risk factors. According to the experts included in our study, 
dromedaries play a major role in transmission. However, the role of bats could not be 
ruled out and should be investigated further.  
Despite the fact that new research reveals traces of antibodies against MERS-CoV 
in two livestock handlers in Kenya in 2013/14 (Liljander et al., 2016), it is surprising that 
no locally acquired primary human cases have been reported where humans and infected 
dromedary camels are present outside the Arabian Peninsula. Recent workshops on 
MERS-CoV (Doha in April 2015 and Cairo in May 2015), organized by WHO, FAO, and 
the World Organisation for Animal Health (OIE), have produced numerous 
recommendations to improve surveillance and suggest research in animal and human 
populations (FAO, 2015). One of these recommendations is to investigate whether and 
why MERS-CoV infections of humans appear not to occur in Africa despite the high 
levels of infection in dromedaries, and why the virus is apparently absent in camels in 
Central Asia (dromedary and Bactrian camels). 
The exact role of dromedary camels as a potential reservoir for MERS-CoV is 
also still unclear, and further investigations should be carried out to identify the 
mechanism of virus transmission and quantify the stability of the virus in various 
conditions more clearly. MERS-CoV has been detected in the oropharyngeal tract, feces, 
milk, and meat of dromedaries (Gossner et al., 2014; Hemida, Chu et al., 2014; Reusken, 
Farag et al., 2014; van Doremalen et al., 2013). However, the modes of transmission are 
not clearly known. Our experts felt that the transmission risk from consumption of raw 
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camel products, including milk, meat, and urine is low. It is assumed that the infection 
from dromedary camels to humans occurs through droplets or contact as high viral loads 
have been detected in the upper respiratory tract and nasal mucous membrane of 
dromedaries (Khalafalla et al., 2015). However, milking activities and drinking 
unpasteurized milk, which is highly prevalent in Saudi Arabia (Faye et al., 2014), are 
considered as risky for the occurrence of primary cases in human populations. There is no 
evidence of MERS-CoV in camel meat, and it is known that cooking would kill the virus. 
One study from Qatar identified MERS-CoV in milk, but it was unclear whether the virus 
was excreted in the milk or if the milk had been contaminated by traditional milking 
techniques, which involves calves being used to initiate the milking process (Reusken, 
Farag et al., 2014). 
The role of and the extent to which infected asymptomatic human cases play a 
role in transmission is unknown. WHO estimates that ~20% of reported MERS cases are 
asymptomatic (WHO, 2015a), but this estimate is likely underestimated given 
surveillance focuses on severe cases requiring hospitalization and evidence from 
serologic studies (WHO, 2015b; Müller et al., 2015). One study documented prolonged 
shedding of MERS-CoV in an asymptomatic health care worker (Al-Gethamy et al., 
2014), which provides evidence that, if not properly isolated, asymptomatic cases in 
health care settings and in the community could lead to onward transmission. The experts 
included in this study believe that contact with asymptomatic cases is as important as that 
with infected dromedaries. Comprehensive testing of contacts of MERS-CoV patients, 
regardless of the presence of symptoms, is required to evaluate infection between known 
cases. The role of asymptomatic cases or carriers, if they are indeed infected, also needs 
careful consideration in the community setting. Not all reported primary cases can be 
traced back to contact with dromedaries, and it is likely, at least in some cases, that an 
asymptomatic or mildly symptomatic case may be an intermediary between dromedary 
contact and a symptomatic human case.!!
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After 4 years, research on the role of camels and/or other sources of primary 
transmissions to human is inadequate. So far, most MERS-CoV studies have focused on 
virological or clinical aspects of the disease. No comprehensive analytical epidemiological 
studies have yet been carried out in MERS-CoV affected countries. With the exception of one 
case–control study (Alraddadi et al., 2016) and individual case studies following investigation 
into single cases, transmission between dromedary herds and between dromedaries and humans 
has not been well studied. Even these detailed investigations are limited in terms of deciphering 
the cause-effect relationship. As human cases of MERS are relatively sporadic/rare, case control 
studies, especially matched case–control studies, can be well adapted during epidemics or 
outbreaks investigations and must be performed. Cohort studies are the best option in order to 
compare incidence among exposed (e.g., camel workers, immunocompromised people, etc.) and 
non-exposed populations. However, conducting cohort studies for rare diseases may be difficult. 
In regions without reported human clinical cases of MERS, cross-sectional surveys based 
on serological investigation in humans and identification and quantification of potential risk 
factors for infection (behaviors, husbandry, contacts with camels and camel products, etc.) will 
assist in the suggestion of hypotheses, if human infection is prevalent and statistically exploitable 
for inference at the population level. Outside of the Middle East, these studies need to be 
undertaken, especially outside of the Arabian Peninsula and in African countries where MERS-
CoV has been detected and/or isolated in dromedaries. Outside of the Arabian Peninsula, a 
number of joint human/camel serological studies are currently underway in North Africa (Pasteur 
Institut, Pers Comm) and planned in sub-Saharan African countries (HKU and Cirad, Pers 
Comm). For instance, in Ethiopia where MERS-CoV strains have been detected in camels (Peiris 
et al., Pers Comm), studies in at-risk human communities (e.g., nomadic people in close contact 
with camels, abattoir workers) have to be implemented: both analytical epidemiological studies 
and surveys on acute febrile illness (Woyessa et al., 2014), including respiratory and other signs 
could lead to clues about MERS-CoV infection and/or MERS-disease in humans. 
 At a more global scale, understanding differences in exposures and behaviors of 
individuals with dromedaries across the Middle East and Africa is likely to explain some of the 
differences in potential infection risk. For that purpose, “ecological studies” could help to explore 
diverse drivers of transmission among different environments and societies. However, studies 
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based on aggregated data are prone to many biases (Lasserre et al., 2000) making it difficult to 
know if individuals have really been exposed to the risk factor in question. Furthermore, social 
sciences have to be enlisted in order to puzzle out the relationships between camels and humans. 
Outputs can serve for epidemiological studies and modeling (e.g., multi-agents systems, see 
hereunder). Additionally, improved surveillance systems in humans and animals in rural and 
nomadic areas are required for MERS-CoV considering possible changes of the public health 
situation due to virus evolution (e.g., toward more pathogenic strains or diffusion of strains from 
areas with human disease, etc.) over time, modification of camel husbandry, etc. For population-
based studies, epidemiology and surveillance, we need to have species-adapted and validated 
serological tools. Indeed, performances of tests are often lacking and should be assessed using 
frequentist or Bayesian approaches. 
In addition to epidemiological studies, additional data from viral ecology studies among 
camels and other species, including bats, are required; phylogeography studies of MERS-CoV, 
and ecological studies on bat species living in the proximity of camels and suspected to play a 
role in the circulation of the virus, including a better understanding of their home ranges, 
migration patterns, biology (especially reproduction), roosting sites, and mechanisms of contact 
with camels are needed. Studies of viral shedding in animals, of virus persistence in different 
biological specimens of humans and animals, and in the environment under different conditions 
would help to quantify, or at least help to characterize, potential transmission risks. 
The effect of MERS-CoV on camel health is not well documented; is the camel an 
asymptomatic carrier (reservoir/vector) or can MERS-CoV infection induce mild symptoms 
and/or pave the way for secondary infections? To address this question, camel studies should 
focus not only on MERS but also on the diverse etiologies of respiratory syndromes (Wako et al., 
2016). This could be significant because, first, if MERS is recognized as a camel disease, more 
research resources could be allocated, second, super-infections could play a role in MERS-CoV 
transmission traits. Finally, multi-pathogens studies and multi-disease surveillance in camel 
populations can improve, through an economy of scale, MERS-CoV detection and the collection 
of data and metadata. Similarly, health conditions and infectious and parasitic diseases of camels 
may have an impact on MERS-CoV ecology and/or MERS epidemiological features. Indeed, 
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immunosuppressive effects of several origins (husbandry and farming conditions, under-nutrition, 
deficiencies, parasites, co-infections, etc.) could enhance the infectivity of the MERS-CoV. 
Considering the recent emergence of MERS-CoV as a zoonotic threat, and the lack of 
information already quantified on it, we appropriately included a small number of experts in this 
EOE exercise, but those who had diverse and extensive experience in relevant fields. The 
questions included in the exercise were feasible for persons who are not accustomed to formal 
prioritization methods; AHP is known to be adapted for complex information situations, to be 
intuitively understandable and to allow scientists to score the attributes with minimal confusion. 
Our study has several limitations. First, it is commonly considered best practice to give a training 
exercise on EOE methods as well as provide a multi-page literature review on the topic in 
question to participating experts, prior to administering the questionnaire, however, this was not 
done here. In this case, experts were provided with a detailed document describing how to fill out 
the questionnaire, with examples, and were invited to contact the authors if they had any 
questions or confusion (see link 5 in Appendix 4). It is possible to “calibrate” experts, by 
including some items in the questionnaire for which a general scientific consensus or 
quantification already exists; the expert response to these questions can then be matched to the 
real answer in order to see how close that expert arrives. There was no calibration done in this 
study, largely due to the fact that there are almost no solidly quantified risks associated with 
MERS-CoV at present. Experts were weighted instead only on their confidence level for each 
question answered; however, it is always possible that experts are overconfident, giving scores 
that do not reflect their real uncertainty on their knowledge of a variable. Linguistic uncertainty 
in the questionnaire could have led to some bias; experts with varied origins and experience can 
interpret questions and imagine contexts differently, and this can be exacerbated by ambiguity or 
lack of specificity in questions. For the aggregation of our results, we used a mathematical 
approach by combining the weighted estimates of all experts. Another option would have been to 
use a more inclusive and participatory behavioral approach that would allow experts to revise 
their answers after seeing those of others and eventually come to a consensus together. However, 
empirical results have suggested that mathematical methods can outperform behavioral 
techniques in certain circumstances (Lawrence et al., 1986; Seaver, 1978), and it is also possible 
that group dynamics could bias estimations of risks toward a more extreme consensus (Plous, 
1993). Overall, the experts were more certain in answering the AHP questions, which involved 
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choosing and ranking risk factors. For all animal–animal or animal–human AHP questions, the 
experts consistently had mean confidence levels of close to 4 (out of 5), however, when asked to 
rank risk factors for asymptomatic human–human transmission, the mean confidence level was 
lower (closer to 3). When estimating minimum, most likely, and maximum transmission risks 
based on scenarios, the experts had lower overall mean confidence in their answers, with scores 
of between 2.8 and 3.2 for all estimations. This lower certainty is likely related to the fact that so 
few transmission risks for MERS have yet been quantified, whereas in choosing and ranking risk 
factors, there are already strong trends as presented in the literature. 
Apart from virological, ecological, and epidemiological approaches, simulation models 
will allow for the testing of different scenarios of transmission, and this can be compared with 
reported cases. However, the scarcity of the data at the animal–human interface impedes the use 
of data-driven models like the stratified (animal–human) susceptible-exposed-infectious-
recovered (SEIR) models, contact networks models, etc. Moreover, in order to analyze and 
simulate the complete pattern of the disease, there is also a need to capture the behaviors of 
animals and people (Funk et al., 2015). The individual-based model built on multi-agents systems 
is a computerized system combining multiple interacting agents (e.g., humans, animals) within a 
given environment (Bradhurst et al., 2016). Such a model could be built in close interaction with 
stakeholders (farmers, camel workers, etc.) and could drive toward more precise hypotheses 
about initial transmissions to humans (Amouroux et al., 2008; Macal, 2016). 
This EOE study has several limitations but it is a preliminary step for implementing a 
more comprehensive risk assessment. Risk assessment is a time-consuming and iterative process 
that needs to be fed by several sources of data, lab experiments and field observations (see Table 
23 for a summary of recommended studies). Risk communication, which is part of the risk 
analysis and closely linked to the risk assessment, is essential, especially considering that MERS 
is a major public health issue and could have indirect economic and social impacts on the 
“dromedary world.” The questionable responsibility of dromedaries regarding human MERS-
CoV cases could indeed spur inappropriate and overdone control measures. More broadly, this 
EOE can help in identifying gaps and needs in terms of experimental, field and modeling studies 
that will give a better understanding of the zoonotic transmission pathways of MERS. 
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4.3.2 Discussion: EOE for supporting response to emerging disease events 
 Expert opinion elicitation can be a useful tool in emerging disease outbreaks, specifically 
to provide rapid guidance for policy action (Russell et al., 2017). In the case of the example 
provided above on MERS-CoV, the EOE study showed that experts enforced already widely 
proposed hypotheses on the importance of camels in transmission of the virus, but also 
demonstrated that some animals and exposures not typically prioritized in recent research 
deserved further investigations. Whether or not these conclusions will lead to research studies on 
typically neglected exposure pathways, that would not have been performed otherwise, remains 
to be seen.  
A review by Morgan (2014), describes well how EOE can be either “used or abused”, and 
describes that when performed well, these studies can make useful inputs into important research 
questions, but, done poorly they can “lead to useless or even misleading results that lead decision 
makers astray, alienate experts, and wrongly discredit the entire approach”. The author goes on to 
describe how the development of questionnaires, interview questions, and other elicitation 
activities need to be well planned, along with an appropriate choice of experts and method for 
combining answers or drawing consensus. Although the Delphi method is popular for drawing 
consensus from expert advice, this technique has also been criticized as being less efficient at 
actually generating accurate predictions but highly effective at pressuring groups into conformity 
(Woudenberg, 1991). In Egypt, Cousien and colleagues (2014), used EOE along with the Delphi 
method to estimate the risks of transition between different stages of HCV-related cirrhosis. They 
found that the chosen experts had great difficulty in estimating quantitative probabilities, and 
were not able to reach a consensus. Indeed, for some topics, and some experts, use of EOE 
techniques and the need for individuals to generate risks, may not be natural or feasible (Morgan, 
2014).  
In the case of ZIKV-related birth defects, there are many disease parameters that are not 
yet well understood, some of which may be difficult to address through highly powered studies in 
a timely manner due to decreasing transmission of the virus. Baud and colleagues (2017) have 
summarized the key knowledge gaps in a recent review. Some of these, such as “What is the 
percentage of transmission from infected pregnant women to fetuses?” and “Does Zika virus 
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infection confer lifelong immunity?”, for which eventual studies may be complex and time 
consuming, it could be interesting to get initial inputs on the likelihoods of these parameters from 
persons with related experience. For example, with regards to the first question, although ZIKV 
as a vertically transmitted agent is novel, other infectious diseases that are transmitted mother-to-
child have well-established experts from whom insights can be sought. In terms of the immunity 
bestowed from an infection with ZIKV, a consensus opinion from experts with extensive 
experience with other arboviral infections, such as yellow fever, could be solicited. Another 
interesting question, posed by Baud and colleagues (2017), is likelihood of a re-emergence of 
ZIKV in Africa and Asia. In this case, an EOE exercise including experts from a range of fields, 
such as epidemiology, genetics, and vector dynamics, may lead to published and focused 
recommendations for research in these regions. These can then be used to justify further funding 
opportunities for these regions where there is a definite risk of neglecting the impact of ZIKV 
(Meda et al., 2016).  
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4.4 Concluding remarks 
 
 In this thesis manuscript, I have described how, historically, the first epidemiological 
studies on emerging diseases have led to initial mis-estimations and misinterpretations of 
important disease parameters. This phenomenon was then supported by my own findings through 
research done on ZIKV-related birth defects and on the effects of new, highly effective 
treatments for HCV in Egyptian populations. Finally, I described how some strategies, such as 
involvement in diverse research networks, protocol standardization, and EOE, might help in 
focusing hypotheses and generating results that can lead to more rapid consensus estimates. 
While formal standardization and best practices for specific emerging disease investigations may 
be subject to delays, transparent and collaborative research will still be able to inform preventive 
actions in the meantime.  
 
 The time that it takes us to come to an agreement on risks related to emerging diseases 
and events linked to them, is the same time by which exposed populations are highly vulnerable. 
In the case of ZIKV, exposed women presenting with positive test results during pregnancy may 
not be provided with an accurate risk of their infant eventually having severe neurological 
defects; if currently overestimated, women in some countries may seek out unnecessary and 
unsafe abortions. For persons in remission from liver cancer waiting to be treated to clear their 
HCV infection, recommending or not the highly effective direct acting antivirals could lead to 
earlier recurrence with a related increased mortality risk. It is not for ourselves, aiming to publish 
in high impact journals, to whom we owe the production of collaborative and robust research, but 
rather to the persons who put their trust in us to inform them on the best probable course of action 
for their own health.  
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BACKGROUND
The risk of congenital neurologic defects related to Zika virus (ZIKV) infection has ranged 
from 6 to 42% in various reports. The aim of this study was to estimate this risk among 
pregnant women with symptomatic ZIKV infection in French territories in the Americas.
METHODS
From March 2016 through November 2016, we enrolled in this prospective cohort study 
pregnant women with symptomatic ZIKV infection that was confirmed by polymerase-
chain-reaction (PCR) assay. The analysis included all data collected up to April 27, 2017, 
the date of the last delivery in the cohort.
RESULTS
Among the 555 fetuses and infants in the 546 pregnancies included in the analysis, 28 
(5.0%) were not carried to term or were stillborn, and 527 were born alive. Neurologic 
and ocular defects possibly associated with ZIKV infection were seen in 39 fetuses and 
infants (7.0%; 95% confidence interval, 5.0 to 9.5); of these, 10 were not carried to term 
because of termination of pregnancy for medical reasons, 1 was stillborn, and 28 were 
live-born. Microcephaly (defined as head circumference more than 2 SD below the mean 
for sex and gestational age) was detected in 32 fetuses and infants (5.8%), of whom 9 
(1.6%) had severe microcephaly (more than 3 SD below the mean). Neurologic and ocular 
defects were more common when ZIKV infection occurred during the first trimester 
(24 of 189 fetuses and infants [12.7%]) than when it occurred during the second trimes-
ter (9 of 252 [3.6%]) or third trimester (6 of 114 [5.3%]) (P = 0.001).
CONCLUSIONS
Among pregnant women with symptomatic, PCR-confirmed ZIKV infection, birth defects 
possibly associated with ZIKV infection were present in 7% of fetuses and infants. Defects 
occurred more frequently in fetuses and infants whose mothers had been infected early in 
pregnancy. Longer-term follow-up of infants is required to assess any manifestations not 
detected at birth. (Funded by the French Ministry of Health and others; ClinicalTrials.gov 
number, NCT02916732.)
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Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
It has been recognized recently that Zika virus (ZIKV) infection during pregnancy can cause severe birth defects,1 including 
microcephaly,2 other brain defects,3 and the con-
genital Zika syndrome.4 However, the magnitude 
of this risk is not clearly defined. It was estimated 
to be higher than 40% in a prospective observa-
tional study in Brazil involving women who had 
symptomatic ZIKV infection during pregnancy.3 
In the U.S. Zika Pregnancy Registry, the estimate 
was 6% overall and 11% when ZIKV exposure 
occurred during the first trimester.5 The latter 
estimate has been updated recently to 15%.6
The ZIKV epidemic in French territories in 
the Americas began in early 2016 and presented 
another opportunity to assess the risk of ZIKV-
related congenital neurologic defects in a popu-
lation of pregnant women living in a region in 
which a ZIKV outbreak occurred. The centralized 
antenatal and maternal care facilities enabled 
enhanced surveillance of all pregnancies during 
the ZIKV epidemic. We present here the preg-
nancy outcomes in a cohort of women living in 
French territories in the Americas (French Guiana, 
Guadeloupe, and Martinique) who had symptom-
atic, laboratory-confirmed ZIKV infection during 
pregnancy.
Me thods
Study Overview
ZIKA-DFA-FE was a cohort study that used four 
different recruitment methods in an attempt to 
capture all women whose pregnancies overlapped 
with the period of the ZIKV epidemic in French 
territories in the Americas (details are provided 
in the Supplementary Appendix, available with 
the full text of this article at NEJM.org). The 
study received ethics approval from Comité de 
Protection des Personnes Sud-Ouest et Outre 
Mer III. All participants provided written informed 
consent. Full details of the study design can be 
found in the protocol, available at NEJM.org. 
The authors vouch for the completeness and ac-
curacy of the data and analyses and for the fidel-
ity of the study to the protocol. The study proto-
col was prepared with the help of the INSERM 
Research and Action Targeting Emerging Infec-
tious Disease (REACTing) network.
A key component of the ZIKA-DFA-FE study 
was the prospective follow-up, until the end of 
pregnancy, of women who had clinical symp-
toms of ZIKV infection during pregnancy. In 
accordance with the guidelines of the French 
High Council for Public Health7 and the French 
National College of Gynecologists and Obstetri-
cians8 that were released on July 28, 2015, and 
February 5, 2016, respectively, whenever a preg-
nant woman presented to the outpatient clinic or 
emergency department of a participating center 
with symptoms consistent with acute ZIKV in-
fection, she underwent a clinical examination, 
and blood and urine specimens were obtained 
for confirmation of recent ZIKV infection.
Enrollment Criteria
Pregnant women with suspected ZIKV infection 
were referred to the prenatal diagnosis center in 
each territory, where they underwent testing for 
ZIKV infection and were invited to participate in 
the study. Women were included in this analysis 
if they met all of the following criteria: ongoing 
pregnancy at any gestational stage; clinical 
symptoms consistent with acute ZIKV infection, 
with at least one symptom of pruritic skin rash, 
fever, conjunctival hyperemia, arthralgia, or myal-
gia; and laboratory confirmation of recent ZIKV 
infection, on the basis of a positive result on a 
reverse-transcriptase–polymerase-chain-reaction 
(RT-PCR) assay performed on a specimen of 
blood, urine, or both. The date of ZIKV infection 
was considered to be the date of the first ZIKV-
related symptom onset.
Cohort Follow-up and End Points
Once women were enrolled, they underwent 
monthly clinical and ultrasonographic examina-
tions until they had a pregnancy outcome. Dur-
ing these follow-up visits, a clinician also in-
quired about events that may have occurred (e.g., 
pregnancy complications or treatments received) 
since the previous visit. If a fetal abnormality 
was identified during a follow-up ultrasonograph-
ic examination, magnetic resonance imaging 
(MRI) of the fetus was performed, and the 
woman was followed up monthly with labora-
tory testing and ultrasonography, as reported 
elsewhere.9-11 The end point for each woman 
enrolled in the study was the pregnancy out-
come: delivery of a live-born infant with or with-
out birth defects, miscarriage, termination of 
pregnancy for medical reasons, or stillbirth.
A Quick Take 
is available at 
NEJM.org
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Data and Sample Collection in Mothers
During the enrollment visit, sociodemographic 
data were collected for each woman. These data 
included age, ethnic group, residence, level of 
education, professional activity, and lifestyle fac-
tors. Clinical information — including the num-
ber of previous pregnancies and live births, his-
tory of adverse pregnancy outcomes, pertinent 
medical history, body-mass index, symptoms of 
ZIKV infection, gestational age of fetuses, and 
any clinically relevant medical event during preg-
nancy — was recorded during this baseline visit, 
and blood and urine specimens were obtained.
Laboratory tests included RT-PCR for the de-
tection of ZIKV (RealStar Zika Virus RT-PCR 
Kit 1.0, Altona Diagnostics) in blood, urine, or 
both at baseline in all women and at the end of 
pregnancy in the case of fetal death, termination 
of pregnancy, or stillbirth. In addition, results of 
TORCH serologic testing12,13 (toxoplasmosis, 
other [syphilis, varicella, parvovirus infection, hu-
man immunodeficiency virus infection], rubella, 
cytomegalovirus infection, and herpes simplex 
virus infection), which is routinely performed 
during pregnancy in French territories in the 
Americas, were recorded. Serologic testing for 
cytomegalovirus was performed only on an elec-
tive basis, when fetal abnormalities were de-
tected.
Data Collection in Infants
For live-born infants, maternal and cord-blood 
specimens were obtained on the day of delivery, 
and serum specimens were frozen. The follow-
ing information on these infants was also re-
corded on the day of birth: gestational age, 
length, weight, head circumference, Apgar score 
at 5 minutes of life, and the results of a stan-
dardized clinical examination.
Pregnancy Outcomes
Pregnancy outcomes included delivery of a live-
born child (with or without abnormalities) or 
pregnancy loss through miscarriage, termination 
of pregnancy, or stillbirth. For the purpose of 
comparison with other studies,5 miscarriage was 
defined as intrauterine fetal death that occurred 
before a gestational age of 20 weeks. Stillbirth 
was defined as intrauterine fetal death that oc-
curred at or after a gestational age of 20 weeks 
or intrapartum death during delivery.
Likewise, to allow for comparison with other 
studies, we summarized our data in two mutu-
ally exclusive categories: birth defects possibly 
associated with ZIKV infection5 (brain abnormali-
ties with or without microcephaly regardless of 
the presence of additional birth defects); and 
neural-tube defects and other early brain malfor-
mations (e.g., anencephaly, acrania, encephalocele, 
holoprosencephaly, or arhinencephaly), eye abnor-
malities, and other consequences of central ner-
vous system dysfunction among fetuses and in-
fants who had neither evident brain abnormalities 
nor microcephaly. Consequences of central ner-
vous system dysfunction included conditions such 
as arthrogryposis, clubfoot, congenital hip dys-
plasia, and congenital deafness. In the case of 
live birth, microcephaly was defined as moderate 
when the head circumference was between 3 SD 
and 2 SD below the mean and severe when the 
head circumference was more than 3 SD below 
the mean, on the basis of INTERGROWTH-21st 
standards (http://intergrowth21 . ndog . ox . ac . uk/ ) for 
sex and gestational age. Moderate microcephaly 
was further defined as proportionate or dispro-
portionate — proportionate if the neonate was 
small for gestational age and disproportionate if 
the neonate was not small for gestational age.14 
Small for gestational age was defined as a 
weight more than 1.28 SD below the mean ac-
cording to the INTERGROWTH-21st standards 
for sex and gestational age. In the case of preg-
nancy loss or termination of pregnancy for 
medical reasons, autopsy measurements when 
available and findings from the last ultrasono-
graphic examination were used to assess for 
microcephaly. When ultrasonographic findings 
were used instead of autopsy data, microcephaly 
was defined as a head circumference more than 
3 SD below the mean.
In addition, we specified the number of fe-
tuses and infants who had any of the severe 
neurologic birth defects that are included in the 
currently proposed definition of the congenital 
Zika syndrome: severe microcephaly (head cir-
cumference more than 3 SD below the mean), 
brain abnormalities with a specific pattern of 
damage (e.g., calcifications, ventriculomegaly, 
or cortical malformations), damage to the back 
of the eye, joints with limited range of motion 
(e.g., clubfoot), or hypertonia that restricts body 
movement (e.g., arthrogryposis).4
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Statistical Analysis
The analysis included all data collected up to 
April 27, 2017, the date of the last delivery in the 
cohort. The percentage of fetuses and infants 
with birth defects possibly associated with ZIKV 
infection was estimated according to the trimes-
ter in which pregnant women were infected, and 
we compared these values across the three groups 
using Fisher’s exact test. Data were analyzed with 
the use of Stata software, version 13 (StataCorp).
R esult s
Patients
From March 2, 2016, to November 24, 2016, a 
total of 1152 pregnant women were evaluated at 
prenatal diagnosis centers for possible acute 
ZIKV infection. Of these, 108 were not enrolled 
in the study because they declined to participate 
(36 women), were lost to follow-up during the 
recruitment process (48), were younger than 18 
years of age (16), or were living outside French 
territories in the Americas (8); 458 had a nega-
tive result on ZIKV RT-PCR; and 25 had none of 
the qualifying symptoms. Thus, 561 women with 
symptomatic, PCR-confirmed, ZIKV infection 
were included in the analysis in this study. Of 
these, 6 women (1.1%) were excluded after it was 
determined that they did not meet specific eligi-
bility criteria regarding clinical or PCR results, 
and 9 women (1.6%) were lost to follow-up. 
Among these 9 women, the last available ultra-
sonographic data were from the third trimester 
for 5 women and from the second trimester for 
4 women; these fetal ultrasonographic examina-
tions were normal. Among the 546 women 
whose pregnancy outcome was known, there 
were 9 twin pregnancies. We were therefore able 
to describe outcomes in 555 fetuses and infants 
(Fig. 1). The 9 twin pregnancies resulted in 17 
live births and 1 miscarried fetus. No abnor-
malities were detected in any of the live-born 
infants from twin pregnancies. In the twin preg-
nancy that resulted in 1 live birth and 1 miscar-
ried fetus, the mother had been infected with 
ZIKV during the sixth week of pregnancy; the 
loss of 1 fetus occurred at 10 weeks of gestation, 
and the other fetus was carried to 41 weeks of 
gestation and was born healthy, without any 
abnormalities. Table 1 shows the main character-
istics of the 546 women (mean age, 29.7 years) 
with known pregnancy outcomes, and Table 2 
shows the main characteristics of ZIKV infection 
in these women. Coinfections with TORCH micro-
organisms are shown in Table 3.
Pregnancy Outcomes
Pregnancy outcomes are shown in Table 4 and in 
Table S2 in the Supplementary Appendix. Of the 
546 women with known outcomes, 185 (33.9%) 
were infected with ZIKV in the first trimester of 
Figure 1. Prospective Maternal Cohort and Pregnancy Outcomes.
The study was performed in the French territories of Martinique, Guade-
loupe, and French Guiana. PCR denotes polymerase chain reaction, RT-PCR, 
reverse-transcriptase–PCR, and ZIKV Zika virus.
1044 Were enrolled in the study
1152 Pregnant women were evaluated
for possible acute ZIKV infection
108 Were excluded
36 Did not give informed consent
48 Were lost during recruitment
process
16 Were <18 yr of age
8 Were living outside French
territories in the Americas
561 Had symptomatic, PCR-confirmed
ZIKV infection
483 Were excluded
458 Were negative for ZIKV by
RT-PCR assay
25 Did not have symptoms
of ZIKV
546 Underwent analysis in this study
15 Were excluded
9 Were lost to follow-up
6 Had secondary exclusion
3 Were determined not to have 
met clinical eligibility criteria
3 Were determined not to have
met PCR eligibility criteria
555 Fetuses and neonates (9 twin pregnancies)
were included in the analysis
527 Were live-born
11 Were miscarried
1 Was not carried to term because
pregnancy was terminated for
voluntary reasons
10 Were not carried to term because
pregnancy was terminated for
medical reasons
6 Died in utero or were stillborn
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pregnancy, 249 (45.6%) in the second trimester, 
and 112 (20.5%) in the third trimester. Overall, 
the mean number of fetal ultrasonographic ex-
aminations performed between the date of ZIKV 
infection and pregnancy outcome was 3.5 when 
ZIKV infection occurred during the first trimes-
ter and 2.2 when it occurred during the second 
trimester. A total of 28 fetuses (5.0%) were not 
carried to term or were stillborn; there were 11 
miscarriages, 10 terminations of pregnancy for 
medical reasons, 6 stillbirths, and 1 voluntary 
abortion. Among the 527 live births, 69 infants 
(13.1%) were small for gestational age, and 75 
infants (14.2%) were delivered through emer-
gency cesarean section. A total of 31 infants 
(5.9%) were hospitalized immediately after birth, 
and 7 of these infants (1.3%) were admitted to the 
neonatal intensive care unit. A total of 8 infants 
(1.5%) had an Apgar score of less than 7 at 5 
minutes after birth. These percentages did not 
differ by trimester of infection.
Neurologic and ocular abnormalities possibly 
associated with ZIKV infection were observed in 
39 fetuses and infants (7.0%; 95% confidence 
interval [CI], 5.0 to 9.5): 28 live-born infants, 10 
fetuses that were not carried to term because of 
termination of pregnancy for medical reasons, 
and 1 stillborn baby. Microcephaly was detected 
in 32 fetuses and infants (5.8%): 9 cases (1.6%) 
were severe, 9 (1.6%) were moderate-dispropor-
tionate, and 14 (2.5%) were moderate-proportion-
ate. Additional defects were observed in only 1 of 
the 23 infants with moderate microcephaly — a 
case involving medical termination of pregnancy 
in which the fetus had moderate-disproportion-
ate microcephaly. Severe microcephaly or other 
brain abnormalities included in the current 
definition of the congenital Zika syndrome were 
seen in 17 fetuses and infants (3.1%). In 3 of the 
527 live births (0.6%), clinical abnormalities 
other than microcephaly were detected at birth. 
Neurologic and ocular abnormalities were more 
common when ZIKV infection had occurred dur-
ing the first trimester (24 of 189 fetuses and 
infants [12.7%]) than when it had occurred dur-
ing the second trimester (9 of 252 [3.6%]) or 
third trimester (6 of 114 [5.3%]) (P = 0.001). The 
same was true for severe microcephaly (3.7%, 
0.8%, and 0.0%, respectively; P = 0.02) and the 
congenital Zika syndrome (6.9%, 1.2%, and 0.9%, 
respectively; P = 0.002). The risk of birth defects 
possibly associated with ZIKV infection was 
similar in Guadeloupe and Martinique (7.2% and 
7.5%, respectively). The risk of birth defects in-
cluded in the current definition of the congenital 
Zika syndrome was also similar in the two terri-
Characteristic
Study Cohort 
(N = 546)
Residence — no. (%)
French Guiana 24 (4.4)
Guadeloupe 245 (44.9)
Martinique 277 (50.7)
Age — yr
Mean 29.7±6.2
Range 18–46
Occupation — no. (%)
Student 23 (4.2)
Artisan, merchant, or business owner 30 (5.5)
Professional 111 (20.3)
Employee 177 (32.4)
Laborer, factory worker, or farmer 5 (0.9)
Unemployed 187 (34.2)
Missing data or declined to respond 13 (2.4)
Medical history — no. (%)
Arterial hypertension 23 (4.2)
Diabetes 8 (1.5)
Sickle cell disease 4 (0.7)
Previous pregnancies — no. (%)
0 131 (24.0)
1 153 (28.0)
2 126 (23.1)
≥3 136 (24.9)
Previous adverse pregnancy outcomes — no. (%)
Congenital abnormalities 6 (1.1)
Stillbirth 10 (1.8)
Termination of pregnancy for medical reasons 10 (1.8)
Mean BMI before pregnancy† 26.1±6.3
Lifestyle practices during this pregnancy — no. (%)
Alcohol consumption 2 (0.4)
Drug use 6 (1.1)
Current smoker 23 (4.2)
Use of mosquito repellents 445 (81.5)
Use of larvicides 337 (61.7)
*  Plus–minus values are means ±SD. Percentages may not total 100 because  
of rounding. PCR denotes polymerase chain reaction, and ZIKV Zika virus.
†  The body-mass index (BMI) is the weight in kilograms divided by the square 
of the height in meters. Data on BMI are missing for 90 women (16.5%).
Table 1. Characteristics of the Women with Symptomatic, PCR-Confirmed 
ZIKV Infection.*
n engl j med 378;11 nejm.org March 15, 2018990
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
tories (3.6% and 2.8%, respectively). In French 
Guiana, where the number of participants (24) 
was small, no birth defects possibly associated 
with ZIKV infection were observed. There was no 
significant association between any potentially 
identifiable toxic prenatal exposures (i.e., larvi-
cides, repellants, alcohol, tobacco, or illicit drugs) 
and birth defects.
No fetal abnormality or birth defect was ob-
served in any of the women who had coinfection 
with syphilis (4 women), human immunodefi-
ciency virus (2), toxoplasmosis (3), or cytomegalo-
virus (1). A total of 31 women underwent amnio-
centesis during the course of their pregnancy, 
with 27 instances of karyotyping and 20 ZIKV 
RT-PCR assays. All karyotypes were normal ex-
cept for one pericentric inversion of chromo-
some 2, and RT-PCR for ZIKV in an amniotic-
f luid specimen was positive in 7 cases. In 
addition, 6 nonneurologic birth defects (in 1.1% 
of the fetuses or infants) were detected in this 
cohort (see Table S3 in the Supplementary Ap-
pendix for a detailed description of all birth 
defects).
Discussion
The main findings of this cohort study are two-
fold. First, we found a 7.0% overall risk of neu-
rologic and ocular defects possibly associated 
with ZIKV infection that were evident at birth in 
the offspring of women in French territories in 
the Americas who had acute, symptomatic, PCR-
confirmed ZIKV infection during pregnancy. 
The overall risk of evident birth defects included 
in the current definition of the congenital Zika 
syndrome was 3.1%, and the overall risk of severe 
microcephaly was 1.6%. Second, although birth 
defects could be observed as a consequence of 
ZIKV infection in any trimester of pregnancy, 
our data showed that the risk of birth defects 
and the risk of the congenital Zika syndrome 
were higher when ZIKV infection occurred early 
in pregnancy — a finding consistent with previous 
reports.5,15 The risk of birth defects was 12.7% 
when ZIKV infection occurred in the first tri-
mester, 3.6% when it occurred in the second 
trimester, and 5.3% when it occurred in the 
third trimester, and the risk of the congenital Zika 
syndrome was 6.9%, 1.2%, and 0.9%, respectively.
The percentage of fetuses and infants with 
neurologic birth defects (7%) in this study is 
similar to the 6% observed in the cohort of 
women in the United States5 and the 5% reported 
more recently in the U.S. territories,15 but it is 
much lower than the 42% observed in the Brazil-
ian cohort.3 The difference is not attributable to 
the percentage of infants and fetuses with micro-
cephaly — which is similar in the current study 
in French territories in the Americas, in the study 
in the United States, and in the study in Brazil 
(5.8%, 4.1%, and 3.4%, respectively) — but 
rather to the percentage with wider neurologic 
birth defects. The percentage of infants who 
were small for gestational age was similar in 
French territories in the Americas and in the 
Brazilian cohort (13.1% and 9%, respectively), 
but differences between those two cohorts are 
apparent when we examine the percentage of 
infants who were admitted to neonatal intensive 
Characteristic
Study Cohort 
(N = 546)
no. (%)
Trimester of symptomatic ZIKV infection
First 185 (33.9)
Second 249 (45.6)
Third 112 (20.5)
Number of symptoms at time of ZIKV diagnosis
1 66 (12.1)
2 111 (20.3)
3 121 (22.2)
4 95 (17.4)
≥5 153 (28.0)
ZIKV symptoms
Rash 519 (95.1)
Arthralgia 300 (54.9)
Itching 263 (48.2)
Conjunctival hyperemia 199 (36.4)
Headache 161 (29.5)
Myalgia 128 (23.4)
Fever 123 (22.5)
Limb swelling 104 (19.0)
Pain behind eyes 102 (18.7)
Petechiae 38 (7.0)
Bleeding 1 (0.2)
Table 2. Characteristics of Infection in the Women with Symptomatic,  
PCR-Confirmed ZIKV Infection.
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care immediately after birth (1.3% in the French 
territories and 21% in Brazil) and the percentage 
of infants with abnormal neurologic findings 
from the clinical examination at birth (0.6% and 
26.5%, respectively). The termination of 10 preg-
nancies for medical reasons in the French terri-
tories (as compared with none in Brazil) may 
have resulted in fewer neurologic abnormalities 
being detected at birth in the French territories 
than in Brazil, but this cannot explain the entire 
difference between the two cohorts. In addition, 
the extensive use of MRI in the Brazilian cohort 
may have resulted in isolated abnormal imaging 
findings that have not been observed in other 
studies in which the use of MRI has been less 
frequent. The clinical implications of these find-
ings in Brazil are not yet known and will be 
determined only through longer-term follow-up 
of infants.
The strengths of our study include the size and 
homogeneity of the cohort of pregnant women 
who were living in a region in which an outbreak 
Test Time of ZIKV Infection
First Trimester Second Trimester Third Trimester
no. of women (%)
ZIKV RT-PCR
Positive results 185 (100.0) 249 (100.0) 112 (100.0)
In blood and urine 121 (65.4) 159 (63.9) 66 (58.9)
In blood only† 40 (21.6) 63 (25.3) 23 (20.5)
In urine only‡ 24 (13.0) 27 (10.8) 23 (20.5)
TORCH§
Positive results on any TORCH test 6 (3.2) 2 (0.8) 2 (1.8)
Toxoplasmosis¶
Tested 165 (89.2) 235 (94.4) 105 (93.8)
Positive 1 (0.6) 0 2 (1.9)
Syphilis
Tested 150 (81.1) 206 (82.7) 87 (77.7)
Positive 4 (2.7) 0 0
HIV
Tested 161 (87.0) 210 (84.3) 97 (86.6)
Positive 1 (0.5) 1 (0.4) 0
Rubella¶
Tested 152 (82.2) 222 (89.2) 97 (86.6)
Positive 0 0 0
Cytomegalovirus¶
Tested 20 (10.8) 30 (12.0) 14 (12.5)
Positive 0 1 (3.3) 0
*  TORCH includes testing for toxoplasmosis, other (syphilis, varicella, parvovirus infection, human immunodeficiency virus 
infection), rubella, cytomegalovirus infection, and herpes simplex virus infection. In highly febrile women, a reverse-
transcriptase–polymerase-chain-reaction (RT-PCR) assay for dengue virus was performed on blood specimens. Of the 
267 tests performed, 1 was positive. HIV denotes human immunodeficiency virus.
†  Results from tests on urine specimens were negative or unknown, or tests were not performed.
‡  Results from tests on blood specimens were negative or unknown, or tests were not performed.
§  In the subcategories of TORCH, the denominators for the percent of women who tested positive are the numbers of 
women tested.
¶  Toxoplasmosis, rubella, and cytomegalovirus tests were for IgM antibodies.
Table 3. Results of ZIKV and TORCH Testing in the 546 Women with Symptomatic, PCR-Confirmed ZIKV Infection.*
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Variable Time of ZIKV Infection
First Trimester 
(N =189)
Second Trimester 
(N = 252)
Third Trimester 
(N = 114)
Total 
(N = 555)
 no. of fetuses or infants (%)
Birth outcome
Stillborn or not carried to term 24 (12.7) 4 (1.6) 0 28 (5.0)
Miscarried 11 (5.8) 0 0 11 (2.0)
Not carried to term because of voluntary termination  
of pregnancy
1 (0.5) 0 0 1 (0.2)
Not carried to term because of termination  
of pregnancy for medical reasons
9 (4.8) 1 (0.4) 0 10 (1.8)
Stillborn 3 (1.6) 3 (1.2) 0 6 (1.1)
Live-born 165 (87.3) 248 (98.4) 114 (100) 527 (95.0)
No prenatal ultrasonography after ZIKV infection† 13 (6.9) 28 (11.1) 55 (48.2) 96 (17.3)
Abnormalities observed
Neurologic or ocular birth defects‡ 24 (12.7) 9 (3.6)§ 6 (5.3) 39 (7.0)
Microcephaly¶ 19 (10.1) 8 (3.2) 5 (4.4) 32 (5.8)
Severe 7 (3.7) 2 (0.8) 0 9 (1.6)
Moderate: disproportionate 4 (2.1) 2 (0.8) 3 (2.6) 9 (1.6)
Moderate: proportionate 8 (4.2) 4 (1.6) 2 (1.8) 14 (2.5)
Intracranial calcifications 8 (4.2) 0 0 8 (1.4)
Ventriculomegaly 7 (3.7) 1 (0.4) 0 8 (1.4)
Lissencephaly 2 (1.1) 0 0 2 (0.4)
Other brain abnormalities 8 (4.2) 1 (0.4) 0 9 (1.6)
Neural-tube defects 1 (0.5) 0 0 1 (0.2)
Eye abnormalities 0 0 0 0
Consequences of central nervous system dysfunction 1 (0.5) 0 1 (0.9) 2 (0.4)
Other birth defects 2 (1.1) 3 (1.2) 1 (0.9) 6 (1.1)
Chromosomal defects 0 1 (0.4)∥ 0 1 (0.2)
Skeletal abnormalities 2 (1.1) 1 (0.4) 1 (0.9) 4 (0.7)
Other 0 1 (0.4) 0 1 (0.2)
Congenital Zika syndrome 13 (6.9) 3 (1.2) 1 (0.9) 17 (3.1)
*  A total of 546 pregnancies were included in the study; there were 9 twin pregnancies, which brought the total number of fetuses and infants 
to 555.
†  Among the 527 live births, 96 infants (18.2%) did not undergo prenatal ultrasonography after the mother had been infected with ZIKV 
(7.9% when ZIKV infection occurred in the first trimester, 11.3% when infection occurred in the second trimester, and 48.3% when infection 
occurred in the third trimester).
‡  These results are possibly associated with ZIKV infection. Fetuses or infants may have had more than one neurologic or ocular defect.
§  The mother of one of these infants also had parvovirus B19 infection.
¶  In the case of live birth, microcephaly was defined as a head circumference more than 2 SD below the mean, on the basis of 
INTERGROWTH-21st standards (http://intergrowth21 . ndog . ox . ac . uk/ ) for sex and gestational age. Microcephaly was considered moderate 
when the head circumference was between 3 SD and 2 SD below the mean and severe when the head circumference was more than 3 SD 
below the mean. Moderate microcephaly was further defined as proportionate or disproportionate — proportionate if the neonate was small 
for gestational age (a weight more than 1.28 SD below the mean for sex and gestational age) and disproportionate if the neonate was not 
small for gestational age. In the case of pregnancy loss or termination of pregnancy for medical reasons, autopsy measurements when avail-
able and findings from the last ultrasonographic examination were used to assess for microcephaly. When ultrasonographic findings were 
used instead of autopsy data, microcephaly was defined as a head circumference more than 3 SD below the mean.
∥  This infant had Down’s syndrome with severe microcephaly.
Table 4. Birth Outcomes and Abnormalities Observed in the Fetuses and Infants.*
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of ZIKV occurred and who were prospectively 
followed from the time that acute symptoms 
developed and ZIKV infection was confirmed by 
PCR until the pregnancy outcome. The diagnosis 
of ZIKV infection was made on the basis of PCR 
testing of specimens of blood or urine or both, 
and the date of infection could be ascertained 
because the date of symptom onset was close to 
the date of ZIKV PCR testing. The study was 
conducted in well-defined geographic areas, and 
high standards of care were available to all preg-
nant women living in these territories. Linkage 
to care of pregnant women with ZIKV infection 
was effective, with a low rate of loss to follow-up 
(1.6%). In addition, the results were consistent 
across the two territories in which the largest 
numbers of women were recruited (Martinique 
and Guadeloupe).
We acknowledge that our study has limita-
tions. First, it focused only on pregnant women 
who had acute, symptomatic ZIKV infection. 
Although the rate of complications would be 
expected to be higher among women with symp-
tomatic infection than among those who were 
asymptomatic, an observational study involving 
U.S. women did not show any significant differ-
ence in the rate of birth defects between the 
offspring of women who had symptomatic ZIKV 
infection and the offspring of women who had 
asymptomatic ZIKV infection during pregnancy.5 
A recent study also showed no significant asso-
ciation between disease severity or viral load and 
adverse outcomes.16 Second, we were not able to 
fully assess the presence of birth defects possi-
bly associated with ZIKV infection in the case 
of the 11 miscarriages, 2 of the 6 stillbirths, 
and the 1 voluntary abortion, as well as in the 
96 live-born infants (18.2% of the 527 live-born 
infants) who did not undergo prenatal ultrasonog-
raphy after ZIKV infection. Although missing 
ultrasonographic data may have led to under-
diagnosis of ZIKV-related birth defects, it should 
be noted that in our cohort, only 1 live-born 
baby had an isolated brain abnormality (ventricu-
lomegaly), detected by MRI, in the absence of 
clinical abnormalities, after infection during the 
second trimester of pregnancy. All other live-
born babies with ZIKV-related defects had at 
least one abnormality that would have been de-
tected during the clinical examination at birth 
(e.g., microcephaly, clubfoot, or a neural-tube 
defect such as spina bifida). Also, the majority of 
missing ultrasonographic data involved pregnan-
cies in which infection occurred during the third 
trimester, and the consequences of infection 
during the third trimester were found to be limit-
ed in the other infants of the same cohort. Third, 
our end point was based on fetal ultrasonography 
and on neonatal clinical examinations and did 
not include postnatal ultrasonography or special-
ized hearing and ophthalmologic examinations. 
We believe that this aspect of the study design 
had a limited effect on the rate of birth defects 
that could have been identified if all neonates 
had undergone brain imaging soon after birth. 
Indeed, it has been reported that when ZIKV 
infection occurs during the first trimester or 
early second trimester, all brain abnormalities 
can be detected with ultrasonography before 28 
weeks of gestation.10 Another study showed that 
none of 103 infants with normal prenatal ultra-
sonographic findings and normal clinical exami-
nations at birth had anomalies attributable to 
ZIKV when MRI of the head was performed after 
birth.17 Still, the absence of microcephaly at birth 
does not exclude the possibility of delayed devel-
opment of microcephaly or other ZIKV-related 
brain and other abnormalities.18 This informa-
tion is now being collected as part of a cohort 
study of the infants (ClinicalTrials.gov number, 
NCT02810210); the study includes regular clini-
cal examinations with specialized hearing and 
ophthalmologic testing. Only the longer-term 
follow-up of the children born to the women in 
the current study will help identify the full spec-
trum of ZIKV-related complications.
In conclusion, among pregnant women with 
PCR-confirmed, symptomatic ZIKV infection, 
birth defects possibly associated with ZIKV infec-
tion were present in 7% of fetuses and infants. 
Defects were more common among fetuses and 
infants whose mothers had been infected early in 
pregnancy. Longer-term follow-up of infants is 
required to assess for late-onset manifestations 
not detected at birth.
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Abstract  (220 words)  
Objectives: To compare the risk of Zika virus (ZIKV)-related congenital abnormalities 
among exposed and non-exposed live born infants in French territories in the Americas. 
Design: Cross-sectional study of pregnant women and live born infants without exposure 
to ZIKV, compared to those from a previously reported prospective cohort with 
confirmed ZIKV exposure.  Setting: Guadeloupe (France) during the 2016 ZIKV 
epidemic period.  Participants: 484 ZIKV negative pregnant women and their 490 live 
born infants. Main outcome measures: ZIKV-related congenital abnormalities as 
measured by clinical examination at birth and foetal ultrasound imaging during 
pregnancy Results: Of the 490 live born infants without in-utero exposure to ZIKV, 42 
infants (8.6%) had indication of neurological abnormalities known as ‘potentially linked 
to ZIKV infection’; all but one of these were microcephaly without any other brain or 
clinical abnormalities. When compared to the 241 live born infants from pregnancies 
with ZIKV exposure, the proportion of such abnormalities was similar (6.6%, p=0.36). 
Conclusions: Isolated microcephaly and other mild neurological conditions were as 
prevalent among infants with and without ZIKV exposur  in-utero. As a result, when 
considering 249 foetuses and infants of women with confirmed ZIKV infection in 
Guadeloupe, only one (0.4%) live born infant and three (1.2%) medically-aborted 
foetuses had birth defects that could be linked to ZIKV infection. Trial registration: 
This study is registered at ClinicalTrials.gov (NCT02916732).  
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What is already known  
• Based on different studies, the risk of birth defects following ZIKV infection 
during pregnancy varies from as low as 5 to as high as 46%. 
 
• The most precise estimate obtained through a prospective cohort study with PCR-
confirmed diagnosis of infection in the pregnant mother comes from French 
territories in the Americas, with a risk estimated at 7.0% (95%CI: 5-10%). 
 
• However, in the absence of a control group of ZIKV non-infected pregnant 
women, it is difficult to attribute all observed birth defects to ZIKV infection.  
 
 
 
What this study adds 
 
• This study found no difference in the prevalence at birth of anthropometric and 
other mild abnormalities that may be potentially associated with ZIKV infection 
when comparing a group of ZIKV-infected and ZIKV non-infected women.   
 
• In both exposure groups, most abnormalities described at birth were isolated 
microcephaly, i.e. without any additional clinical or imaging abnormalities.  
 
• This study leads to a reduction of our estimate of the risk of ZIKV-related birth 
defects among women infected during pregnancy down to 1.6% (95% CI: 0.4% - 
4.1%), with no risk related to ZIKV infection in the 3rd trimester of pregnancy.  
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INTRODUCTION 
 
Since the first evidence surfaced that linked Zika virus (ZIKV) to foetal microcephaly 
and other brain abnormalities,1,2 key research priorities have been to define the range of 
defects associated with ZIKV infection during pregnancy, as well as to establish the risk 
of a foetus or infant being affected by them following infection during pregnancy. A 
multitude of case-series and case-control studies of foetuses and infants exposed to ZIKV 
in-utero have now been summarized to establish a preliminary definition of Zika 
congenital syndrome (ZCS) that includes a range of ocular abnormalities and 
neurological defects, such as microcephaly, structural brain abnormalities (e.g. 
calcifications, lissencephaly, ventriculomegaly), consequences of central nervous system 
dysfunction (e.g. congenital contractures, abnormal muscle tension, hearing impairment), 
swallowing disorders, irritability, seizures, neurodevelopmental issues, and others.3-9 In 
addition, studies from Brazil, the United States of America, and the French Territories in 
the Americas, have attempted to answer the question of how likely it is for the foetus or 
infant to be affected by any of these negative outcomes after infection during pregnancy, 
deriving differing risks of 46% (95%CI: 37-56%), 5% (95%CI: 4-6%), and 7% (95%CI: 
5-10%), respectively.10-12 In addition, a retrospective cohort study of 86 pregnancies in 
Colombia found a 2.4% (95%CI: 0.3-8%) risk of adverse foetal outcomes; all of these 
were microcephaly cases without indication of brain abnormalities or cli ical signs.13 
 
For the purpose of determining those birth defects that can actually be attributed to ZIKV 
in an exposed population, the estimation of the baseline level of birth defects in an 
appropriate ZIKV non-infected control group is necessary. In Brazil, a prospectively 
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followed control group of 61 symptomatic pregnant women negative for ZIKV by RT-
PCR was compared to 125 symptomatic pregnant women showing evidence of ZIKV 
infection; they found that total adverse outcomes were significantly less in women 
without evidence of ZIKV  (11.5% versus 46.0%, p<0.001), although for some specific 
outcome categories, such as foetal demise and proportion of infants with microcephaly, 
there were no differences between the two groups.10 Two other prospective studies have 
used control groups: a prospective ultrasound study examined foetopathy in French 
Guiana and found central nervous system abnormalities in 9.0% and 4.3% of the ZIKV-
exposed and non-exposed foetuses, respectively, and a prospective study of 29 ZIKV 
exposed pregnancies compared to 518 ZIKV non-exposed in the United States found no 
difference in outcomes between the two.14,15 
 
 
In the French Territories in the Americas, in the absence of co-circulation of viral 
infections with similar symptoms at the time of the Zika epidemic, it was not possible to 
enrol a non-ZIKV symptomatic control group as done in Brazil.  We therefore enrolled 
women and their live born infants at the time of delivery, known for not being infected 
with ZIKV during pregnancy.  Thus, we were able to compare the proportion of live 
births with anthropometric abnormalities, including microcephaly and small weight for 
gestational age, and other neurological abnormalities in the recently published 
prospective cohort of ZIKV symptomatic women12 with that of a control group of ZIKV 
non-infected pregnant women and their live born infants.  To optimize the comparability 
of the two groups and study environment, the analysis was restricted to the women from 
Guadeloupe where sufficient numbers were available. 
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METHODS   
 
 
Study design and participants  
The ZIKA-DFA-FE cohort study (a French acronym representing “Zika in the French 
Territories in the Americas in Pregnant Women”), which has been described elsewhere,12 
used four different recruitment methods in an attempt to capture all women whose 
pregnancies overlapped with the ZIKV epidemic period, 2016-2017, in the French 
Territories in the Americas (Guadeloupe, Martinique, French Guyana). These included: 
enrolment of women presenting to hospital with symptoms consistent with ZIKV 
infection, enrolment of pregnant women for which a foetal abnormality was detected 
during routine ultrasound, enrolment of pregnant women for which there was foetal 
demise, and finally, enrolment of pregnant women not yet included through other 
methods who presented at participating hospitals to deliver during and up until nine 
months following the ZIKV epidemic period. Those final women recruited at delivery in 
Guadeloupe, and their live born infants, were used for the study presented in this article.    
 
Procedures 
 
At the time of admission to hospital for labour, each eligible woman was informed of the 
study and invited to participate; oral consent was obtained before delivery and written 
informed consent was obtained before delivery whenever possible or within 24 hours 
after delivery otherwise. A questionnaire including socio-demographic data, such as age, 
ethnic origin, residence, education, professional activity, and lifestyle factors, was 
administered. Clinical information, including the number of previous pregnancies, history 
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of adverse pregnancy outcomes, significant medical history, symptoms of ZIKV 
experienced during pregnancy, and any clinically significant medical event during 
pregnancy, was also collected at this time. From the live born infants of participating 
women, clinical data such as gestational age, length, weight, and head circumference, 
APGAR score at 1, 5 and 10 minutes of life were collected on the day of birth, and a 
standardized clinical examination was carried out in the first four days of life. After 
enrolment, the medical files of participating women were retrospectively reviewed and 
data were collected on clinical and ultrasound examinations that had been performed 
during the pregnancy.  
 
Blood samples were collected from all participating women recruited at the time of 
delivery.  These were tested for serological presence of ZIKV, including immunoglobulin 
G (IgG), using the Euroimmun ZIKV IgG immunoassay (Euroimmun, Medizinische 
Labordiagnostika AG, Lübeck, Germany). In addition, some women had had other 
biological samples collected during the pregnancy that were tested for the presence of 
ZIKV by serological tests and/or by RT-PCR; when available these results were also 
taken into account. Results of TORCH serologic tests that were routinely performed 
during pregnancy in the French territories in the Americas were recorded, which included 
syphilis, toxoplasmosis, rubella, and HIV.16,17 CMV serology was performed only on an 
elective basis, for high-risk pregnancies or when foetal abnormalities were detected.  
 
Statistical analysis 
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Out of the women enrolled in the study, data was included in this analysis if they gave 
birth in Guadeloupe, had a confirmed negative IgG serology test for ZIKV from maternal 
blood taken at time of delivery as well as no other positive ZIKV tests during pregnancy, 
and if their infant was live born.  Evidence (ie. seen and reported by a clinician) or 
recollection of symptoms evocative of ZIKV infection during the pregnancy was not an 
exclusion criterion.  
 
Microcephaly was defined as moderate when head circumference was between – 2 SD 
and – 3 SD and severe when head circumference was less than – 3 SD, based on the 
INTERGROWTH-21st standards (http://intergrowth21.ndog.ox.ac.uk/) for gestational age 
and sex. Moderate microcephaly was further defined as proportionate or disproportionate 
depending on whether the neonate was small for gestational age.10,12,18 Small for 
gestational age was defined as having a weight less than –1.28 SD according to the 
INTERGROWTH-21st standards for gestational age and sex.10,12 
 
In addition to determination of anthropometric abnormalities, we reviewed clinical 
examination records and ultrasound files of participants for evidence of birth defects that 
are considered to be potentially associated with ZIKV infection according to the current 
definition of ZCS, including: structural brain abnormalities (e.g. calcifications, 
ventriculomegaly, lissencephaly), neural tube defects and other early brain 
malformations, eye abnormalities, hearing impairment, and other consequences of central 
nervous system dysfunction (e.g arthrogryposis, clubfoot).6,12  Other birth defects that are 
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not currently considered to be associated with ZIKV infection during pregnancy (e.g. 
skeletal and other malformations) were also noted. 
 
Baseline characteristics of women with ZIKV infection during pregnancy were compared 
to those of women without ZIKV infection during pregnancy using the Student’s t test for 
continuous variables and chi-square or Fisher’s exact test for categorical variables. The 
proportion of infants with anthropometric abnormalities and other birth defects was 
compared to data of live born infants whose mothers had RT-PCR confirmed ZIKV 
infection during pregnancy within the same setting and timeframe in Guadeloupe,12 
using Fisher’s exact test. Data were analyzed using Stata 13 (StataCorp LP Lakeway, TX, 
USA).  
 
The ZIKA-DFA-FE study is registered with ClinicalTrials.gov (NCT02916732) and 
received ethics approval by the Comité de Protection des Personnes Sud-Ouest et 
Outremer III (CEBH2016/03).  
 
 
Patient involvement 
 
The pregnant women and their infants were not involved in the development of the 
research question or design of the study. Each woman was notified of her Zika virus 
status following testing by her attending physician. Women have been given information 
to able them to contact the study investigators to receive information on the results of the 
study.  
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RESULTS  
 
Participants 
Of 1484 women enrolled at delivery in Guadeloupe, 1088 had available ZIKV test 
results. Of these, 588 showed evidence of ZIKV infection through either serological or 
RT-PCR testing, 16 had negative RT-PCR results but indeterminate ZIKV serological 
tests, and 484 were confirmed negative by serological tests at the time of delivery with no 
other positive test seen during pregnancy. Of these 484 ZIKV non-infected women, 6 had 
twin pregnancies; 490 live born infants were therefore considered in this analysis. In the 
previously published prospective cohort by Hoen et al,12 of the 254 pregnant women in 
Guadeloupe who had symptomatic RT-PCR confirmed ZIKV infection during pregnancy 
and were enrolled into the prospective cohort, nine pregnancies were excluded either 
because of loss to follow-up (n=5) or for mistaken inclusion in the cohort (n=4). Of the 
remaining 245 pregnancies, there were four sets of twins, and eight cases of foetal 
demise, including: two miscarriages and three stillbirths all without evidence of 
neurological birth defects, and three cases of medical abortion all with evidence of 
neurological abnormalities potentially linked to ZIKV infection. The lack of neurological 
birth defects was confirmed via autopsy for one of the two miscarriages, and all three of 
the stillborn infants. Therefore, we were able to compare 490 ZIKV-unexposed live born 
infants with 241 ZIKV exposed live born infants (with ZIKV exposure confirmed by RT-
PCR), all born to mothers living in Guadeloupe during the Zika outbreak. See Figure 1. 
 
The mean age of ZIKV non-infected women was 30.7 years (SD=6.4), and that of ZIKV 
infected women was 30.0 years (SD=6.3). There was a higher proportion of reported 
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smoking in the ZIKV-infected cohort during pregnancy compared to the ZIKV non-
infected: 4.2% (95%CI: 2.0-7.6%) versus 0.6% (95%CI: 0.4-1.8%). There were also 
more unemployed women in the ZIKV non-infected group compared to the ZIKV-
infected one: 48.1% (95%CI: 43.3-52.4) versus 34.6% (95%CI: 28.6-41.0). See Table 1.  
 
Anthropometric and other birth defects in live born infants 
Of the 490 live born infants of women without ZIKV infection during pregnancy, 66 
(13.5%, 95%CI: 10.6-16.8) were small for gestational age, and 41 (8.4%, 95%CI: 6.1-
11.2) had microcephaly. One of these moderate microcephaly cases had a possible 
genetic aetiology (Adams Oliver syndrome). Of the remaining infants with microcephaly, 
29 (5.9%, 95%CI: 4.0-8.4%) had either moderate-proportionate or moderate-
disproportionate microcephaly with no other structural brain or clinical abnormalities. 
Eleven (2.2%, 95%CI: 1.1-4.0) infants had severe microcephaly, seven of which were 
proportionate. One infant (0.2%, 95%CI: 0.01-1.1) had an abnormality that could be a 
consequence of CNS dysfunction, which was clubfoot.  Five infants (1.0%, 95CI: 0.3-
2.4) had skeletal or other abnormalities that are not currently classified as potentially 
linked to ZIKV infection, including: skeletal abnormalities of the fingers or toes (n=2) 
anal imperforation (n=1), and urinary tract abnormalities (n=2). Besides two small-for-
gestational-age infants whose mothers were HIV-positive, there were no other 
abnormalities (including microcephaly) identified in the remaining four infants of 
TORCH-positive mothers. See Table 2. 
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There were no significant differences in the anthropometric or other birth defects in live 
born infants whose mothers had a symptomatic PCR-confirmed ZIKV infection during 
pregnancy compared to those whose mothers had no evidence of prior ZIKV infection at 
the time of delivery in Guadeloupe. In two categories, ‘neurological or ocular 
abnormalities without microcephaly’ and ‘neural tube defects’, there were no cases seen 
in live born infants of women without ZIKV infection during pregnancy, and one case 
each in infants born to women infected with ZIKV during pregnancy. See Table 3.  
 
DISCUSSION 
 
We found no statistically significant difference in the risk of neurological birth defects in 
live born infants of ZIKV infected and non-infected women in Guadeloupe during the 
epidemic period in 2016-2017. These findings have important implications for the 
estimation of the number of congenital birth defects that can be attributed to ZIKV when 
the mother is infected during pregnancy. Originally, through a prospective cohort of 249 
RT-PCR confirmed ZIKV infected pregnant women in Guadeloupe, we reported a total 
of 18 (7.2%) neurological or ocular birth defects that were potentially linked to ZIKV 
infection; 13 (72%) of these were isolated anthropometric abnormalities (i.e. 
microcephaly) or isolated mild CNS dysfunction defects (i.e. clubfoot) in live born 
infants,12 which on the basis of the current study cannot be linked to ZIKV exposure. In 
live born infants, we are left then only with two severe neurological abnormalities (i.e. 
ventriculomegaly and spina bifida) that have no known alternative etiologies; this is, 
however, reduced to one abnormality when we remove the neural tube defect (ie. spina 
bifida), which is no longer considered as linked to ZIKV infection.19,20 As our ZIKV non-
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exposed study looked back retrospectively from the time of delivery, we are unable to 
compare the proportion of foetal demise with that of the full 249 ZIKV-exposed foetuses 
in the prospective cohort. However, the two (0.5%) miscarriages and three (1.2%) 
stillbirths of the ZIKV-exposed cohort are within the generally expected historical 
range,20,21 and had no evidence of neurological abnormalities during autopsy for the four 
that could be examined. There were three (1.2%) further cases of foetal demise in the 
prospective cohort, which were all medically indicated terminations of pregnancy due to 
ultrasound detection of severe structural brain abnormalities with microcephaly.12 If 
combining the severe neurological abnormalities in foetuses from medically terminated 
pregnancies (n=3) and live born infants (n=1) our new adjusted estimate of birth defects 
that could be attributed to ZIKV exposure in Guadeloupe would be 1.6% (95%CI: 0.4-
4.1%). See Figure 2. This would translate to a 4.1% (95%CI: 0.9-11.5%), 0·8% (95%CI: 
0.02-4.6%), and 0% (one-sided 97·5%CI:0–6·3%) risk of birth defects per first, second, 
and third trimester, respectively. 
 
This is the largest study of ZIKV non-infected women from a defined epidemic region 
that has been used as a comparative control group against ZIKV-infected pregnant 
women followed up during pregnancy. This study was conducted in a resource-rich 
setting where the standard of care for pregnant women is high. The exposure statuses of 
each of the two groups included in this study were well defined. The ZIKV infected 
women from Guadeloupe were confirmed via RT-PCR within days of infection,12 and the 
ZIKV non-infected group was defined so based on the absence of IgG at the time of 
delivery. Recent studies support a rapid appearance of ZIKV IgG after infection; it was 
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100% detectable within 11 days following infection for 15 subjects in Guadeloupe and 
within 26 days following infection for 29 returned travelers to the United States of 
America.23,24 The Guadeloupe study also showed consistently positive IgG results 
throughout follow-up for all subjects, which was up to at least 120 days for around 90% 
of subjects included. This evidence suggests that subjects infected with ZIKV, even early 
in pregnancy, would still have detectable IgG at delivery and would have been excluded 
from our ZIKV non-infected control group. 
 
This study has several limitations. As we had no directly comparable prospective cohort 
to that of recently published ZIKV confirmed infected women, we used a group of ZIKV 
non-infected women delivering at the same hospitals and in the same time period. The 
prevalence of TORCH infections did not differ significantly between the two groups and 
in terms of most baseline characteristics, the two groups were similar, although ZIKV 
non-infected women were more likely to be unemployed, and ZIKV infected women 
were more likely to report smoking during pregnancy. This may reflect recall ability and 
employment situation differences according to the timing of data collection, as ZIKV 
non-infected women were all recruited at the time of delivery and ZIKV infected women 
were recruited at various earlier time points during their pregnancy. Furthermore, the 
quality of follow-up and collection of data on the course of pregnancy was likely of a 
higher quality in the ZIKV-exposed group as this was a prospective cohort where women 
had been symptomatic during pregnancy. Highlighting this is the fact that the study team 
was able to retrieve ultrasound records for 88.4% of ZIKV infected women and only 
51.6% for ZIKV non-infected women. However, such a difference would only lead to an 
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underestimation of birth defects in the ZIKV non-infected group. Furthermore, the 
completeness of data at the time of delivery for live births, which was used to determine 
anthropometric and clinically apparent abnormalities, was very high in both ZIKV-
exposed (97·9%) and non-exposed (98·8%) infants. Recruitment of ZIKV non-exposed 
pregnant women at delivery also prevented us from determining the number of expected 
miscarriages, stillbirths, and abortions that may occur in the ‘baseline’ population, but 
this also indicates a potential under rather than over-estimation of birth defects in this 
group.  
 
Most of the originally reported ‘potentially linked to ZIKV’ abnormalities seen in both 
the exposed and non-exposed pregnancies of our study represent identification of 
microcephaly in live births; these cases were defined based only on anthropometric 
measurements, with known clinical and radiological findings for each infant being 
normal. This diagnostic approach to microcephaly, which does not require clinician 
judgment on the appearance of microcephaly, but relies solely on the comparison of a 
head circumference measurement against a normalized birth curve, has been used in all of 
the cohort studies describing the risk of birth defects following maternal ZIKV exposure 
during pregnancy, to date.10-15 However, defining microcephaly based on ‘metrics’ does 
not reflect the real-life clinical diagnosis of this condition, and can lead to a false surge in 
cases if applied to an entire population for surveillance purposes.25 Registries using more 
stringent definitions (e.g. -3SD) and/or clinician specific criteria indicate that true 
disease-related microcephaly is very rare; the European Surveillance of Congenital 
Anomalies (EUROCAT) recently estimated the prevalence of microcephaly in Europe to 
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be 1.53 per 10,000 births (~0.02%) with data from 2012-2016.26 However, as infant 
growth is approximately normally distributed, the INTERGROWTH-21st study itself 
prescribes that approximately 2% and 0.1% of healthy infants should have a head 
circumference at birth that falls below -2 and -3SD, respectively.27 Corroborating this, a 
recent study applying this definition of microcephaly to birth cohorts from two Brazilian 
cities, Ribeirão Preto and São Luís, estimated the baseline prevalence of microcephaly in 
2010 to be of 2.5% and 3.5%, respectively.28 Our own estimates of the prevalence of 
moderate and severe microcephaly and small weight for gestational age in ZIKV exposed 
infants was similar to that which the INTERGROWTH-21st standards prescribes. 
However, in our larger ZIKV non-infected control group, our estimates for each of these 
anthropometric abnormalities, while not different from those in the ZIKV-exposed 
cohort, were higher than what is prescribed by the INTERGROWTH-21st growth 
standards. This may be due to a ‘non-perfect-fit’ of the Guadeloupian population to this 
international pooled growth standard. Other authors,29-31 as well as the 
INTERGROWTH-21st study themselves,27 have noted varying levels of fit for individual 
populations when compared to this pooled standard.  
 
This study highlights the importance of a control group to estimate the baseline risk of 
anthropometric and other birth defects when determining the risk of severe congenital 
abnormalities that can be attributed to a given infection during pregnancy. This is 
particularly true for anthropometric measurements where regional variations may 
exist.27,29-31 Pre-Zika microcephaly baseline prevalence estimates are increasingly being 
reported. 25,27,32-34 While such reports can be used to give general clues as to the 
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magnitude of birth defects seen through cohort studies that can be attributed to ZIKV 
infection, the definition of microcephaly and Congenital Zika Syndrome used, and 
whether or not clinician expertise was considered, will be key to their interpretation.  As 
with other congenital infections that cause neurological abnormalities, such as 
cytomegalovirus and rubella,35,36 longer term studies that postnatally follow-up infants 
that are exposed to ZIKV in-utero but who are apparently healthy at birth are needed in 
order to understand the true overall risk of defects. However, in terms of the risk of 
immediate severe congenital defects that are potentially linked to ZIKV infection during 
pregnancy, and that may impact pregnancy outcome, our findings have further 
diminished our own estimate for pregnant women in Guadeloupe from 7.2% to 1.6% 
overall. Communication of the most possibly accurate estimate of the risk of severe birth 
defects linked to this infectious exposure, as well as the likelihood that such 
abnormalities will be detected early in pregnancy, will have an important influence on the 
family planning decisions of pregnant women with ZIKV-positive test results.  
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TABLES 
 
Table 1: Baseline characteristics of ZIKV non-infected and infected12 women from Guadeloupe who delivered live born infants  
 
Characteristic ZIKV  
non-infected 
 (N=484) 
ZIKV 
infected 
(N=237) 
Age — yr (mean and range) 30·7 (18-46) 30·0 (18-46) 
Missing 0 0 
Occupation — no. (%)   
Student  13 (2·7) 6 (2·5) 
Artisan, merchant, or business owner  14 (2·9) 17 (7·2) 
Professional  75 (15·5) 39 (16·5) 
Employee  148 (30·4) 91 (38·4) 
Laborer, factory worker, or farmer  1 (0·2) 1 (0·4) 
Unemployed  233 (48·1)* 82 (34·6)* 
Missing data or declined to respond 0 1 (0·4) 
Medical history — no. (%)   
Arterial hypertension  12 (2·5) 7 (3·0) 
Diabetes  12 (2·5) 4 (1·7) 
Sickle cell disease 7 (1·5) 2 (0·8) 
Previous pregnancies — no. (%)   
0 110 (22·7) 65 (27·4) 
1 133 (27·5) 57 (24·1) 
2 109 (22·5) 52 (21·9) 
>=3 130 (26·9) 63 (26·6) 
Missing 2 (0·4) 0  
Previous adverse pregnancy outcomes — no. (%)   
Congenital abnormalities  2 (0·4) 3 (1·3) 
Stillbirth  6 (1·2) 2 (0·8) 
Termination of pregnancy for medical reasons 4 (0·8) 4 (1·7) 
Lifestyle practices during this pregnancy — no. (%)   
Alcohol consumption 0 0 
Drug use 1 (0·2) 2 (0·8) 
Current smoker 3 (0·6)* 10 (4·2)* *Comparison between Zika non-infected and infected women with p=0.001  
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Table 2: TORCH results in ZIKV non-infected and ZIKV-infected12 women giving birth in Guadeloupe during the ZIKV epidemic period 2016-2017 
 
 ZIKV non-infected 
(N=484) 
ZIKV infected 
 (N=237) 
Positive results on any TORCH test 6 (1·2) 5 (2·1) 
Toxoplasmosis   
Tested 468 (96.9) 219 (92.4) 
Positive 3 (1·0) 0 
Syphilis   
Tested 249 (51·6) 184 (77·6) 
Positive 0 2 (0·8) 
HIV   
Tested 449 (93·0) 188 (79·3) 
Positive 3 (0·6) 2 (0·8) 
Rubella   
Tested 464 (96·1) 199 (84·0) 
P sitive 0  0 
Cytomegalovirus   
Tested 17 (3·5) 36 (15·2) 
Positive 0  1 (0·4) 
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Table 3: Abnormalities in live births of ZIKV non-infected and infected12 women in Guadeloupe during the epidemic period in 2016-2017 
 
 ZIKV non-infected 
(N=490) 
ZIKV infected 
 (N=241) 
 
Any neurological or ocular abnormalities  
 
42 (8·6) 
 
16 (6·6) 
Microcephaly (<-2SD) 41 (8·4) 12 (5·0) 
Severe microcephaly alone 11 (2·2) 1 (0·4) 
Moderate-disproportionate alone 10 (2·0) 6 (2·5) 
Moderate-proportionate alone 19 (3·9) 4 (1·7) 
Severe or moderate microcephaly with other 
neurological abnormalities 0 0 
Severe or moderate microcephaly with a genetic 
or chromosomal syndrome 1 (0·2) 1 (0·4) 
Missing 6 (1·2) 5 (2·1) 
Structural brain abnormalities  0 1 (0·4) 
Ocular abnormalities 0 0 
Neural tube defects 0 1 (0·4) 
Consequences of CNS dysfunction 1 (0·2) 2 (0·8)^ 
   
Other abnormalities 5 (1·0) 2 (0·8) 
Skeletal abnormalities 2 (0·4) 2 (0·8)^ 
Other 3 (0·6) 0 
 
Small for gestational age (weight <-1.28 SD) 
(with or without any of the above abnormalities) 
 
66 (13·5) 
 
33 (13·7) 
Missing 1 (0·2) 3 (1·2) 
^ One infant represented in each category as they had both club-foot and polydactyly.  Note: No significantly different values  
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FIGURE LEGENDS 
 
Figure 1: Flow chart of inclusion of ZIKV un-exposed and exposed pregnant women for inclusion of live births in this analysis    
Figure 2: Determination of excess risk of birth defects associated with ZIKV infection, based on autopsy findings and comparison with the ZIKV non-infected group    
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Figure 1: Flow chart of inclusion of ZIKV un-exposed and exposed pregnant women for inclusion of live 
births in this analysis  
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Figure 2: Determination of excess risk of birth defects associated with ZIKV infection, based on autopsy 
findings and comparison with the ZIKV non-infected group  
 
254x190mm (72 x 72 DPI)  
 
 
Page 29 of 29
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Review Copy
Microcephaly surveillance in Africa and Asia using a -2SD 
cut-off and international growth charts
Journal: Pediatrics
Manuscript ID Draft
Article Type: Regular Article
Date Submitted by the 
Author: n/a
Complete List of Authors: Funk, Anna; Institut Pasteur, Emerging Disease Epidemiology Unit
Soumahoro, Man-Koumba; Institut Pasteur de Cote d'Ivoire, 
Epidemiology Unit
Jayaratne, Kapila; Family Health Bureau - Ministry of Health Sri Lanka, 
National Maternal and Child Morbidity and Mortality Surveillance 
Programme
Tejiokem, Mathurin; Centre Pasteur du Cameroun, Epidemiology and 
Public Health Service
Qiu, Xiu; Guangzhou Women and Children’s Medical Center, Division of 
Birth Cohort Study
Saman Kumara, Lahanda Purage; Castle Street Hospital for Women, 
Neonatology
Njom Nlend, Anne ; Essos Hospital Centre, Service of Pediatric and 
Preventive Child Health
Xiao, Wanqing; Guangzhou Women and Children’s Medical Center, 
Division of Birth Cohort Study
Konan-Ble, Remy; General Hospital of Yopougon Attie, Obstetrics and 
Gynecology Service
Gamaathige, Nalin; De Soyza Hospital for Women, Neonatology
He, Jianrong; Guangzhou Women and Children’s Medical Center,, 
Division of Birth Cohort Study
Fouelifack, Florent Ymele; Hopital Central de Yaounde, Obstetrics and 
Gynecology Unit
Oura, N'Guessan Pierre; General Hospital of Abobo Sud, Obstetric and 
Gynecology Service
Tano, Kouadio Narcisse; Institut Pasteur de Cote d'Ivoire, Epidemiology 
Unit
Kunkel, Amber; Institut Pasteur, Centre for Global Health
Lucas, Nishani; University of Colombo, Department of Pediatrics, Faculty 
of Medicine
Leung, Gabriel; The University of Hong Kong, Community Medicine
Fontanet, Arnaud; Institut Pasteur, Emerging Disease Epidemiology Unit
Keyword/Topic: Birth Defects < Fetus/Newborn Infant, Epidemiology < Infectious Diseases
 
https://mc.manuscriptcentral.com/pediatrics
Confidential - Not for Circulation
Review Copy
Page 1 of 28
https://mc.manuscriptcentral.com/pediatrics
Confidential - Not for Circulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Review Copy
1
Microcephaly surveillance in Africa and Asia using a -2SD cut-off and international growth 
charts
Authors: Anna L Funk, Man-Koumba Soumahoro, Kapila Jayaratne, Mathurin Cyrille Tejiokem, 
Xiu Qiu, Lahanda Purage C Saman Kumara, Anne E Njom Nlend, Wanqing Xiao, Rémy Konan-
Blé, Nalin I Gamaathige, Jianrong He, Fouelifack Ymele Florent, N'Guessan Pierre Oura, 
Kouadio Narcisse Tano, Amber Kunkel, M Nishani Lucas, Gabriel M Leung, Arnaud Fontanet
Author Affiliations:
Anna Funk, MSc, Emerging Disease Epidemiology Unit, Institut Pasteur, 25-28 Rue du Dr. 
Roux, Paris, France, 75015
Man-Koumba Soumahoro, DDS PhD, Epidemiology Unit, Institut Pasteur of Cote d’Ivoire, 01 
BP, 490 Abidjan 01, Cote d’Ivoire
Kapila Jayaratne, MD, National Maternal & Child Morbidity and Mortality Surveillance 
Programme, Family Health Bureau, Ministry of Health, 231 De Saram Place, Colombo 10, Sri 
Lanka
Mathurin Cyrille Tejiokem, MD PhD MPH, Epidemiology and Public Health Service, Centre 
Pasteur of Cameroon, Member of the Institut Pasteur International Network, 451, Street 2005, 
Yaounde 2, P.O. Box 1274, Yaoundé, Cameroon
Xiu Qiu, MD PhD, Division of Birth Cohort Study and Department of Woman and Child Health 
Care, Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, 9 
Jinsui Rd., Zhujiang Newtown, Tianhe District, Guangzhou 510623, P.R. China
Lahanda Purage C Saman Kumara, MD, Castle Street Hospital for Women, Sri 
Jayawardenapura Road, Colombo 08, Sri Lanka
Anne E Njom Nlend, MD (Ped), Paediatric and Preventive Child Health Service, Essos Hospital 
Centre, National Social Insurance Fund, P.O. Box 5777, Yaoundé, Cameroon
Wanqing Xiao, MSc, Division of Birth Cohort Study and Department of Woman and Child 
Health Care, Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, 
9 Jinsui Rd., Zhujiang Newtown, Tianhe District, Guangzhou 510623, P.R. China
Rémy Konan-Blé, MD, Obstetric and Gynaecology Service, General Hospital of Yopougon 
Attié, 21 BP 632, Abidjan 21, Cote d’Ivoire
Nalin I Gamaathige, MD, De Soyza Hospital for Women, Kynsey Road, Colombo 08, Sri 
Lanka
Jianrong He, MSc, Division of Birth Cohort Study and Department of Woman and Child Health 
Care, Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, 9 
Jinsui Rd., Zhujiang Newtown, Tianhe District, Guangzhou 510623, P.R. China
Florent Ymele Fouelifack, MD, Obstetric and Gynaecology Unit, Yaoundé Central Hospital, 
P.O. Box 87, Yaoundé, Cameroon
N’Guessan Pierre Oura, MD, Obstetric and Gynaecology Service, General Hospital of Abobo 
Sud, 13 BP 969, Abidjan 13, Cote d’Ivoire
Page 2 of 28
https://mc.manuscriptcentral.com/pediatrics
Confidential - Not for Circulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Review Copy
2
Kouadio Narcisse Tano, MD (candidate), Epidemiology Unit, Institut Pasteur of Cote d’Ivoire, 
01 BP, 490 Abidjan 01, Cote d’Ivoire
Amber Kunkel, SD, Centre for Global Health, Institut Pasteur, 25-28 Rue du Dr. Roux, Paris, 
France, 75015
M Nishani Lucas, MD, MRCPCH, DCH, Senior Lecturer and Consultant Neonatologist, 
Department of Paediatrics, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
Gabriel M Leung, MD MPH, WHO Collaborating Centre on Infectious Disease Epidemiology 
and Control, School of Public Health, The University of Hong Kong, 7 Sassoon Road, Pokfulam, 
Hong Kong SAR, China
Arnaud Fontanet: MD, DrPH; Emerging Disease Epidemiology Unit, Institut Pasteur, 25-28 
Rue du Dr. Roux, Paris, France, 75015 and Unité Pasteur-Cnam Risques Infectieux et Émergents, 
Conservatoire National des Arts et Métiers, Paris, France
Corresponding Author: Professor Arnaud Fontanet, MD, DrPH, Head of the Emerging Disease 
Epidemiology Unit, Institut Pasteur, 25-28 Rue du Dr. Roux, Paris, France, 75015, +33 (0) 1 40 
61 37 63, arnaud.fontanet@pasteur.fr
Short title: Microcephaly surveillance in Africa and Asia
Financial Disclosure: The authors have no financial relationships relevant to this article to 
disclose
Funding source: This work was supported by the European Union’s Horizon 2020 Research and 
Innovation Programme under ZIKAlliance Grant Agreement no. 73458, as well as by the 
Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases programme (grant 
ANR-10-LABX-62-IBEID).  Anna Funk is part of the Pasteur - Paris University (PPU) 
International PhD Program, which has received funding from the Institut Carnot Pasteur Maladie 
Infectieuse (ANR 11-CARN 017-01). Amber Kunkel is supported by the Pasteur Foundation US. 
Potential Conflicts of Interest: The authors have no conflicts of interest relevant to this article 
to disclose
Abbreviations: CDC - Centres for Disease Control and Prevention; ECLAMC - Latin American 
Collaborative Study of Congenital Malformations; EUROCAT - European Surveillance of 
Congenital Anomalies; HCZ – head circumference Z score; INTERGROWTH-21st – 
International Fetal and Newborn Growth Consortium for the 21st Century; NICHD – National 
Institute of Child Health and Human Development; SD - standard deviations; WHO - World 
Health Organisation; ZIKV – Zika virus;
Table of contents summary: The proportion of live births with microcephaly from four cities in 
sub-Saharan Africa and Asia varied greatly using the INTERGROWTH-21st growth charts and a 
-2SD cut-off.
WHAT’S KNOWN ON THIS SUBJECT? 
In sub-Saharan African and Asian regions suitable for Zika transmission, little information on the 
baseline prevalence of microcephaly in live born infants is available. However, the prevalence in 
Europe and the United States was recently estimated at less than 0.1%. 
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WHAT THIS STUDY ADDS?
A -2SD cut-off with pooled international growth standards classifies many infants (3 to 35%) as 
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ABSTRACT (250 words)
Background and Objectives: Little data on microcephaly baseline estimates exists in sub-
Saharan Africa and Asia. We aimed to estimate the proportion of live births with microcephaly 
from four cities in sub-Saharan Africa and Asia using the INTERGROWTH-21st growth charts 
and a -2 standard deviation (SD) cut-off. 
Methods: Large maternities in Yaoundé (Cameroon), Abidjan (Ivory Coast), Colombo (Sri 
Lanka) and Guangzhou (China) collected data for live born infants through retrospective and/or 
prospective surveillance, as feasible in each setting. Head circumference, gestational age, and sex 
were compared to the INTERGROWTH-21st standards to obtain head circumference Z-scores 
(HCZ) for each infant. Moderate and severe microcephaly were defined as between -2 and -3SD, 
and less than -3SD, respectively.
Results: Sufficient data for 19914 live births across all study sites were analysed. The proportion 
of infants with microcephaly, according to the definition, was between 2.9% and 34.8% through 
retrospective surveillance in three countries. Prospective surveillance in Guangzhou, Colombo, 
and Abidjan, labelled 3.8%, 7.5%, and 18.6% of infants as having microcephaly, respectively. 
The retrospective data from Abidjan differed the most from the INTERGROWTH-21st 
distribution, with a shifted mean HCZ -1.41 SD, whereas the HCZ for infants from Guangzhou, 
following prospective surveillance, differed the least (mean HCZ -0.02SD). 
Conclusions. A cut-off of -2SD will most likely lead to labelling large numbers of healthy babies 
as having microcephaly, with important regional variations.  For the purpose of microcephaly 
surveillance, we suggest using regional growth charts, increasing consideration of infant body 
size, and defining the cut-off at -3SD (severe microcephaly). 
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INTRODUCTION
Microcephaly is a congenital anomaly that can appear in neonates following abnormal brain 
development due to infectious, genetic or environmental causes.1,2 This birth defect has attracted 
increased attention recently, following the rapid spread of Zika Virus (ZIKV) throughout the 
Americas in 2015-2016 and the realisation that microcephaly due to abnormal brain development 
can occur in the infants of women infected with ZIKV during pregnancy.3 Although few recent 
cases have been reported so far outside of the South-Pacific and Americas, a large proportion of 
sub-Saharan Africa and Asia is equally suitable for ZIKV transmission.4 The lack of 
understanding of the effects of current or impending transmission of ZIKV in these latter regions 
further emphasizes the need for strong surveillance systems and clear case definitions for 
microcephaly.5 
From 2003 to 2012, the European Surveillance of Congenital Anomalies (EUROCAT) registry 
estimated the prevalence of microcephaly in Europe to be 1.5 per 10,000 births (~0.02%).6 In the 
United States, between 2009 and 2012, pooled results from 30 birth defects registries, estimated 
the prevalence of microcephaly to be 9 per 10,000 births (0.09%)7.To our knowledge, there are 
no recent microcephaly registries or causality profiles for most regions of sub-Saharan Africa and 
Asia. In these regions we may expect different figures than in Europe due to environmental 
factors, differences in nutrition, and increased circulation of and lower vaccine coverage for 
infectious agents such as rubella. For the purpose of screening live neonates born to women at 
risk of ZIKV exposure during pregnancy, at the beginning of the recent outbreak in the Americas, 
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the Centres for Disease Control and Prevention (CDC) and the World Health Organisation 
(WHO) recommended defining moderate and severe microcephaly as a head size of less than -
2SD (or < 3rd percentile) and -3SD, respectively, for gestational age and sex using the 
INTERGROWTH-21st or WHO growth standards.8,9 The same definition has been used by many 
of the key cohort and case-control studies defining Zika related birth defects,3, 10-12 as well as in 
some recent estimations of the pre-Zika (ie. <2015) microcephaly prevalence in South 
America..13-15 Therefore, we sought to understand the distribution of newborn head sizes, and in 
particular the prevalence of microcephaly at birth, that could be expected using data from real-life 
settings in sub-Saharan Africa and Asia, according to a -2SD cut-off with a pooled international 
growth standard. Such results could be used as a baseline reference in these regions, for 
interpretation of disease-related microcephaly surveillance following a Zika epidemic. 
METHODS
Eight hospitals across four countries, two in sub-Saharan Africa and two in Asia, participated: 
Essos Hospital Maternity in Yaoundé, Cameroon; the General Hospitals of Yopougon-Attie and 
Abobo-Sud in Abidjan, Ivory Coast; Guangzhou Women and Children’s Medical Center, 
Guangzhou Huadu Women and Children Health Care Hospital and Guangzhou Liwan Women 
and Children Health Care Hospital; the Castle Street and De Soyza Hospitals for Women in 
Colombo, Sri Lanka. These are large hospitals in urban areas suitable for ZIKV transmission,4  
and have many births per day (mean: 22, range: 7-55) in relation to other regional hospitals. Most 
regions in which the study sites are situated would be considered low-income, besides 
Guangzhou. 
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Data from birth registers was collected retrospectively, with an aim to record data for at least 
3000 births consecutively moving back from the day at which the collection started, in the 
participating hospitals in Yaoundé (January 1st 2015 – December 31st 2016), Abidjan (August 
14th, 2016 – November 2nd 2016), and Colombo (June 13th 2016 –December 14th 2016). Head 
circumference in these maternities is measured within the first 24 hours of life using vinyl 
measuring tapes which are crossed over at the front of the head to get a reading of the head 
circumference. Birth register entries that were missing one or more data points were equally 
recorded and missing values noted in the data collection form. 
In Guangzhou (February 10th 2017 to March 13th 2017), Colombo (December 15th 2016 to April 
5th 2017), and Abidjan (April 4th 2018 to 14th July 2018), the participating maternities collected 
data prospectively with the aim to review 3000 consecutive births moving forward from the date 
of the collection start. Prior to this prospective data collection, the participating maternities 
reinforced their standard procedures for head measurement and birth register data collection.16 
They also introduced use of non-stretch Teflon seca 212 head measuring bands, which remain in 
a loop format with a viewing window in order to read head circumference measurements to the 
nearest millimetre (https://us.secashop.com/products/pediatric-measuring-systems/seca-212).  
Gestational age calculation
According to standard procedure at each participating maternity, gestational age is calculated 
based on the first date of the last menstrual period; for varying proportions of patients within each 
country, this estimate is confirmed using ultrasound examination carried out in the first trimester 
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of pregnancy. In Ivory Coast, women frequently first present at the hospital at a stage very late in 
pregnancy (e.g. onset of labour or first prenatal visit in the third trimester); in this case, the 
calculation of gestational age based on the date of last menstruation is still attempted and is often 
complemented by symphysis fundal height.
Data analysis
A newborn was included in the analysis if they had all of sex, gestational age and head 
circumference recorded in the birth register; this data is needed to calculate the infant’s head 
circumference Z-score (HCZ). Moderate microcephaly was considered as having a HCZ of less 
than or equal to -2SD & greater than -3SD and severe microcephaly was considered as having a 
HCZ of less than or equal to -3SD.3,8-12 Data was uploaded into the open access 
INTERGROWTH-21st online application retrieved at: http://intergrowth21.ndog.ox.ac.uk, which 
gave an exportable HCZ for each infant. We calculated a mean HCZ for each country, by type 
(retrospective/prospective) of data collection, to compare with the pooled mean from the 
INTERGROWTH-21st standards (i.e. 0SD). The Student’s t-test, or the Chi-squared test were 
was used to compare continuous data and categorical data, respectively. We excluded stillborn 
and very preterm (< 33 weeks gestational age) measurements as these were excluded in the 
elaboration of the growth standards.17,18 To facilitate the visual comparison between our data and 
the INTERGROWTH-21st standards for Figure 1, we recreated the distributions of newborn head 
circumferences by sex of the INTERGROWTH-21st charts (Supplementary Material). Data 
analysis and graphics were produced using R version 3.4.0. 
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Ethical considerations
In Sri Lanka and Ivory Coast, national ethical committee approval was not required in order to 
publish the aggregated results of the routinely collected data used for this analysis, however, 
institutional approval from participating hospitals was obtained. In Cameroon and China, 
institutional ethics committee clearance and approval of hospital authorities was obtained.
RESULTS
In total, data was collected for 21426 births that occurred between January 2015 and July 2018 
across eight hospitals in the four participating countries. After exclusion of stillbirths (n=298, 
1.4%), very preterm births (n=472, 2.2%), and birth records with missing variables (n=742, 
3.5%), data from 19914 (92.9%) live births was analyzed (Table 1). 
The distribution of HCZ from each country differed from that of the INTERGROWTH-21st 
standards by varying degrees (see Table 2). Figure 1 compares the HCZ distribution for each 
country with the HCZ distribution that would be expected based on the INTERGROWTH-21st 
standards. The prospective data from Guangzhou was the most similar (mean HCZ = -0.02SD, 
95%CI: -0.06 – 0.02) to the INTERGROWTH-21st standards, whereas the retrospective data 
from Abidjan was the least similar (mean HCZ = -1.41SD, 95%CI: -1.45 - -1.37). We found a 
significant difference in mean HCZ between male and female infants in the retrospectively 
collected data in Cameroon and Ivory Coast, as well as in the prospectively collected data in 
Ivory Coast and Sri Lanka (Table 2, Figure 1). 
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Overall, in the retrospectively collected data, the prevalence of moderate microcephaly ranged 
from 2.4% (Cameroon, 95%CI: 2.0-2.9%) to 25.8% (Ivory Coast, 95%CI: 24.2-27.4%), and the 
prevalence of severe microcephaly ranged from 0.5% (Cameroon, 95%CI: 0.3-0.8%) to 9.0% 
(Ivory Coast, 95%CI: 8.0-10.1%). In the prospectively collected data, the prevalence of moderate 
microcephaly ranged from 3.6% (China, 95%CI: 2.9-4.3%) to 14.6% (Ivory Coast, 95%CI: 13.4-
15.8%), and the prevalence of severe microcephaly ranged from 0.2% (China, 95%CI: 0.1-0.5%) 
to 4.1% (Ivory Coast, 95%CI: 3.4-4.8%) (See Table 2).
In Abidjan, where the mean HCZ was the furthest from zero (HCZ=-1.41SD, 95%CI: -1.45 -  -
1.37), a sensitivity analysis demonstrated a more shifted HCZ distribution (ie. disaccord with the 
INTERGROWTH-21st standards) when mothers presented late in pregnancy (62.4% of women) 
and uterine measurements were used to confirm the gestational age estimation, compared to when 
this was not needed: -1.48SD (95%CI: -1.53 - -1.42) vs -1.28SD (95%CI: -1.37 - -1.23, p<0.001). 
The prospectively collected data from the maternities in Colombo showed less microcephaly and 
a mean HCZ closer to 0 (-0.22SD, 95%CI: -0.26 - -0.18) when compared to the retrospectively 
collected data from the same site (-0.49SD, 95%CI: -0.54 - -0.44, p<0.001).  Similarly, the 
prospectively collected data from the maternities in Abidjan showed less microcephaly and a 
mean HCZ closer to 0 (-0.85SD, 95%CI: -0.89 - -0.81) when compared to the retrospectively 
collected data (-1.41SD, 95%CI: -1.45 - -1.37, p<0.001).  
DISCUSSION
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Defining microcephaly strictly as less than -2SD according to the INTERGROWTH-21st 
standards resulted in a prevalence at birth at our study sites in sub-Saharan Africa and Asia that 
far exceeded estimates observed in birth defect registries of Europe, the United States, and Latin 
America.6,7,19 These findings were in part expected, since the approximation of the distributions 
underlying these standards suggests that 2.2% of the healthy newborns included in the creation of 
the INTERGROWTH-21st standards would be classified as having at least moderate 
microcephaly given this definition.20 This prevalence would already be between 25 and 125 times 
the proportion of microcephaly as estimated through recent reports from birth defects 
registries.6,7,19 Supporting this, the ECLAMC (Latin American Collaborative Study of Congenital 
Malformations) determined a pre-Zika hospital-based microcephaly baseline prevalence of 0.08% 
in Brazil,19 whereas another study from Brazil that applied a standard definition (-2SD according 
to the INTERGROWTH-21st standards) to two hospital populations, without other criteria, found 
that more than 2.5% of infants were labelled as having microcephaly.13 These differences are not 
surprising considering that microcephaly cases in birth defects registries are likely classified as so 
by clinicians who have considered additional factors such as proportionality of the infant, 
dysmorphic features, and regional norms. 
There are many limitations of determining the prevalence of microcephaly in real-life settings if 
using pooled international standards that reflect ideal growth under optimal conditions. These 
constraints may explain the variation in our own estimates, as well as some of the extreme 
estimates for some sites, such as Abidjan, that we obtained.  Certain clinical practices and tools 
are needed in order for newborn data to best be compared with growth standards, some of which 
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are not always feasible in real-life settings of low-income countries. First, accurate measurement 
of the infant head circumference is needed, requiring multiple measurements using a non-stretch 
measuring tape with correct positioning on the neonate’s head. In the analysis we present, these 
methods were employed in a controlled fashion during the prospective surveillance in China, Sri 
Lanka and Ivory Coast, but not in the retrospective data from birth registers. In both Sri Lanka 
and Ivory Coast, the prospectively collected data that followed reinforcement of head 
measurement techniques and introduction of standard non-stretch headbands demonstrated mean 
HCZ estimates closer to zero when compared to the retrospective data; this indicates that 
reduction of measurement error leads to increased, but not total, assimilation with the 
INTERGROWTH-21st standards.  Furthermore, estimation of gestational age, which is best done 
with an ultrasound assessment in the first trimester, or otherwise using the date of last 
menstruation,17,18 is a measure that is complex to determine for a high proportion of women in 
our two participating countries in sub-Saharan Africa. In Abidjan, around 60% of the women 
presented for the first time at the hospital towards the end of their pregnancy, leading to uterine 
measurements being used to help estimate the gestational age. In Guangzhou, which is not a low-
income setting, women typically undergo 4-8 ultrasounds per pregnancy, allowing for precise 
determination of gestational age and early detection and abortion of infants with any 
abnormalities. This level of care and availability of tools may partially explain the similarity of 
the Guangzhou prospectively collected data to that of INTERGROWTH-21st standards. 
The differences observed between the populations in each of our study sites and the 
INTERGROWTH-21st standards likely also reflect regional differences in the head sizes of 
infants due to environmental and socioeconomic factors, such as poor nutrition and circulation of 
Page 13 of 28
https://mc.manuscriptcentral.com/pediatrics
Confidential - Not for Circulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Review Copy
13
infectious agents. These factors are, by definition, limited as much as possible in the creation of 
prescriptive growth standards, but cannot be teased out when comparing real-life data to the 
standards on a large-scale for surveillance purposes. Some criteria employed in the creation of the 
INTERGROWTH-21st standards, such as that for maternal height and body mass index, led to 
exclusion of more than 10% of otherwise eligible women and disproportionately affected specific 
countries.18 In a real-life setting where factors influenced by environmental and socioeconomic 
factors (e.g. maternal height and weight) are not adjusted for, the distribution of infant head 
circumference Z scores may be shifted away the pooled standard, further exacerbating extreme 
microcephaly estimates when using a fixed cut-off.  For example, within our two sub-Saharan 
Africa sites, the included hospitals in Ivory Coast, whose HCZ are shifted left compared to the 
INTERGROWTH-21st distribution (mean HCZ -1.39SD with retrospective collection, -0.85SD 
with prospective collection), are public with low-income catchment areas, while the hospital in 
Cameroon, with data shifted right with a mean H Z 0.75SD (retrospective collection), is a semi-
private institution with most patients coming from a higher socioeconomic status, and therefore 
likely with different environmental exposures. 
Variation in fetal growth has been noted recently across the 10 countries included in the creation 
of WHO fetal growth standards,21 as well as across the four ethnic groups included in the 
National Institute for Child Health and Human Development (NICHD) fetal growth study in the 
United States.22 Even after strict inclusion criteria, the INTERGROWTH-21st study noted 
variance in the mean HCZ for each of their participating countries when compared to their 
eventual pooled standard, which they call the standardized site discrepancy (SSD). Their eventual 
range of SSD for head circumference at birth varied from as low as -0.55SD to as high as 0.42 
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SD depending on the study country,18 which was within their predetermined limits to justify a 
pooled growth standard.20 It was demonstrated by Albert and Grantz that this allowed variance 
means that the probability of falling below the 5th percentile of the INTERGROWTH-21st 
percentiles would be as high as 12.6% in a setting with an SSD of -0.5 and as low as 1.6% in a 
setting with an SSD of 0.5.23 Applied to microcephaly surveillance, in the first case, such pooled 
standards could lead to over-diagnosis in healthy infants, and in the second, under-diagnosis of 
potential clinical cases. The mean HCZ (a measure similar to the INTERGROWTH-21st ‘SSD’) 
from our study sites had an even wider range, from –1.41 to 0.67SD, which may explain the very 
high proportion of microcephaly classifications that we observed in some countries, such as Ivory 
Coast. Indeed some recent studies corroborate this, noting that replacement of regionally specific 
growth charts with the INTERGROWTH-21st growth standards would reclassify a significant 
proportion of infants/foetuses as having either macrocephaly or microcephaly in Canada and 
China, respectively.24,25 A systematic review evaluating the WHO pooled international growth 
standards also corroborates this finding, with individual country means matching particularly 
poorly to the head circumference standards and leading to misdiagnosis of micro and 
macrocephaly.26
CONCLUSIONS
Our study raises several issues regarding microcephaly surveillance. The use of a -2SD cut-off 
based on the INTERGROWTH-21st chart implies that by definition, around 2% of healthy 
newborns will be categorised as having microcephaly. As mentioned by Morris et al,6 this will 
result in a high proportion of babies labelled as microcephalic who will have no detectable 
neurological impairment, generating unnecessary additional diagnostic costs and anxiety. To this 
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group will be added those who have underlying morbid or nutritional conditions associated with 
small body size, and who have been excluded from the elaboration of pooled prescriptive 
standards that describe ideal growth.  These conditions may be particularly common in poor 
settings of low-income countries.  Finally, in regions with high variation in head circumference 
size due to environmental and socioeconomic factors, the proportion of babies diagnosed with 
microcephaly may reach proportions so high that any surveillance or diagnostic work-up based 
on this definition would become very impractical.  The Ivory Coast maternities sampled in our 
study, with 19% of babies diagnosed with microcephaly through reinforced prospective 
surveillance, may be one example of that situation. 
As the ZIKV epidemic has ended,27 the focus of surveillance shifts towards increased specificity 
in identifying neurological birth defects. As a result, a cut-off of -3SD for microcephaly 
surveillance should be reconsidered, to conform with EUROCAT as well as guidelines and a 
systematic review predating the ZIKV epidemic.28-31 The predictive value of developmental 
disabilities for infants with an at-birth head circumference Z-score of less than -3SD compared to 
the norm, as opposed to -2SD, is also much higher,32 and this should be further validated using 
data from cohorts of infants with ZIKV exposure during pregnancy. In addition to a more specific 
cut-off, consideration of the proportionality of newborn head circumference length and/or weight 
should be considered; inclusion of these criteria will mimic the procedures of birth defects 
registries more closely, and is echoed in updated recommendations from the WHO and CDC.33,34 
Finally, there is a need to perform further country-specific and regional studies to develop local 
standards for foetal and newborn head circumference that can be used on a large-scale for 
surveillance purposes. A growing body of research, including our own study, challenges the idea 
Page 16 of 28
https://mc.manuscriptcentral.com/pediatrics
Confidential - Not for Circulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Review Copy
16
that foetal and newborn growth across the world can be assessed with a ‘one size fits all’ 
standard.21,22,26,35 If the international definitions for microcephaly adapt to be considerate of this 
evidence, our global epidemiological understanding of this condition will benefit. 
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TABLE LEGENDS
Table 1: Number of births collected and used in this analysis by participating country  
Table 2: Mean head circumference Z-score (HCZ), and microcephaly prevalence broken down 
by study site, type of data collection, and sex
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FIGURE LEGEND
Figure 1: Distribution of Head Circumference Z-Scores (HCZ), by sex, according to the 
INTERGROWTH-21st standards (in grey), for retrospectively collected data (Cameroon, Ivory 
Coast, Sri Lanka) and prospectively collected data (Ivory Coast, Sri Lanka, China). 
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T
able 1: N
um
ber of births collected and used in this analysis by participating country  
C
am
eroon
Ivory C
oast
Sri L
anka
C
hina
D
ata collection m
ethod
R
etrospective
R
etrospective
Prospective
R
etrospective
Prospective
Prospective
T
otal births recorded
5031
3212
3526
3147
3281
3229
Still births
84 (1.7%
)
83 (2.6%
)
112 (3.2%
)
3 (0.1%
)
4 (0.1%
)
12 (0.4%
)
V
ery preterm
 (<33 w
eeks gestation)
208 (4.1%
)
14 (0.4%
)
26 (0.7%
)
74 (2.4%
)
114 (3.5%
)
36 (1.1%
)
Live births (m
issing data)
312 (6.2%
)
158 (4.9%
)
81 (2.3%
)
11 (0.3%
)
21 (0.6%
)
159 (4.9%
)
Live births (sufficient data
a)
4427 (88.0%
)
2957 (92.1%
)
3307 (93.8%
)
3059 (97.2%
)
3142 (95.8%
)
3022 (93.6%
)
of w
hich w
ere m
ale
b 
2242 (50.6%
)
1542 (52.1%
)
1698 (51.3%
)
1592 (52.0%
)
1561 (49.7%
)
1621 (53.6%
)
aW
ith sufficient data for analysis, including sex, gestational age estim
ation, head circum
ference m
easurem
ent bPercentage of live births w
ith sufficient data 
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T
able 2: M
ean head circum
ference Z-score (H
C
Z), and m
icrocephaly prevalence broken dow
n by study site, type of data collection, 
and sex
*D
enotes significant difference betw
een m
ale and fem
ale m
ean H
C
Z *a p<0.001 *
b p=0.002 *
c p=0.007 
M
ean H
C
Z ±
 SD
Total m
icrocephaly
(≤-2SD
)
M
oderate m
icrocephaly
≤-2SD
 &
 >
-3SD
Severe m
icrocephaly
≤-3SD
R
E
T
R
O
SPE
C
T
IV
E
 D
A
T
A
 C
O
L
L
E
C
T
IO
N
C
am
eroon                                 Total (n=4427)
0.67 ± 1.33
129 (2.9%
)
105 (2.4%
)
24 (0.5%
)
M
ale (n=2242)
0.61 ± 1.32
*a
62 (2.8%
)
49 (2.2%
)
13 (0.6%
)
Fem
ale (n=2185)
0.74 ± 1.33
*a
67 (3.1%
)
56 (2.6%
)
11 (0.5%
)
Ivory C
oast 
Total (n= 2957)
-1.41 ± 1.20
1029 (34.8%
)
762 (25.8%
)
267 (9.0%
)
M
ale (n=1542)
-1.48 ± 1.16
*b
632 (41.0%
)
506 (32.8%
)
126 (8.2%
)
Fem
ale (n=1415)
-1.33 ± 1.25
*b
397 (28.1%
)
256 (18.1%
)
141 (10.0%
)
Sri L
anka 
Total (n=3059)
-0.49 ± 1.27
335 (11.0%
)
280 (9.2%
)
55 (1.8%
)
M
ale (n=1592)
-0.52 ± 1.28
193 (12.1%
)
165 (10.4%
)
28 (1.8%
)
Fem
ale (n=1467)
-0.46 ± 1.27
132 (9.0%
)
115 (7.8%
)
27 (1.8%
)
PR
O
SPE
C
T
IV
E
 D
A
T
A
 C
O
L
L
E
C
T
IO
N
Ivory C
oast
Total (n=3307)
-0.85 ± 1.24
616 (18.6%
)
482 (14.6%
)
134 (4.1%
)
M
ale (n=1698)
-0.96 ± 1.20
*a
341 (20.1%
)
272 (16.0%
)
69 (4.1%
)
Fem
ale (n=1609)
-0.74 ± 1.28
*a
275 (17.1%
)
210 (13.1%
)
65 (4.0%
)
Sri L
anka
  Total (n=3142)
-0.22 ± 1.24
236 (7.5%
)
203 (6.5%
)
33 (1.1%
)
M
ale (n=1561)
-0.16 ± 1.25
*c
126 (8.1%
)
113 (7.2%
)
13 (0.8%
)
Fem
ale (n=1581)
-0.28 ± 1.23
*c
110 (7.0%
)
90 (5.7%
)
20 (1.3%
)
C
hina                                       Total (n= 3022)
-0.02 ± 1.13
115 (3.8%
)
108 (3.6%
)
7 (0.2%
)
M
ale (n=1621)
-0.06 ± 1.11
60 (3.7%
)
59 (3.6%
)
1 (0.1%
)
Fem
ale (n=1401)
0.02 ± 1.16
55 (3.9%
)
49 (3.5%
)
6 (0.4%
)
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Supplementary Material: Recreation of INTERGROWTH-21st newborn standards 
distribution
Following the methods described for the creation of the INTERGROWTH-21st newborn 
standards, we used a skew t distribution (ST3 in R package GAMLSS) with four 
parameters and fit separate models for girls and boys.1,2,3 For each gestational age, we 
based the parameters μ and σ on the means and standard deviations from the on the 
INTERGROWTH-21st z-score charts. In particular, we set the mean equal to the reported 
value for z-score = 0 and the standard deviation to one-fourth the difference of +2SD and 
-2SD (similar definitions based on 1 or 3 SD produced similar but not identical results). 
We assumed the parameters υ and τ were fixed across all gestational ages, and fitted their 
values so as to minimize the sum of squared differences between the INTERGROWTH-
21st head circumferences and modelled head circumferences for each gestational age-
percentile combination provided in the INTERGROWTH-21st percentile charts. The 
INTERGROWTH-21st percentile charts list head circumference in centimetres for 7 
percentile values (the 3rd, 5th, 10th, 50th, 90th, 95th, and 97th percentiles) and 70 
gestational ages (33+0 to 42+6); the fit was thus based on 490 points each for boys and 
girls. We then transformed the resulting distributions of head circumferences into 
distributions of z-scores, removing the dependence on gestational age. 
Our recreation of the distributions underlying the INTERGROWTH-21st newborn head 
circumference standards matched the INTERGROWTH-21st percentile charts reasonably 
well, with only 9/490 (boys) and 10/490 (girls) head circumference values differing from 
the INTERGROWTH-21st standards by more than 0.1 cm, and none by more than 0.15 
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cm.  For comparison, a normal distribution with mean and standard deviation defined 
using the same methods resulted in 51/490 (boys) and 79/490 (girls) head circumference 
percentile values differing by more than 0.1 cm, and 5/490 (boys) and 16/490 (girls) by 
more than 0.15 cm.
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STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies 
Item No Recommendation Page #(s)
(a) Indicate the study’s design with a commonly used term in the 
title or the abstract
1, 4Title and abstract 1
(b) Provide in the abstract an informative and balanced summary 
of what was done and what was found
4
Introduction
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported
5,6
Objectives 3 State specific objectives, including any prespecified hypotheses 6
Methods
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periods of recruitment, exposure, follow-up, and data collection
6, 7
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applicable
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Data sources/ 
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8
(c) Explain how missing data were addressed 8
(d) If applicable, describe analytical methods taking account of 
sampling strategy
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Statistical methods 12
(e) Describe any sensitivity analyses 8
Results
(a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and 
analysed
9, Table 1
(b) Give reasons for non-participation at each stage 9, Table 1
Participants 13*
(c) Consider use of a flow diagram N/A
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
N/A
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(b) Indicate number of participants with missing data for each 
variable of interest
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Outcome data 15* Report numbers of outcome events or summary measures 9, 10, Table 
2
(a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included
9, 10
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categorized
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Main results 16
(c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period
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10
Discussion
Key results 18 Summarise key results with reference to study objectives 10, 11
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias
11, 12
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence
12, 13
Generalisability 21 Discuss the generalisability (external validity) of the study results 14, 15
Other information
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which 
the present article is based
2
*Give information separately for exposed and unexposed groups.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available 
at www.strobe-statement.org.
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Abstract
Background & Aims: In 2015, a national Egyptian health issue survey was conducted to describe the prevalence of
hepatitis C virus (HCV) infection. In this paper, we describe the HCV burden in 2015, compare the results with the
national survey conducted in 2008, and discuss the implications of the new findings on prevention of HCV in
Egypt. Methods: A multistage probability sampling approach was used, similar to the national demographic survey con-
ducted in 2008. More than 90% of sampled individuals complied with the interview and provided blood samples. Results:
In the 15–59-year age groups, the prevalence of HCV antibody was found to be 10.0% (95% CI 9.5–10.5) and that of HCV
RNA to be 7.0% (95% CI 6.6–7.4). In children, 1–14 years old, the prevalence of HCV antibody and HCV RNA were 0.4%
(95% CI 0.3–0.5) and 0.2% (95% CI 0.1–0.3) respectively. Approximately, 3.7 million persons have chronic HCV infection in
the age group 15–59 in 2015. An estimated 29% reduction in HCV RNA prevalence has been seen since 2008, which is
largely attributable to the ageing of the group infected 40–50 years ago during the mass schistosomiasis treatment
campaigns. Prevention efforts may have also contributed to this decline, with an estimated 75% (95% CI 6–45) decrease in
HCV incidence in the 0–19 year age groups over the past 20 years. Conclusions: These findings can be used to shape
future HCV prevention policies in Egypt.
Keywords
hepatitis C Egypt – incidence HCV – nation-wide surveys – prevalence HCV
Hepatitis C Virus (HCV) infection is a major global
health challenge; it is estimated that more than 80 mil-
lion people are chronically infected worldwide, with 3–4
million new infections and 350 000 deaths occurring
each year because of HCV-related complications (1–3).
Egypt is the country with the highest HCV prevalence in
the world; in 2008, the Egyptian Demographic Health
Survey (EDHS), which was conducted on a large nation-
ally representative sample, estimated the prevalence of
HCV antibodies and HCV RNA, among the 15–59 year
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age group, to be 14.7 and 9.8% respectively. Based on
the population census and the EDHS done in 2008, it
was estimated that more than 6.8 million persons aged
15–59 years had HCV antibodies, of which more than
4.5 million individuals had active HCV infection (4). In
2015, the Egyptian Health Issues Survey (EHIS) was
done to re-estimate the prevalence of HCV infection in
Egypt. In this paper, we describe the prevalence of HCV
in Egypt in 2015, using measures of both HCV RNA,
which indicates the burden of disease, and of HCV anti-
body, which provides an estimate of past infection. We
also compare the results of the two national surveys
conducted in 2008 and 2015 in order to estimate
national changes in prevalence and incidence, and dis-
cuss the implications of these findings on the national
policy for HCV prevention and treatment in Egypt.
Materials and methods
Source of data
We obtained data from the EDHS 2008 (4) and EHIS
2015 (5), both of which were conducted by El-Zanaty
and Associates with support from the United States
Aid of International Development-sponsored DHS-7
project.
Sampling strategy
The national surveys in 2008 and 2015 were cross-sec-
tional household surveys, where sampling weights were
used to provide estimates considered representative of
the Egyptian population on the basis of a complex,
three-stage probability sampling approach. The two sur-
veys provide estimates of HCV prevalence in Egypt for
the country as a whole and broken down for the major
administrative regions (Urban Governorates, Lower
Egypt, Upper Egypt and the Frontier Governorates). In
both EDHS 2008 and EHIS 2015, those aged 15–
59 years were invited to participate, however, in EHIS
2015, children aged 6 months to 14 years were also
included (4, 5).
Data collection
Individuals within sampled households were invited and
consented for participation. Basic demographic infor-
mation was collected, including: age, gender, marital
status, place of residence, level of education, work status
and wealth status.
Laboratory procedures
The laboratory procedures applied in 2015 were similar
to those in 2008 (4, 5). In 2015, consented individuals
provided 7 ml of venous blood added to an EDTA vacu-
tainer tube. In the field laboratory, the 2015 EHIS bio-
marker staff centrifuged the blood and transferred the
serum to five microvials that were stored in liquid nitro-
gen tanks before being transferred to the Central Public
Health Laboratory (CPHL) in Cairo. A hepatitis C test-
ing algorithm used third-generation enzyme immunoas-
say (ELISA) to determine the presence of HCV
antibodies. A more specific assay, the chemiluminescent
microplate immunoassay (CIA) was used to confirm
HCV antibody status for ELISA-positive samples and
5% of the ELISA-negative samples. Quantitative real-
time PCR was used to test for HCV RNA in HCV anti-
body-positive samples to confirm active infections. A
quality control procedure of retesting of approximately
10% of all samples was undertaken at the CPHL and a
further external quality control was done at the Theodor
Bilharz Research Institute, in Cairo, by retesting approx-
imately 5% of the samples tested at the CPHL (5). The
only key difference between this procedure and that of
the previous survey is that, in 2008, the quality control
measure (10% of samples retested) at CPHL was not
carried out.
Statistical analysis
Comparisons were carried out for HCV antibody- and
HCV RNA-positive tests, by estimating the absolute and
relative risk reductions between the two surveys in com-
parable age groups. To calculate the 95% confidence
interval for the risk difference, Newcombe–Wilson’s
method without continuity correction was applied (6).
In order to estimate confidence intervals for the relative
risk, we used the methods described by Armitage and
Berry (7). The level of significance (P-value) was
inferred to be less than 0.05 if the corresponding 95%
confidence intervals for the relative and absolute effect
measures were devoid of ‘zero’ (8). HCV virus clearance
was estimated by finding the absolute difference
between the proportion of HCV antibody and HCV
RNA-positive participants, and dividing this by the pro-
portion of HCV antibody-positive participants. Com-
parisons of HCV clearance between combined age
groups in 2008 and 2015 were done using the chi-square
test. In order to demonstrate the cohort effect, the 2008
DHS data were shifted forward; 7 years were added to
Key points
• There has been an approximate 30% decrease in
HCV prevalence in Egypt between 2008 and 2015.
• This decline is mostly related to the ageing of the
initially infected cohort; this phenomenon will be
seen in most countries as the bulk of worldwide HCV
infections took place between 1960 and 1980.
• Still, a 28% decline in incidence in younger age
groups is estimated, most likely related to prevention
efforts such as injection safety and awareness pro-
grammes.
• Treatment has not yet demonstrated an impact on
decline of HCV prevalence in Egypt.
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each participant’s age from the 2008 DHS survey and
the HCV antibody and HCV RNA prevalence estimates
were re-calculated using the new numerator and
denominator in each age category. The estimated num-
ber of population positive for HCV antibodies and
HCV RNA was calculated by multiplying the age- and
gender-specific prevalence of 2015 by the population
census of January 2015 categorised by age and gender.
Ethical considerations
No ethical approval was needed for the data analysis
presented in this paper; the anonymised data is publi-
cally available online. El-Zanaty and Co is the responsi-
ble party for the ethical considerations of the EDHS
2008 and EHIS 2015; verbal informed consent was
obtained from all individuals aged 18 years and older
and from married minors aged 15–17 years. For chil-
dren less than 18 years, consent was obtained from the
parent or child caretaker.
Results
In EDHS 2008, 4757 households including 12 780 indi-
viduals aged 15–59 years were identified for interview
and blood testing. A total of 4662 households complied
(98%), 12 008 persons were interviewed (93.9%) and
out of these, 11 126 persons provided blood samples for
testing (92.7%). In EHIS 2015, 7649 households includ-
ing 28 079 individuals were identified. A total of 7516
households complied (98.3%), and 27 549 persons (age:
1–59 years) were interviewed (98.1%). Of the total
28 079 persons identified, 17 182 were aged 15–
59 years, of which 16 671 were interviewed (97.0%) and
out of these, 16 003 provided blood samples for testing
(96.0%). The remaining 10 897 persons identified were
children aged 1–14 years, and of these, 10 878 (99.8%)
were interviewed through their caregivers and 10 044
(92.3%) children provided blood samples for testing.
Children therefore represented 39.5% of the total study
population (those interviewed) in EHIS 2015. The char-
acteristics of the two populations surveyed in EDHS
2008 and EHIS 2015 are presented in Table 1. For com-
parison purposes, we describe the age group of 15–
59 years who were targeted in both surveys.
There was an overall significant reduction of 32 and
29% in the prevalence of HCV antibody and HCV
RNA-positive individuals, respectively, between the
DHS in 2008 and the EHIS in 2015 (Table 2). The age-
specific prevalence of HCV antibody and HCV RNA-
positive individuals in 2008 and 2015 is presented in
Table 2 and Fig. 1. The pattern of increased prevalence
of HCV antibody and HCV RNA-positive persons with
age was observed in both the 2008 and the 2015 survey.
A statistically significant reduction in HCV antibody
prevalence was observed in all age groups, and the great-
est relative prevalence reduction (75%) was observed
among those aged 15–19 years. A statistically significant
reduction in HCV RNA-positive individuals was
observed in all except the two age groups encompassing
those 20–29 years of age. The age-specific prevalence of
HCV antibody and HCV RNA-positive individuals from
2008 shifted forward by 7 years is presented alongside
the 2015 prevalence estimates (Fig. 1). The current data
Table 1. Participant characteristics of Egyptian Demographic
Health Surveys in 2008 compared to EHIS 2015
2008 2015
No. % No %
Study population
(15–59 years),
total interviewed
12 008 100 16 671 100
Laboratory tested
Yes 11 126 92.7 16 003 95.9
No 882 7.3 668 4.1
Households, total sampled 4953 100 7813 100
Interviewed
Yes 4662 94.1 7516 96.2
No 291 5.9 297 3.8
Age group (years), total 15–59
15–19 2151 17.9 2713 16.3
20–24 1960 16.3 2044 12.3
25–29 1635 13.6 2433 14.6
30–34 1322 11.0 2118 12.7
35–39 1209 10.1 1917 11.5
40–44 1148 9.6 1550 9.3
45–49 1044 8.7 1424 8.5
50–59 1539 12.8 2472 14.8
Gender, total
Males 5718 47.6 7462 44.8
Females 6290 52.4 9209 55.2
Marital status, total
Never married 3863 32.2 4375 26.2
Married 7588 63.2 11 372 68.2
Widowed 400 3.3 329 2.0
Divorce/separated 157 1.3 595 3.6
Residence, total
Urban 5288 44.0 6206 37.2
Rural 6720 56.0 10 465 62.8
Place of residence
Urban governorates 2445 20.4 2267 13.6
Lower Egypt 5213 43.4 8204 49.2
Upper Egypt 4168 34.7 6081 36.5
Frontier governorates 182 1.5 119 0.7
Education
No education 2588 21.6 2652 15.9
Some primary 1084 9.0 1459 8.8
Primary complete/
some secondary
2919 24.3 4552 27.3
Secondary complete/
higher
5417 45.1 8008 48.0
Wealth quintile
Lowest 2042 17.0 3268 19.6
Second 2442 20.3 3234 19.4
Middle 2425 20.2 3212 19.3
Fourth 2440 20.3 3436 20.6
Highest 2659 22.1 3521 21.1
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(EHIS 2015) for the three oldest age groups (45–
59 years) show a similar HCV clearance percentage
when compared to the same age groups in the shifted-
forward 2008 data (31.2% in 2015, 32.0% in the shifted
2008, P = 0.756). For the cohort of children aged 1–
14 years in 2015, the overall prevalence of HCV anti-
body and HCV RNA-positive individuals was 0.4%
(95% CI 0.3–0.5) and 0.2% (95% CI 0.1–0.3) respec-
tively (Table 3).
A significant reduction of HCV antibody and HCV
RNA-positive individuals was observed when looking at
the overall prevalence in the Urban Governorates and,
and for Lower and Upper Egypt Governorates (Fig. 2).
No significant change in prevalence of either HCV anti-
body or HCV RNA positivity was observed in the fron-
tier governorates.
Table 3 shows the age- and gender-specific preva-
lence of HCV antibody and HCV RNA-positive persons
in 2015, as well as the estimated total number of persons
positive for HCV antibody and HCV RNA in Egypt at
this time. In the population aged 0–59 years, we esti-
mated a total of 3 693 180 persons with chronic HCV
infection (HCV RNA positive), and 5 309 555 persons
with HCV antibodies.
Discussion
In 2015, HCV still affects a substantial proportion of the
Egyptian population, where it is estimated that, in the
1–59-year age group, 5.3 million persons are positive for
HCV antibodies and, of these, approximately 3.7 million
(69.5%) are HCV RNA positive. This is an underesti-
mate of the total human HCV reservoir in Egypt
because older age groups (> 59 years) were not included
in the EHIS 2015. This recent survey shows a similar
epidemiological pattern of increased HCV antibody
prevalence with age as did the EDHS 2008. This phe-
nomenon was described in many studies (9, 10) and is
because of the continuing exposure and risk of infection
with age (11), while the proportion of persons with
HCV infection who go on to develop severe disease and
die of it remains low until 30 years after infection; the
rate of progression to cirrhosis is estimated at 7% after
20 years of being infected (12). The increase in HCV
antibody prevalence with age is therefore demonstrating
the cumulative HCV incidence over time until HCV-
related mortality becomes manifest.
This study shows a significant reduction in the overall
prevalence of HCV antibody from 14.7 to 10.0%, and
Table 2. Prevalence of hepatitis C virus (HCV) antibody and HCV RNA positive persons (age 15–59 years) by age, gender and region (EDHS
2008 and EHIS 2015 surveys)
Characteristic
HCV antibody positive HCV RNA positive
%
Positive
2008
%
Positive
2015
Prevalence
difference
(95% CI)
% Prevalence
reduction
(95% CI)
%
Positive
2008
%
Positive
2015
Prevalence
difference
(95% CI)
% Prevalence
reduction
(95% CI)
Overall prevalence 14.7 10.0 4.7 (3.9–5.5)* 32 (60–69)* 9.9 7.0 2.9 (2.2–3.6)* 29 (23–35)*
Age group
15–19 4.1 1.0 3.1 (2.2–4.1)* 75 (64–85)* 2.8 0.8 2.2 (1.2–2.8)* 73 (55–83)*
20–24 4.9 3.2 1.6 (0.4–2.9)* 34 (10–52)* 3.0 2.2 0.8 (!0.2 to 1.8) 27 (!8.8 to 51)
25–29 6.1 4.4 1.7 (0.3–3.2)* 28 (6–45)* 3.9 3.0 0.9 (!0.2 to 2.1) 24 (!7 to 45)
30–34 11.8 7.1 4.5 (2.5–6.7)* 40 (25–51)* 8.3 4.9 3.3 (1.6–5.2)* 41 (23–55)*
35–39 13.8 8.2 5.5 (3.2–7.9)* 40 (26–52)* 9.9 6.0 3.8 (1.9–6.0)* 39 (22–53)*
40–44 23.0 11.6 11.4 (8.4–14.5)* 50 (40–58)* 15.0 8.9 6.1 (3.5–8.7)* 41 (26–52)*
45–49 28.6 16.3 12 (8.6–15.5)* 43 (33–51)* 18.9 11.5 7.3 (4.3–10.4)* 39 (26–50)*
50–54 38.3 27.9 10.6 (6.3–14.8)* 27 (17–36)* 25.3 19.7 5.6 (1.8–9.4)* 22 (8–34)*
55–59 39.4 33.9 5.1 (0.4–9.8)* 14 (2–24)* 27.4 22.3 5.0 (0.8–9.2)* 18 (3–31)*
Gender
Males 17.4 12.4 5 (3.7–6.2)* 29 (22–35)* 12.1 8.9 3.1 (2.1–4.3)* 26 (18–34)*
Females 12.2 8.1 4 (2.9–5.0)* 33 (26–39)* 7.8 5.5 2.3 (1.4–3.2)* 30 (20–38)*
Work status
Working for
cash
18.8 13.3 5.5 (4.1–6.8)* 29 (23–35)* 13.0 9.5 3.5 (2.3–4.6)* 27 (19–34)*
Not working
for cash
11.3 7.4 3.9 (2.9–4.8)* 35 (28–41)* 7.3 5.1 2.2 (1.4–3.0)* 30 (21–38)*
Region
Urban
governorates
9.5 6.9 2.6 (0.98–4.21)* 27 (11–41)* 6.2 4.4 1.8 (0.4–3.0)* 29 (8–45)*
Lower Egypt 17.5 12.2 5.3 (4.0–6.6)* 30 (24–36)* 11.5 8.7 2.8 (1.7–3.9)* 24 (16–32)*
Upper Egypt 14.7 8.2 6.5 (6.9–9.5)* 44 (37–50)* 10.2 5.8 4.4 (3.2–5.5)* 43 (35–50)*
Frontier
governorates
3.0 3.5 !0.2 (!5.7 to 5.0) !17 (!369 to 71) 2.5 2.6 !0.1 (!5.2 to 4.6) !4 (!402 to 78)
*Statistically significant (P < 0.05).
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HCV RNA from 9.9 to 7.0%, between 2008 and 2015
among those aged 15–59 years. The main explanation
for this marked reduction in HCV prevalence is the dis-
appearance of the group infected during the mass schis-
tosomiasis treatment campaign with reused syringes
(1960s through early 1980s) to outside the age range
covered by the survey (i.e. those older than 59 years)
(13, 14). Indeed, as demonstrated in Fig. 1, the age-spe-
cific HCV antibody and HCV RNA prevalence for 2015
matches well with the 2008 prevalence estimates shifted
by 7 years, suggesting that the ageing of the infected
cohort, the so-called ‘cohort effect’, is the driving mech-
anism underlying the HCV age distribution; this was
also demonstrated in the earlier reduction of HCV anti-
body prevalence from 30% in 1996 (14) to 14.7% in
2008 (4).
In order to see whether or not a decrease in HCV
incidence may have also been a contributor to the
reduction in HCV prevalence, the most interesting age
groups to look at are those less than 20 years of age; per-
sons who were not affected by the mass treatment cam-
paigns and for whom HCV-related mortality remains
low. If we assume that mother-to-child HCV transmis-
sion is a negligible source of infant infection, as sug-
gested by the <0.5% HCV antibody prevalence in the 1–
4-year age group, then the HCV antibody prevalence at
age 19 indicates the cumulative incidence over the past
20 years. In 2008 and 2015, the prevalence of HCV anti-
bodies in those aged 15–19 years was 4.1 and 1.0%,
respectively; the percentage of relative risk reduction
was 75% (95% CI 64–85), implying a very substantial
reduction in HCV incidence in the past 20 years in this
age group. Furthermore, the prevalence of HCV anti-
body (0.4%) and HCV RNA-positive persons (0.2%)
observed in EHIS 2015 among the age group 1–14 years
is low compared to several studies conducted in early
2000s, which described the HCV antibody prevalence to
be ranging from 2 to 7% in children under 10 years in
rural areas of the Nile Delta (15–17).
This change in incidence in the younger age groups
could possibly be because of the various public health
interventions implemented by the Ministry of Health
and Population and its partners since 2008. In this time,
several efforts have been made to promote and expand
Fig. 1. (A) Age-specific prevalence of hepatitis C virus (HCV) antibody-positive persons in 2008 and 2015 (left), then shifted (by 7 years)
2008 and 2015 (right). (B) Age-specific prevalence of HCV RNA-positive persons in 2008 and 2015 (left), then shifted (by 7 years) 2008 and
2015 (right).
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the infection prevention and control programmes
beyond Ministry of Health and Population hospitals,
particularly to the university hospitals. Auto disabled
syringes were introduced to the routine immunisation
sector in 2008 in order to promote safe injection prac-
tices among children. Safe blood transfusion activities,
including policies and guidelines, have been intensified
since 2009. Raising the awareness of the public, by tar-
geting universities and schools to improve their under-
standing on the epidemiology and prevention of viral
hepatitis, was also carried out. Pre-service education tar-
geting healthcare staff has been carried out since 2008 to
enforce the concepts of safe healthcare and prevention
of blood-borne pathogens.
One may question whether the national treatment
programme, which managed to treat more than 350 000
persons in the past 7 years (18) using pegylated inter-
feron and ribavirin (19), has had an impact on HCV
prevalence figures. In such a case, it would be expected
that cured patients would have cleared HCV RNA, but
kept HCV antibodies. Therefore, the impact would be
seen through an increase in HCV clearance percentage
in the age groups most targeted by the national treat-
ment programme. Owing to established approximate
50% cure rates of the combination of pegylated inter-
feron and ribavirin (20), only half of these persons (i.e.
175 000) would have cleared their HCV infection after
treatment. The national treatment programme priori-
tises persons with more advanced forms of liver disease,
and therefore, at least half of the beneficiaries of this ser-
vice are in their 40s or 50s. Indeed, in a group of 3235
patients treated for HCV in a hospital run by the Min-
istry of Health in Cairo, between 2007 and 2011, the
mean age was 41 years with a standard deviation of
approximately 10 years (21). In order to see whether or
not treatment has, as of yet, had an impact on lowering
the prevalence of persons with HCV RNA in Egypt, we
can see whether or not there has been increased clear-
ance in the four older age groups (i.e. encompassing 40–
59 years) over the past 7 years. If we assume that
around half (87 500) of the total persons cured was in
the 40–59-year age group, and considering that we have
estimated 2.87 million persons with HCV antibodies in
the same age group in 2015 (Table 3), we would have
expected to see around a 3% higher clearance percent-
age in this group, in comparison with 2008. However,
an increase in clearance in these older age groups was
not observed when comparing data from 2015 and the
shifted-forward 2008 data. Indeed, it would require
around 4000 anti-HCV-positive persons in this age
group, in each data set, in order to have enough power
to demonstrate this expected 3% difference; unfortu-
nately, the anti-HCV population examined in this sur-
vey was much lower than that.
Treatment may show a larger impact in the near
future as it is expected that emphasis will be put on an
upscale of treatment of infected persons to prevent
long-term complications (22), particularly consideringTa
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that new direct-acting antiviral (DAA) drugs were
approved for the treatment of HCV by the U.S. Food
and Drug Administration (FDA) in late 2013, and
then introduced into Egypt in late 2014. These new
treatment regimens have reduced treatment duration to
12–24 weeks, decreased side effects and improved
outcomes, with cure rates of 85–95% across all patient
populations (23, 24).
Fig. 2. Prevalence of hepatitis C virus antibody in the 2008 and 2015 Egyptian Demographic and Health Surveys.
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Finally, differential migration and mortality of per-
sons infected with HCV could have contributed to the
reduced prevalence of both HCV antibody and HCV
RNA-positive persons in 2015, as long as these rates are
higher than infection incidence (25–27); these topics
needs to be explored further.
The prevalence of HCV antibody and HCV RNA-
positive individuals varied among governorates and was
reduced in several geographical regions. Lower Egypt
governorates, which are mostly rural in nature, still
show a higher prevalence of HCV antibodies and HCV
RNA when compared to urban governorates. This pat-
tern of high HCV prevalence in rural areas is similar to
previous multiple studies conducted in rural Lower
Egypt governorates which showed a prevalence ranging
from 14.4 to 18.5% (28–30). The frontier governorates
did not show any significant change, however, this is
possibly owing to the fact that the sample size was very
low (n < 200), in both the 2008 and 2015 surveys.
Based on our findings in this study, we recommend
the expansion of national health surveys in Egypt in
order to include older age groups and allow further fol-
low-up of elderly persons who have been the most
affected by HCV and who, by the cohort effect, are
being pushed out of view. Furthermore, there should be
continued prioritisation of prevention programmes to
increase the effects we are seeing in incidence in young
age groups, with a focus on interventions which pro-
mote injection safety by reducing the frequency of
unnecessary injections and syringe reuse. Interventions
could include introduction of single-use materials and
engineered safety devices, such as auto-disabled or auto-
destructive syringes into the curative sector. Expansion
of infection prevention and control programmes are of
utmost importance, along with development of elabo-
rate systems for delivering and renewing licenses of
healthcare facilities to ensure continuity of safe proce-
dures and application of standard precautions. Other
analyses of the EHIS data should be done, using tools
such as mathematical modelling, in order to properly
estimate and explain changes in HCV incidence in
Egypt; this could lead to further evidence-based recom-
mendations related to prevention and control efforts.
Finally, access to treatment should be a priority, and
although economic constraints are faced by the country,
treatment has been shown to be cost-effective in this
context (31, 32) and focused, early treatment strategies
may be effective in supporting prevention measures and
reducing transmission (33).
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Summary
In	 Egypt,	 hepatocellular	 carcinoma	 (HCC)	 is	 the	most	 common	 form	of	 cancer	 and	
direct-	acting	antivirals	(DAA)	are	administered	on	a	large	scale	to	patients	with	chronic	
HCV	infection	to	reduce	the	risk.	In	this	unique	setting,	we	aimed	to	determine	the	
association	of	DAA	exposure	with	early-	phase	HCC	recurrence	in	patients	with	a	his-
tory	 of	HCV-	related	 liver	 cancer.	 This	was	 a	 prospective	 cohort	 study	of	 an	HCV-	
infected	population	from	one	Egyptian	specialized	HCC	management	centre	starting	
from	the	time	of	successful	HCC	intervention.	The	incidence	rates	of	HCC	recurrence	
between	DAA-	exposed	and	nonexposed	patients	were	compared,	starting	from	date	
of	HCC	complete	 radiological	 response	and	censoring	after	2	years.	DAA	exposure	
was	treated	as	time	varying.	Two	Poisson	regressions	models	were	used	to	control	for	
potential	differences	in	the	exposed	and	nonexposed	group;	multivariable	adjustment	
and	balancing	using	inverse	probability	of	treatment	weighting	(IPTW).	We	included	
116	patients:	53	treated	with	DAAs	and	63	not	treated	with	DAAs.	There	was	37.7%	
and	25.4%	recurrence	in	each	group	after	a	median	of	16.0	and	23.0	months	of	follow-
	up,	respectively.	Poisson	regression	using	IPTW	demonstrated	an	association	between	
DAAs	and	HCC	recurrence	with	an	incidence	rate	ratio	of	3.83	(95%	CI:	2.02-	7.25),	
which	was	similar	in	the	multivariable-	adjusted	model	and	various	sensitivity	analyses.	
These	results	add	important	evidence	towards	the	possible	role	of	DAAs	in	HCC	re-
currence	and	stress	the	need	for	further	mechanistic	studies	and	clinical	trials	to	ac-
curately	confirm	this	role	and	to	identify	patient	characteristics	that	may	be	associated	
with this event.
K E Y W O R D S
DAAs,	Egypt,	hepatitis	c,	hepatocellular	carcinoma,	recurrence
Abbreviation:	BCLC,	Barcelona	clinic	liver	cancer;	CT,	computerized	tomography;	DAA,	direct-acting	antivirals;	HCC,	hepatocellular	carcinoma;	HCV,	hepatitis	C	virus;	IPTW,	inverse	probability	
of	treatment	weighting;	IRR,	incidence	rate	ratio;	MWA,	microwave	ablation;	PEI,	percutaneous	ethanol	injection;	RFA,	radiofrequency	ablation;	SVR,	sustained	virological	response;	TACE	tran-
sarterial	chemoembolization
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1  | INTRODUCTION
Several	studies	and	meta-	analyses	have	concluded	that	eradication	of	
hepatitis	C	virus	(HCV)	with	antiviral	therapy	reduces	the	risk	of	he-
patocellular	carcinoma	(HCC)	in	patients	with	chronic	hepatitis	C,	in-
dependent	of	their	fibrosis	stage.1	During	the	era	of	interferon-	based	
therapy,	patients	with	a	sustained	virological	response	(SVR)	including	
those	on	combination	therapy	with	pegylated	interferon	and	ribavirin	
showed	 both	 histological	 improvement	 through	HCV	 eradication	 as	
well	as	a	decrease	 in	the	risk	of	HCC	development.2	Other	research	
concluded	that	patients	achieving	SVR	through	interferon-	based	ther-
apies	who	had	previously	received	curative	HCC	treatment,	including	
local	ablation	therapy	and	hepatic	resection,	had	favourable	outcomes	
compared	with	non-	SVR	patients.	The	introduction	of	the	new	wave	
of	direct-	acting	antivirals	(DAAs)	in	2014,	with	increased	tolerance	and	
effectiveness,	was	seen	as	a	continuing	step	forward	in	the	treatment	
of	persons	with	a	history	of	HCC	and	thought	likely	to	improve	their	
overall	prognosis.
The	new,	highly	effective	DAAs	were	expected	to	dramatically	
decrease	HCV-	related	 liver	disease	progression	to	end-	stage	 liver	
disease	 and	 HCC;	 however,	 these	 optimistic	 expectations	 were	
questioned	by	an	initial	report	from	Spain	in	2016.	Reig3 and col-
leagues	 reported	 a	 “more	 than	 expected”	 early	 recurrence	 rate	
(27.6%)	 in	 patients	with	HCC	who	 received	DAA	 treatment	 after	
an	initial	good	response	to	HCC	treatment.	This	report	represented	
a	 red	 flag	 and	 opened	 the	 door	 for	 a	 debate	 about	 the	 relation-
ship	 between	DAA	 treatment	 and	HCC	 recurrence.	 Reports	 from	
Italy	 and	 the	United	States,	both	demonstrating	and	 refuting	any	
increase	in	recurrence	following	DAAs	in	varying	groups,	were	re-
leased	soon	after.4-7	These	initial	reports	lacked	any	form	of	com-
parative	survival	analysis	between	DAA-	exposed	and	nonexposed	
groups.	 Subsequently,	 a	 comparison	of	DAA-	exposed	and	nonex-
posed	 groups	 from	 the	 French	ANRS	 Hepather	 cohort,	 reported	
by	Pol	and	colleagues,8	treated	DAA	exposure	as	time	varying	and	
found	no	 increased	 risk	 of	 recurrence	 in	 those	 exposed	 to	DAAs	
(HR:	1.21,	95%	CI	0.62-	2.34).	However,	this	cohort	started	follow-
ing	 future	DAA-	exposed	patients	 from	a	median	23	months	after	
the	original	HCC	diagnosis	and	was	criticized	for	possible	underre-
porting	of	HCC	recurrence.9 A recent review by Reig et al10	presents	
an	overview	of	the	conflicting	evidence	that	has	been	presented	so	
far	in	this	debate;	the	types	of	studies	conducted,	heterogeneity	in	
the	populations	included,	and	variability	in	the	analytical	methods	
used,	suggesting	that	no	firm	conclusions	can	yet	be	drawn	on	this	
topic.
HCC	 is	 the	most	common	cancer	 in	Egypt,11 largely due to the 
country	having	the	highest	global	prevalence	of	HCV.12 Due to the 
availability	 of	 low-	cost	 branded	 and	 generic	 DAAs,	 the	 Egyptian	
Ministry	 of	Health	 and	 the	National	Committee	 for	 the	Control	 of	
Viral	Hepatitis	have	treated	approximately	one	million	Egyptian	pa-
tients	since	2014,	with	cure	rates	over	90%	using	various	DAA	com-
binations.13	Therefore,	we	examined	HCC	recurrence	within	2	years	
of	 initial	 HCC	 complete	 radiological	 response	 in	 an	 HCV-	infected	
Egyptian	cohort,	for	those	who	either	were	or	were	not	given	DAAs	
through	use	of	comparative	time-	dependent	analysis	and	propensity	
scoring.
2  | MATERIALS AND METHODS
2.1 | Study design and participants
This	 study	 was	 carried	 out	 at	 one	 HCC	 treatment	 centre	 in	 Cairo,	
Egypt.	Patients	of	all	Barcelona	Clinic	Liver	Cancer	(BCLC)	stages	and	
prognoses	were	 consulted	 at	 this	 centre	 through	 clinical	 and	 imag-
ing	examinations	and	those	with	BCLC	stages	0	and	A	were	treated	
through	local	ablation	procedures;	these	patients	had	a	maximum	of	
three	cancerous	lesions,	with	the	largest	lesion	being	<5	cm	in	diam-
eter.	 Local	 ablative	procedures	 available	 at	 this	 centre	 included	 the	
following:	radiofrequency	ablation	(RFA),	microwave	ablation	(MWA),	
percutaneous	ethanol	injection	(PEI),	surgical	resection	and	transarte-
rial	 chemoembolization	 (TACE).	 Following	 the	 ablative	 procedure,	
patients	were	followed	up	after	one	and	3	months	with	dynamic	com-
puterized	tomography	(CT)	and	ultrasound	imaging	to	assess	tumour	
response.	 After	 complete	 radiological	 response	 according	 to	 modi-
fied	RECIST	 criteria	 (hereafter	 referred	 to	 as	 “complete	 radiological	
response”)	 had	 been	 confirmed	 by	 a	 senior	 radiologist	 using	 these	
imaging	techniques	at	both	month	one	and	months	three	visits,	 the	
patients	returned	for	follow-	up	imaging	every	three	to	6	months,	for	
continued	confirmation	of	complete	radiological	response	until	death	
or	 loss	 to	 follow-	up.	HCC	follow-	up	 imaging	at	 these	 time	 intervals	
was	 the	 same	 for	 patients	 both	 eventually	 treated	 and	 not	 treated	
with DAAs.
Following	HCC	complete	radiological	response,	patients	were	re-
ferred	back	to	local	hepatologists	at	varying	National	HCV	Treatment	
Centers	where	 they	were	 examined	 for	DAA	 treatment	 eligibility.	 If	
the	patient’s	clinical	indicators	fit	within	the	national	HCV	treatment	
guidelines,	they	were	given,	free	of	charge,	either	a	three-	or	six-	month	
regimen	of	DAA.	These	patients’	viral	loads	were	assessed	at	the	end	
of	 their	 DAA	 treatment	 period	 (EOT)	 as	well	 as	 12	weeks	 of	 post-	
treatment to establish whether or not there has been a sustained viro-
logical	response	(SVR12).	The	choice	of	whether	or	not	a	patient	with	
a	history	of	HCC	will	 receive	DAAs	was	dependent	on	 the	patient’s	
decision	to	seek	treatment	and	the	decision	of	the	consulting	hepatol-
ogist	at	the	HCV	treatment	centre.	Patient	eligibility,	in	the	Egyptian	
context,	 refers	to	the	patient	having	no	contraindication	to	DAAs,	a	
good	prognosis	and	limited	liver	damage.	During	the	first	wave	of	DAA	
introduction,	this	meant	that	patients	with	Child-	Pugh	scores	greater	
than	6	were	not	eligible	 for	DAA	 treatment,	 nor	 those	greater	 than	
65	years	of	age.	The	decision	of	the	consulting	hepatologist	to	either	
treat	 immediately,	wait	 to	 treat	or	never	 treat,	 a	patient	with	 a	his-
tory	of	HCC	was	based	on	treatment	ineligibility	or	their	own	personal	
practice	 method	 with	 some	 hepatologists	 recommending	 waiting	
during	the	 first	2	years	post-	HCC	complete	radiological	 response	as	
this	is	a	period	when	recurrence	is	common.
According	to	the	current	Egyptian	national	 treatment	guidelines,	
all-	oral	DAAs	can	be	given	as	soon	as	1	month	following	the	HCC	ab-
lative	manoeuvre,	as	long	as	the	patient	was	seen	to	have	a	complete	
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radiological	response	through	dynamic	CT	and	ultrasound	during	this	
visit.	Patients	with	a	history	of	HCC	being	examined	for	DAA	treat-
ment	eligibility	need	to	have	had	a	dynamic	CT	scan	and	ultrasound	
confirming	lack	of	HCC	recurrence	in	the	3	months	prior	to	the	DAA	
start	date;	any	patient	who	has	not	had	this	imaging	performed	within	
this	time	frame	through	their	regular	visits	at	the	HCC	treatment	cen-
tre,	was	required	to	return	to	the	centre	to	do	so.
2.2 | Procedures
For	the	presented	analysis,	we	applied	various	inclusion	and	exclusion	
criteria	to	the	total	population	of	BCLC	A	and	0	patients	who	visited	
the	HCC	treatment	centre	 for	 local	ablation	between	January	2013	
and	March	2016	(Figure	1).
We	 consecutively	 included	 patients	 who	 achieved	 HCC	 com-
plete	 radiological	 response	 according	 to	 modified	 RECIST	 criteria	
between	2013	and	2016.	All	 patients	needed	 to	be	HCV-	positive	
and	not	coinfected	with	HBV	or	HIV.	HCV	genotype	was	not	spec-
ified	 for	 inclusion,	 and	 indeed,	genotyping	was	not	carried	out	on	
all	patients;	however,	most	HCV	infection	in	Egypt	is	with	genotype	
4.14	All	included	patients	were	treated	for	their	HCC	with	local	abla-
tive	procedures	including	the	following:	RFA,	MWA,	PEI	and	surgical	
resection.
We	excluded	patients	who	were	treated	using	TACE,	as	this	ma-
noeuvre	can	be	considered	palliative.	For	those	who	were	treated	with	
DAAs	during	the	two-	year	analysis	window,	we	excluded	any	patients	
who	had	received	interferon-	containing	DAA	regimens	(ie	Sofosbuvir/
Interferon/RBV).	We	also	excluded	any	patients	with	early	recurrence	
within	3	months	of	the	date	of	complete	radiological	response,	to	fur-
ther	ensure	that	newly	detected	tumours	represented	true	recurrence	
and	were	not	residual	but	previously	undetected.15
This	 study	obtained	ethical	 approval	 by	 the	 Institutional	Review	
Board	 for	Human	Subject	Research	at	 the	National	Hepatology	and	
Tropical	Medicine	Research	Institute	in	Cairo,	Egypt,	which	is	organized	
and	 operated	 according	 to	 the	 Declaration	 of	 Helsinki	 for	 Human	
Subject	Research	(2013).	All	patients	provided	written	informed	con-
sent to have their data included in this analysis.
2.3 | Statistical analysis
After	 applying	 the	 previously	 described	 inclusion	 and	 exclusion	 cri-
teria	 to	 our	 original	 population,	 persons	 eventually	 treated	 or	 not	
treated	with	DAAs	within	the	two-	year	follow-	up	period	were	com-
pared	for	their	baseline	characteristics	(ie	at	the	time	of	HCC	ablative	
manoeuvre)	 using	 the	 Student’s	 t	 test	 for	 continuous	 variables	 and	
chi-	square	or	Fisher’s	 exact	 test	 for	 categorical	 variables.	 For	 time-	
dependent	analysis,	Poisson	regression	models	were	preferred	to	Cox	
models	because	they	allow	the	estimation	of	incidence	rates	accord-
ing	 to	 DAA	 exposure	 (or	 nonexposure).	 Censoring	 was	 performed	
when	a	patient	died,	was	lost	to	follow-	up	or	was	at	the	end	of	their	
two-	year	follow-	up	period.	For	the	main	analysis,	DAA	treatment	was	
treated	as	time	varying,	with	exposure	starting	from	the	date	of	DAA	
start	and	ending	at	the	endpoint/censoring	(thus	reflecting	a	current	
or	past	exposure	to	DAA).
Incidence	 rate	 ratio	 for	DAA	 treatment	 exposure	was	 estimated	
using univariable and multivariable Poisson regression models. 
Covariates	included	in	the	multivariable	model	were:	time	since	entry	
into	 the	 cohort	 (<8	months,	 8-	16	months	 and	 16-	24	months),	 sex,	
age	 (categorized	 as	 <	 or	 ≥65	years	 old),	 baseline	 Child-	Pugh	 score	
(categorized	as	≤	or	>6)	and	whether	or	not	the	patient	had	ever	had	
gastroesophageal	varices	(a	possible	indicator	of	portal	hypertension).	
Furthermore,	to	minimize	the	effect	of	confounding	by	treatment	in-
dication,	we	used	 inverse	probability	of	 treatment	weighting	 (IPTW)	
using	 propensity	 scores.16	 The	 probability	 of	 receiving	 DAA	 treat-
ment	was	modelled	based	on	 time	 since	entry	 into	 the	 cohort,	 sex,	
age,	baseline	Child-	Pugh	score	and	history	of	gastroesophageal	var-
ices.	Stabilized	weights	were	calculated	using	the	R	package	“ipw”.17 
The	average	treatment	effect	was	estimated	using	a	robust	variance	
F IGURE  1 Application	of	inclusion	and	
exclusion	criteria	to	study	population	with	
basic	recurrence	proportions
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estimator	to	account	for	the	weighted	nature	of	the	sample.	IPTW	di-
agnostics	were	conducted	as	recommended	by	Austin	and	Stuart.18
A	sensitivity	analysis	removed	all	patients	with	Child-	Pugh	score	7	
and	over	the	age	of	65,	as	these	were	DAA	treatment	ineligibility	crite-
ria	during	the	first	phase	of	DAA	introduction	in	Egypt.	For	a	subanal-
ysis,	DAA	treatment	exposure,	still	treated	as	time	varying,	was	broken	
down	 into	 three	periods:	 no	 treatment,	 the	 first	6	months	 after	 the	
start	of	DAA	treatment	and	6	months	after	the	start	of	DAA	treatment.	
A	further	subanalysis	examined	the	difference	between	exposure	to	
three-	and	six-	month	DAA	treatment	regimens.	All	statistical	analyses	
were conducted using R.
3  | RESULTS
Between	January	2013	and	May	2016,	129	HCV-	infected	HCC	pa-
tients,	all	BCLC	stage	A	or	0,	were	consulted	and	treated	with	 local	
ablation	procedures	at	the	HCC	treatment	centre	in	Cairo,	Egypt.	Of	
these,	 the	 following	were	excluded:	 two	patients	who	were	treated	
with	TACE;	two	patients	who	never	achieved	a	complete	radiological	
response;	six	patients	who	had	early	recurrence	of	HCC	(two	of	these	
were	 already	 taking	 DAAs);	 three	 patients	 who	 were	 eventually	
treated	with	DAA	regimens	containing	interferon.	This	left	us	with	a	
total	of	116	patients,	53	of	whom	eventually	received	DAAs	during	
the	 two-	year	 analysis	 follow-	up	period	 and	63	who	did	not	 (Figure	
S1A,B).
The	DAA-	exposed	and	nonexposed	groups	were	similar	 in	terms	
of	sex,	age	and	diabetes	as	well	as	their	number	of	hepatic	focal	lesions	
and	size	of	their	largest	lesion	at	baseline	(Table	1).	No	patients	in	our	
cohort	were	alcoholic	or	had	a	history	of	alcoholism.
The	Child-	Pugh	score	was	lower	in	those	treated	with	DAAs;	1.9%	
of	the	DAA-	exposed	group	had	a	score	of	7,	whilst	in	the	DAA	nonex-
posed	group,	17.5%	(P	=	.006)	had	a	score	of	7.	The	ablative	manoeu-
vres	performed	on	patients	in	both	groups	were	similar—the	majority	
of	 patients	 in	 both	 groups	 underwent	 radiofrequency	 ablation.	 The	
DAA-	exposed	 group	 received	 varying	 all-	oral	 regimens	 for	 either	
three-	or	 six-	month	periods.	 SVR12	was	 confirmed	 in	77.4%	of	 the	
DAA-	treated	patients	overall	and	in	89.2%	of	patients	when	excluding	
those	treated	with	Sofosbuvir/RBV	(Table	2).
Among	 the	53	patients	 treated	with	DAAs,	we	observed	37.7%	
recurrence	 after	 a	median	 of	 16.0	months	 of	 follow-	up.	Among	 the	
63	 patients	 not	 treated	with	DAAs,	we	 observed	 a	 25.4%	HCC	 re-
currence	 after	 a	median	 23.0	months	 of	 follow-	up.	 The	 association	
between	DAA	exposure	and	 recurrence	can	be	seen	 in	Table	3.	The	
unadjusted	rate,	per	100	person-	months,	of	recurrence	was	1.00	(95%	
Confidence	Interval,	CI:	0.51-	1.49)	in	the	DAA	nonexposed	group	vs	
4.06	 (95%	CI:	2.30-	5.85)	 in	the	DAA-	exposed	group,	 representing	a	
crude	incidence	rate	ratio	(IRR)	of	4.08	(95%	CI:	2.14-	7.76)	associated	
with	DAA	treatment.	After	controlling	 for	 time	since	HCC	complete	
radiological	response	(ie	time	in	cohort)	as	well	as	sex,	age,	Child-	Pugh	
score	and	history	of	gastroesophageal	varices	using	 IPTW,	exposure	
to	DAA	treatment	was	associated	with	a	significantly	increased	risk	of	
recurrence	of	3.82	(95%	CI:	2.00-	7.30),	consistently	with	results	found	
in	the	multivariate	analysis	(Table	3).	The	results	of	IPTW	diagnostics	
are	presented	in	Supplementary	Material.
For	patients	with	recurrence,	the	location	of	cancerous	lesions	was	
found	in	a	new	site	for	15	(93.8%)	of	those	not	treated	with	DAAs	and	
19	 (95.0%)	 of	 those	 treated	with	DAAs.	 In	 examination	 of	whether	
or	not	patients	treated	with	DAAs	had	a	more	aggressive	recurrence	
compared	to	their	non-	DAA-	exposed	counterparts,	we	observed	that	
six	(30.0%)	of	the	recurring	patients	with	DAA	exposure	had	greater	
than	three	hepatic	focal	lesions,	but	we	did	not	have	enough	statistical	
power	to	show	whether	or	not	this	was	higher	than	the	two	(18.0%)	
patients	with	this	characteristic	in	the	DAA	nonexposed	recurring	pop-
ulation.	Among	 the	DAA-	treated	group,	 the	 incidence	of	 recurrence	
was	not	different	among	those	who	did	achieve	SRV12	as	compared	
to	those	who	did	not	(unadjusted	IRR	=	1.64,	95%	IC:	0.64-	4.20).
Although	 three	 (2.6%)	patients	were	censored	due	 to	being	 lost	
to	follow-	up,	there	was	no	censorship	due	to	death	within	the	2	years	
following	 inclusion	 in	 the	 study	 for	patients	without	 recurrence.	No	
patients	underwent	liver	transplantation.
When	 excluding	 patients	who	 did	 not	 achieve	 SVR12	 (n	=	12),	
the	recurrence	IRR	was	4.18	(95%	CI:	1.64-	10.69).	The	results	were	
TABLE  1 Baseline	characteristics,	at	the	time	of	HCC	complete	
radiological	response,	for	patients	eventually	treated	and	not	treated	
with DAAs
Baseline 
Characteristic
DAA- treated 
(N = 53)
Not DAA- 
treated (N = 63) P- value
Male,	#	(%) 35	(66.0) 41	(65.1) .91
Age,	mean	
(P25-	P75)
56.7	(52-	62) 57.3	(51-	62) .70
Diabetes,	#	(%) 17	(32.1) 16	(25.4) .43
Child-	Pugh	score .006a
5 26	(49.1) 30	(47.6)
6 26	(49.1) 22	(34.9)
7 1	(1.9) 11	(17.5)
#	Hepatic	focal	
lesions	[HFL]
.06
1 50	(94.3) 57	(90.5)
2 1	(1.9) 6	(9.5)
3 2	(3.8) 0
History	of	
gastroesophageal	
varices
30	(56.6%) 42	(66.7%) .34
Largest	HFL	in	cm,	
mean	(P25-	P75)
2.4	(2.0-	3.0) 2.5	(2.0-	3.0) .50
HCC	Treatment	
Manoeuvre,	#	(%)
.30
RFA 31	(58.5) 48	(76.2)
PEI	or	PEI/RFA 13	(24.5) 7	(11.1)
MWA 7	(13.2) 6	(9.5)
Surgical	
Resection
2	(3.8) 2	(3.2)
aChild-	Pugh	score	5	and	6	against	Child-	Pugh	score	7.
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consistent	 when	 considering	 only	 patients	 treated	 with	 six-	month	
DAA	regimens	(IRR	=	3.39;	95%	CI:	1.56-	7.37)	or	when	considering	
only	 patients	 treated	with	 three-	month	 regimens	 (IRR	=	3.66;	 95%	
CI:	 1.73-	7.76).	 A	 sensitivity	 analysis	 using	 IPTW	 and	 excluding	 all	
patients	with	Child-	Pugh	 score	of	7	 and	aged	>65	demonstrated	 a	
recurrence	IRR	of	5.62	(95%	CI:	2.52-	12.18)	for	DAA-	exposed	vs	non-
exposed	 patients.	A	 second	 sensitivity	 analysis	 split	DAA	exposure	
into	two	periods:	the	first	6	months	after	the	start	of	DAAs	and	the	
time	following	6	months	after	the	start	of	DAAs.	Using	multivariable	
Poisson	regression	(nondichotomous	nature	of	this	exposure	variable	
prevented	 the	use	of	 IPTW),	we	 found	an	 adjusted	 recurrence	 IRR	
of	3.24	 (95%	CI:	1.50-	7.01)	 in	 the	 first	6	months	of	DAA	exposure	
and	4.17	(95%	CI:	1.73-	10.05)	 in	the	post	six-	month	DAA-	exposed	
groups,	respectively.
4  | DISCUSSION
Our	data	point	to	a	high	(ie	almost	4	times)	increased	rate	of	recurrence	
after	DAA	treatment	for	patients	with	a	history	of	successfully	treated	
HCC,	when	compared	to	similar	patients	who	were	not	given	DAAs.	
This	significantly	higher	rate	of	recurrence	in	the	DAA-	exposed	group	
remained	after	 adjustment	 for	baseline	 factors	 and	 time	 since	HCC	
complete	 radiological	 response	 through	 inverse	 probability	 weight-
ing,	as	well	as	across	the	sensitivity	analyses	performed.	As	far	as	we	
know,	this	is	the	first	propensity	scored	comparative	time-	dependent	
analysis	for	DAA-	exposed	and	nonexposed	patients	followed	from	the	
moment	of	HCC	complete	radiological	response.
It	has	been	suggested	that	rapid	changes	to	the	immune	surveil-
lance	 system	 and/or	 antitumour	 response	 following	DAA	 treatment	
could	be	 the	 reason	 for	 the	apparent	 increase	 in	HCC	recurrence.19 
A	 recent	 observational	 study	 by	 Villani	 et	 al20	 supported	 this	 idea	
through	demonstration	 that	 during	 treatment	with	DAAs,	 an	 angio-
genesis	inducer	called	vascular	endothelial	growth	factor,	which	sup-
ports	 tumour	 development,	 increases	 significantly	 and	 can	 remain	
high	until	3	months	after	DAA	treatment.	However,	our	own	results	
showed	a	similar	association	between	DAAs	and	HCC	recurrence	for	
those	with	 longer	 (6	months)	 vs	 shorter	 (3	months)	 DAA	 exposures	
(IRR	3.39	vs	3.66,	respectively).
The	 necessary	 assumption	 of	 this	 comparative	 analysis	 is	 that	
DAA-	exposed	and	nonexposed	patients	are	similar.	However,	 it	can	
be	argued	that	in	an	era	of	highly	expensive	DAA	treatments	for	HCV,	
it	 is	 possible	 that	 clinicians	 systematically	 choose	 to	 treat	 patients	
with	 certain	 clinical	 indicators	 over	 others;	 for	 example,	 in	 Egypt,	
treating	patients	with	better	prognoses	has	been	estimated	as	more	
cost-	effective	based	on	quality-	adjusted	life	expectancy	outcomes.21 
Our	 inclusion	criteria,	especially	treatment	 initiation	from	2013	on-
wards	and	rapid	complete	radiological	response	in	response	to	initial	
HCC	treatment	(ie	seen	already	at	one-	month	postablative	manoeu-
vre),	 were	 specifically	 chosen	 to	 improve	 comparability	 between	
treated	and	untreated	patients.	As	 a	 result,	 baseline	 characteristics	
of	the	DAA-	exposed	and	DAA	nonexposed	groups	in	the	study	pre-
sented	here	appeared	to	be	balanced,	except	for	baseline	Child-	Pugh	
score.	Moreover,	 in	 the	 analysis,	we	used	 IPTW	 to	 further	 balance	
measured	covariates	between	treated	and	untreated	patients,	includ-
ing	possible	 time-	varying	 confounders	 such	 as	 time	 since	 inclusion	
in	 the	cohort.	Our	 sensitivity	analysis,	which	 further	 controlled	 the	
groups	through	exclusion	of	all	patients	with	a	Child-	Pugh	score	of	7,	
showed	the	same	magnitudes	of	effect	and	significance	level	as	our	
primary	analysis.
It	is	possible	that	there	are	other	confounding	factors	that	were	
not	collected	as	part	of	this	study.	Indeed,	although	baseline	char-
acteristics	are	similar	for	all	patients	 in	our	study,	we	do	not	have	
updated	records	of	liver	enzyme	changes	at	each	imaging	follow-	up	
visit.	We	argue,	though,	that	we	can	assume	that	any	selection	bias	
in	DAA	administration	would	trend	towards	the	treatment	of	those	
with	better	prognosis	(eg	younger	age,	limited	liver	damage),	at	least	
in	the	case	of	patients	with	a	history	of	HCC	in	Egypt.	Within	the	
Egyptian	National	Treatment	 Program,	 a	 patient	with	 a	 history	 of	
HCC	would	 not	 be	 given	DAAs	 immediately	 following	HCC	 com-
plete	radiological	response	because	of	either	ineligibility	for	treat-
ment	 according	 to	 the	 Egyptian	 national	 treatment	 guidelines,	 or	
due	to	the	personal	opinion	of	 the	attending	hepatologist	 regard-
ing	 the	 need	 to	wait	 to	make	 sure	 the	 cancer	 is	 truly	 gone	 first.	
DAA Treatment 
Regimen
Duration of 
Treatment (mo) # Treated % EOT % SVR12
SOF/RBV 6 16	(30.2) 75.0 50.0
SIM/SOF 3 9	(17.0) 100 88.9
SOF/DCV/RBV 3 8	(15.1) 100 100
6 1	(1.9) 100 100
SOF/DCV 3 11	(20.8) 90.9 81.8
6 4	(7.5) 100 75.0
SOF/LDV/RBV 6 2	(3.8) 100 100
SOF/LDV 6 2	(3.8) 100 100
Total -	 53	(100) 90.6 77.4
EOT	=	undetectable	viremia	at	end	of	DAA	treatment,	SVR12	=	sustained	virological	response	12	wk	
after	the	end	of	DAA	treatment.
TABLE  2 DAA	treatment	regimens,	end	
of	treatment	and	SVR12	proportions	in	the	
DAA-	exposed	group	(N	=	53)
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Ineligibility	for	treatment	in	this	case	relates	mainly	to	when	a	pa-
tient	had	a	worse	prognosis	 (eg	older	age,	more	deteriorated	 liver	
function);	this	was	the	case	for	11	of	our	patients	who	had	Child-	
Pugh	score	7,	and	two	patients	who	were	too	old	(>65	years),	who	
did	not	receive	DAAs	according	to	the	applied	treatment	protocol	at	
that	time.	For	the	remaining	50	patients	who	did	not	receive	DAAs	
within	our	 two-	year	analysis	period,	14	eventually	 received	DAAs	
afterwards,	15	had	recurrence	within	this	time	and	were	therefore	
not	eligible,	and	for	21,	the	attending	hepatologist	decided	not	to	
recommend	 treatment	 at	 all	 within	 the	 viewed	 follow-	up	 period.	
Although	our	results	cannot	approximate	a	clinical	trial	in	terms	of	
random	 treatment	 assignment,	we	 do	 assess	 that	 any	 underlying	
differing	factors	between	the	groups	would	likely	be	negative	con-
founders;	we	would	expect	patients	with	a	better	prognosis	to	be	
treated with DAAs.
One	of	the	biggest	strengths	of	this	study	was	our	ability	to	fol-
low	and	analyse	recurrence	depending	on	eventual	DAA	exposure	
in	an	entire	cohort	of	HCV-	positive	patients	 from	 the	moment	of	
HCC	complete	radiological	response.	This	has	not	yet	been	done	in	
any	other	robust	study;	the	survival	analysis	performed	by	Pol	et	al8 
followed	patients	from	time	of	“cohort	inclusion”;	this	was	a	median	
1.9	and	1.6	years	after	HCC	diagnosis	for	DAA-	exposed	and	unex-
posed	groups,	respectively.	All	other	currently	published	papers	on	
this	subject	report	recurrence	in	DAA-	exposed	groups	after	varying	
median	number	of	months	following	their	HCC	complete	radiolog-
ical	response.	A	demonstration	of	these	differences,	using	some	of	
the	first	studies	published	within	this	debate,	can	be	seen	in	Table	4.	
The	issue	with	a	delayed	observation	window	in	these	populations	is	
twofold:	1.	The	biological	mechanisms	behind	early-	(within	2	years)	
and	late	(>	2	years)-	phase	recurrence	have	been	reported	to	differ22 
and	2.	All	patients	with	recurrence	or	death	prior	to	the	observation	
window	are	 inherently	excluded	from	the	analysis	and	final	recur-
rence	rates.	The	former	indicates	that	studies	observing	recurrence	
in	the	first	2	years	since	HCC	complete	radiological	response,	such	
as	the	study	we	present	here	or	that	of	Reig	or	Conti	are	not	com-
parable	to	those	of	Pol	or	Zavaglia.3,4,7,8 The second issue with the 
use	of	this	delayed	observation	window	is	that	some	studies,	such	
as	that	of	Pol	and	Zavaglia,	who	have	reported	“no	apparent	effect	
of	DAAs”	have	done	so	 in	survivor	populations.	Recurrence	 in	the	
first	 2	years	 since	 HCC	 complete	 radiological	 response	 has	 been	
linked	to	microscopic	vascular	invasion,	high	serum	AFP	levels	and	
having	 had	 nonanatomical	 resection,	 whereas	 after	 2	years	 since	
HCC	complete	radiological	response,	tumours	can	be	considered	de	
novo	and	are	linked	to	the	grade	of	hepatitis	activity,	tumour	nodule	
multiplicity	and	gross	tumour	classification.22
In	 order	 to	 draw	 any	 interim	 guidance	 from	 the	 currently	 pub-
lished	data	on	this	subject,	 the	findings	that	have	been	put	 forth	to	
date	should	be	considered	and	grouped	according	to	the	population	
included,	analysis	methods	used	and	the	time	window	of	observation	
for	the	included	patients.	Perhaps	DAA	treatment	of	surviving	patients	
without	 any	 recurrence	2	years	 after	HCC	complete	 radiological	 re-
sponse	poses	no	additional	 risk,	whereas	administration	of	DAAs	to	
patients	in	the	first	2	years	after	HCC	complete	radiological	response	
should	be	avoided	until	clinical	trials	provide	more	concrete	evidence	
of	their	benefit.
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TABLE  4 Previous	studies	evaluating	the	association	between	DAA	and	frequency	of	recurrence	in	patients	who	achieved	complete	
radiological	response	following	HCC	treatment
Author Country # DAA- exposed
Median time (mo) HCC 
treatment to DAA exposure
Per cent recurrence in DAA- 
exposed; (median # moa)
Rate Ratio; 
(P- value)
A	cohort	of	DAA-	exposed	patients	without	a	control	group	(descriptive	study)
Reig et al.3 Spain 58 11.2 27.6	(5.7	mo) -	
Conti	et	al4 Italy 59 12.4 28.8	(not	available) -	
Torres et al6 USA 8 7.5 0	(12	mo) -	
Zavaglia	et	al7 Italy 31 19.3 3.2	(8	mo) -	
Time-	dependent	analysis	DAA-	exposed	and	nonexposed	patients	(analytical	study)
Pol et al8 France 189 >22.8b 12.7	(20.2	mo) 1.2	(P	=	.58)
El Kassas et al 
[Data 
presented	in	
this	article]
Egypt 53 8.0 37.7	(16.0	mo) 3.8	(P	<	.001)
aDAA	initiation	until	HCC	recurrence	in	studies	of	type	1,	and	median	months	total	follow-	up	in	studies	of	type	2.
bMedian	22.8	mo	from	HCC	diagnosis	to	cohort	inclusion,	and	an	additional	median	1.4	mo	until	DAA	administration	in	those	eventually	exposed	to	DAAs.
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Abstract
Background & Aims:	Hepatitis	B	virus	(HBV)	reactivation	in	chronic	hepatitis	C	(CHC)	
patients	treated	with	direct-	acting	antivirals	(DAAs)	became	an	issue.	However,	its	fre-
quency	has	been	poorly	estimated,	because	of	the	varying	definitions	used	and	evalua-
tion	of	heterogeneous	study	populations,	including	those	concurrently	treated	for	HBV.
Methods:	 We	 prospectively	 followed	 HBV	 surface	 antigen	 (HBsAg)-	positive	
Egyptians	undergoing	interferon-	free	DAAs,	to	estimate	the	risk	of	HBV	reactivation	
and	HBV-	related	hepatitis.	We	also	conducted	a	meta-	analysis	to	estimate	the	reac-
tivation	 risk	 using	published	data	obtained	 from	a	 systematic	 review	of	PubMed/
Embase,	in	addition	to	our	Egyptian	data.	We	applied	a	standard	definition	of	HBV	
reactivation	proposed	by	the	international	liver	associations	(APASL	and	AASLD).
Results:	Of	 4471	CHC	patients,	 35	HBsAg-	positive	 patients	 started	 interferon-	free	
DAAs	without	HBV	nucleos(t)ide	analogues	in	our	Egyptian	cohort.	Ten	experienced	
HBV	reactivation	(28.6%),	of	whom	1	developed	hepatitis	(10.0%).	Our	systematic	re-
view	identified	18	papers.	The	pooled	reactivation	risk	in	HBsAg-	positive	patients	was	
18.2%	(95%	CI:	7.9%-	30.7%)	without	HBV	therapy	and	0.0%	(95%	CI:	0.0%-	0.0%)	with	
HBV	nucleos(t)ide	analogue.	The	pooled	risk	of	hepatitis	in	those	with	HBV	reactivation	
was	12.6%	(95%	CI:	0.0%-	34.7%).	The	pooled	reactivation	risk	in	HBsAg-	negative,	an-
tibody	to	HBV	core	antigen-	positive	(anti-	HBc-	positive)	patients	was	negligible	(0.1%,	
95%	CI:	0.0%-	0.3%),	irrespective	of	the	presence	of	antibody	to	HBsAg	(anti-	HBs).
Conclusions:	We	confirmed	high	HBV	reactivation	risk	 in	HBsAg-	positive	patients	
undergoing	DAAs,	with	only	a	minority	developing	clinically	important	hepatitis.	The	
risk	is	negligible	for	HBsAg-	negative	anti-	HBc-	positive	patients.
K E Y W O R D S
direct-acting	antivirals,	hepatitis	B,	hepatitis	C,	reactivation
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1  | INTRODUC TION
The	recent	advent	of	direct-	acting	antivirals	(DAAs)	for	chronic	hep-
atitis	C	virus	(HCV)	infection	has	dramatically	changed	the	landscape	
of	HCV	management.	DAA	regimens	are	associated	with	a	sustained	
virological	 response	 (SVR)	 rate	 of	 >90%-	95%,	 and	 are	 considered	
safe;	nevertheless,	a	few	serious	complications	have	been	reported	
including	reactivation	of	hepatitis	B	virus	(HBV).1,2
In	 2015-	2016,	 several	 case	 reports	 alerted	 to	 the	 risk	 of	HBV	
reactivation	and	HBV-	related	hepatitis	during	the	course	of	DAAs	in	
patients	with	chronic	HCV	infection	positive	for	hepatitis	B	surface	
antigen	 (HBsAg)	 (chronic	HBV	 infection)3,4	 and	 those	negative	 for	
HBsAg	but	positive	 for	 antibody	 to	hepatitis	B	 core	 antigen	 (anti-	
HBc)	 (past	 or	 resolved	HBV	 infection).3,5	 Following	 these	 reports,	
including	a	case	of	fulminant	hepatic	failure	requiring	liver	transplan-
tation,5	 the	U.S.	Food	and	Drug	Administration	and	 the	European	
Medicine	Agency	issued	a	warning	about	the	risk	of	HBV	reactiva-
tion	with	 the	 use	 of	DAAs.6,7	Now,	 both	 European	 and	American	
guidelines	recommend	to	screen	for	HBsAg,	anti-	HBc	and	antibody	
to	HBsAg	 (anti-	HBs)	 in	all	patients	 initiating	DAAs,	and	to	concur-
rently	start	anti-	HBV	nucelos(t)ide	analogue	therapy	 in	 those	who	
are	eligible	(ie,	high	HBV	DNA	levels	≥2000	IU/mL	and	elevated	ala-
nine	transaminase	(ALT)	and/or	significant	liver	fibrosis).1,2	However,	
the	recommended	management	for	chronic	hepatitis	C	patients	who	
are	ineligible	for	anti-	HBV	treatment	itself	differs	considerably	be-
tween	these	2	guidelines.	While	 the	European	Association	for	 the	
Study	of	 the	Liver	 (EASL)	 guidelines	 recommend	 to	 systematically	
administer	 concomitant	 nucleos(t)ide	 analogue	 prophylaxis	 to	 all	
the	HBsAg-	positive	patients	 irrespective	of	HBV	DNA	 levels	 until	
12	weeks	 post-	DAAs,8	 the	 American	 Association	 for	 the	 Study	
of	 Liver	 Diseases	 (AASLD)	 just	 recommends	 to	 monitor	 inactive	
HBsAg-	positive	patients	with	low	HBV	viraemia	and	to	start	nucle-
os(t)ide	analogues	only	when	their	viral	load	reaches	a	level	fulfilling	
HBV	treatment	criteria.2	For	persons	HBsAg-	negative	but	anti-	HBc-	
positive,	 EASL	 recommends	 to	 closely	 monitor	 and	 test	 for	 HBV	
reactivation	 in	case	of	ALT	elevation,	while	the	AASLD	recognizes	
that	there	is	too	little	data	to	make	a	clear	recommendation	for	mon-
itoring	 these	 patients.	 The	 discrepancies	 between	 these	 2	 major	
guidelines	highlight	 the	 lack	of	 robust	evidence	 in	the	risk	of	HBV	
reactivation	in	DAA-	treated	HCV	patients.
Few	cohort	studies	have	attempted	to	investigate	the	frequency	
of	HBV	 reactivation	 during	DAAs	 in	HBsAg-	positive	 patients	 and	
HBsAg-	negative	 anti-	HBc-	positive	 patients.	 These	 studies	 have	
shown	 that	 the	 risk	 is	 substantial	 in	 the	 former	 (>30%,	 except	 in	
1	study)	and	minimal	 in	 the	 latter	group	 (<2%).9-13	However,	 these	
studies	were	 limited	because	of:	 (i)	heterogeneity	 in	study	partici-
pants	(inclusion	of	patients	under	HBV	antiviral	treatment);	(ii)	use	of	
different	criteria	for	HBV	reactivation,	and	(iii)	very	small	sample	size	
in	the	estimates	for	the	concurrent	HBV	infection	(number	assessed	
in	each	study	was	between	7	and	12).9-13	Retrospective	analyses	of	
an	electronic	database	of	USA	veterans	provided	estimates	based	
on	a	 large	number	of	patients;	however,	HBV	reactivation	was	not	
systematically	ascertained	during	and	after	the	course	of	DAAs,	and	
those	under	anti-	HBV	nucleos(t)ide	analogue	therapy	were	not	sep-
arated	out	from	the	cohort,	hampering	an	accurate	estimation	of	the	
risk	of	HBV	reactivation.14,15
Here,	we	prospectively	estimated	 the	 risk	of	HBV	reactivation	
and	HBV-	related	 hepatitis	 in	 a	 cohort	 of	 HBsAg-	positive	 patients	
treated	for	HCV	using	interferon	(IFN)-	free	DAAs	in	Egypt.	We	also	
conducted	 a	 systematic	 review	 and	meta-	analysis	 to	 estimate	 the	
frequency	of	HBV	reactivation	in	HBV	co-	infected	patients	treated	
for	 IFN-	free	 DAAs,	 by	 applying	 the	 well-	established	 definition	 of	
HBV	reactivation16,17	to	the	previously	published	data	and	our	new	
data.
2  | PATIENTS AND METHODS
2.1 | Egyptian cohort study
2.1.1 | Patients
In	Egypt,	a	country	with	the	highest	HCV	prevalence	in	the	world,	
the	National	Treatment	Program	introduced	sofosbuvir	(SOF)-	based	
treatment	 in	 2014.18	 As	 of	 March	 2017,	 more	 than	 one	 million	
Egyptian	patients	with	chronic	HCV	infection	have	been	treated,19 
with	>90%	achieving	a	SVR.20
Between	March	2015	and	March	2016,	we	prospectively	 re-
cruited	 patients	 co-	infected	 with	 HBV	 and	 HCV	 who	 initiated	
DAAs	 at	 the	New	Cairo	Viral	Hepatitis	 Treatment	Unit	 in	Cairo,	
Egypt.	According	to	the	Egyptian	guidelines,	patients	with	chronic	
HCV	infection	(positive	antibody	to	HCV	and	positive	HCV	RNA)	
who	were	 referred	 to	our	Unit	were	 systematically	 assessed	 for	
their	 eligibility	 for	 DAA	 therapy	 through	 a	 standardized	 clinical	
and	virological	 assessment,	 including	complete	blood	count,	 ala-
nine	 aminotransferase	 (ALT),	 aspartate	 aminotransferase	 (AST),	
bilirubin,	 albumin,	 creatinine,	 alpha-	foetoprotein,	 prothrombin	
Key points
•	 In	 a	 cohort	 of	 HBsAg-positive	 Egyptians	 with	 chronic	
HCV	infection	treated	with	DAAs,	the	risk	of	HBV	reac-
tivation	was	28.6%	(95%	CI:	15.6%-46.4%)	and	the	risk	
of	 hepatitis	 in	 those	 who	 developed	 reactivation	 was	
10.0%	(0.9%-57.8%)	in	the	absence	of	concurrent	HBV	
treatment.
•	 In	 a	 systematic	 review	 that	 incorporated	 the	 Egyptian	
data,	the	pooled	reactivation	risk	in	HBsAg-positive	pa-
tients	was	18.2%	(95%	CI:	7.9%-30.7%)	and	the	risk	of	
hepatitis	was	12.6%	(95%	CI:	0.0%-34.7%)	in	those	who	
had	reactivation.
•	 The	 pooled	 reactivation	 risk	 in	 HBsAg-negative	 anti-
HBc-positive	 patients	 was	 negligible	 (0.1%,	 95%	 CI:	
0.0%-0.3%),	irrespective	of	the	presence	of	anti-HBs.
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time,	 anti-	HIV	 antibody	 (MINI	 VIDAS®,	 Biomerieux,	 France),	
HBsAg	 (Stat	 Fax	 4200,	 Dia	 Sorin,	 USA),	 alpha-	foetoprotein	 and	
abdominal	 ultrasonography.	 Some	 patients	 underwent	 liver	 bi-
opsy.	 Patients	 with	 the	 following	 characteristics	 were	 ineligible	
for	 DAAs	 according	 to	 the	 national	 guidelines:	 Child-	Pugh	 class	
C	 cirrhosis,	 hepatocellular	 carcinoma,	 platelet	 counts	 <50	 109 
cells/L,	current	pregnancy	or	breast-	feeding.	All	the	patients	test-
ing	positive	for	HBsAg	during	the	recruitment	period	were	invited	
to	 participate	 in	 the	 current	 prospective	 study.	 After	 obtaining	
written	informed	consent,	the	patients	identified	to	carry	HBsAg	
at	baseline	were	 further	assessed	 for	other	HBV	markers:	hepa-
titis	B	e	antigen	(HBeAg,	Stat	Fax	4200,	Dia	Sorin,	USA)	at	base-
line,	and	serum	HBV	DNA	measurement	(DT	Lite	Real	Time	PCR,	
DNA-	Technology,	Russia,	limit	of	detection:	25	IU/ml)	at	baseline,	
week	 4,	 end	 of	 treatment	 and	 12	weeks	 post-	treatment.	 All	 the	
patients	received	HCV	antiviral	therapy	according	to	the	Egyptian	
guidelines,	and	were	followed	clinically	every	2	weeks	with	com-
plete	blood	count,	AST	and	ALT.	SVR	was	assessed	at	12	weeks	
after	the	end	of	treatment	using	HCV	RNA.	Patients	co-	infected	
with	 HIV	 and	 those	 receiving	 immunosuppressive	 therapy	were	
excluded	 from	 the	 current	 analysis.	 The	 study	was	 approved	 by	
the	 Institutional	 Review	 Board	 at	 the	 National	 Hepatology	 and	
Tropical	Medicine	Research	Institute	in	Cairo,	Egypt.
2.1.2 | Definition
We	used	the	definition	of	HBV	reactivation	proposed	by	the	Asian	
Pacific	 Association	 for	 the	 Study	 of	 the	 Liver	 (APASL)	 guidelines,	
and	 by	 the	 American	 Association	 for	 the	 Study	 of	 Liver	 Diseases	
(AASLD)’s	consensus	conference:	≥2	log	increase	for	those	who	had	
detectable	HBV	DNA	at	baseline	or	a	new	appearance	of	HBV	DNA	
to	a	level	of	≥100	IU/mL	for	those	who	had	undetectable	HBV	DNA	
at	baseline.16,17	HBV-	related	hepatitis	was	defined	as	ALT	≥5	times	
upper	 limit	of	normal	or	≥2	 times	of	 the	baseline	 level	 in	patients	
who	experienced	HBV	reactivation.13,21
2.1.3 | Statistical analysis
Baseline	 characteristics	were	 presented	 using	 percentage	 for	 cat-
egorical	variables	and	median	and	interquartile	range	(IQR)	for	con-
tinuous	 variables.	 Factors	 associated	 with	 HBV	 reactivation	 were	
assessed	 using	 logistic	 regression	 analysis.	 Variables	 found	 to	 be	
associated	 with	 HBV	 reactivation	 (P	<	.25)	 were	 further	 assessed	
using	 multivariable	 logistic	 regression	 using	 STATA	 13.1	 (STATA	
Corporation,	College	Station,	TX,	USA).
2.2 | Systematic review and meta- analysis
2.2.1 | Systematic review
After	developing	a	review	protocol,	we	searched	PubMed	and	Embase	
up	 to	 January	 2018,	 using	 the	 following	 search	 terms	 and	 their	
variation:	 hepatitis	 B,	 hepatitis	 C,	 antiviral	 agents,	 and	 reactivation	
(Appendix	S1).	We	also	conducted	a	manual	search	through	bibliogra-
phies.	Without	any	language	restriction,	we	included	cohort	studies	of	
chronic	HCV	patients	undertaking	IFN-	free	DAAs	who	were	HBsAg-	
positive	or	HBsAg-	negative/anti-	HBc-	positive	before	starting	DAAs.	
For	 the	 studies	which	 also	 had	 IFN-	treated	 patients,	 we	 only	 used	
those	within	 the	 cohort	 that	were	 treated	with	 IFN-	free	 regimens.	
We	excluded	case	series,	which	described	the	clinical	courses	of	only	
those	who	developed	hepatitis	B	reactivation,	because	this	does	not	
allow	us	 to	estimate	 the	 risk	 (frequency)	of	 reactivation.	HBV	DNA	
and	ALT	needed	to	have	been	measured	at	least	once	during	or	after	
(up	 to	 24	weeks	 post-	treatment)	 DAAs.	 Since	 the	 definition	 of	 the	
primary	endpoints,	HBV	reactivation	and	HBV-	related	hepatitis	var-
ied	substantially	between	studies,	we	did	not	use	the	risks	reported	
in	each	paper,	but	rather	we	applied	the	definitions	proposed	by	the	
APASL	and	AASLD.11,13-15	We	only	included	studies	in	which	the	end-
points	could	be	stratified	by	 the	concurrent	HBV	nucleos(t)ide	ana-
logue	therapy	at	baseline.	Two	authors	 (YS	and	ALF)	 independently	
screened	titles	and	abstracts	of	all	papers	identified	by	the	electronic	
searches.	Potentially	eligible	papers	were	independently	reviewed	for	
their	eligibility.	Data	were	extracted	for	the	following	variables:	study	
design,	setting,	baseline	characteristics,	DAAs	regimen,	SVR	rate	and	
when	the	outcome	(HBV	DNA)	was	measured.	The	included	studies	
were	assessed	for	the	risk	of	bias	(Appendices	S2	&	S3).22
2.2.2 | Meta- analysis
The	risk	of	HBV	reactivation	was	calculated	as	the	number	of	patients	
with	 reactivation	 divided	 by	 the	 total	 number	 assessed.	The	 risk	 of	
HBV-	related	hepatitis	was	calculated	as	the	number	with	HBV-	related	
hepatitis	divided	by	the	number	of	patients	who	developed	HBV	re-
activation.	The	risks	were	pooled	by	meta-	analysis	using	“metaprop”	
command	in	STATA	13.1.23	The	variance	of	the	proportions	was	sta-
bilized	 using	 Freeman-	Tukey	 double	 arcsine	 transformation,24 and 
the	estimates	were	pooled	by	the	DerSimonian-	Laird	random-	effects	
model.25	The	confidence	intervals	for	the	pooled	estimates	were	as-
sessed	with	the	Wald	test.23	The	percentage	of	total	variation	between	
studies	 because	 of	 heterogeneity	was	 evaluated	 by	 the	 I2	 statistic.	
The	 pooled	 estimates	 were	 presented	 separately	 according	 to	 the	
HBV	serology	at	baseline:	HBsAg-	positive,	and	HBsAg-	negative/anti-	
HBc-	positive.	 Subgroup	analyses	were	made	 to	explore	 the	 sources	
of	between-	study	heterogeneity	in	the	risk	of	HBV	reactivation	using	
a	 test	 of	 heterogeneity	 of	 the	 “metaprop”	 command,23	 and	 the	 fol-
lowing	variables	were	assessed:	concurrent	anti-	HBV	therapy	at	base-
line;	HBV	genotype;	HCV	genotype;	HIV	co-	infection;	achievement	of	
SVR12;	and	positivity	of	antibody	to	hepatitis	B	surface	antigen	(anti-	
HBs)	in	those	negative	for	HBsAg	but	positive	for	anti-	HBc.
3  | RESULTS
3.1 | Egyptian cohort study
Between	March	2015	and	March	2016,	4471	patients	with	chronic	
HCV	 infection	 were	 assessed	 at	 the	 New	 Cairo	 Viral	 Hepatitis	
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Treatment	 Unit	 for	 the	 eligibility	 for	 DAAs.	 All	 were	 tested	 for	
HBsAg,	 and	 40	 were	 found	 to	 carry	 HBsAg	 (prevalence:	 0.89%,	
95%	CI:	0.66-	1.22%).	Of	these,	3	patients	who	received	DAA	regi-
mens	that	included	IFN	were	excluded	from	the	analysis	(Figure	1).	
None	were	co-	infected	with	HIV	or	receiving	immunosuppressive	
therapy.
Baseline	 characteristics	 of	 the	 37	 patients	 with	 concurrent	
HBV	infection	are	presented	in	Table	1.	Median	age	was	52	years	
(IQR:	48-	56),	and	62.2%	were	men.	Ten	 (27.0%)	patients	had	cir-
rhosis,	 based	 on	 liver	 histopathology	 (n	=	5)	 or	 abdominal	 ultra-
sonography	(n	=	5).	None	carried	HBeAg,	and	HBV	viral	load	was	
detectable	 in	 13	 patients	 (35.1%).	 The	 median	 HBV	 DNA	 level	
was	 2.8	 log10	IU/ml	 (range:	 1.4-	4.7).	 Two	 patients	 were	 under	
treatment	for	HBV	at	baseline:	one	treated	with	lamivudine	since	
1	year,	 and	 another	 concurrently	 initiated	 entecavir	 because	 of	
high	 HBV	 viral	 load	 (43	600	IU/mL)	 found	 at	 baseline.	 The	 fol-
lowing	DAA	regimens	were	administered:	daclatasvir	 (DCV)/SOF	
with	or	without	ribavirin	(RBV)	for	12	weeks	(n	=	19),	SOF/RBV	for	
24	weeks	(n	=	10),	simeprevir	(SMV)/SOF	for	12	weeks	(n	=	7)	and	
ombitasvir	 (OBV)/paritaprevir	 ritonavir	 (PTV)/dasabuvir	 (DSV)	
with	ribavirin	for	12	weeks	(n	=	1).	All	patients	completed	the	full	
course	 of	 treatment	 except	 for	 one	who	was	 treated	with	 SOF/
RBV.	This	patient,	without	cirrhosis	at	baseline,	developed	fatigue	
and	anorexia	at	week	12,	with	HBV	reactivation	(HBV	DNA	levels	
increased	 from	 544	IU/mL	 at	 baseline	 to	 400	000	IU/mL),	 after	
which	entecavir	was	added	to	the	SOF/RBV	regimen.	At	week	16,	
the	 patient	 developed	 HBV-	related	 hepatitis	 with	 mild	 ascites,	
elevated	 liver	 enzymes	 (ALT	465	U/mL,	AST	406/mL	U/mL)	 and	
jaundice	(total	bilirubin	3.3	mg/dL),	which	necessitated	the	cessa-
tion	of	anti-	HCV	treatment.	One	month	after	the	cessation	of	the	
DAAs,	the	ascites	resolved	and	liver	functions	returned	to	normal.	
Of	 the	 36	 patients	who	 completed	DAAs,	 34	 patients	 achieved	
SVR12	(Table	1).	The	2	who	did	not	achieve	SVR12	had	both	re-
ceived	SOF/RBV	 for	 24	weeks,	 and	had	undetectable	HCV	RNA	
at	 the	 end	of	 treatment;	 however,	 the	 relapse	was	 confirmed	 at	
12	weeks	post-	treatment.
Out	 of	 the	 35	 co-	infected	 patients	 without	 HBV	 therapy	 at	
baseline,	 10	 developed	 HBV	 reactivation	 either	 during	 the	 course	
of	DAAs	or	in	the	period	up	to	12	weeks	post-	treatment;	the	risk	of	
reactivation	was	28.6%	(95%	CI:	15.6%-	46.4%).	The	clinical	courses	
of	these	patients	are	summarized	 in	Appendix	S4.	Except	for	the	1	
patient,	 reported	above,	who	developed	HBV-	related	hepatitis	and	
subsequently	started	entecavir,	none	had	a	clinically	important	ALT	
elevation	compared	to	the	baseline	level	and	thus	required	anti-	HBV	
therapy.	The	risk	of	hepatitis	in	those	who	experienced	HBV	reacti-
vation	was	10.0%	(1/10,	95%	CI:	0.9%-	57.8%).	HBV	reactivation	was	
not	observed	in	any	of	the	2	patients	under	anti-	HBV	treatment	at	
baseline.
We	 tried	 to	 identify	 factors	 associated	with	HBV	 reactivation	
among	 those	without	HBV	 therapy	 at	 baseline	 (n	=	35).	No	 factor	
was	 significantly	 associated	with	HBV	 reactivation	 (Appendix	 S5).	
Neither	of	the	2	HCV	relapsers	had	HBV	reactivation.
3.2 | Systematic review and meta- analysis
The	search	strategy	identified	862	papers.	After	excluding	dupli-
cates,	 774	were	 screened,	 and	 63	 papers	were	 assessed	 in	 full-	
text.	Finally,	18	articles	(comprising	17	unique	cohorts)	were	found	
to	be	eligible,	 and	after	adding	our	Egyptian	study,	a	 total	of	18	
cohorts	were	 included	 in	 our	meta-	analysis	 (Figure	2).	 The	 large	
retrospective	studies	of	USA	veterans	were	not	eligible	because	
of	 the	 fact	 that	 the	 study	 reported	 the	 overall	 risk	 of	 HBV	 re-
activation	 regardless	of	whether	or	not	 the	patients	were	under	
anti-	HBV	 nucleos(t)ide	 analogue	 treatments,	 and	 we	 could	 not	
stratify	the	analysis	by	the	concurrent	administration	of	anti-	HBV	
treatment.14,15	The	characteristics	of	the	included	studies	and	our	
Egyptian	study	are	summarized	in	Table	2.	A	total	of	425	patients	
positive	 for	HBsAg	 (including	 the	37	patients	 from	 the	Egyptian	
study),	 and	 1900	 patients	 negative	 for	 HBsAg	 but	 positive	 for	
anti-	HBc	 were	 used	 to	 estimate	 the	 pooled	 risks.	 Nine	 studies	
(10	articles)	were	from	East	Asia,10,12,13,26-32	6	from	Europe,11,33-37 
1	from	USA38	 and	1	 from	New	Zealand.9	All	of	 these	studies	 in-
cluded	patients	on	IFN-	free	DAAs	regimens	for	8-	24	weeks.	While	
most	of	studies	reported	HCV	genotype,	only	3	studies	reported	
HBV	genotype.9,31,32	Risk	of	bias	in	these	studies	is	summarized	in	
Appendix	S3.
3.2.1 | Pooled risk of HBV reactivation
In	patients	with	concurrent	chronic	HBV	 infection,	 the	pooled	risk	
of	HBV	reactivation	without	anti-	HBV	therapy	was	18.2%	(95%	CI:	
7.9%-	30.7%;	 Figure	3A).	 This	was	 significantly	 higher	 than	 the	 risk	
in	HBsAg-	positive	patients	concurrently	treated	with	HBV	nucelos(t)
ide	 analogue,	 in	which	 none	 experienced	HBV	 reactivation	 (0.0%,	
95%	CI:	0.0%-	0.0%,	P	<	.001;	Figure	3B).	In	HBsAg-	positive	patients	
F IGURE  1 Flow	chart	of	study	participants	in	Egyptian	cohort	
study
Positive for HBsAg (n = 40)
Included in the analysis 
(n = 37)
Excluded:
- IFN-based HCV treatment regimen 
(n = 3)
Patients with chronic HCV 
infection assessed at the New 
Cairo Viral Hepatitis 
Treatment Unit (N = 4471)
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without	HBV	 therapy,	 the	 risk	of	 reactivation	 tended	 to	be	higher	
in	 those	 who	 achieved	 HCV	 SVR	 (21.8%,	 95%	 CI:	 11.5%-	33.6%)	
than	those	without	SVR	(0.0%,	95%	CI:	0.0%-	57.0%)	(Appendix	S6).	
However,	this	did	not	reach	statistical	significance	(P	=	.4)	given	the	
TABLE  1 Baseline	and	follow-	up	data	(n	=	37)a
Baseline data
Median	age 52	(48-	56)
Male	gender	(%) 23	(62.2)
Median	BMI 31	(29-	34)
Diabetes	(%) 8/36	(22.2)
HCV	treatment-	naïve 31	(83.8)
HCV	treatment	regimen
DCV/SOF±RBV 19	(51.3)
SMV/SOF 7	(18.9)
SOF+RBV 10	(27.0)
OBV/PTV/DSV+RBV 1	(2.7)
HCV	RNA	(IU/mL)
<103 1	(2.7)
103-	106 26	(70.3)
≥106 10	(27.0)
Median	HCV	RNA	(log10	IU/mL) 5.6	(4.7-	6.1)
HBsAg	(%) 37	(100)
HBeAg	(%) 0
HBV	DNA	(IU/mL)
Undetectable 24	(64.9)
<2000 11	(29.7)
≥2000 2	(5.4)
Median	HBV	DNA	(log10	IU/mL)b 2.8	(2.3-	3.2)
Concurrent	HBV	antiviral	therapy 2	(5.4)
ALT	(U/mL)
<40 15	(40.5)
40-	80 15	(40.5)
≥80 7	(19.0)
AST	(U/mL)
<40 14	(37.8)
40-	80 17	(46.0)
≥80 6	(16.2)
Median	total	bilirubin	(mg/dL) 0.7	(0.6-	1.0)
Median	albumin	(g/dL) 4.1	(3.8-	4.4)
Median	creatinine	(mg/dL) 0.8	(0.7-	0.9)
Median	platelet	count	(109/L) 146	(116-	208)
Fib-	4
<1.45 13	(35.1)
1.45-	3.25 12	(32.4)
≥3.25 12	(32.4)
Cirrhosisc 10	(27.0)
Follow- up data
HCV	SVR12
Achieved 34	(91.9)
Not	achieved 2	(5.4)
Stopped	treatment 1	(2.7)
F IGURE  2 Flow	diagram	of	study	selection	in	systematic	review
Articles identified (N = 862) 
through:
PubMed (n = 143)
Embase (n = 719)
Full-text articles assessed for 
eligibility (N = 63)
Excluded by screening (n = 711)
Included articles (N = 18, a total 
of 17 cohorts)
Duplicates removed (n = 88)
Included in the meta-analysis (a 
total of 18 cohorts)
Egyptian study (n = 1)
Excluded articles (N = 47)
Reasons for exclusion:
Case reports/series (n = 16)
Corresponding letter (n = 8)
Review article (n = 8)
Conference proceedings (n = 7)
Not dually infected (n = 2)
Systematic review (n = 1)
IFN-based HCV therapy (n = 1)
Reactivation not assessed (n = 2)
Patients under HBV treatment 
cannot be separated (n = 2)
Manually added (n = 2)
Articles screened on the basis of 
title and abstract (N = 774)
Follow- up data
HBV	reactivation	in	those	without	HBV	therapy 10/35	(28.6)
HBV-	related	hepatitis	in	those	without	HBV	
therapy
1/35	(2.9)
HBV	reactivation	in	those	under	HBV	therapy 0/2	(0)
HBV-	related	hepatitis	in	those	under	HBV	therapy 0/2	(0)
aMedian	values	are	presented	with	IQR.
bExcluding	those	with	undetectable	HBV	DNA.
cThe	 diagnosis	was	 based	 on	 liver	 histopathology	 (n	=	9)	 or	 abdominal	
ultrasonography	(n	=	28).
TABLE  1  (Continued)
(Continues)
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TABLE  2 Characteristics	of	the	studies	identified	by	the	systematic	review	(n	=	17)	and	our	Egyptian	study
Author Country
No. included in the current analysis Baseline characteristics before starting DAAs
DAAs regimens SVR 12 (%)
When the outcome (HBV DNA) 
measured Definition of HBV reactivation used in each studybHBsAg (+)
HBsAg (−) and 
Anti- HBc (+) Agea Men (%) Cirrhosis (%) HCV genotype (%)
HBV therapy in HBsAg 
(+) patients (%) HIV (%)
Gane	EJ New	Zealand 8 ND Mean	(SD)	53	(7) 75 25 1a: 75 
1b: 25
0 0 LDV/SOF 100 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
NR
Wang	C China 10 124 54	(20-	75) 57 58 1a: 82 
2a: 18
0 NR LDV/SOF 
DCV/SOF 
OBV/PTV+DSV
100 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
>2.0	log	increase	in	HBV	DNA
Sulkowski MS Korea 
Taiwan
0 103 58	(36-	75) 42 18 1: 1 
1a: 8 
1b:	91
0 NR LDV/SOF 98 Once	at	24	wks	after	the	EOT Abrupt	reappearance/rise	of	HBV	DNA
Londono	MC Spain 10 64 61	(20-	84) 53 44 1a: 14 
1b: 70 
2: 2 
3: 7 
4: 7
40 1 OBV/PTV±DSV±RBV 
LDV/SOF±RBV 
DCV/SOF±RBV 
SOF+RBV 
DCV/SMV
NR Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
>1.0	log	increase	in	HBV	DNA
Yeh	ML Taiwan 7 57 63	(35-	81) 27 34 1: 72 0 0 LDV/SOF±RBV 
OBV/PTV+DSV 
DCV/SOF 
DCV/ASV 
SOF+RBV
97 Multiple	from	the	start	of	DAA	till	
the	EOT
>1.0	log	increase	in	HBV	DNA	for	those	with	HBV	
DNA(+); 
Reappearance	of	HBV	DNA	for	those	with	HBV	
DNA(−); 
Reappearance	of	HBsAg	or	HBV	DNA	>2000	IU/mL	
for	those	with	HBsAg(−)
Kawagishi	N Japan 1 82 69	(44-	87) 47 51 1: 72 
2: 28
0 NR LDV/SOF 
DCV/ASV 
SOF+RBV
95 Once	at	the	EOT >1.3	log	increase	in	HBV	DNA
Liu	CH Taiwan 12 81 Mean	(SD)	56	(8) 50 33 1a: 2 
1b: 82 
2:	16
0 0 LDV/SOF±RBV	 
SOF+RBV 
OBV/PTV/DSV±RBV
NR Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
AASLD/APASL
Doi	A Japan 4 143 73	(36-	90) 52 26 1: 80 
2: 20
0 NR LDV/SOF 
SOF+RBV
98 4	and	12	wks	after	the	start	of	
DAA
HBV	DNA	>20	IU/mL	for	those	with	<20	IU/mL;	or	
>1.0	log	change	in	HBV	DNA
Ogawa	E Japan 0 63 71	(43-	82) 41 24 1:	65 
2: 35
0 0 LDV/SOF 
SOF+RBV
94c Multiple	from	the	start	of	DAA	till	
24	wks	after	the	EOT
HBV	DNA	>20	IU/mL
Mucke	VT Germany 8 249 57	(18-	86) 59 36 1a: 28 
1b: 35 
2: 7 
3: 20 
4-	6:	10
13 1 LDV/SOF±RBV 
DCV/SOF±RBV 
OBV/PTV±DSV±RBV 
SOF+RBV
94 Once	at	the	EOT Abrupt	reappearance/rise	of	HBV	DNA
Loggi	E Italy 2 42 62	(48-	86) 70 93 1a: 18 
1b: 52 
2:	9 
3: 11 
4:	9
50 NR LDV/SOF±RBV 
DCV/SOF±RBV 
SMV/SOF±RBV 
OBV/PTV/DSV±RBV 
SOF+RBV 
OBV+RBV
93 Once	at	24	wks	after	the	EOT AASLD/APASL
Calvaruso	V Italy 8 37 Mean	(SD) 
64	(9)
69 100 1a:	9 
1b:	60 
2: 22 
3: 4 
4: 4
50 0 LDV/SOF±RBV 
DCV/SOF+RBV 
SMV/SOF+RBV 
OBV/PTV/DSV+RBV 
SOF+RBV
94 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
HBV	DNA	>20	IU/mL	for	HBsAg(+)	with	HBV	DNA(−);	
Reappearance	of	HBV	DNA	for	HBsAg(−)	and	HBV	
DNA(−)
Macera M Italy 29 ND 61	(38-	80) 72 86 NR 55 NR SMV/SOF 
LDV/SOF 
DCV/SOF 
OBV/PTV/DSV
93 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
>1.0	log	increase	in	HBV	DNA	for	those	with	HBV	
DNA(+); 
Reappearance	of	HBV	DNA	for	those	with	HBV	
DNA(−)
Tamori	A Japan 25 765 70	(22-	92) 48 28 1:	79 
2: 21
12 NR LDV/SOF 
DCV/ASV 
OBV/PTV 
SOF+RBV
99 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
>2.0	log	increase	in	HBV	DNA	for	those	with	HBV	
DNA(+); 
Reappearance	of	HBV	DNA	>20	IU/mL	for	those	with	
HBV	DNA(−)
Liu	CJ Taiwan 110 ND Mean	(range)	55	(32-	76) 38 16 1:	61 
2:	39
0 0 LDV/SOF 100 Multiple	from	the	start	of	DAA	till	
108	wks	after	the	EOT
>1.0	log	increase	in	HBV	DNA	for	those	with	HBV	
DNA(+); 
Reappearance	of	HBV	DNA	for	those	with	HBV	
DNA(−)
Preda	CM Romania 15 ND 60	(51-	72) 27 100 1b: 100 0 0 OBV/PTV/DSV+RBV 100 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
AASLD/APASL
Yanny	BT USA 139 90 Mean	(SD) 
60	(7)
58 43 1:	93 
4: 7
70 NR LDV/SOF 91	(G1)	and	
84	(G4)
At	least	once	from	the	start	of	
DAA	till	12	wks	after	the	EOT
Increase	in	AST	or	ALT	≥3	times	the	ULN	and	
reappearance	of	HBV	DNA 
detection	or	HBsAg
El Kassas M Egypt 37 ND 52	(48-	56) 62 32 NR 5 0 DCV/SOF±RBV 
SMV/SOF 
SOF+RBV 
OBV/PTV/DSV+RBV
92 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
AASLD/APASL
AASLD,	American	Association	for	the	Study	of	Liver	Diseases;	APASL,	Asian	Pacific	Association	for	the	Study	of	the	Liver;	DCV,	daclatasvir;	DSV,	 
dasabuvir;	LDV,	ledipasvir;	ND,	not	done;	NR,	not	reported;	OBV,	ombitasvir;	PTV,	paritaprevir/ritonavir;	RBV,	ribavirin;	SD,	standard	deviation;	 
SMV,	simeprevir;	SOF,	sofosbuvir.
aMedian	age	(range)	is	presented	unless	indicated.
bFor	the	meta-	analysis,	we	did	not	use	these	definitions.	We	used	the	definition	of	HBV	reactivation	proposed	by	the	AASLD	and	APASL.
cSVR	24	is	presented.
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TABLE  2 Characteristics	of	the	studies	identified	by	the	systematic	review	(n	=	17)	and	our	Egyptian	study
Author Country
No. included in the current analysis Baseline characteristics before starting DAAs
DAAs regimens SVR 12 (%)
When the outcome (HBV DNA) 
measured Definition of HBV reactivation used in each studybHBsAg (+)
HBsAg (−) and 
Anti- HBc (+) Agea Men (%) Cirrhosis (%) HCV genotype (%)
HBV therapy in HBsAg 
(+) patients (%) HIV (%)
Gane	EJ New	Zealand 8 ND Mean	(SD)	53	(7) 75 25 1a: 75 
1b: 25
0 0 LDV/SOF 100 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
NR
Wang	C China 10 124 54	(20-	75) 57 58 1a: 82 
2a: 18
0 NR LDV/SOF 
DCV/SOF 
OBV/PTV+DSV
100 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
>2.0	log	increase	in	HBV	DNA
Sulkowski MS Korea 
Taiwan
0 103 58	(36-	75) 42 18 1: 1 
1a: 8 
1b:	91
0 NR LDV/SOF 98 Once	at	24	wks	after	the	EOT Abrupt	reappearance/rise	of	HBV	DNA
Londono	MC Spain 10 64 61	(20-	84) 53 44 1a: 14 
1b: 70 
2: 2 
3: 7 
4: 7
40 1 OBV/PTV±DSV±RBV 
LDV/SOF±RBV 
DCV/SOF±RBV 
SOF+RBV 
DCV/SMV
NR Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
>1.0	log	increase	in	HBV	DNA
Yeh	ML Taiwan 7 57 63	(35-	81) 27 34 1: 72 0 0 LDV/SOF±RBV 
OBV/PTV+DSV 
DCV/SOF 
DCV/ASV 
SOF+RBV
97 Multiple	from	the	start	of	DAA	till	
the	EOT
>1.0	log	increase	in	HBV	DNA	for	those	with	HBV	
DNA(+); 
Reappearance	of	HBV	DNA	for	those	with	HBV	
DNA(−); 
Reappearance	of	HBsAg	or	HBV	DNA	>2000	IU/mL	
for	those	with	HBsAg(−)
Kawagishi	N Japan 1 82 69	(44-	87) 47 51 1: 72 
2: 28
0 NR LDV/SOF 
DCV/ASV 
SOF+RBV
95 Once	at	the	EOT >1.3	log	increase	in	HBV	DNA
Liu	CH Taiwan 12 81 Mean	(SD)	56	(8) 50 33 1a: 2 
1b: 82 
2:	16
0 0 LDV/SOF±RBV	 
SOF+RBV 
OBV/PTV/DSV±RBV
NR Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
AASLD/APASL
Doi	A Japan 4 143 73	(36-	90) 52 26 1: 80 
2: 20
0 NR LDV/SOF 
SOF+RBV
98 4	and	12	wks	after	the	start	of	
DAA
HBV	DNA	>20	IU/mL	for	those	with	<20	IU/mL;	or	
>1.0	log	change	in	HBV	DNA
Ogawa	E Japan 0 63 71	(43-	82) 41 24 1:	65 
2: 35
0 0 LDV/SOF 
SOF+RBV
94c Multiple	from	the	start	of	DAA	till	
24	wks	after	the	EOT
HBV	DNA	>20	IU/mL
Mucke	VT Germany 8 249 57	(18-	86) 59 36 1a: 28 
1b: 35 
2: 7 
3: 20 
4-	6:	10
13 1 LDV/SOF±RBV 
DCV/SOF±RBV 
OBV/PTV±DSV±RBV 
SOF+RBV
94 Once	at	the	EOT Abrupt	reappearance/rise	of	HBV	DNA
Loggi	E Italy 2 42 62	(48-	86) 70 93 1a: 18 
1b: 52 
2:	9 
3: 11 
4:	9
50 NR LDV/SOF±RBV 
DCV/SOF±RBV 
SMV/SOF±RBV 
OBV/PTV/DSV±RBV 
SOF+RBV 
OBV+RBV
93 Once	at	24	wks	after	the	EOT AASLD/APASL
Calvaruso	V Italy 8 37 Mean	(SD) 
64	(9)
69 100 1a:	9 
1b:	60 
2: 22 
3: 4 
4: 4
50 0 LDV/SOF±RBV 
DCV/SOF+RBV 
SMV/SOF+RBV 
OBV/PTV/DSV+RBV 
SOF+RBV
94 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
HBV	DNA	>20	IU/mL	for	HBsAg(+)	with	HBV	DNA(−);	
Reappearance	of	HBV	DNA	for	HBsAg(−)	and	HBV	
DNA(−)
Macera M Italy 29 ND 61	(38-	80) 72 86 NR 55 NR SMV/SOF 
LDV/SOF 
DCV/SOF 
OBV/PTV/DSV
93 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
>1.0	log	increase	in	HBV	DNA	for	those	with	HBV	
DNA(+); 
Reappearance	of	HBV	DNA	for	those	with	HBV	
DNA(−)
Tamori	A Japan 25 765 70	(22-	92) 48 28 1:	79 
2: 21
12 NR LDV/SOF 
DCV/ASV 
OBV/PTV 
SOF+RBV
99 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
>2.0	log	increase	in	HBV	DNA	for	those	with	HBV	
DNA(+); 
Reappearance	of	HBV	DNA	>20	IU/mL	for	those	with	
HBV	DNA(−)
Liu	CJ Taiwan 110 ND Mean	(range)	55	(32-	76) 38 16 1:	61 
2:	39
0 0 LDV/SOF 100 Multiple	from	the	start	of	DAA	till	
108	wks	after	the	EOT
>1.0	log	increase	in	HBV	DNA	for	those	with	HBV	
DNA(+); 
Reappearance	of	HBV	DNA	for	those	with	HBV	
DNA(−)
Preda	CM Romania 15 ND 60	(51-	72) 27 100 1b: 100 0 0 OBV/PTV/DSV+RBV 100 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
AASLD/APASL
Yanny	BT USA 139 90 Mean	(SD) 
60	(7)
58 43 1:	93 
4: 7
70 NR LDV/SOF 91	(G1)	and	
84	(G4)
At	least	once	from	the	start	of	
DAA	till	12	wks	after	the	EOT
Increase	in	AST	or	ALT	≥3	times	the	ULN	and	
reappearance	of	HBV	DNA 
detection	or	HBsAg
El Kassas M Egypt 37 ND 52	(48-	56) 62 32 NR 5 0 DCV/SOF±RBV 
SMV/SOF 
SOF+RBV 
OBV/PTV/DSV+RBV
92 Multiple	from	the	start	of	DAA	till	
12	wks	after	the	EOT
AASLD/APASL
AASLD,	American	Association	for	the	Study	of	Liver	Diseases;	APASL,	Asian	Pacific	Association	for	the	Study	of	the	Liver;	DCV,	daclatasvir;	DSV,	 
dasabuvir;	LDV,	ledipasvir;	ND,	not	done;	NR,	not	reported;	OBV,	ombitasvir;	PTV,	paritaprevir/ritonavir;	RBV,	ribavirin;	SD,	standard	deviation;	 
SMV,	simeprevir;	SOF,	sofosbuvir.
aMedian	age	(range)	is	presented	unless	indicated.
bFor	the	meta-	analysis,	we	did	not	use	these	definitions.	We	used	the	definition	of	HBV	reactivation	proposed	by	the	AASLD	and	APASL.
cSVR	24	is	presented.
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small	sample	size	in	the	latter	group	(n	=	3).	Subgroup	analysis	accord-
ing	to	HBV	genotype,	HCV	genotype,	and	HIV	co-	infection	could	not	
be	performed	as	in	most	of	the	studies	not	enough	data	was	provided	
to	stratify	the	outcomes	(HBV	reactivation)	by	these	variables.
In	patients	with	negative	HBsAg	and	positive	anti-	HBc,	only	2	
out	of	1900	patients	developed	HBV	reactivation;	 the	pooled	 risk	
was	 0.1%	 (95%	 CI:	 0.0%-	0.3%;	 Figure	3C).	 This	 was	 significantly	
lower	than	the	risk	 in	HBsAg-	positive	patients	without	HBV	treat-
ment	(18.2%,	95%	CI:	7.9%-	30.7%,	P	<	.001).	The	risk	of	reactivation	
in	 HBsAg-	negative	 anti-	HBc-	positive	 patients	 was	 negligible	 irre-
spective	of	the	presence	of	anti-	HBs:	0.0%	(95%	CI:	0.0%-	0.0%)	in	
patients	negative	for	anti-	HBs	(isolated	anti-	HBc)	and	0.1%	(95%	CI:	
0.0%-	0.5%,	P	=	.5)	in	patients	positive	for	anti-	HBs	(Appendix	S7).
3.2.2 | Pooled risk of HBV- related hepatitis
Of	61	HBsAg-	positive	patients	without	concurrent	HBV	nucelos(t)
ide	 analogue	 treatment	 who	 experienced	 HBV	 reactivation	 after	
DAAs,	11	developed	hepatitis.	The	pooled	risk	of	HBV-	related	hepa-
titis	in	those	with	HBV	reactivation	was	12.6%	(95%	CI:	0.1%-	34.7%;	
Figure	4).	Of	2	HBsAg-	negative	anti-	HBc-	positive	patients	who	ex-
perienced	 HBV	 reactivation,	 none	 had	 HBV-	related	 hepatitis;	 the	
pooled	risk	was	0.0%	(95%	CI:	0.0%-	78.7%).
4  | DISCUSSION
In	the	cohort	of	chronic	hepatitis	C	patients	positive	for	HBsAg	who	
underwent	DAAs	 in	 Egypt,	we	 found	 that	 in	 the	 absence	 of	 con-
current	 HBV	 treatment	 the	 risk	 of	 reactivation	 was	 28.6%	 (95%	
CI:	15.6%-	46.4%)	and	the	risk	of	hepatitis	 in	those	who	developed	
reactivation	 was	 10.0%	 (95%	 CI:	 0.9%-	57.8%).	 In	 the	 subsequent	
systematic	 review	 that	 also	 incorporated	 these	 Egyptian	 data,	we	
found	that:	(i)	the	pooled	risk	of	HBV	reactivation	in	patients	concur-
rently	infected	with	HBV	was	18.2%	(95%	CI:	7.9%-	30.7%)	without	
HBV	therapy	and	0.0%	(95%	CI:	0.0%-	0.0%)	with	HBV	suppressive	
treatment;	 (ii)	 the	 pooled	 risk	 of	 reactivation	 in	 HBsAg-	negative	
anti-	HBc-	positive	patients	was	negligible	0.1%	(95%	CI:	0.0%-	0.3%),	
irrespective	of	the	presence	of	anti-	HBs;	(iii)	the	pooled	risk	of	hepa-
titis	 in	patients	who	developed	HBV	reactivation	was	12.6%	 (95%	
CI:	0.1%-	34.7%)	in	HBsAg-	positive,	and	0.0%	(95%	CI:	0.0%-	78.7%)	
in	HBsAg-	negative	group.
Recently,	a	systematic	review	was	conducted	to	estimate	the	risk	
of	HBV	 reactivation	 in	HBV/HCV	dually	 infected	 patients	 treated	
with	HCV	antiviral	 agents39	and	 found	 that	12.2%	 (95%	CI:	0.2%-	
33.2%)	 of	 those	 treated	 with	 IFN-	free	 DAAs	 developed	 HBV	 re-
activation.	 However,	 the	 review	was	 limited	 because	most	 of	 the	
In HBsAg-positive patients without concomitant anti-HBV nucleos(t)ide analogue therapy
Overall  (I2 = 67.54%, P = 0.00)
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included	 studies	 used	 patients	 on	 IFN-	based	 regimens,	 and	 there	
were	only	2	studies	with	patients	on	IFN-	free	DAAs.	Moreover,	the	
meta-	analysis	endpoint	was	HBV	reactivation	as	defined	by	the	au-
thors	of	each	article,	which	varied	considerably.40	In	the	systematic	
review	and	meta-	analysis	that	we	present	here,	we	were	able	to	in-
clude	18	studies	with	patients	on	IFN-	free	DAAs	and	use	a	common	
endpoint	definition,	proposed	by	the	APASL	and	AASLD.	This	stan-
dard	definition	requires	≥2.0	log	increase	in	viral	load	for	those	who	
had	detectable	HBV	DNA	at	baseline.16,17	In	contrast,	many	of	the	
studies	included	in	our	systematic	review	used	lower	cut-	off	values	
in	 their	 published	 papers:	 ≥1.0	 log,11,12,29	 or	 ≥1.3	 log27,28 increase 
in	HBV	DNA.	Previous	 longitudinal	studies	of	HBV	mono-	infected	
patients	have	shown	that	25%-	50%	of	chronic	HBV	carriers	experi-
enced	a	spontaneous	fluctuation	of	HBV	DNA	levels	≥1.0	log	IU/ml	
over	short	period	of	time,41,42	suggesting	that	the	use	of	these	lower	
cut-	off	levels	might	result	in	overestimation	of	the	frequency	of	HBV	
reactivation.
Considering	that	only	around	20%	of	HBsAg-	positive	co-	infected	
patients	develop	HBV	 reactivation	during	or	 after	DAAs,	 it	would	
be	useful	for	clinicians	to	be	able	to	identify	patients	at	a	high-	risk	
for	 this	 event	who	would	most	 benefit	 from	concurrent	 anti-	HBV	
nucleos(t)ide	 analogue	 prophylaxis.	 A	 Taiwanese	 study	 suggested	
that	higher	quantified	HBsAg	levels	at	baseline	might	be	associated	
with	higher	 risk	of	HBV	reactivation	during	DAA	therapy.13 In our 
Egyptian	 cohort,	 no	 factor	was	 found	 to	 be	 associated	with	HBV	
reactivation,	 probably	 because	 of	 lack	 of	 power.	 Although	 it	 did	
not	 reach	statistical	 significance,	our	meta-	analysis	 found	 that	 the	
pooled	risk	of	reactivation	tended	to	be	higher	in	those	who	achieved	
SVR	than	non-	SVR.	The	positive	association	between	HCV	SVR	and	
higher	 risk	of	HBV	reactivation	has	been	confirmed	 in	co-	infected	
patients	treated	with	IFN	plus	RBV.43	These	findings	support	the	hy-
pothesis	 that,	 in	dually	 infected	 individuals,	 the	 successful	 control	
of	HCV	may	result	 in	an	upsurge	of	HBV	that	has	previously	been	
suppressed	by	the	dominant	HCV.
Some	studies	have	reported	factors	associated	with	reactivation	
in	 HBsAg-	negative	 anti-	HBc-	positive	 patients	 treated	 with	 DAAs:	
lower	 anti-	HBs	 antibody	 titre	 at	 baseline,28,29	 higher	ALT	 levels,29 
younger	age35	and	certain	HCV	genotypes.35	 In	our	meta-	analysis,	
we	did	not	see	any	difference	in	reactivation	risk	between	the	iso-
lated	 anti-	HBc	 group	 (anti-	HBs-	negative)	 and	 the	 resolved	 HBV	
group	(anti-	HBs-	positive);	the	risk	of	former	group	was	already	very	
low	(0.0%,	95%	CI:	0.0%-	0.0%).
Although	 the	 total	number	of	patients	was	small	 (n	=	132),	our	
systematic	review	found	that	no	HBsAg-	positive	patients	who	had	
been	under	HBV	nucleos(t)ide	analogue	therapy	had	HBV	reactiva-
tion	after	 the	 start	of	DAAs.	This	 is	 reassuring,	 as	 it	 supports	 the	
preventive	efficacy	of	the	concurrent	nucleos(t)ide	analogues	in	re-
ducing	the	risk	of	reactivation	in	patients	receiving	DAAs.
In	our	Egyptian	study,	we	found	that	0.9%	(40/4471)	of	patients	
with	 chronic	 HCV	 infection	 were	 co-	infected	 with	 HBV.	 This	 co-	
infection	rate	is	very	similar	to	the	prevalence	of	HBsAg	reported	in	
the	general	population	in	Egypt.44,45
Our	study	has	several	limitations.	Firstly,	in	the	Egyptian	cohort	
we	 only	 studied	 HBsAg-	positive	 patients	 and	 not	 those	 HBsAg-	
negative	 but	 anti-	HBc-	positive.	 This	 was	 a	 result	 of	 the	 fact	 that	
anti-	HBc	screening	 is	not	part	of	 the	Egyptian	national	guidelines.	
Nevertheless,	 our	 systematic	 review	 found	 that	 the	 risk	of	 reacti-
vation	in	this	group	is	homogeneously	very	small	throughout	other	
published	studies	 (Figure	3C).	Secondly,	we	could	not	assess	other	
factors	that	may	modify	the	effect	of	IFN-	free	DAA	regimens	on	the	
risk	of	reactivation,	such	as	HIV	co-	infection,	HCV	genotype,	HBV	
genotype	or	quantified	HBsAg	levels.	There	were	a	few	studies	in-
cluded	in	the	systematic	review	which	reported	these,	but	it	was	not	
possible	to	stratify	the	estimates	by	these	variables.
In	conclusion,	our	study	confirmed	the	importance	of	screen-
ing	 for	 HBV	 in	 patients	 undergoing	 DAA	 therapy.	 For	 those	
negative	 for	HBsAg	 but	 positive	 for	 anti-	HBc,	 the	 EASL	 recom-
mendation	of	monitoring	and	testing	for	HBV	DNA	in	case	of	ALT	
elevation	seems	reasonable	as	HBV	reactivation	and	particularly	
HBV-	related	hepatitis	are	rare	in	this	group.	In	contrast,	for	those	
positive	for	HBsAg,	the	risk	of	reactivation	was	substantial	(18.2%,	
95%	CI:	7.9%-	30.7%).	However,	only	the	minority	(12.6%,	95%	CI:	
0.1%-	34.7%)	 of	 these	 HBV	 reactivation	 events	 resulted	 in	 clini-
cally	important	ALT	elevation,	which	may	limit	the	benefit	of	sys-
tematic	nucleos(t)ide	analogue	prophylaxis	for	all	HBsAg-	positive	
patients.	In	our	Egyptian	cohort,	for	example,	if	we	had	followed	
the	EASL	recommendation	(ie,	starting	nucleos(t)ide	analogue	pro-
phylaxis	 for	 all	 35	 HBsAg-	positive	 patients	 irrespective	 of	 their	
HBV	DNA	levels	at	baseline),	this	could	have	prevented	1	case	of	
HBV-	related	hepatitis	during	the	course	of	DAAs,	but	might	have	
resulted	in	over-	treatment	in	the	rest	of	the	subjects	(n	=	34).	As	
has	 been	 studied	 in	 lymphoma	 patients	 undergoing	 chemother-
apy,46	this	question	deserves	to	be	addressed	through	a	random-
ized	controlled	trial	assessing	the	efficacy	of	systematic	nucelos(t)
ide	 analogue	 prophylaxis	 (EASL	 recommendation)	 in	 preventing	
F IGURE  4 Pooled	risk	of	hepatitis	in	HBsAg-	positive	patients	
who	developed	HBV	reactivation
Overall  (I2 = 37.08%, P = 0.08)
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HBV-	related	hepatitis,	compared	to	“on-	demand”	HBV	therapy	im-
plemented	only	when	HBV	DNA	levels	become	elevated	(AASLD	
recommendation),	 in	 chronic	 HCV	 patients	 with	 inactive	 HBV	
infection	with	 low	HBV	viraemia	who	are	 administered	 IFN-	free	
DAAs.
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Letter: concordance of SVR4 and SVR12 following
direct-acting anti-viral treatment in Egypt1
EDITORS,
In your recently published paper by Omar and colleagues, we are
presented with the results of 18 378 patients treated for chronic
hepatitis C (HCV) with direct-acting anti-virals (DAAs) through the
Egyptian National Treatment Program.1 During the same time period
within the programme, retention of patients until the assessment of
sustained virological response (SVR12) posed a significant logistical
hurdle and led to 29%-40% of patients being lost to follow-up.2,3
Use of a more prompt endpoint, 4 weeks after the end of treatment
(SVR4), could potentially lower these proportions and subsequently
support evaluations of Egyptian and other national treatment pro-
grammes administering DAAs; however, SVR4 has previously shown
to be inadequate.4
To compare SVR4 to the conventional endpoint, SVR12, in a
real-life setting, the programme carried out a prospective, observa-
tional cohort study of patients receiving interferon-free DAAs at
the New Cairo Hospital treatment centre in Cairo, Egypt, between
September 2014 and December 2016. All patients eligible for treat-
ment according to the Egyptian National Guidelines were invited to
participate. Participants received 2 vouchers for free quantitative
HCV RNA testing 4 and 12 weeks post-treatment and real-time
PCR was done at the centre’s laboratory or other selected national
laboratories. Patients had clinical follow-up at the centre every
4 weeks until the end of treatment, then at 4 and 12 weeks post-
treatment.
Of the 2899 patients treated at the centre who agreed to partici-
pate, 233 (8.0%) were treated with IFN containing DAA regimens,
and 196 (6.8%) were lost to follow-up, leaving 2470 (85.2%) eligible
for analysis. Patient characteristics are described in the Table 1. The
DAAs administered include sofosbuvir and daclatasvir with or with-
out ribavirin (n = 1559, 63.1%), sofosbuvir and simeprevir (n = 586,
23.7%), sofosbuvir with ribavirin (n = 285, 11.5%), ombitasvir/pari-
taprevir with ribavirin (n = 40, 1.6%). A total of 5 and 15 patients
had detectable HCV RNA at 4 and 12 weeks post-treatment, leading
to an estimation of SVR4 and SVR12 as 99.8% (95% CI:
99.5%-99.9%) and 99.4% (95% CI: 99.0%-99.7%) respectively. The
sensitivity of viral load testing at 4 weeks compared to 12-week
post-treatment was 33.3% (5/15, 95% CI: 11.8%-61.6%) and the
specificity was 100% (2455/2455; one-sided 97.5% CI: 99.9%-
100%). The negative and positive predictive values were 99.6%,
(2455/2465, 95% CI: 99.3%-99.8%) and 100% (5/5, one-sided
97.5% CI: 47.8%-100%) respectively.
In this study, viral load testing 4 weeks post-treatment misclas-
sified a small number of individuals (ie 10/2470, 0.4%), but did not
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identify the majority (66.6%) of eventual treatment failures. Practi-
cally, within the Egyptian National Treatment Program, which aims
to treat 350 000 persons annually, this would leave 1400 viremic
persons returning to their communities as transmitters, with a
higher risk of complications and without a referral for further DAA
treatment.5-7 Evaluations of other intermediate endpoints, such as
SVR8 as well as studies examining patient factors contributing to
relapse between the end of treatment and SVR12, are needed. In
the meantime, various other measures have been employed in
Egypt to ensure higher proportions of patients undertake viral load
testing at SVR12, including text message and phone call reminders
as well as delivery of “cure” certificates upon demonstration of
SVR12 results.2,8
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TABLE 1 Baseline characteristics and viral load dynamics for treatment failing discordant and concordant patients, with summary baseline
characteristics for all study patients
Baseline evaluation
SVR4 SVR12
Sex Age
Viral load
log10 IU/mL Past HCV treatment DAA regimen/duration in wk Fib4 score
Viral loada
log10 IU/mL
Viral loada
log10 IU/mL
Discordant treatment failures (n = 10), summary: male = 7 (70.0); age = 55.4 (11.4); viral load in log10 IU/mL = 13.1 (1.5); treatment experienced = 0;
fib4 score = 6.6 (4.9)
F 64 14.3 No SOF/DCV/RBV; 12 5.7 Not detected 9.8
M 67 10.8 No SOF/RBV; 24 14.4 Not detected Detected;UA
M 61 14.7 No SOF/DCV/RBV; 12 15.8 Not detected 10.7
M 47 12.5 No SOF/SIM; 12 2.3 Not detected 11.2
M 29 11.5 No SOF/DCV; 12 0.6 Not detected 11.0
F 57 13.1 No SOF/DCV/RBV; 12 4.8 Not detected 11.4
M 58 12.9 No SOF/RBV; 24 5.4 Not detected Detected;UA
M 59 13.9 No SOF/SIM; 12 8.8 Not detected 13.2
M 47 15.3 No SOF/DCV/RBV; 12 4.8 Not detected 10.6
F 65 12.0 No SOF/SIM; 12 3.9 Not detected 11.7
Concordant treatment failures (n = 5), summary: male = 2 (40.0); age = 56.0 (7.8); viral load in log10 IU/mL = 13.0 (0.9); treatment experienced = 2
(20.0); fib4 score = 7.6 (5.8)
M 59 13.7 No SOF/RBV; 24 4.9 Detected; UA 13.7
F 68 13.0 No SOF/RBV; 24 17.7 14.0 Detected; UA
F 53 11.8 IFN/RBV SOF/SIM; 12 7.3 6.9 6.9
M 52 12.2 IFN/RBV SOF/RBV; 24 4.6 Detected; UA Detected; UA
F 48 14.0 No SOF/RBV; 24 3.7 Detected; UA 11.1
Concordant treatment successes (n = 2455), summary: male = 1045 (42.6%); age = 51.8 (11.3); viral load in log10 IU/mL = 13.0 (1.9); treatment
experience = 249 (10.1); fib4 score = 2.4 (2.2)
ALL PATIENTS (N = 2470), summary: male = 1054 (42.7); age = 51.8 (11.3); viral load in log10 IU/mL = 13.0 (1.9); treatment experience = 251 (10.2);
fib4 score = 2.5 (2.3)
Summary statistics are presented as n (%) or mean (SD) for categorical and continuous variables respectively.
aUA indicates a detected viral load, but quantitative value unavailable.
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Letter: tacrolimus may be hazardous in decompensated
autoimmune liver disease with hyperbilirubinaemia
2
EDITORS,
This letter is with regard to the published article by Liberal et al.1 The
authors described expert clinical management of autoimmune hepatitis
in the real world. The article provides useful information managing
the therapy of autoimmune hepatitis (AIH); however, there was little
data regarding tacrolimus as a second-line treatment. We describe our
own experience of the effectiveness and safety of tacrolimus in the
treatment of decompensated autoimmune liver disease.
In the last 6 months, 6 patients with autoimmune liver disease in
our department have been treated with tacrolimus. One was diag-
nosed as AIH and hepatitis B cirrhosis, and the others were diag-
nosed as AIH-primary biliary cirrhosis overlap syndrome. Their basic
clinical data are shown in Table 1. As described in Table 1, all
patients were prescribed tacrolimus when they proved refractory to
standard treatment (predniso[lo]ne alone or a combination with aza-
thioprine). However, no patient achieved a biochemical remission
despite the change to tacrolimus treatment. Importantly, 3 patients
died shortly after they were treated with tacrolimus.
According to the data shown in Table 1, the median serum tacro-
limus concentration of the 6 patients was 4.6 (3.3, 7.2) ng/mL, which
conformed to the effective dose described in most other studies,2-6
but the outcome was not the same. After analysing the basic status
of these patients, we found that all 6 patients had hepatic decom-
pensation prior to treatment with tacrolimus. Notably most of them
had hyperbilirubinaemia, with a median total bilirubin of 182.7 (49.5,
270.2) lmol/L and a median direct bilirubin of 158.4 (26.6, 219.1)
lmol/L. Highest serum bilirubin was present in the 3 patients who
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MERS-CoV at the Animal–Human 
Interface: Inputs on Exposure 
Pathways from an Expert-Opinion 
Elicitation
Anna L. Funk1, Flavie Luce Goutard2, Eve Miguel2,3, Mathieu Bourgarel2,  
Veronique Chevalier 2, Bernard Faye2, J. S. Malik Peiris4,5, Maria D. Van Kerkhove6*† and 
Francois Louis Roger 2*†
1 UEME, Institut Pasteur, Paris, France, 2 Cirad, UPR AGIRs Research Unit, Montpellier, France, 3 UMR MIVEGEC, IRD 
224-CNRS 5290-UM, Montpellier, France, 4 HKU-Pasteur Research Pole, Hong Kong, China, 5 School of Public Health, 
University of Hong Kong, Hong Kong, China, 6 Center for Global Health, Institut Pasteur, Paris, France
Nearly 4 years after the first report of the emergence of Middle-East respiratory syndrome 
Coronavirus (MERS-CoV) and nearly 1800 human cases later, the ecology of MERS-
CoV, its epidemiology, and more than risk factors of MERS-CoV transmission between 
camels are poorly understood. Knowledge about the pathways and mechanisms of 
transmission from animals to humans is limited; as of yet, transmission risks have not 
been quantified. Moreover the divergent sanitary situations and exposures to animals 
among populations in the Arabian Peninsula, where human primary cases appear to 
dominate, vs. other regions in the Middle East and Africa, with no reported human 
clinical cases and where the virus has been detected only in dromedaries, represents 
huge scientific and health challenges. Here, we have used expert-opinion elicitation in 
order to obtain ideas on relative importance of MERS-CoV risk factors and estimates 
of transmission risks from various types of contact between humans and dromedaries. 
Fourteen experts with diverse and extensive experience in MERS-CoV relevant fields 
were enrolled and completed an online questionnaire that examined pathways based on 
several scenarios, e.g., camels–camels, camels–human, bats/other species to camels/
humans, and the role of diverse biological substances (milk, urine, etc.) and potential 
fomites. Experts believed that dromedary camels play the largest role in MERS-CoV 
infection of other dromedaries; however, they also indicated a significant influence of the 
season (i.e. calving or weaning periods) on transmission risk. All experts thought that 
MERS-CoV-infected dromedaries and asymptomatic humans play the most important 
role in infection of humans, with bats and other species presenting a possible, but yet 
undefined, risk. Direct and indirect contact of humans with dromedary camels were 
identified as the most risky types of contact, when compared to consumption of various 
camel products, with estimated “most likely” incidence risks of at least 22 and 13% for 
direct and indirect contact, respectively. The results of our study are consistent with avail-
able, yet very limited, published data regarding the potential pathways of transmission of 
MERS-CoV at the animal–human interface. These results identify key knowledge gaps 
and highlight the need for more comprehensive, yet focused research to be conducted 
to better understand transmission between dromedaries and humans.
Keywords: MERS-CoV, animal–human interface, transmission, epidemiology, infection, risk factors
FIGURE 1 | Review of MERS-CoV exposure pathways for animal-to-animal transmission and animal-to-human transmission based on literature 
evidence and the expert opinions elicited in this study (67–71).
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INTRODUCTION
Nearly 4 years after the first report of the emergence of Middle-
East respiratory syndrome Coronavirus (MERS-CoV) in humans 
and more than 1800 human cases later (1), mainly in Saudi Arabia 
(~75% of cases and almost all of the primary cases), the ecology 
of MERS-CoV and its epidemiology remain poorly understood 
(2). Human-to-human transmission of MERS-CoV accounts 
for approximately half of all the MERS-CoV cases reported to 
date (2). Inter-human transmission has been well documented 
in health care-associated outbreaks in the Middle East and Korea 
(3–5), and there appears to be limited inter-human transmission 
in household settings (6).
Many studies have now identified dromedary camels (Camelus 
dromedarius; dromedaries) as a natural host for MERS-CoV, 
and there appears to be ample evidence of widespread infection 
(either past or present) in dromedaries in the Middle East (7–10) 
and in many parts of Africa (11–15). High levels of MERS-CoV 
specific seroprevalence have been observed in dromedaries, rang-
ing from 0% in Central Asia to as much as 100% in Africa and 
the Arabian Peninsula (7–17) (see Figure 1). MERS-CoV strains 
isolated from dromedaries are genetically and phenotypically 
very similar or identical to those infecting humans (18, 19).
Since the beginning of the MERS-CoV outbreak, animals 
and specifically dromedaries, have been suspected of playing a 
role in transmission. The global camel population has more than 
doubled in the past 50 years, reaching ~30 million today, 95% of 
which are dromedaries. Approximately 60% of camels are found 
in East African countries, which are important exporters to the 
Arabian peninsula and Egypt (20). Camels play a major role in 
socio-cultural traditions in Saudi Arabia; a place where the camel 
population has increased from 80,000 to 200,000 heads over the 
last 50 years; a number which some experts estimate is actually 
closer to 800,000 heads (21). In parallel, a drastic decrease (from 
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10 to 1.5%) of nomadic camel populations has been observed 
over this time period in favor of permanent (or semi-permanent) 
settlements often at the borders of cities (21). It is possible that 
the mentioned changes in global dromedary population dynam-
ics have led to an increased spread and heightened detection of 
MERS-CoV in this species, both of which have made dromedar-
ies the focus of most of the research conducted on MERS-CoV 
to date.
While coronaviruses are widespread in the animal kingdom 
(22), MERS-CoV seems to have a narrow host range. In the last 
few years, a large spectrum of domestic species have been nega-
tive after MERS-CoV serology tests, including horses, cattle, pig, 
water buffalo, chickens, goats, and Bactrian camels (13, 14, 17, 
23, 24). An exception was published recently when antibodies 
were detected in Alpaca (Vicugna pacos) in Qatar; this is notably 
in a specific region where MERS-CoV is already endemic in 
dromedary camels (25) (Figure 1).
A number of studies on wild birds and swine in Hong Kong, 
feral camels in Australia and bats in several countries have 
not identified MERS-CoV in these species (13, 26) (Figure 1). 
Putative precursors of MERS-CoV have been detected in species 
of African bats (27), and Corman and colleagues raised hypoth-
eses on the emergence of MERS-CoV from other animal species 
(28). They characterized the full genome of an African bat virus 
closely related to MERS-CoV and showed that human, camel, and 
bat viruses have phylogenetic relationships although these bat 
viruses are not closely similar to MERS-CoV. They suggest that, 
according to available serologic data on camels and humans since 
2012 and molecular investigations of known cases, MERS-CoV 
moved from bats to camels in sub-Saharan Africa. They also sug-
gest that camelids could be “mixing vessels for MERS-CoV and 
other mammalian CoVs” and that the virus can be transmitted 
between humans and camels (28). Up to now, MERS-CoV-like 
viruses have not been detected in any species other than camels, 
with the exception of an unconfirmed report of the detection of a 
very small fragment of MERS-CoV-like RNA in a specimen from 
a Taphozous perforatus bat collected in Saudi Arabia (29). T. per-
foratus and other bat species sampled in Egypt and Lebanon did 
not reveal MERS-CoV like viruses, although other coronaviruses 
were detected (30).
However, after more than 1800 reported cases over the past 
4 years from 27 countries, only one case–control study evaluat-
ing non-human risk factors for infection has been performed 
and published (31). This study, which included 30 primary 
cases and 116 age, sex, and neighborhood-matched controls, 
confirmed suspicions that direct and indirect exposure to 
dromedary camels in the 14 days prior to symptom onset are risk 
factors for infection (31). This study also found that advanced 
age (>60 years old), being male, and having certain underlying 
chronic health conditions, such as diabetes, heart conditions, 
and chronic lung disease, were independent risk factors for 
disease (31). Several other seroprevalence studies evaluating 
the extent of MERS-CoV infection in occupationally exposed 
persons (e.g., farmers, herders, slaughterhouse workers) have 
identified that these populations have a higher levels of sero-
prevalence (32, 33) when compared to the general population 
(32) (see Figure 1).
What is currently unclear is why all primary human MERS-
CoV cases have been reported from the Arabian Peninsula 
(2). Given that there is evidence of MERS-CoV circulation in 
dromedaries across large parts of Africa (11–15), it is likely that 
cases of MERS-CoV in humans have been missed. There are 
several potential hypotheses to explain this. First, surveillance 
for MERS-CoV in human populations focuses mostly on severe 
disease and on travelers returning from the Arabian Peninsula 
rather than on patients without a history of travel. Moreover, 
on-going surveillance in Saudi Arabia is now very intensive (34). 
Second, the prevalence of chronic underlying medical conditions 
in many countries in Africa is far lower than in the Middle East, 
with high rates of heart disease, diabetes, and obesity; third, it is 
likely that asymptomatic, mild or sub-clinical cases are missed 
with even the most robust surveillance systems. Fourth, the 
nature of contact with and the use of dromedary products differ 
between countries and cultures. Lastly, the viruses circulating in 
the Arabian Peninsula may be different. Although MERS-CoV 
in Africa are >99% identical at the nucleotide level with those in 
the Arabian Peninsula (35), it is conceivable that a few key amino-
acid differences may make a major change in transmissibility and 
virulence.
In the case of MERS-CoV transmission, there is a large 
uncertainty about the various exposure pathways associated 
with new dromedary camel or human cases, and, although 
published research on MERS-CoV is actively increasing (36), 
few transmission risks have yet been quantified. There is an obvi-
ous need to collect more critical information from virological 
and eco-epidemiological studies, but also from social sciences 
(anthropology, sociology) studies about camel–human relation-
ships, including behaviors at the interface. These studies can 
evaluate contact patterns, modes of transmission, viral shedding 
from animals, virus persistence in different environments, and 
biological samples. In view of all that remains to be done, we 
advocate a risk-ranking approach based on exposure pathways 
to guide allocation of resources for future data collection on the 
main sources of transmission of MERS-Cov. Risk assessment is 
a powerful modeling tool that enables decision-makers to deter-
mine the likelihood of disease occurrence and the magnitude of 
its consequences, which, in turn, allows identification of key steps 
and appropriate management measures to take. It is a structured 
and a systematic process that helps in the gathering of diverse 
and disparate information and data. However, when data are 
scarce and knowledge gaps are highly prevalent, such as with the 
recently identified MERS-CoV, too many transmission pathways 
would have been presented for the risk analysis. This is why we 
proposed, as a preliminary step, to call upon experts using expert-
opinion elicitation (EOE), to explore scenarios and hypotheses of 
transmission among animal(s), fomites, and humans. From the 
EOE outputs, a qualitative and/or quantitative risk assessment 
model could then be implemented. Expert-opinion elicitation 
has proven to be useful in other zoonotic disease risk assess-
ments, especially in cases where little quantitative information 
for the disease is already known (37, 38). The aim of this work is 
to allow for a triage of highly likely and unlikely pathways, and 
highlight areas that deserve increased attention for field surveys 
and studies.
FIGURE 2 | Simplified Saaty Scale used for comparing risk factors in the analytical hierarchy process.
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MATERIALS AND METHODS
In our study, experts were defined as being persons with 
relevant experience on the topic, including having extensive 
technical experience in epidemiological or virological research 
through MERS-CoV or related animal and/or human studies. 
Considering the recent emergence of the virus as a cause for 
human disease, extensive experience in MERS-CoV research 
itself was not an inclusion criteria; however, all included experts 
needed to have some experience working on MERS-CoV and/
or camel research topics within North Africa and the Arabian 
Peninsula, if not elsewhere. Furthermore, the experts’ publica-
tions and professional affiliations should have been significant 
enough to reflect this expertise. Recruitment was done first 
through relevance screening, where the researchers chose 
persons based on their own judgment. Following this original 
recruitment, “snowball” recruitment was used; experts who 
chose to participate were asked to recommend other experts to 
fill out the questionnaire. We aimed to enroll at least 10 experts, 
with extensive experience in relevant fields, for the exercise 
and, therefore, started by emailing invitations to 13 persons. All 
persons recommended by the first group of experts were invited 
to participate if their expertise was judged relevant for our study. 
All experts gave an informed consent before starting their par-
ticipation in the survey. Written consent was not necessary for 
this type of study; experts could withdraw themselves from the 
study at any time and all opinion “results” would be presented 
in an anonymous fashion.
Searching into MERS-CoV literature (36, 39) and meeting 
reports (40) allowed us to identify potential pathways and risk 
factors needed for designing the EOE (see Figure 1).
The questionnaire was designed online using the tool Survey 
Monkey (www.surveymonkey.com). A pilot survey was sent to 
the team members in order to test the survey and optimize the 
consistency of the questions. A clear description of the study 
objectives and of what was expected for their participation was 
provided to experts in the invitation email. Following their 
acceptance to participate, the experts were emailed a link to 
the online survey. The beginning of the online survey included 
instructions, examples, and contact information of the adminis-
tering researchers.
The questionnaire was designed to take about 30–40 min, and 
be filled in by experts individually using a link to online soft-
ware (see Image S1 in Supplementary Material). It consisted of 
expertise questions, relative importance of risk factor questions, 
transmission risk estimations, and open-ended responses, in that 
order, all of which will be described in more detail below.
The analytical hierarchy process (AHP) (41, 42) is widely used 
in marketing research (43) and has more recently been introduced 
as a tool in veterinary epidemiology (38, 44). AHP obtains opin-
ions on the weight of the relative importance of one attribute of an 
object or event over another, through pair-wise comparisons. In 
our questionnaire, we used the technique to obtain experts opin-
ions about the most relevant exposure pathways and their relative 
importance for five different animal–animal or animal–human 
transmission scenarios. Where appropriate, simple transmission 
diagrams were used to explain the potential exposure pathways 
in question. Experts were first asked to identify which exposure 
pathway they “believed in” out of a provided list, always with 
the opportunity to specify “other.” They were then asked to do 
pair-wise comparisons of each exposure pathway, comparing the 
risk factors of transmission, using the Saaty scale (41) (Figure 2).
In order to obtain quantitative estimates on the transmission 
risks from dromedaries to humans, we asked experts for their 
3-point estimation (minimum, most likely, and maximum) con-
sidering different types of exposure between 10 susceptible camel 
workers and dromedaries. Exposures included consumption 
of camel products (e.g., milk, urine, meat), direct and indirect 
contact; separate estimations were asked for different scenarios of 
younger (≤50 years) or older (>50 years) camel workers and adult 
or juvenile dromedaries. Using the same method, experts were 
also asked their estimates for transmission between potentially 
asymptomatic camel workers and family contacts.
Finally, a few open-ended questions on factors that may 
increase or decrease transmission and were posed to experts.
The survey was not anonymous in order to be able to come 
back to the experts in case of inconsistency in their answers. 
For every question, the experts were asked to respond not only 
expressing their opinion but also to assess their own confidence in 
their answers for each question, with a score from 1 to 5.
The analytical hierarchy process allowed us to weight each 
exposure pathway according to the level of importance given to it 
by each expert. Additional weight was attributed to each answer 
according to the level of confidence given by the expert. Then, for 
each pathway, a weighted aggregation of all expert answers was 
generated. An expert’s data were excluded from the combined 
estimates in case of any of the following criteria: <30% consist-
ency ratio, obvious erroneous entry, missing data for part of or 
the entire question. In this case, a 30% consistency ratio cut-off, 
taking into consideration that the historically recommended 
TABLE 1 | Included Expert Profiles.
Degree Epidemiology Virology Camel studies Risk analysis Chiropterology (bats)
1 MD ✓a 1–5 years ✓a 1–5 years
2 DVM ✓a 10+ years ✓a 10+ years ✓ 10+ years
3 MD ✓a 10+ years ✓a 10+ years
4 MPH ✓a 6–10 years ✓ 1–5 years ✓ 1–5 years
5 PhD ✓a 10+ years ✓ 1–5 years ✓ 6–10 years
6 DVM ✓a 10+ years ✓a 10+ years ✓ 10+ years ✓ 6–10 years ✓ 10+ years
7 DVM ✓ 10+ years ✓a 10+ years
8 DVM ✓a 1–5 years
9 PhD ✓a 1–5 years ✓a 6–10 years ✓ 10+ years
10 DVM ✓ 10+ years ✓ 10+ years
11 DVM ✓a 10+ years ✓ 6–10 years
12 PhD ✓a 1–5 years ✓ 1–5 years ✓ 1–5 years
13 MD ✓a 6–10 years ✓a 10+ years ✓ 6–10 years
14 DVM ✓a 10+ years ✓a 10+ years ✓ 1–5 years ✓ 6–10 years ✓ 1–5 years
aIncluding MERS-CoV specific.
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10% cut-off is shown to be too severe for comparison matrices 
that have >3 variables and that the cut-off should increase with 
number of variables (45, 46); our questions introduced up to eight 
variables for each matrix. The overall level of agreement across 
experts in their ranking of the selected risk factors was calculated 
using the Kendall’s W coefficient. The average weighted mini-
mum, most likely and maximum transmission risk for each of the 
3-point estimation questions was also generated using a similar 
weighting mechanism. An expert’s data was excluded from the 
3-point distribution combined estimates in case of consistently 
highly outlying estimates or missing data for part of or the entire 
distribution. Outliers were defined as estimated risks that were 
consistently greater than twice the estimates of all other experts. 
When possible, for missing or erroneous data, experts were re-
contacted by email to clarify. The mean confidence level, across all 
included experts, was calculated for each pair-wise comparison 
and 3-point distribution question. Open-ended responses were 
summarized qualitatively.
RESULTS
Overall, 18 experts were contacted to take part in the question-
naire. Of these, 16 responded to the invitation, and 14 filled out the 
questionnaire in full, contributing data to this study. All respond-
ents, except 1, had expertise in either MERS-CoV epidemiology 
and/or virology; the remaining expert had significant experience 
in camel production and husbandry and general epidemiology. 
Six and three respondents had experience in conducting studies 
of camels and bats, respectively. A detailed description of each 
participant’s expertise can be found in Table 1.
MERS-CoV Infection of  
Dromedary Camels
On the topic of how dromedaries become infected with MERS-
CoV, the following exposure pathways were presented to experts: 
infestation of infected bats in close proximity, daily close contact 
with infected camel workers (both ≤50 and >50 years old), short-
term contact with an infected dromedary herd, short-term con-
tact with a non-dromedary species infected with MERS-CoV, and 
infection occurring during dromedary calving season. All of the 
above risk factors were selected by at least 5/14 experts. However, 
the most highly selected and importantly weighted exposures 
were “short-term contact with an infected dromedary herd” and 
“timing coinciding with dromedary calving season” (Figure 3A). 
Two experts selected the “other” option and specified the most 
risky season is dromedary-weaning season. Furthermore, one 
expert selected “other” and included the possible risk associated 
with contaminated camel feed.
MERS-CoV Infection between  
Dromedary Herds
Risk factors that were presented to experts, when asking about 
the possibility of dromedaries from different herds infecting 
each other, were: nomadic dromedary herds, introduction of 
a new dromedary into the herd, high dromedary density area, 
dromedaries taken to racetracks, dromedaries entered into/taken 
to beauty contests, dromedaries brought to communal water-
points, dromedaries brought to/sold at markets, dromedaries 
pass through border points. Each factor was considered risky 
by at least 5 (36%) of the 14 experts, and no additional risk fac-
tors from experts were provided. The most highly selected (i.e., 
>70% of experts) risk factors, in order of weighted importance, 
were: bringing dromedaries to markets, introduction of a new 
dromedary into the herd, high dromedary density area, and 
bringing dromedaries to communal water-points. The first three 
of these risk factors were given similar weights by experts, while 
the last (communal water-points) was thought to only be half as 
important as them. Experts had sufficient agreement on their 
ranking of risk factors (Kendalls W = 0.25, p = 0.003), and had a 
mean response certainty of 3.9 and 3.8 (out of 5) for choosing risk 
factors and the subsequent rankings, respectively.
MERS-CoV Primary Infection in Humans
Exposure pathways for human primary case occurrence included: 
infestation of MERS-CoV infected bats in close proximity to 
human populations, contact with a MERS-CoV infected herd of 
dromedaries, contact with a non-dromedary MERS-CoV infected 
species, blood-biting pests (e.g., fleas, ticks) on an infected 
FIGURE 3 | (A) (left). Exposure pathways and relative weights of risk factors for a dromedary camel from an uninfected herd to become infected with 
MERS-CoV. ^p < 0.001. (B) (right). Exposure pathways and relative weights of risk factors for a camel worker or other human to become infected with 
MERS-CoV. ^^p < 0.01. *Mean confidence for overall choice of risk factors for this question with a scale of confidence between 1 (not confident) and 5 (very 
confident).
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animal species or on humans, contact with another human who 
is asymptomatically infected with MERS-CoV. All experts agreed 
that contact with infected dromedaries or asymptomatic humans 
were major risks for disease transmission, with the former being 
of higher risk (Figure 3B). About a third of experts (29–36%) 
thought that contact with MERS-CoV infected species other than 
dromedaries or bats may also play a role in human infection. 
Only one expert considered the possibility of blood-biting pests 
transmitting infection between dromedaries or other species and 
humans. Experts suggested no “other” risk factors.
Transmission from Infected Dromedaries 
to Camel Workers
The following possible exposure pathways from dromedaries to 
camel workers were presented to the experts: direct contact (e.g., 
face-to-face, touching, kissing), indirect contact (e.g., cleaning 
camel environment, contact with dromedary waste), consump-
tion of unpasteurized milk, consumption or use of dromedary 
urine, and consumption of raw dromedary meat. All pathways 
were thought to be possible by the experts (≥50% each) and direct 
contact with dromedaries was thought to be a transmission risk 
factor by all experts (Figure 4). When asked to quantify these 
risks, by estimating the likely incidence of human cases, sepa-
rately for adult and juvenile camels and older (>50 years) and 
younger (≤50 years) camel workers, experts estimated direct and 
then indirect contact with the highest risk; generally there was 
a slightly higher risk estimated when contact was with juvenile 
camels, and a clear trend for higher estimated risk when older vs. 
younger camel workers were exposed (see Table 2). Specifically, 
the risk of transmission was thought to be low (≤5%) for camel 
workers consuming or using camel products, such as milk, urine, 
or raw meat. The estimation of the incidence was quantified as 
being between 13 and 24% for indirect contact with an infected 
dromedary regardless of whether adult or juvenile, and between 
22 and 33% with direct contact, varying by the age of both the 
camels and camel workers.
Transmission from Asymptomatic  
MERS-CoV Cases to Contacts
Experts were asked to estimate the risk of transmission from an 
asymptomatic infected individual to other individuals in close 
contact. The estimated “most likely” risk of transmission if the 
potentially asymptomatic camel workers were either ≤50 years or 
>50 years old was 9%. The experts had a mean confidence of 2.8 
(out of 5) for their answers for both age groups.
Risk Factors for Symptomatic  
MERS-CoV Infection in Humans
At least 10 of the 14 experts agreed that older age (>50 years), 
being immunocompromised, and the amount of viral dose 
transmitted, increases the chances that infected camel workers or 
other persons will become symptomatic after MERS-CoV infec-
tion. Being immunocompromised was given the highest overall 
comparative weight as a risk factor, followed by amount of viral 
dose transmitted. Also, genetic susceptibility and recent occur-
rence of an epidemic period for another disease (e.g., Influenza) 
were identified as risky by three and four experts, respectively. 
Experts had a good level of agreement on their ranking of the 
selected risk factors (Kendalls W = 0.61, p < 0.01), and had a 
mean response certainty of 3.4 and 3.3 (out of 5) for choosing risk 
factors and the subsequent rankings, respectively.
Responses to Open-Ended Questions on 
Transmission Dynamics
Experts were asked which factors led to increase viral shed-
ding in MERS-CoV infected dromedaries. The most highly 
FIGURE 4 | Exposure pathways and relative weights of risk factors for types of transmission between dromedaries and camel workers. ^p < 0.01. 
*Mean confidence for overall choice of risk factors for this question with a scale of confidence between 1 (not confident) and 5 (very confident).
TABLE 2 | Estimated percentage transmission risk from adult and juvenile dromedaries to camel workers (CW).
Adult dromedary Juvenile dromedary
≤50-year-old CW >50-year-old CW ≤50-year-old CW >50-year-old CW
Most likely Min/max Ca Most likely Min/max Ca Most likely Min/max Ca Most likely Min/max Ca
Milk 3 0/13 2.9 4 1/16 2.8 – – – – -
Urine 3 0/9 3.2 3 0/12 2.9 5 0/12 3 4 0/12 2.9
Raw meat 4 0/15 2.8 3 0/13 2.9 1 1/6 2.9 5 2/14 2.8
Direct 
contact
25 4/45 2.9 29 5/55 3 22 7/39 2.9 33 8/57 3.2
Indirect 
contact
13 1/33 2.9 18 4/36 2.8 19 4/34 3.1 24 6/48 3.1
aC = Mean level of expert confidence for estimate with a scale of confidence between 1 (not confident) and 5 (very confident).
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suggested items included: juvenile dromedaries lacking anti-
body immunity (n = 4), immunosuppressive conditions and 
secondary disease (n = 4), animal density (n = 2) and stress-
ful environments for the animals (e.g., at slaughterhouses, 
markets) (n =  2). Experts believed factors that may lead to 
increased or more efficient transmission between MERS-CoV 
infected dromedaries and humans include repeated close 
contact with dromedaries with the chance of contact with 
respiratory secretions (n = 3), host susceptibility or immune 
status (n = 2), increased virulence of the virus through genetic 
recombination or other (n = 2), and environmental contami-
nation of camel-visited areas (n = 2). Experts were also asked 
whether or not they thought any other viruses might cross-
immunize with MERS-CoV for either dromedaries or humans. 
Of the 12 experts who answered this question, 3 said “No,” 
while 6 were unsure or thought this was possible, and 3 experts 
believed that other coronaviruses might cross-immunize with 
MERS-CoV.
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DISCUSSION
Our results use expert opinion to weigh the different transmis-
sion risks of MERS-CoV between animals and from animals 
to humans. Despite a lack of quantitative data, our results are 
supported by growing evidence from research published from 
MERS-CoV affected countries. Risk assessment is a tool that 
allows for the gathering of accessible data and information (e.g., 
expert opinion). The preliminary approach proposed in this 
paper synthesized available evidence regarding primary MERS-
CoV transmission to humans. Our results highlight a general 
consensus in the order/rank of pathways, as well as for potential 
drivers and risk factors. According to the experts included in our 
study, dromedaries play a major role in transmission. However, 
the role of bats could not be ruled out and should be investigated 
further.
Despite the fact that new research reveals traces of antibodies 
against MERS-CoV in two livestock handlers in Kenya in 2013/14 
(47), it is surprising that no locally acquired primary human 
cases have been reported where humans and infected dromedary 
camels are present outside the Arabian Peninsula. Recent work-
shops on MERS-CoV (Doha in April 2015 and Cairo in May 
2015), organized by WHO, FAO, and the World Organisation for 
Animal Health (OIE), have produced numerous recommenda-
tions to improve surveillance and suggest research in animal and 
human populations (48). One of these recommendations is to 
investigate whether and why MERS-CoV infections of humans 
appear not to occur in Africa despite the high levels of infection 
in dromedaries, and why the virus is apparently absent in camels 
in Central Asia (dromedary and Bactrian camels).
The exact role of dromedary camels as a potential reservoir 
for MERS-CoV is also still unclear, and further investigations 
should be carried out to identify the mechanism of virus 
transmission and quantify the stability of the virus in various 
conditions more clearly. MERS-CoV has been detected in the 
oropharyngeal tract, feces, milk, and meat of dromedaries (21, 
49–51). However, the modes of transmission are not clearly 
known. Our experts felt that the transmission risk from con-
sumption of raw camel products, including milk, meat, and 
urine is low. It is assumed that the infection from dromedary 
camels to humans occurs through droplets or contact as high 
viral loads have been detected in the upper respiratory tract and 
nasal mucous membrane of dromedaries (52). However, milk-
ing activities and drinking unpasteurized milk, which is highly 
prevalent in Saudi Arabia (53), are considered as risky for the 
occurrence of primary cases in human populations. There is 
no evidence of MERS-CoV in camel meat, and it is known that 
cooking would kill the virus. One study from Qatar identified 
MERS-CoV in milk, but it was unclear whether the virus was 
excreted in the milk or if the milk had been contaminated by 
traditional milking techniques, which involves calves being used 
to initiate the milking process (50).
The role of and the extent to which infected asymptomatic 
human cases play a role in transmission is unknown. WHO 
estimates that ~20% of reported MERS cases are asymptomatic 
(54), but this estimate is likely underestimated given surveil-
lance focuses on severe cases requiring hospitalization (55) and 
evidence from serologic studies (32). One study documented 
prolonged shedding of MERS-CoV in an asymptomatic health 
care worker (56), which provides evidence that, if not properly 
isolated, asymptomatic cases in health care settings and in the 
community could lead to onward transmission. The experts 
included in this study believe that contact with asymptomatic 
cases is as important as that with infected dromedaries. 
Comprehensive testing of contacts of MERS-CoV patients, 
regardless of the presence of symptoms, is required to evaluate 
infection between known cases. The role of asymptomatic cases 
or carriers, if they are indeed infected, also needs careful consid-
eration in the community setting. Not all reported primary cases 
can be traced back to contact with dromedaries, and it is likely, at 
least in some cases, that an asymptomatic or mildly symptomatic 
case may be an intermediary between dromedary contact and a 
symptomatic human case.
After 4  years, research on the role of camels and/or other 
sources of primary transmissions to human is inadequate. So far, 
most MERS-CoV studies have focused on virological or clinical 
aspects of the disease. No comprehensive analytical epidemio-
logical studies have yet been carried out in MERS-CoV affected 
countries. With the exception of one case–control study (31) and 
individual case studies following investigation into single cases, 
transmission between dromedary herds and between dromedar-
ies and humans has not been well studied. Even these detailed 
investigations are limited in terms of deciphering the cause-effect 
relationship. As human cases of MERS are relatively sporadic/
rare, case control studies, especially matched case–control studies, 
can be well adapted during epidemics or outbreaks investigations 
and must be performed. Cohort studies are the best option in 
order to compare incidence among exposed (e.g., camel workers, 
immunocompromised people, etc.) and non-exposed popula-
tions. However, conducting cohort studies for rare diseases may 
be difficult.
In regions without reported human clinical cases of MERS, 
cross-sectional surveys based on serological investigation 
in humans and identification and quantification of potential 
risk factors for infection (behaviors, husbandry, contacts with 
camels and camel products, etc.) will assist in the suggestion 
of hypotheses, if human infection is prevalent and statistically 
exploitable for inference at the population level. Outside of the 
Middle East, these studies need to be undertaken, especially 
outside of the Arabian Peninsula and in African countries 
where MERS-CoV has been detected and/or isolated in drom-
edaries. Outside of the Arabian Peninsula, a number of joint 
human/camel serological studies are currently underway in 
North Africa (Pasteur Institut, Pers Comm) and planned in 
sub-Saharan African countries (HKU and Cirad, Pers Comm). 
For instance, in Ethiopia where MERS-CoV strains have been 
detected in camels (Peiris et al., Pers Comm), studies in at-risk 
human communities (e.g., nomadic people in close contact with 
camels, abattoir workers) have to be implemented: both analyti-
cal epidemiological studies and surveys on acute febrile illness 
(57), including respiratory and other signs could lead to clues 
about MERS-CoV infection and/or MERS-disease in humans.
At a more global scale, understanding differences in expo-
sures and behaviors of individuals with dromedaries across the 
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Middle East and Africa is likely to explain some of the differ-
ences in potential infection risk. For that purpose, “ecological 
studies” could help to explore diverse drivers of transmission 
among different environments and societies. However, studies 
based on aggregated data are prone to many biases (58) making 
it difficult to know if individuals have really been exposed to the 
risk factor in question. Furthermore, social sciences have to be 
enlisted in order to puzzle out the relationships between camels 
and humans. Outputs can serve for epidemiological studies 
and modeling (e.g., multi-agents systems, see hereunder). 
Additionally, improved surveillance systems in humans and 
animals in rural and nomadic areas are required for MERS-CoV 
considering possible changes of the public health situation due 
to virus evolution (e.g., toward more pathogenic strains or dif-
fusion of strains from areas with human disease, etc.) over time, 
modification of camel husbandry, etc. For population-based 
studies, epidemiology and surveillance, we need to have species-
adapted and validated serological tools. Indeed, performances of 
tests are often lacking and should be assessed using frequentist 
or Bayesian approaches.
In addition to epidemiological studies, additional data from 
viral ecology studies among camels and other species, includ-
ing bats, are required; phylogeography studies of MERS-CoV, 
and ecological studies on bat species living in the proximity 
of camels and suspected to play a role in the circulation of the 
virus, including a better understanding of their home ranges, 
migration patterns, biology (especially reproduction), roost-
ing sites, and mechanisms of contact with camels are needed. 
Studies of viral shedding in animals, of virus persistence in 
different biological specimens of humans and animals, and 
in the environment under different conditions would help to 
quantify, or at least help to characterize, potential transmission 
risks.
The effect of MERS-CoV on camel health is not well 
documented; is the camel an asymptomatic carrier (reservoir/
vector) or can MERS-CoV infection induce mild symptoms 
and/or pave the way for secondary infections? To address this 
question, camel studies should focus not only on MERS but 
also on the diverse etiologies of respiratory syndromes (59). 
This could be significant because, first, if MERS is recognized 
as a camel disease, more research resources could be allocated, 
second, super-infections could play a role in MERS-CoV 
transmission traits. Finally, multi-pathogens studies and 
multi-disease surveillance in camel populations can improve, 
through an economy of scale, MERS-CoV detection and the 
collection of data and metadata. Similarly, health conditions 
and infectious and parasitic diseases of camels may have an 
impact on MERS-CoV ecology and/or MERS epidemiological 
features. Indeed, immunosuppressive effects of several origins 
(husbandry and farming conditions, under-nutrition, deficien-
cies, parasites, co-infections, etc.) could enhance the infectivity 
of the MERS-CoV.
Considering the recent emergence of MERS-CoV as a 
zoonotic threat, and the lack of information already quantified 
on it, we appropriately included a small number of experts in 
this EOE exercise, but those who had diverse and extensive 
experience in relevant fields. The questions included in the 
exercise were feasible for persons who are not accustomed to 
formal prioritization methods; AHP is known to be adapted 
for complex information situations, to be intuitively under-
standable and to allow scientists to score the attributes with 
minimal confusion. Our study has several limitations. First, it 
is commonly considered best practice to give a training exercise 
on EOE methods as well as provide a multi-page literature 
review on the topic in question to participating experts, prior 
to administering the questionnaire, however, this was not 
done here. In this case, experts were provided with a detailed 
document describing how to fill out the questionnaire, with 
examples, and were invited to contact the authors if they had 
any questions or confusion (see Image S1 in Supplementary 
Material). It is possible to “calibrate” experts, by including some 
items in the questionnaire for which a general scientific consen-
sus or quantification already exists; the expert response to these 
questions can then be matched to the real answer in order to see 
how close that expert arrives. There was no calibration done in 
this study, largely due to the fact that there are almost no solidly 
quantified risks associated with MERS-CoV at present. Experts 
were weighted instead only on their confidence level for each 
question answered; however, it is always possible that experts 
are overconfident, giving scores that do not reflect their real 
uncertainty on their knowledge of a variable. Linguistic uncer-
tainty in the questionnaire could have led to some bias; experts 
with varied origins and experience can interpret questions and 
imagine contexts differently, and this can be exacerbated by 
ambiguity or lack of specificity in questions. For the aggregation 
of our results, we used a mathematical approach by combining 
the weighted estimates of all experts. Another option would 
have been to use a more inclusive and participatory behavioral 
approach that would allow experts to revise their answers after 
seeing those of others and eventually come to a consensus 
together. However, empirical results have suggested that 
mathematical methods can outperform behavioral techniques 
in certain circumstances (60, 61), and it is also possible that 
group dynamics could bias estimations of risks toward a more 
extreme consensus (62). Overall, the experts were more certain 
in answering the AHP questions, which involved choosing and 
ranking risk factors. For all animal–animal or animal–human 
AHP questions, the experts consistently had mean confidence 
levels of close to 4 (out of 5), however, when asked to rank risk 
factors for asymptomatic human–human transmission, the 
mean confidence level was lower (closer to 3). When estimating 
minimum, most likely, and maximum transmission risks based 
on scenarios, the experts had lower overall mean confidence in 
their answers, with scores of between 2.8 and 3.2 for all estima-
tions. This lower certainty is likely related to the fact that so few 
transmission risks for MERS have yet been quantified, whereas 
in choosing and ranking risk factors, there are already strong 
trends as presented in the literature.
Apart from virological, ecological, and epidemiological 
approaches, simulation models will allow for the testing of 
different scenarios of transmission, and this can be compared 
with reported cases. However, the scarcity of the data at the ani-
mal–human interface impedes the use of data-driven models like 
the stratified (animal–human) SEIR models, contact networks 
TABLE 3 | Recommended MERS-CoV studies at the animal–human interface.
Studies Main outputs Key strengths Shortcomings and constraints
1. Experimental studies
1.1 Virology Virus strains comparisons among 
animals and humans. Phylogeography
Deciphering of pathways between mammals 
species
Statistical power: require sufficient and 
representative strains to be analyzed
1.2 Experimental infections 
in bats and camels (and 
other livestock species)
Pathophysiology and clinical 
outcomes. Immunological response. 
Virus ecology; virus shedding in 
animals
Epidemiological parameters for modeling, 
e.g., shedding, viral excretion
Bioethics. Biosecurity. Costly
2. (Empirical) Observational studies
2.1 Ecological studies on 
bats and camels
Roles as reservoirs and/or vectors of 
MERS-CoV
Identification of drivers of MERS-CoV ecology Authorization to work on endangered bats. 
Need efficient non-invasive methods. Devices to 
follow livestock movements and bats migrations
2.2 Epidemiological studies Prevalence and incidence in camels/
humans. Serological test performance 
in humans/animals. At-risk behaviors 
and risk factors for MERS-disease in 
humans
Cross-sectional and ecological studies, 
which are relatively simple to be carried out
Costly for case–control and cohort studies
2.3 Sociology and 
anthropology studies
At-risk human behaviors at individual 
and community levels
Will feed epidemiological studies and models Implementation of participatory approaches in 
pastoral and challenging territories (e.g., low-
income countries, remote areas)
2.4 One health surveillance 
systems
Follow-up of virus, antibodies, clinical 
signs in humans and animals
Detection of emergence in humans; 
collection of viruses. infection timeline
Complex (need agreement among public health 
and vet services) and costly (need sustainability)
3. Modeling
3.1 Probabilistic models 
(e.g., QRA)
At-risk pathways of transmission Useful for disease management even if all 
mechanisms are not known
Long and iterative process for QRA. Data and 
information needed, including experiment data
3.2 Dynamic models  
(e.g., SIR, IBM, SNA)
Testing hypotheses (simulation) of 
MERS-CoV transmission. Drawing up 
the levels of vaccination needed
Deciphering of transmission ways between 
mammals species
Need data. Complex models required  
(SIR stratification animal/human, joint models, 
e.g., SIR and SNA, etc.)
3.3 Multiple-criteria  
decision-making or MCDA
Decision process. Risk mapping for 
spatialized MCDA
Straightforward to be implemented  
(literature review and expert opinions)
Model validation (but could be done with Human 
cases in Arabian peninsula)
SIR, compartmental models; IBM, individual-based modeling or multi-agent systems; SNA, social network analysis or contact network analysis; MCDA, multi-criteria decision 
analysis; QRA, quantitative risk assessment.
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models, etc. Moreover, in order to analyze and simulate the 
complete pattern of the disease, there is also a need to capture 
the behaviors of animals and people (63). The individual-based 
model built on multi-agents systems is a computerized system 
combining multiple interacting agents (e.g., humans, animals) 
within a given environment (64). Such a model could be built 
in close interaction with stakeholders (farmers, camel workers, 
etc. (65)) and could drive toward more precise hypotheses about 
initial transmissions to humans (66).
This EOE study has several limitations but it is a preliminary 
step for implementing a more comprehensive risk assessment. 
Risk assessment is a time-consuming and iterative process that 
needs to be fed by several sources of data, lab experiments and 
field observations (see Table 3 for a summary of recommended 
studies). Risk communication, which is part of the risk analysis 
and closely linked to the risk assessment, is essential, especially 
considering that MERS is a major public health issue and could 
have indirect economic and social impacts on the “dromedary 
world.” The questionable responsibility of dromedaries regarding 
human MERS-CoV cases could indeed spur inappropriate and 
overdone control measures. More broadly, this EOE can help in 
identifying gaps and needs in terms of experimental, field and 
modeling studies that will give a better understanding of the 
zoonotic transmission pathways of MERS.
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